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Abstract 
Background  
Acute, decompensated heart failure is a serious and common 
presentation in patients attending Emergency Departments. Diagnosis of 
this condition in this environment can be challenging. 
Main Objective:   
 To assess the diagnostic utility of variables related to the diagnosis of 
decompensated heart failure in the Emergency Department setting.  
 To create a Clinical Decision Rule to facilitate the diagnosis of 
decompensated heart failure in the Emergency Department setting. 
Methods:    
 A systematic review and meta-analysis of literature related to the 
diagnosis of acute heart failure in the Emergency Department was 
performed to assess and rank the diagnostic utility of all potential 
predictor variables. Bivariate meta-analysis was performed where 
appropriate to provide summary statistics for variable utility.  
 A diagnostic study performed in a single, urban Emergency 
Department to allow multivariable analysis of the data to derive a 
Clinical Decision Rule. Logistic regression, Random Forest analysis 
and CART analysis were used in the analysis.  
Results:  
44 papers were included in the systematic review providing data on 41 
potential diagnostic variables. A history of heart failure, clinical opinion of 
heart failure, natriuretic peptide levels and the findings of cardiomegaly, 
pulmonary oedema or cephalisation of vessels on the chest x-ray had the 
greatest diagnostic utility.  
 105 patients were recruited in the diagnostic study and 62 potential 
variables were assessed against a reference standard of two 
cardiologists opinions. Cardiothoracic ratio, natriuretic peptide levels, 
the presence of pulmonary oedema, clinical impression of heart failure 
and urea levels were found to be the best performing variables. 
 Two or more of these variables, using selected cut-off values for 
continuous variables, had a specificity of nearly 100% for definite or 
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possible heart failure. Different cut-off values could be used with these 
variables to provide high sensitivity for this condition. 
Conclusion: The clinical and investigative findings with the greatest 
diagnostic utility for the acutely dyspnoeic patient with heart failure have 
been identified and can be used to rule in heart failure.    
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Chapter 1 Background 
 
1.1 Heart Failure 
 
1.1.1 The Burden of Heart Failure 
 
Heart failure is a condition affecting the lives of millions of people 
throughout the world. It is currently incurable and it shortens and 
impinges on the lives of those afflicted and their carers, impairing their 
ability to perform their daily activities due to the symptoms of 
breathlessness and fatigue. There is a pattern of gradual decline with 
terrifying acute exacerbations. In the patient with pulmonary symptoms, 
they are unable to breath adequately due to the collection of fluid within 
their lungs. It is possible to provide treatment for patients during these 
episodes of acute decompensation, to relieve symptoms and improve 
survival, but this relies on the accurate and early diagnosis of this 
condition. Acute decompensation of cardiac failure causes severe 
breathlessness but so do many other conditions; the treatments for the 
other conditions may be radically different. Rapid and accurate diagnosis 
allows the correct treatment can be started as early as possible. 
 
1.1.2 The Definition of Heart Failure 
 
There is no universally agreed definition for the diagnosis of heart failure; 
a fact that makes it difficult to compare epidemiological, diagnostic and 
intervention research in this area. The diagnosis is made on clinical 
grounds based on the interpretation of numerous historical, clinical and 
investigative findings. There is general agreement that it is a syndrome 
rather than a single entity and there are numerous underlying aetiologies 
and clinical symptom presentations. 
 
Heart failure may be classified as right heart failure causing peripheral 
symptoms and left heart failure causing pulmonary oedema. The term 
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‘congestive’ is added if there is a suggestion of oedema present due to 
vascular ‘congestion’. 
 
The lack of a clear definition of heart failure hampers the research into 
this subject. For therapeutic trials there are few objective criteria to define 
the target cohort of patients are recruited to ensure that this is consistent, 
and the measured outcomes may be controversial, aside from all-cause-
mortality (Yasue et al., 1994; Allen et al., 2009). Even the assessment of 
dyspnoea is subjective with no universally agreed and validated 
instrument, and it may be hard to separate symptoms due to a 
pathological process from those due to the physiological process of 
ageing (Eriksson, Svärdsudd, et al., 1987; Baxter, 2004). 
 
Even with an individual patient, the degree of decompensation is not 
constant with variation in the clinical and diagnostic findings over a period 
of time. The diagnostic findings from clinical examination and 
investigations can also be subjectively interpreted.  For these reasons, it 
can be difficult to perform research comparing the effectiveness of 
treatments or even diagnostic tests for this condition. 
 
The Oxford Textbook of Medicine defines heart failure as, “a clinical 
syndrome that results from any structural or functional cardiac disorder 
that reduces the ability of the heart to function as a pump” (Cowie & 
Chandrasekaran, 2011;1). 
 
The NHS National Institute for Health and Clinical Evidence (NICE) 
defines the condition as the following: “Heart failure is a complex clinical 
syndrome of symptoms and signs that suggest impairment of the heart as 
a pump supporting physiological circulation. It is caused by structural or 
functional abnormalities of the heart. The demonstration of objective 
evidence of these cardiac abnormalities is necessary for the diagnosis of 
heart failure to be made” (NICE, 2010;19). 
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The American Heart Association (AHA) describes heart failure as a 
complex condition resulting from any structural or functional cardiac 
disorder that impairs the ability of the ventricle to fill with or eject 
blood(AHA, 2002). The European Society of Cardiology (ESC) defines 
heart failure as an abnormality of cardiac structure or function leading to 
failure of the heart to deliver oxygen at a rate commensurate with the 
requirements of metabolising tissues(McMurray et al., 2012). 
 
The definition of acute, decompensated heart failure used for the 
purposes of this study is where “the symptom of acute dyspnoea is 
caused in whole or mainly by the impaired ability of the heart to function 
as a pump sufficient to support a physiological circulation whether or not 
it is accompanied by other symptoms or signs”. In the absence of any 
more closely defined parameters for this condition, the clinical impression 
of heart failure, based on the assessment of clinical signs, the symptoms 
expressed by the patient and their progress and response to treatment, 
as assessed by at least one cardiologist, has been accepted as a 
reasonable reference standard for the studies included in this research 
(Felker et al., 2003). 
 
1.1.3 Demographics 
 
In Western society, improved survival from traditional causes of mortality 
such as infectious disease has improved general longevity to the point 
that many more people live long enough to develop ischaemic heart 
disease. There has also been increasing prevalence of some of the 
known risk factors for heart disease such as obesity and diabetes. These 
factors combined are thought to be responsible for the increasing 
incidence of heart failure in the UK. Overall, the number and proportion of 
elderly people in the community continues to rise, and advancing medical 
care has improved survival from cardiac events leading to more patients 
living with a damaged heart. 
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The prevalence of heart failure increases with increasing age (Eriksson, 
Svärdsudd, et al., 1987; Lloyd-Jones, 2002). In the UK, the British Heart 
Foundation estimates that 94,200 men and 105,400 women over the age 
of forty-five years have definite heart failure (Townsend et al., 2012).  
 
In the US, current estimates are that 2.4% of the population has heart 
failure, with 12% of people over the age of 80 years affected by this 
condition(Roger et al., 2012). The estimated annual total cost of treating 
patients with heart failure in the US is around $32 billion (Go et al., 2013). 
 
 
Heart failure is generally described as more common in men than women 
in all ages, and the higher incidence of myocardial infarction in men has 
been suggested as a possible reason.(Tudor et al., 1997; Nieminen et al., 
2006; BHF, 2008). Large registry studies such as AHERE in the US show 
a slightly higher incidence in females so this belief may be due to a bias 
in recruitment of males for heart failure studies (Adams et al., 2005). The 
overall lifetime risk of developing heart failure is thought to be twenty per 
cent for both men and women (Struthers, 2000; Lloyd-Jones, 2002; 
Heidenreich et al., 2013).  
 
Data from the latest national heart failure audit for England and Wales 
showed that the mean age of patients on their first admission for heart 
failure in 2011 was 77.7 years, with a median age of 80.1 years. In 
patients up to 85 years of age, the majority were men (61.1%) while in 
patients over 85 years there were more women (57.9%) (Cleland et al., 
2012). 
 
38,973 men and 39,017 women over the age of 45 years were admitted 
to English hospitals with a main diagnosis of heart failure in 1999/2000. 
This represents a five per cent increase in the number of admissions for 
men and a four per cent increase in admissions for women over the 
previous ten years (Drazner et al., 2001; Gnani & Ellis, 2002). There are 
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significant costs associated with the increased level of morbidity in terms 
of society and direct financial cost to the NHS.  
 
The National Heart Failure Audit (2010) estimates that providing services 
to patients with heart failure costs the NHS £625 million per year (NHSIC, 
2010). Almost 90% of heart failure admissions are emergency admissions 
and overall they account for 5% of all emergency medical admissions. 
The figures for 2008-2009 were of 58,164 admissions with 740,697 bed 
days for patients with heart failure (NHSIC, 2010). 
 
 
1.1.4 The Consequences of Heart Failure 
 
 
The British Heart Foundation (BHF) suggests that the one-year survival 
for patients following initial diagnosis of heart failure is around 60% 
(Townsend et al., 2012). This is worse than the one-year survival rates for 
patients diagnosed with cancer of the breast or prostate and similar to the 
survival rate for patients with cancer of the colon (ONS, 2012). Data from 
the Framingham study shows five-year survival rates of 25% in males 
and 38% in females following the diagnosis of heart failure (Kannel, 1999; 
Fonseca et al., 2004). Other data from the United States suggests a 5-
year mortality rate of 50% (Levy et al., 2002; Roger et al., 2004). 
 
The overall in-patient mortality rate for patients admitted to hospital with 
heart failure is around fifteen per cent. This figure rises to twenty-three 
per cent for the patients over the age of eighty-five years (Henriksson et 
al., 1990; Nicol et al., 2008). In 2011/2012 the National Heart Failure 
Audit for England and Wales showed an 11.1% overall in-hospital 
mortality rate for patients admitted with a primary diagnosis of heart 
failure. The in-hospital mortality rate for men was 10.2% and for women 
was 12.1%. The mortality rates increased with age with a 2.5% mortality 
rate for patients aged less than forty-five years, compared with a 16.8% 
mortality rate for patients over 85 years. The overall one-year mortality for 
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this audit group was 26.2%, with a similar distribution for men and women 
(Cleland et al., 2012). This data was derived from the 24,724 patients on 
whom a mortality status could be obtained.  
 
There was a significant difference in the in-patient mortality rates within 
this audit group depending on where patients were treated: the mortality 
rate for patients treated on cardiology wards was 7.8%; for general 
medical wards was 13.2%; and for patients admitted to other wards 
17.4%. These differences persisted in the data for one-year survival 
(Cleland et al., 2012). Data from the ADHERE study, a multicentre, 
prospective registry for patients hospitalised with acute decompensated 
heart failure in the US showed an overall mortality of 4.2% for patients 
admitted between 2001 and 2003(Abraham et al., 2005). 
 
The diagnosis of heart failure is often associated with numerous hospital 
admissions and poor quality of life. Caring for a person with heart failure 
is also associated with psychological and physical problems for family 
members and caregivers (Pattenden et al., 2007). Patients with end-
stage heart failure receive less health and palliative care services and 
have a poorer understanding of their condition compared with patients 
with lung cancer despite sharing a similar prognosis (Murray et al., 2002). 
 
 
1.1.5 The Aetiology of Heart Failure 
 
There have been several studies examining the aetiology of heart failure 
and a wide variety of causes for the syndrome of heart failure have been 
found; the commonest cause of heart failure in the UK, Europe and the 
United States is coronary artery disease, either due to ischaemia or as a 
result of a myocardial infarction (Kannel, 1999; Zannad et al., 1999; 
McMurray & Stewart, 2000; Fox et al., 2001; He et al., 2001). 
 
Other causes include cardiomyopathies and valvular heart disease. 
Valvular heart disease in less common now in Western Europe due to the 
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decreased incidence of Rheumatic heart disease although this remains a 
significant condition in other countries. Mitral incompetence and aortic 
stenosis are the commonest valvular defects leading to heart failure. 
Cardiomyopathies and congenital anomalies may also lead to heart 
failure. Cor pulmonale, where a primary disorder of the respiratory system 
(e.g. severe COPD) results in right ventricular hypertrophy and eventually 
progresses to right ventricular failure is less common but remains a 
significant cause. Abdelhafiz (2002) suggests that although there is a 
higher prevalence of heart failure in older patients, the underlying causes 
are similar. 
 
Ho et al. (1993), examining the data from the Framingham study found 
hypertension and coronary heart disease to be the commonest underlying 
causes. A history of cigarette smoking, diabetes and changes of left 
ventricular hypertrophy on the ECG were found to be significant risk 
factors for the subsequent development of heart failure.  
 
Cowie et al. (1999) looked at patients presenting with a new diagnosis of 
heart failure over the period of one year, in the area of Hillingdon, which 
had a population of 150,852. Of the 220 patients who were diagnosed 
with heart failure the commonest single aetiology was coronary heart 
disease. This made up 36% of the cases. Many of the patients also had a 
history of hypertension although this was not usually attributed as the 
main cause of heart failure. 31% of the patients with heart failure had 
atrial fibrillation at the time of presentation. 
 
Zannad et al. (1999) examined a population in Northern France and 
found an overall incidence for heart failure of 225 patients per million. The 
underlying aetiology for the 499 patients diagnosed with heart failure, 
during the time of the study, was considered to be coronary heart disease 
in 46% of the patients while 15% of patients had the condition attributed 
to cardiomyopathy. 
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Fox et al. (2001), examined a population in southern London and found 
that there was an incidence of heart failure of 0.9 cases per 1,000 
population. The majority of the patients who were diagnosed with heart 
failure had unknown aetiology (42%). The commonest identified causes 
were ischaemic heart disease (29%) and hypertension (9%). 
 
He et al. (2001) describe the National Health and Nutritional Examination 
Survey (NHANES) epidemiological cohort study where 5545 men and 
8098 women, with no known history of heart disease, were followed up 
for an average of nineteen years. 1388 people developed heart failure 
during this period. The commonest aetiology was ischaemic heart 
disease, accounting for 61.6% of the patients while 17.1% were attributed 
to cigarette smoking and 10.1% to hypertension. 
 
Rudiger et al. (2005) looked at patients presenting with acute onset of 
dyspnoea at two hospitals, one in Zurich, Switzerland and the other in 
Helsinki, Finland. The diagnosis of heart failure was made on the basis of 
a history of heart failure, symptoms consistent with heart failure and a 
characteristic chest x-ray. These researchers found that ischaemic heart 
disease; dilated cardiomyopathy and valvular heart disease were the 
three commonest underlying aetiologies for the heart failure.  
 
The national heart failure audit for England and Wales 2011-2012 found 
hypertension (54%) and ischaemic heart disease (46%) to be the 
commonest contributory causes of heart failure with 26% of admitted 
patients having a history of both.  31% of patients had a history of 
previous myocardial infarction and 22% had a history of valvular heart 
disease (Cleland et al., 2012). 
 
The 2013 Annual Report from the American Heart Association stated that 
a history of hypertension or previous myocardial infarction were the risk 
factors most closely associated with the presence of heart failure (Go et 
al., 2013). 
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1.1.6 The Presentation of Heart Failure 
 
Heart failure is usually associated with dyspnoea, fatigue, and fluid 
retention. Other symptoms may include nocturia, anorexia, abdominal 
bloating and discomfort, constipation, and cerebral symptoms such as 
confusion, dizziness, and memory impairment (Fromm et al., 1995; 
Warrell et al., 2010). 
 
One of the cardinal symptoms of heart failure is breathlessness. This is 
usually in the form of dyspnoea on mild exertion but may also present as 
a cough, which may be nocturnal (Rudiger et al., 2005). Extreme fatigue, 
poor exercise tolerance, sleep disturbance and anorexia all combine to 
provide a very poor quality of life for patients with heart failure (Boyd et 
al., 2004). 
 
The jugular venous pressure may be raised, reflecting the high filling 
pressure of the heart. This may also be related to an increase in total 
body water as a result of the physiological changes required to maintain 
cardiac filling. A gallop rhythm may be present on palpation of the pulse, 
and a third or fourth heart sound can be present due to cardiac strain and 
dilatation. Peripheral oedema may be present in gravity dependent areas; 
in severe cases the oedema may be present as far up as the sacrum 
(anosarca). 
 
Paroxysmal nocturnal dyspnoea (PND) is another common complaint, 
which is likely to be caused by the natural circadian narrowing of airways 
during the night in combination with the redistribution of the fluid due to 
the change in physical position. Patients may also complain of cough or 
wheeze and may mention white, frothy sputum. The patient with acute 
decompensation is usually tachypnoeic and tachycardic (Fromm et al., 
1995). In some cases, especially during severe decompensation, the 
patient may be normocardiac or even bradycardic. 
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The National Heart Failure Audit for England and Wales found that 40% 
of patients were in NYHA Class III at first admission, with breathlessness 
on mild exertion while 32 % were in Class IV with breathlessness at rest. 
Other patients were admitted due to peripheral oedema. The proportion 
of patients with Class IV symptoms in patients who were readmitted to 
hospital was higher at 78% and 52% of these patients had moderate or 
severe oedema (Cleland et al., 2012). In the large ADHERE registry 
study, recording patients admitted to hospital due to heart failure in the 
US, 87% of patients presented in NHYA Class III or IV (Gheorghiade, 
2005). 
 
 
 
1.1.7 Differential Diagnosis 
 
Why is the diagnosis of heart failure so difficult to make? 
 
Breathlessness, the subjective sensation of inadequate breathing, is a 
very common presentation to the Emergency Department. There are 
numerous causes for this symptom that may be pulmonary in origin, for 
example asthma, extra-pulmonary, for example anaemia or even 
psychological. DiagnosisPro, a website providing an online diagnosis tool 
has a list of 518 potential causes, including 110 due to specific agent 
poisoning (DiagnosisPro, 2014).  
 
Even in the patient who has a confirmed diagnosis of heart failure, there 
are numerous aetiologies for developing this syndrome. Although there 
are associations between numerous conditions and the syndrome of 
heart failure the relationship between the cause and effect is not always 
clear. For example, patients may develop heart failure after a myocardial 
infarction but not every patient who has a myocardial infarction will 
develop heart failure.  
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The signs and symptoms associated with heart failure are wide-ranging 
and often open to subjective assessment; their severity, or even 
presence, varies between patients and even within the same patient at 
different times.  
 
Pathological processes may occur simultaneously and it is not unusual 
for a patient to have a diagnosis of both Chronic Obstructive Pulmonary 
Disease (COPD) and heart failure. Although the main presenting 
symptom is the same, the underlying pathology and therefore the 
treatments are very different. Not only will incorrect treatment fail to 
benefit the patient, inappropriate medication may cause harm to the 
patient, especially in the patient who is already significantly compromised 
by their acute condition.  
 
There is some evidence to suggest that improving the diagnostic process 
can have positive effects on patient care. Mueller et al. (2004) followed 
452 patients who presented to their hospital with acute dyspnoea. The 
patients were randomised as to whether or not to have a Brain Natriuretic 
Peptide (BNP) level measured. The patient group who had a BNP level 
measured to aid the diagnosis of the attending clinician, were less likely 
to be admitted to hospital, had a lower length of stay and a non-significant 
trend towards a lower mortality rate.  
 
 
1.1.8 Diagnosing in the Emergency Department  
 
The Emergency Department can be a challenging environment in which 
to assess the patient who may have acute heart failure: the patient is 
often too unwell to give a clear history of events; relatives may not be 
available to provide a corroborative account of events; the patient’s 
hospital notes or results of previous investigations may not be available; 
there is a limited repertoire of investigations available in the Emergency 
Department setting; and even positive findings on examination or from 
investigation are not definitive of heart failure. 
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Most Emergency Departments have a limited array of tests that they will 
perform. The majority of tests are intended to rapidly aid the clinician in 
confirming or refuting a particular diagnosis. Patients requiring subtler, 
more time-consuming, more invasive or more specialised tests will either 
have these as following admission to hospital or on an elective basis as 
an out-patient. Specialised tests also require specialist interpretation in 
order to be of greatest utility. There has to be a pragmatic approach to 
produce a balance of appropriate and efficient investigation; it has been 
shown that routinely applying screening tests to attending patient’s 
increases costs without demonstrating improvements in patient outcomes 
(Durbridge et al., 1976). 
 
Diagnostic testing within the emergency department is designed to risk-
manage the patient until there is an acceptably probability of disease 
presence, at which time appropriate treatment can be commenced, or an 
acceptably low risk of disease at which point other conditions can be 
considered or the patient reassured and discharged.  
 
The time taken to make a diagnosis in a patient is limited, in the 
management of an acutely ill patient one would wish to commence the 
appropriate treatment as quickly as possible. In the UK setting, 
Emergency Department staff are required to see, diagnose, treat and 
either discharge or admit to an inpatient speciality, 95% of the attending 
patients within four hours of the patient’s arrival (DOH, 2014). The 
restricted time frame limits the diagnostic processes that can be 
facilitated within this period. For the most gravely ill patients treatment 
must often be started on an empirical basis for likeliest diagnosis based 
on the immediately available information. 
 
The limitations of working within this environment might be expected to 
produce less than perfect diagnostic accuracy and this is reflected in the 
available data. Collins, Lindsell, Peacock, Eckert, et al. (2006) showed 
that 14.3% of patients with an end-diagnosis of heart failure following a 
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period of hospital admission did not have heart failure diagnosed as the 
underlying cause within the Emergency Department. 
 
1.1.9 The Pathophysiology of Heart Failure 
 
Heart failure exists when the cardiac pump fails to provide adequate 
circulation for the respiratory needs of the body and is usually primarily 
due to a problem of the cardiac pump. The dysfunction may be due to 
myocardial dysfunction, valvular dysfunction, an abnormality of the 
pericardium, an arrhythmia or a pre-load / after-load mismatch. Examples 
of extra-cardiac causes of failure are the increase in after-load due to a 
massive pulmonary embolism, increased pre-load due to increased 
volume intake or decrease in excretion, or the high-output states seen in 
thyrotoxicosis or sepsis. 
 
The underlying pathology may be sudden in onset, for example a sudden 
decrease in function due to myocardial infarction or may develop over a 
long period of time in conditions such as persistent hypertension or a 
cardiomyopathy. The ability of the heart to compensate for some loss in 
function means that there is often a latent period of asymptomatic 
ventricular dysfunction. 
 
The initial compensation occurs by allowing the left ventricular end 
diastolic volume to increase, which in turn, increases the cardiac output. 
This mechanism works by Starling’s principal that the force of myocardial 
contraction is increased in response to stretch (Starling, 1896). This 
mechanism assists cardiac function initially but is often overwhelmed, and 
increasing the end diastolic volume further then leads to decreased 
efficiency of the heart function. 
 
Hypertrophy of the myocardium decreases the load on individual cells but 
leads to increased distance between capillaries, impaired diffusion of 
substrates and increases in the cell volume. There are molecular-level 
36 
 
changes in protein synthesis including reversion to foetal iso-forms of 
proteins. 
 
Cardiac function tends to diminish incrementally over time until a certain 
tipping point is reached and the patient becomes symptomatic. This 
progression is accompanied by changes within the myocardium and 
further activation of the neuro-hormonal and cytokine systems. It has 
been suggested that this progression is independent of physical 
haemodynamics and is dependent on the hormonal effects for this 
remodelling. This raises the possibility of a mechanism for drugs to 
prevent this remodelling (Yan et al., 2008). 
 
Compensatory mechanisms for evolving heart failure involve the 
stimulation of the sympathetic nervous system. This utilises a variety of 
methods to improve cardiac output. It is part of the ‘flight or fight’ 
response and works most effectively as a short-term response to acute 
haemorrhage. Hormones such as adrenaline and noradrenaline are 
released, causing constriction of the blood vessels to increase their 
resistance and an increase in the force and rate of the heart contractions. 
The renin-angiotensin pathway is also activated, promoting salt and fluid 
retention by hormonal action on the kidney and other tissues. There is 
also increased excretion of vasodilatory molecules including natriuretic 
peptides, prostaglandins (PGE2 and PGEI2) and nitric oxide (Fletcher & 
Thomas, 2001). 
 
Heart failure can broadly be split into systolic and diastolic dysfunction. 
Systolic dysfunction is the aspect that is most often considered when 
using the term cardiac failure, and is somewhat easier to diagnose than 
diastolic failure. The failure results from the heart’s inability to contract 
effectively, most commonly due to the results of ischaemic heart disease. 
The reduced coronary artery blood flow to the cardiac tissue either 
causes impaired contraction directly due to the reduced delivery of 
nutrients and oxygen or has caused an area of infarction at some point in 
the past where the cardiac muscle is permanently damaged. The 
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damaged area will not contract with the rest of the ventricle and there 
may even be paradoxical movement further diminishing the efficiency of 
the contraction (Dhalla et al., 1993). 
 
Peripheral oedema is caused by an increase in cardiac preload due to 
backpressure secondary to pump failure. The increased orthostatic 
pressure drives fluid out of the vessels into the tissues, particularly in 
gravity-dependent areas. 
 
1.1.10 Neuroendocrine response 
 
 
In response to the cardiac insufficiency there are several compensatory 
mechanisms. Mechanoreceptors sense arterial under-filling and are 
involved in the regulation of fluid volume. These receptors are present in 
the left ventricle, carotid sinus, aortic arch and renal afferent arterioles. A 
reduction in the stimulation of these receptors results in increased 
sympathetic activity, activation of the renin-angiotensin system, the 
release of arginine vasopressin (anti-diuretic hormone) and increased 
thirst sensation. The renin-angiotensin system increases the reabsorption 
of sodium by the renal system with the accompaniment of water. The 
angiotensin released is also a powerful vasoconstrictor. 
 
The increase in sympathetic tone that results from baroreceptor 
stimulation results in increased myocardial contractility, tachycardia and 
arterial vasoconstriction, and therefore, increased cardiac after-load. It 
also stimulates veno-constriction resulting in increased preload. 
Increased sympathetic activity is beneficial in the short-term for patients 
with cardiac failure as a result of positive chronotropic and inotropic 
effects, but in the long-term the compensatory effects are overcome and 
damage to the cardiac muscle occurs, with remodelling of the myocardial 
tissue over time (Packer, 1995a). 
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Renal vasoconstriction, stimulation of the renin-angiotensin system and 
direct effects on the proximal convoluted tubule lead to renal sodium and 
water retention. Not only is the renin-angiotensin system activity 
increased in patients with heart failure, but also the action of aldosterone 
is more persistent in these patients than in normal controls. If aldosterone 
levels rise in an individual who does not have heart failure, after an initial 
increase in sodium retention the hormonal effect plateaus and sodium 
levels do not increase further even if a high aldosterone is maintained. 
This seems to result from an increased sodium concentration in the 
collecting ducts where the aldosterone causes its main action (Kjaer & 
Hesse, 2001). In patients with heart failure this tolerance of aldosterone 
does not seem to happen and there is continuous stimulation promoting 
sodium retention. These patients have a substantial diuresis in response 
to spironolactone. The use of spironolactone in patients with heart failure 
has been shown to substantially decrease mortality (Pitt et al., 1999). 
 
Progressively deteriorating cardiac function is often associated with 
impaired renal function, described as cardio-renal syndrome. The exact 
mechanism of this relationship remains unknown but there is a correlation 
between decompensated heart failure and a decreased glomerular 
filtration rate (GFR). Impaired renal function in patients admitted to 
hospital with acute heart failure is associated with longer periods of 
hospital stay and a higher mortality (Ronco et al., 2008; Tang & Mullens, 
2010) 
 
A diagram representing the main neurological and hormonal factors 
involved in the regulation of the circulation is presented in Figure 1-1. 
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Figure 1-1 Neurohormonal Circulatory Effects 
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1.1.11 Remodelling 
 
Both the structure and the composition of the cardiac walls change in 
patients with heart failure. There is a reduction in the number of 
myocytes, hypertrophy of the remaining myocytes and changes to the 
make up of the extracellular matrix with increased fibrosis. The changes 
to the myocardium as a result of the remodelling produce a ventricle that 
is larger, more spherical and has thinner walls; this results in a less 
efficient pump with a greater oxygen demand. 
 
Norepinephrine, angiotensin II, endothelin, aldosterone and tumour 
necrosis factor have all been suggested as having a role in the 
progression of this condition. An increased level of epinephrine is thought 
to contribute to myocardial cell hypertrophy. Norepinephrine is toxic to 
cardiac cells causing calcium overload or apoptosis although the 
norepinephrine-induced cell death can be prevented by the use of beta-
blockers (Mann, 1999).  
 
Although these changes, termed remodelling, are agreed to be 
associated with heart failure the level to which they are a result of cardiac 
dysfunction and the degree to which they actually contribute to further 
impairment of cardiac function remains a subject of debate. It has been 
noted that the heart failure phenotype is very similar in all patients with 
heart failure despite the failure being caused by a variety of different 
pathologies (Mann, 1999). There are on-going attempts to synthesise 
pharmacological products that modify the remodelling of the left 
ventricular myocardium. Brain natriuretic peptide may also have some 
anti-fibrotic properties (Ogawa et al., 2001). 
 
Although the pathological processes underlying the common concept of 
heart failure are complex and intertwined, this also presents opportunities 
in terms of therapeutic interventions and diagnostic modalities. 
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1.1.12 Current Guidelines 
 
The American College of Cardiology Foundation / American Heart 
Association (ACC/AHA) guidelines were published in 2009 (Jessup et al., 
2009). The guidelines are mainly directed towards the diagnosis and 
management of chronic heart failure although there is some guidance 
provided regarding patients who have been acutely admitted to hospital. 
The guidelines state that the diagnosis should be based on the signs and 
symptoms suggestive of heart failure but that natriuretic peptide levels 
may be considered if the diagnosis remains unclear. The authors stress 
in the text that the levels of natriuretic peptides should be interpreted with 
reference to the clinical picture and not in isolation. 
 
NICE (2010) has published guidelines for diagnosis and management of 
chronic heart failure. NICE recommends referring patients with suspected 
heart failure who have a history of myocardial infarction for an urgent 
echocardiogram (within two weeks). For patients with no history of 
myocardial infarction, NICE recommends checking BNP or NT-proBNP. 
For those patients with BNP levels greater than 400 pg/ml (NT-proBNP > 
2000 pg/ml) NICE recommend an echocardiogram within two weeks, and 
for patients with BNP levels between 100 and 400 pg/ml (NT-proBNP 400 
– 2000 pg/ml) the recommendation is for an echocardiogram within six 
weeks. The authors state that it is very unlikely for a patient to have heart 
failure if there is no history of MI and natriuretic peptides levels are low. 
The guidelines also recommend obtaining an ECG and considering the 
following tests: chest x-ray; urea and electrolytes; estimated GFR; TFTs; 
LFTs; lipids; glucose; FBC; urinalysis; peak flow or spirometry. 
 
The European Society of Cardiology (ESC) has also published guidelines 
for the diagnosis and management of heart failure (McMurray et al., 
2012). These guidelines suggest that a chest x-ray and ECG be 
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performed initially and then the patient should either undergo 
echocardiography or have BNP (or NT-proBNP) levels checked. The 
guidelines state that heart failure will be the underlying cause in less than 
2% of patients with both acute symptoms and a normal ECG. The ESC 
recommends that patients with a normal ECG and a BNP level <100 
pg/ml should not be diagnosed with heart failure, while patients with 
either an abnormal ECG or a BNP value ≥100pg/ml, should undergo 
echocardiography as further investigation. In the presence of shock or 
haemodynamic compromise, immediate echocardiography is 
recommended. 
 
These institutional guidelines focus on the diagnosis of patients with 
chronic heart failure rather than the acute and possibly primary 
presentation of the patient in extremis. While echocardiography provides 
the closest thing that there is to a gold standard in terms of assessing 
cardiac structure and function, numerous hurdles exist to the provision of 
this service in the average Emergency Department. Other investigations 
are more likely to be performed but the optimum combination of 
investigative and clinical findings to robustly confirm or refute the 
diagnosis of heart failure in the breathless patient presenting to the 
Emergency Department has yet to be defined. 
 
1.1.13 Aims of This Thesis 
 
The intention of this study was to look at the myriad of signs, symptoms, 
historical findings and investigative results related to the condition of 
heart failure in order to quantify the diagnostic utility of each within the 
Emergency Department environment. A systematic review was performed 
to examine all diagnostic studies carried out in this setting, with a 
reasonable reference standard diagnosis of heart failure as the end-point 
of the study. The intention was to synthesise a list of practical diagnostic 
criteria and quantify these in terms of sensitivity and specificity based on 
meta-analysis of data from the available literature.  
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The next step was the execution of original research in this diagnostic 
area in order to allow assessment of the independence of the suggested 
variables.  
 
Using the results of this research, various techniques of combining the 
selected variables were examined in order to determine the optimal 
method in terms of sensitivity and specificity. The ultimate aim was to 
produce a clinical rule to allow the Emergency Physicians to confirm or 
refute the diagnosis of heart failure in the acutely dyspnoeic patient in the 
most reliable and timely fashion. 
 
 
 
The aims this research are summarised thus: 
 
Primary Aim: Develop and assess a clinical decision rule for patients with 
heart failure. 
 
In [adult patients with suspected heart failure] what [diagnostic variables] 
can be combined to [confirm or refute the diagnosis]? 
 
Secondary Aims: 
1.  To conduct a systematic review of medical literature relating to the 
diagnosis of heart failure 
2.  To carry out a meta-analysis of all the potential diagnostic 
variables for heart failure 
3.  To assess whether the selected variables were independent 
predictors of the diagnosis of heart failure 
4.  To explore the different methods for synthesizing a clinical 
decision rule and the assess the optimum rule 
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Chapter 2 Diagnosing Heart Failure 
 
2.1.1 Diagnosing Heart Failure 
 
 
The diagnosis of heart failure is difficult, although interestingly, this only 
appears to have been acknowledged in medical literature following the 
discovery of the natriuretic peptides. Patients with heart failure tend to 
experience waves of exacerbation and remission in terms of their 
symptoms and so findings may not be consistent even within the same 
individual. The associations between smoking and the development both 
heart disease and lung disease is particularly problematic; not only can it 
be difficult to differentiate between chronic obstructive pulmonary disease  
and heart failure, but the patient may well have some elements of both 
present at the time of assessment.  
 
Even in stable patients who have been investigated over a period of time 
the diagnosis may only be made from a combination of signs, symptoms, 
clinical history, investigations and progress over time, including response 
to treatment. More definitive investigations such as echocardiography or 
radionuclide angiography can be difficult to perform, are relatively 
expensive, take time to arrange and may carry some risk to the patient. 
 
The presence of an acute exacerbation of one disease process in a 
patient with multiple pathologies can also cause worsening of the 
patient’s condition with regard to their other conditions. It can be very 
difficult to decide which condition is primarily responsible for the patient’s 
illness in a patient with multiple pathologies. 
 
In attempting to differentiate which patients have presented due to acute, 
decompensated heart failure and which patients have presented due to 
another cause, it is important to recognise that the ‘non-heart failure’ 
group are not a homogeneous group. These patients will all have acute 
pathology causing their dyspnoea and the diagnostic strategies applied to 
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these patients will all have sensitivities and specificities that may be 
affected by their underlying condition.  
 
In modern medical practice, the traditional diagnostic tools of careful 
history taking and exhaustive clinical examination, often using 
eponymous tests to skilfully elicit clinical signs of disease, have been 
supplemented and to some degree replaced by medical investigations. 
The skill of selectively applying these investigations in order to achieve 
the greatest utility, without subjecting the patient to unnecessary 
procedures or even risk of harm, has not always been appreciated 
(Moynihan et al., 2012). 
 
2.1.2 Studies on the Presentation of Heart Failure 
 
Fonseca et al. (2004) recruited 5434 patients who had attended their GP 
for unrelated complaints and assessed the patients to decide if they had 
heart failure. Patients were considered to have possible heart failure if 
they scored 3 or more on the Boston questionnaire or were on diuretics 
for possible heart failure. The Boston criteria are described in a later 
section. Of the attending patients, 1058 patients were selected for further 
investigation and a further 174 of these patients were excluded due to 
technical difficulties in performing an echocardiogram. ECG, chest x-ray, 
laboratory tests and echocardiograms were performed on the remaining 
patients. Heart failure was considered the likeliest diagnosis in 551 of the 
patients. Paroxysmal nocturnal dyspnoea (LR 35.5), orthopnoea (LR 
39.1) and breathlessness walking on flat (LR 25.8) were associated with 
having heart failure but the overall sensitivity was less than 36% as these 
were relatively uncommon findings in the patients who were considered 
to have heart failure. 
 
Certain clinical findings were found to be specific for heart failure but 
were relatively uncommon findings in the patients with heart failure and 
so lacked sensitivity for this condition; the overall sensitivity was around 
10%. The best performing variables are recorded in Table 2-1. 
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Table 2-1 Likelihood Ratios of Diagnostic Findings from Fonseca et al 
(2004) 
Historical or clinical finding Likelihood Ratio 
Paroxysmal Nocturnal Dyspnoea 35.5 
Orthopnoea 39.1 
Breathlessness on walking on the flat 25.8 
JVP >6cm and lower leg oedema  130.3 
Rales on auscultation     23.3 
Ventricular gallop     30.0 
Heart rate >110    26.7 
 
 
Wang et al. (2005) performed a systematic review and meta-analysis on 
studies that examined the diagnosis of heart failure in the Emergency 
Department setting. The methods for the meta-analysis are not described 
in detail but the likelihood ratios and confidences intervals were 
performed using random-effects models based on the delta method. The 
features that best predicted the diagnosis of heart failure were a previous 
history of heart failure (LR 5.8 95% CI 4.1-4.8), the symptom of 
paroxysmal nocturnal dyspnoea (LR 2.6 95% CI 1.5-4.5) and the 
presence of a third heart sound (LR 11, 95% CI 4.9 – 25.0). The features 
that best predicted a cause other than heart failure were the absence of a 
history of heart failure (LR .45 95% CI .38 - .53), the absence of 
dyspnoea on exertion (LR .48 95% CI .35 - .67) and a BNP level less 
than 100 pg/ml (LR .11 95% CI .07 - .16). A summary of the findings of 
this study is provided in Table 2‑ 2. 
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Table 2-2 Results from SR & Meta-analysis from Wang et al (2005) 
Results from the Systematic Review and Meta-analysis by Wang et al. 
Features Predictive of Heart Failure Likelihood Ratio 
Previous history of heart failure LR 5.8 (95% CI 4.1- 4.8) 
Paroxysmal Nocturnal Dyspnoea LR 2.6 (95% CI 1.5 - 4.5) 
Presence of Third Heart Sound LR 11.0 (95% CI 4.9 – 25.0) 
Pulmonary Venous Congestion LR 12.0 (95% CI 6.8 – 21.0) 
Atrial Fibrillation LR 3.8 (95% CI 1.7 – 88.8) 
Features Predicting Absence of HF Likelihood Ratio 
BNP < 100 pg/ml LR 0.11 (95% CI 0.07 -0.16) 
Absence of History of Heart Failure LR 0.45 (95% CI 0.38 - 0.53) 
Absence of Dyspnoea on Exertion LR  0.48 (95% CI 0.35  - 0.67) 
Absence of Rales LR 0.51 (95% CI 0.37 – 0.71) 
Absence of Cardiomegaly on XR LR 0.33 (95% CI 0.23 - .0.48) 
 
Mant et al. (2010) performed a systematic review and meta-analysis of 
the diagnostic features and investigations involved in the diagnosis of 
heart failure in patients in primary care. The authors used the results of 
this study to develop a clinical rule to identify which patients should be 
referred for echocardiography as investigation for possible heart failure. 
The following features had diagnostic utility for this condition: dyspnoea; 
history of myocardial infarction; orthopnoea; oedema; elevated jugular 
venous pressure; cardiomegaly; added heart sounds; lung crepitations; 
hepatomegaly; ECG; and natriuretic peptides. The sensitivity and 
specificity of each of these findings is listed in  along with the 95% 
confidence intervals (CI). The clinical decision rule derived was that in 
patients with suspected heart failure and breathlessness, the patient 
should be sent directly for echocardiography if there was a history of 
myocardial infarction, crepitations on auscultation or if the patient was a 
male with ankle oedema. In the absence of any of these features the 
recommendation was to measure the BNP or NT-proBNP level and refer 
patients with a raised level. 
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Table 2-3 Results of Meta-analysis Mant (2010) 
Feature Sensitivity (95% 
CI) 
Specificity (95% 
CI) 
Diagnostic 
Odds Ratio 
(95% CI) 
Hx of MI 0.26 (0.19-0.37) 0.89 (0.85-0.91) 2.87 (1.71-4.82) 
Dyspnoea 0.83 (0.62 – 
0.94) 
0.54 (0.4 – 0.67) 5.71 (1.78 – 
18.31) 
Orthopnoea 0.44 (0.33 – 
0.56) 
0.89 (069 – 0.96) 6.23 (2.3 – 
16.92) 
Oedema 0.53 (0.44 – 
0.62) 
0.72 (0.62 – 0.8) 2.91 (1.89 - 
4.49) 
Raised JVP 0.52 (0.41 – 
0.63) 
0.7 (0.56 – 0.80) 2.52 (1.51 4.22) 
Added HS 0.11 (0.04 -
0.24) 
0.99 (0.97 -1.0) 13.4 (6.58 – 
27.3) 
Crepitations 0.51 (0.44 – 
0.58) 
0.81 (0.71 – 0.88) 4.34 (2.91 – 
6.47) 
Abnormal 
ECG 
0.89 (0.77 – 
0.95) 
0.56 (0.46 – 0.66) 4.8 (4.36 – 
25.7) 
Abnormal 
CXR 
0.68 (0.40 – 
0.88) 
0.83 (0.66 – 0.93) 10.7 (4.45 – 
25.5) 
CTR 0.67 (0.53 – 
0.78) 
0.76 (0.65 – 0.84) 6.25 (3.6 – 
10.8) 
BNP 0.93 (0.91 – 
0.95) 
0.74 (0.63 – 0.83) 39.5 (21.44 – 
72.6) 
NT-proBNP  0.93 (0.88 – 
0.96) 
0.65 (0.56 – 0.74) 24.6 (14.4 – 
42.2) 
 
 
Madhok et al. (2008) performed a similar systematic review and meta-
analysis in 2008 looking at the diagnosis of heart failure in primary care. 
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There was a substantial overlap with studies included in the Mant paper 
although some differences in perceived utility of the diagnostic features 
as shown in Table 2-4.  
 
 
 
 
 
 
Table 2-4 Results of Meta-analysis Madhok (2008) 
Diagnostic 
Test Pooled PLR (CI) or Range Pooled NLR (CI) or Range 
Clinical 
History       
History of MI 2.86 1.37 - 4.40 0.69 0.48 - 0.89 
Diabetes 2.29 0.86 - 6.65 0.95 0.89 - 1.02 
Hypertension 0.58 (0.39 - 0.87) 1.30 (1.13 - 1.50) 
Male  1.61 (1.41 - 1.84) 0.68 (0.60 - 0.77) 
Symptoms       
Dyspnoea 1.15 (1.09 - 1.21) 0.50 (0.20 - 1.26) 
Orthopnoea 1.59 0.89 - 3.58 0.89 0.77 - 1.04 
PND 1.71 1.12 - 2.23 0.87 0.75 - 0.99 
Signs       
Peripheral 
oedema 1.18 0.96 - 1.48 0.92 0.74 - 1.05 
Abnormal 
Breath 
Sounds 1.53 (1.17 - 1.19) 0.85 0.64 - 0.94 
Raised JVP 4.36 2.66 - 7.44 0.88 (0.83 - 0.91) 
Displaced 
Apex Beat 15.96 (8.24 - 30.93) 0.58 0.35 - 0.93 
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3rd Heart 
Sound 7.34 1.56 - 32.37 0.92 0.77 - 0.96 
Tests       
CXR 1.47 1.19 - 1.71 0.58 0.49 - 0.77 
ECG 2.13 (1.95 - 2.33) 0.27 0.06 - 0.76 
BNP (cut -
offs nearest 
15pmol/L) 1.90 1.26 – 6.20 0.30 0.02 - 0.80 
NT-proANP 2.98 (2.24 - 3.97) 0.18 0.04 - 0.64 
NT-proBNP 1.39 1.09 - 1.80 0.26 0.02 - 0.80 
Combined       
ECG and Hx 
of MI 2.80 (2.43 - 3.24) 0.13 0.03 - 0.48 
 
 
These studies show that while there is a wide variety of signs and 
symptoms that are associated with heart failure, there are no clinical 
variables that either define heart failure or rule it out completely. The 
presence of a displaced apex beat was strongly predictive of heart failure 
although was only assessed in two studies and was found in a very small 
number of patients. Natriuretic peptide concentrations and the presence 
of abnormal ECGs had a similar value in terms of ruling out this 
syndrome. Although there are common themes within the findings of 
these studies there is also significant variation within the results and the 
reasons for this are not clear. It is not clear if the best performing 
variables are independent of each other. 
 
2.1.3 Clinical History 
 
In keeping with the fluctuating nature of this condition, patients with heart 
failure will often have a history of previous attendances with the same 
condition. The majority of patients with heart failure also have a history of 
ischaemic heart disease with angina or a previous myocardial infarction. 
A history of hypertension is also a significant factor, as is diabetes. Other 
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associated conditions include peripheral vascular disease, valvular heart 
disease and impaired renal function (Acanfora et al., 1998). 
 
Davie et al. (1997) looked at 259 patients referred by their General 
Practitioner to an outpatient echocardiography service with suspected 
chronic heart failure. 41 patients were found to have significant left 
ventricular systolic dysfunction on echocardiography. The positive 
predictive factors were past medical history of myocardial infarction 
(sensitivity 59%, specificity 86%, PPV 44%, NPV 92%) and hypertension 
(sensitivity 20%, specificity 65%, PPV 10%, NPV 81%). Cigarette 
smoking was sensitive but had poor predictive value due to high 
prevalence (sensitivity 73%, specificity 41%, PPV 19%, NPV 89%). The 
use of diuretic as a discriminator performed in a similar manner 
(sensitivity 73%, specificity 41%, PPV 19%, NPV 89%). 
 
In the study by Wang et al. (2005) the historical features that contributed 
to the diagnosis of heart failure were examined. A previous history of 
heart failure (LR 5.8; 95% CI 4.1-8.0), myocardial infarction (LR 3.1; 95% 
CI 2.0-4.9) or coronary artery disease (LR 1.8; 95% CI 1.1-2.8) was 
predictive of heart failure. Absence of any of these conditions also 
reduced the likelihood of heart failure being the cause of the patient’s 
dyspnoea. 
 
2.1.4 Clinical Examination 
 
A variety of clinical findings are associated with the condition of heart 
failure and form part of the standard cardiovascular examination as 
described in any medical textbook. The diagnostic value of the presence 
or absence of these disease markers is less easy to ascertain from these 
texts. 
 
A review article by Cleland and Habib (1996) on the assessment and 
diagnosis of heart failure suggests that pulse, blood pressure, jugular 
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venous pressure, the presence of pitting oedema, the apex beat and 
parasternal heave, the presence of a third heart sound and cardiac 
murmurs all have some diagnostic value. 
 
The study by Davie et al. (1997) found a displaced apex beat to be the 
best clinical sign (sensitivity 66%, specificity 96%, PPV 75%, NPV 94%). 
Orthopnoea (sensitivity 22%, specificity 74%, PPV 14%, NPV 83%) and 
paroxysmal nocturnal dyspnoea (sensitivity 39%, specificity 80%, PPV 
27%, NPV 87%) were of limited value.  
You need to make a comment on some of the figures e.g. 14NPV etc. 
 
Drazner et al. (2001) performed a retrospective analysis of the data from 
a large study looking at the benefit of enalapril in the treatment of heart 
failure. Multivariate analysis of this data in patients with a diagnosis of 
heart failure suggested that the presence of a raised JVP or a third heart 
sound are associated with an increased risk of death or hospitalisation for 
heart failure.  
 
Knudsen, Riis, et al. (2004) examined a subgroup of patients originally 
recruited to the Breathing Not Properly study, by only including patients 
who were not missing any of their clinical data (Maisel et al., 2002). This 
limited the new data set to 880 patients out of the original 1586 patients. 
The diagnostic value of the following clinical features was calculated from 
this subset of patients as shown in Table 2-6. 
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Table 2-5 Diagnostic Value of Clinical Findings, Knudsen (2004) 
 Sensitivity  Specificity 
Hx of HF 62 87 
Previous MI 43 87 
Orthopnoea 66 57 
JVP 38 90 
S3 Gallop 38 90 
Rales 59 77 
 
 
 
2.2 Investigations 
 
2.2.1 The Electrocardiograph 
 
 
Electrocardiograms (ECG) represent the flow of electrical energy through 
the cardiac tissue as observed from specified points on the surface of the 
body. As a diagnostic test they are superb in providing diagnosis-
confirming findings, while being cheap, fast, safe, portable and non-
invasive. ECGs are often abnormal in patients with heart failure, which 
reflects the fact that the conducting system is traversing diseased or 
damaged tissue. Although it is uncommon to have a completely normal 
ECG in a patient with heart failure, there are no findings that are specific 
to heart failure (Davie et al., 1997). The patient with heart failure is 
usually tachycardic and may be in atrial fibrillation or have another 
rhythmic disturbance. Changes associated with left ventricular 
hypertrophy are commonly present and changes suggestive of ventricular 
strain may also be present. The ECG may also show inter-ventricular 
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conduction delay, which can be associated with ventricular dysynchrony. 
The diagnosis of acute myocardial infarction must be considered in the 
patient with a sudden onset of cardiogenic symptoms. 
 
Davie et al. (1996) investigated 534 patients referred by GPs to an open-
access echocardiography service and found that an ECG was a very 
good predictor of LV dysfunction. When interpreted by the cardiologists 
this test had a sensitivity of 93.6% and a specificity of 61.4%. 
 
Houghton et al. (1997) examined the ECGs from 200 patients with 
suspected heart failure who had been referred to a heart failure clinic. 
The ECGs were read and reported by a cardiologist and two General 
Practitioners. The patients all underwent echocardiography and were 
reported as having normal or impaired LV function. The ECGs were 
reported simply as normal or abnormal. There was agreement between 
the cardiologists report and that of the two GPs, in 165 out of 200 ECGs 
although no Kappa scores were provided. The presence of an abnormal 
ECG, when interpreted by the cardiologist, had a sensitivity of 89.1% and 
a specificity of 45.7% in predicting LVSD.  
 
Brooksby et al. (1999) looked at the QT parameters on ECGs in 554 
patients with known heart failure who were followed up for over one year. 
The QT interval length was significantly associated with all-cause 
mortality although this was not demonstrated to be an independent 
predictor on multivariable analysis.  
 
Shamim et al. (1999) retrospectively looked at data from 241 patients with 
heart failure. On univariate analysis by the Cox proportional Hazard 
method both inter-ventricular conduction delay (IVCD) and a prolonged, 
corrected QT interval were shown to be independent predictors of 
mortality over a mean follow-up period of 31 months. IVCD had better 
predictive power than the corrected QT interval. 
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Baldasseroni et al. (2003) analysed primary follow-up data from the 
Italian Registry of CHF. They found that the presence of left bundle 
branch block (LBBB) on the ECG was associated with a significantly 
higher one-year-mortality rate than those patients without (16.1% vs. 
11.9%). Right bundle branch block (RBBB) was not associated with a 
higher mortality rate.  
 
Ng et al. (2003) looked at a random selection of 1360 patients from 
Leicestershire in the UK who underwent investigation for possible left 
ventricular dysfunction. The patients were stratified according to GP list 
size and deprivation scores. All of the recruited patients had 
echocardiography, resting ECG, assessment of ponderal index and blood 
sampling for natriuretic peptide levels. Significant factors on univariate 
analysis were BNP levels, gender, major ECG abnormality (Q waves, 
LVH, AF, LBBB), a history of ischaemic heart disease and plasma 
creatinine levels. Sensitivity of the presence of major ECG abnormalities 
as a predictor of left ventricular dysfunction was 88%.  
 
Khunti et al. (2004) performed a systematic review published in 2004 and 
found four studies examining the value of a normal or abnormal ECG in 
determining which primary care patients had heart failure. The sensitivity 
from the included studies varied from 73% to 91% while the specificity 
ranged from 20% to 65%. 
 
Kruger et al. (2004) looked at 128 patients referred for an 
echocardiogram due to suspected heart failure. Left ventricular systolic 
dysfunction (LVSD) was defined as an ejection fraction less than 50%. 
Cardiac catheterisation was carried out in all of the patients. They found 
that a cut-off for the QRS complex of greater than 0.12s had a sensitivity 
of 76% and a specificity of 95%. Sixty-six of the one hundred and twenty-
eight patients referred were diagnosed with LVSD.  
 
Fonseca et al. (2004) explored a random selection of 6300 patients over 
the age of 25 years to examine the prevalence of heart failure within the 
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population of Portugal. Patients who were suspected of having heart 
failure were underwent chest radiography, ECG, blood tests and an 
echocardiogram. Seventeen per cent of the patients were excluded from 
the study, as they did not have an echocardiogram performed. In the 
selected group of patients, the finding of an abnormal ECG had a 
sensitivity of 80% and a specificity of 40% for heart failure.  
 
Knudsen, Omland, Clopton, et al. (2004) examined a subset of the data 
from the Breathing Not Properly study where more complete data was 
available to determine the value of the chest x-ray, ECG and clinical 
findings. These authors only examined the findings for 880 patients with 
complete data out of the 1580 patients recruited for the larger study. The 
gold standard was the consensus opinion of two cardiologists who 
reviewed all the results and responses to treatment. The presence of an 
abnormal ECG was associated with a sensitivity of 58% and a specificity 
of 78% for the end-diagnosis of heart failure. 
 
Murkofsky et al. (2005) found that the presence of a prolonged QRS 
interval suggests LV dysfunction. A QRS segment duration greater than 
0.10s had specificity of 83.6% but a sensitivity of 43.8%. Increasing the 
cut-off value of the QRS duration up to 0.12s increased specificity to 
99.3% but decreased sensitivity to 13.8%. 
 
In the meta-analysis by Wang et al. (2005), the presence of AF was the 
most important factor with a LR of 3.8 (95% CI 1.7-8.8). The presence of 
a completely normal ECG decreased the likelihood of heart failure with a 
LR of 0.6 (95% CI 0.47-0.88) but there were no specific findings 
associated with the condition.  
 
The variability demonstrated by the findings of these studies is likely to 
reflect the diversity of the aetiology of heart. Although it is logical to 
assume that heart failure is unlikely to occur in a non-diseased heart and 
that cardiac disease will often cause ECG changes it is difficult to define 
anything stronger than a positive correlation. 
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2.2.2 The Chest X-Ray 
 
Pulmonary vascular congestion occurs as a result of impaired pumping 
by the left ventricle resulting in an increased left atrial pressure. This 
leads, in turn, to pulmonary hypertension. In the absence of heart failure, 
more blood is distributed to the lower parts of the pulmonary circulation 
and less to the upper vessels due to gravitational pull. In pulmonary 
hypertension this pattern of distribution is lost as the increased pressure 
causes the upper lobe vessels to dilate. Once the mechanisms to 
compensate for increased hydrostatic pressure are overcome, excess 
fluid accumulates in the interstitium before eventually accumulating within 
the alveoli and pleural spaces. This accumulation of the excess fluid 
causes distinctive patterns on the chest radiograph (Chen, 1992).  
 
Madsen et al. (1984) looked at 229 patients who were discharged 
following a myocardial infarction, defined as a history of chest pain and a 
rise in creatinine kinase. All patients had a chest x-ray and radionuclide 
ventriculography done prior to discharge. An ejection fraction less than or 
equal to 0.51 was considered abnormal. The presence of pulmonary 
venous congestion on chest x-ray was found to have a sensitivity of 
20.1% and a specificity of 91.6% for predicting a reduced ejection 
fraction. Cardiothoracic ratio (CTR), the relationship between the internal 
thoracic diameter and the diameter of the heart at its widest point, was 
also recorded for each patient. The internal diameter of the chest was 
measured at the highest point of the left hemi-diaphragm. The presence 
of a CTR greater than, or equal to 0.50, was considered abnormal. This 
had a sensitivity of 47.3% and a specificity of 65.6%. 
 
A paper by Henriksson et al. (1990) examined the level of agreement 
between three radiologists in reporting chest x-rays performed on 27 
patients with suspected heart failure. The paper was originally designed 
to look at differences in two different types of film-screen for viewing the 
x-rays so each patient had two x-rays taken, a few minutes apart, with 
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each film system. The radiologists were asked to grade the presence of 
congestive heart failure from 0 to 2 for each x-ray. In fact, the study 
showed poor correlation between even the same radiologists reporting on 
the same patient with Kappa scores of 0.6, 0.42 and 0.1 for three 
radiologists. There was no consistent difference based on the type of film 
used. Comparing the three radiologists results with each other gave 
Kappa scores of 0.26, 0.18 and 0.02. 
 
Knudsen, Omland, Clopton, et al. (2004) looked at the data from the 
Breathing Not Properly study to determine the value of the chest x-ray. 
This article only included 880 patients with complete data out of the 1580 
patients recruited for the main study. A radiologist from the recruiting 
hospital reported the x-rays. The gold standard was the consensus 
opinion of two cardiologists who reviewed all the results and responses to 
treatment. They found that the presence of cardiomegaly had a sensitivity 
of 79% and a specificity of 80% while cephalisation of the vessels had a 
sensitivity of 41% but a specificity of 96%. 
 
In a study by Fonseca et al. (2004), 6300 patients over the age of twenty-
five years were assessed as to whether they may have heart failure, the 
finding of an abnormal chest x-ray had sensitivity of 57% and a specificity 
of 78%. The most sensitive component of chest x-ray abnormality was 
the presence of cardiomegaly with an enlarged cardio-thoracic ratio 
greater than 0.50, which provided a sensitivity of 54% with a specificity of 
79%. Pulmonary vessel cephalisation and lung interstitial oedema both 
had had a sensitivity of 18% with specificities of 94% and 95% 
respectively. 
 
Wang et al. (2005) also evaluated the diagnostic use of chest x-rays. The 
authors included data from seven studies and concluded that the finding 
of pulmonary venous congestion (LR 12.0, 95% CI 6.8-21.0) and 
cardiomegaly (LR 3.3, 95%CI 2.4-4.7) increased the chances of the 
patient having heart failure. Conversely the absence of cardiomegaly had 
a negative LR of 0.33 (95% CI 0.23-0.48) as did the presence of 
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pneumonia or hyperinflation although these were only mentioned in one 
of the included studies. 
 
Høilund-Carlsen et al. (2005) also looked at patients who had suffered a 
myocardial infarction and who underwent both chest x-ray and 
radionuclide ventriculography on the same day, during the second week 
following their infarction. The presence of an enlarged left ventricle, as 
defined by a single radiologist on the basis of their chest x-ray had a 
sensitivity of 63% and a specificity of 68% for predicting a LVEF of 
<0.53%. 
 
There are two issues associated with determining the presence of 
pulmonary oedema on chest x-ray in order to diagnose heart failure; the 
first is the degree of subjectivity in interpreting the film which is 
demonstrated by the relatively poor level of agreement reported. These 
findings are consistent with other studies examining the level of 
agreement between radiologists reporting on chest x-ray findings for 
various different conditions. (Badgett et al., 1996; Tudor et al., 1997; 
Robinson et al., 1999). It is reasonable to assume that similar levels of 
disagreement will exist if one were to assess the interpretation of chest x-
rays by Emergency Physicians rather than radiologists. Although there is 
some suggestion that training can improve consistency in the reporting of 
the presence of the signs of cardiac failure this would limit the 
applicability of any decision pathway that relied upon it.  
The second factor is that retrospective studies suggest that up to 20% of 
patients with a discharge diagnosis of heart failure do not have pulmonary 
oedema on their initial chest x-ray (Collins, Lindsell, Storrow, et al., 2006). 
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2.2.3 Blood Tests 
 
Several blood tests may be abnormal in the patient with heart failure, and 
this may provide useful information suggestive of the underlying aetiology 
although none are pathognomonic. For example, patients may present 
with an exacerbation of heart failure due to anaemia or hyperthyroidism 
(Struthers, 2000). There is also a strong, though incompletely 
understood, association between renal impairment and heart failure. 
Other compounds levels, such as cholesterol levels, may not aid in the 
acute diagnosis but may be relevant in this patient group. 
 
 
2.2.4 Echocardiography 
 
 
 
Figure 2-1 Echocardiography 
 
The AHA/ ACC Guidelines (Jessup et al., 2009) describe 
echocardiography as the single most useful diagnostic test in the 
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evaluation of patients with heart failure. Echocardiography uses 
ultrasound technology to allow an evaluation of the heart in terms of 
structure and function. The reflection of high-frequency sound waves is 
used to make various measurements during the contraction cycle. Two-
dimensional measurements of the heart walls and chambers can be 
recorded at different stages in the cardiac cycle and the rate of flow of 
blood during the contraction can be measured using the Doppler 
phenomenon. This provides information throughout the cardiac cycle and 
presents both systolic and diastolic function (Porter et al., 1990; 
Kirkpatrick et al., 2007). 
 
Although standard echocardiography displays a series of two-dimensional 
images to represent a three-dimensional object, the combination of 
different views and dynamic imaging is the best representation available 
of cardiac function, in life, to allow estimations of the cardiac size and 
function. Various methods are used to quantify the ejection fraction, 
although these are inherently inaccurate, as assumptions have to be 
made regarding the shape of the ventricle; it is necessary to represent a 
three-dimensional form by a series of two-dimensional measurements 
(Bellenger et al., 2000). It is also possible to obtain a measurement of the 
degree of cardiac contraction in various regions of the cardiac muscle 
wall; identifying localised areas abnormal contraction can identify the area 
of pathology (Zimmerman & Vacek, 2011). 
 
The quality of the images recorded depends on the patient body habitus, 
the quality of the equipment and the operator experience and skill: there 
is also an element of operator-dependent variability in the reporting of the 
results (Bellenger et al., 2000). Patient cooperation is required to acquire 
optimal images and this may be difficult to obtain in the acutely ill patient. 
 
Trans-thoracic echocardiography is performed through the anterior chest 
wall. This is non-invasive but depends on obtaining images through 
echocardiographic ‘windows’ between ribs and through the patient’s lung 
tissue. Trans-oesophageal echocardiography, in which the probe is 
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passed down the patient’s oesophagus, produces better views from the 
other side of the heart but usually requires the administration of sedation 
to be tolerable.  
 
Techniques allow the use of echo to look at myocardial contraction, 
valvular structure and function, pericardial pathology and pathological 
consequences of myocardial infarction or ischaemia. Measurements 
obtained allow an estimate of cardiac output and pulmonary artery 
pressure. The investigation can also be repeated in the same patient over 
time to assess progression of the disease process or response to 
treatment. The echocardiogram findings suggestive of cardiac disease 
are presented in Table 2-6. This is based upon a table from the ESC 
Heart Failure Guidelines (McMurray et al., 2012). 
 
Diastolic failure is due to the inability of the heart muscle to relax fully to 
allow diastolic filling of the heart. This form of disease is more common in 
elderly patients and, although it presents with similar symptoms, it can be 
more difficult to diagnose, as the echocardiogram findings associated 
with this variation are subtler (Aurigemma et al., 2001). 
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Table 2-6 Abnormal Echocardiogram Findings  
Common Echocardiographic Abnormalities  
Parameters related to systolic function 
LV ejection fraction Decreased 
LV fractional shortening Decreased 
LV regional function Dyskinesia, akinesia 
LV end-diastolic size Increased 
LV end-systolic size Increased 
Parameters related to diastolic function 
LV diastolic dysfunction parameters Abnormal mitral inflow pattern 
LA volume index Increased 
LV mass index Increased 
 Parameters related to valvular function 
Valvular structure / function Stenosis or regurgitation 
Other parameters  
RV function Decreased 
Tricuspid regurgitation Increased 
Systolic pulmonary artery pressure Increased 
 Inferior vena 
cava 
Dilated, no respiratory collapse 
Pericardium Effusion, haemopericardium, 
calcification 
 
 
 
2.2.5 Invasive Techniques 
 
Cardiac output can also be measured by invasive techniques although 
these methods have the potential disadvantages; the insertion of a 
central line exposes the patient to risks of harm such as bleeding or 
infection and it is possible that the presence of line within the vessel or 
chamber lumen may itself affect the measurements (Binanay et al., 2005; 
Lavdaniti, 2008; Mathews & Singh, 2008). 
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Pulmonary Artery Balloon Flotation Catheterisation is an invasive 
examination that can confirm the diagnosis of heart failure, and 
sometimes define the exact cause. It is possible to measure the 
pulmonary artery occlusion (wedge) pressure, central venous pressure, 
right ventricular end-diastolic pressure and cardiac output. Although there 
is a theoretical benefit of using PAC monitoring to confirm the diagnosis 
and guide therapy there are also risks associated with the invasive nature 
of this technique. Overall no survival or outcome benefit was 
demonstrated when this monitoring was applied to patients with heart 
failure in a randomised controlled trial (Vesely, 2003; Binanay et al., 
2005). 
 
2.2.6 Magnetic Resonance Imaging 
 
Magnetic resonance imaging can provide still and even moving images of 
the heart as an assessment of cardiac function. Unfortunately the 
procedure requires the patient to lie flat within an enclosed space for a 
prolonged period of time (Hundley et al., 1999). This requirement, in 
addition to the limited monitoring that is available for these patients during 
this time, means that this investigation is not practical for the acute 
setting. 
 
2.2.7 Nuclear Studies 
 
Radionuclide studies are useful for measuring both systolic and diastolic 
cardiac function (Klocke et al., 2003). This study involves labelling the red 
blood corpuscles from a patient, and then measuring the radiation emitted 
during the cardiac cycle. The investigation is recommended for patients 
with suspected heart failure who cannot be investigated by other means, 
for example echocardiography. Due to the time that this procedure takes, 
the equipment that it requires, and the expertise necessary to interpret 
the results, it is not practical to perform this in an acute setting (Hendel et 
al., 2009). 
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2.2.8 Peripheral Temperature 
 
Temperature has been found to be a significant marker of prognosis in 
terms of mortality and serious complications in patients admitted to 
hospital due to cardiac failure (Casscells et al., 2005; Ahmed et al., 
2008). It is not clear why this should be the case but is possible that this 
is a marker of other underlying conditions causing the exacerbation of the 
cardiac failure (Payvar et al., 2006). 
 
One paper by Clarke et al. (2005) has attempted to define cardiac from 
non-cardiac causes of shortness of breath by the difference in peripheral 
versus central temperature. This small study did suggest a significant 
difference but contained small numbers and did not assess variations in 
the acquisition of the peripheral temperature. 
 
2.2.9 Response to Treatment 
 
Theoretically the response of a patient to a particular treatment could be 
used as part of a reference standard for a condition if the effect is specific 
for that condition. In practice, several interventions are likely to be applied 
to any patient at the same time and so it is difficult to elicit which, if any, 
the patient derived benefit from. Obviously, the response to treatment for 
any individual is only known after the treatment has been commenced 
and so is of no value in the emergency setting. 
 
2.2.10 Scoring Systems for the Diagnosis of Heart Failure 
 
As it has been recognised that there is no single diagnostic feature that 
can identify patients with heart failure with any consistency, attempts 
have been made to combine relevant variables into scoring systems in 
order to facilitate the diagnosis process. 
 
The Framingham Criteria for Congestive Heart Failure were derived from 
the long established, and still on-going cohort study based in the 
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eponymous city (McKee et al., 1971). The population of 5209 adults 
present in Framingham in 1948 were recruited as a prospective cohort. A 
biennial assessment was carried out on each person in the study that 
consisted of a medical history, examination and laboratory tests. The 
criteria to define heart failure were derived from the observations made of 
this population over the first twenty-three years of this study (McKee et 
al., 1971; Tamura et al., 1996). In the Framingham classification system, 
the diagnosis of CHF requires that either 2 major criteria or 1 major and 2 
minor criteria be present concurrently. This is shown in Table 2-7. Minor 
criteria are accepted as evidence of heart failure only if they cannot be 
attributed to another medical condition. The authors found the criteria to 
be 100% sensitive and 78% specific. 
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Table 2-7 Framingham Criteria for Heart Failure 
Framingham Criteria for Heart Failure 
Major Criteria   
Paroxysmal nocturnal dyspnoea 
Neck vein distension 
Rales 
Radiographic 
Acute pulmonary oedema 
Neck vein distension 
Circulation time of 25 seconds 
Hepato-jugular reflux 
Pulmonary oedema or visceral congestion at autopsy 
Central venous pressure greater than 16 cm water 
Weight loss of 4.5 kg in 5 days in response to treatment 
Minor Criteria  
Bilateral ankle oedema 
Nocturnal cough 
Dyspnoea on ordinary exertion 
Hepatomegaly 
Pleural effusion 
A decrease in vital capacity by one third the maximal value recorded 
Tachycardia (rate of at least 120 bpm) 
 
Killip and Kimball (1967) published a paper promoting the use of coronary 
care units for patients who had suffered a myocardial infarction.  Two 
hundred and fifty patients were treated either on a regular ward or a 
coronary care unit and the mortality rate of each group was compared. In 
order to keep the groups comparable, the severity of their condition was 
stratified using a clinical classification score derived by the authors: the 
Killip Classification as shown in Table 2-4. 
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Table 2-8 Killip Classification of Severity of Heart Failure 
Class Definition 
I No clinical signs of heart failure 
 
II Rales or crackles in the lungs an S3, and elevated jugular 
venous pressure. 
 
III Frank acute pulmonary oedema 
 
IV In cardiogenic shock or hypotension measured as systolic 
blood pressure lower than 90 mmHg), and evidence of 
peripheral vasoconstriction (oliguria, cyanosis or sweating). 
 
 
The Boston criteria for heart failure were originally derived from 96 
patients undergoing right heart catheterisation. A score greater than 4 
was found to correspond with a pulmonary capillary wedge pressure 
greater than 12mmHg with a sensitivity of 90% and a specificity of 85%. A 
maximum of 4 points allowed from each category leading to a maximum 
possible score of 12. 8-12 points is considered definite heart failure, 5-7 
possible heart failure and <5 unlikely to be heart failure (Carlson et al., 
1985). 
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Table 2-9 Boston Criteria for Heart Failure 
Criterion Point value 
Category 1: history  
Rest dyspnoea 4 
Orthopnoea 4 
PND 3 
Dyspnoea walking on flat 2 
Dyspnoea while climbing 1 
Category II: physical examination 
Heart rate abnormality (1pt 91-110bpm, 2 pts 
>110bpm) 
1 or 2 
JVP (2 pts if >6cmH2O, 3 pts >6cm H2O and 
hepatomegaly) 
2 or 3 
Lung crackles (1pt basilar, 2pts more than 
basilar) 
1 or 2 
Wheezing 3 
Third heart sound 3 
Category III: chest radiography 
Alveolar pulmonary oedema 4 
Interstitial pulmonary oedema 3 
Bilateral pleural effusion 3 
Cardiothoracic ratio > 0.50 3 
Upper zone flow redistribution 2 
 
Remes et al. (1991) validated the Boston criteria, applying it to 88 
patients suspected by their GP to have heart failure. They compared it 
against their own system that included clinical and radiological findings, a 
respiratory physician’s opinion and response to treatment over a six-
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month period. They found that the diagnosis of ‘definite’ heart failure by 
the Boston criteria, i.e. a score of 8 or greater had a sensitivity of 80% 
and a specificity of 92% using their own final diagnosis as the reference 
standard. 
 
Eriksson, Caidahl, et al. (1987) used the prospective population of study 
of cardiovascular disease, the Study of Men Born in 1913 to construct a 
scoring index to differentiate causes of dyspnoea. Dyspnoea graded 
according to Fletcher questionnaire from no dyspnoea on exertion (grade 
0) to dyspnoea at rest (grade 4). 
 
Di Bari et al. (2004) compared four methods of diagnosing heart failure in 
unselected adults in the community. The authors collected data on people 
aged 65y or over and applied the criteria from the Framingham, Boston 
and Gothenburg studies and also from the guidelines published by the 
European Society of Cardiology. The authors evaluated the patients and 
measured left ventricular mass index, LVEF, left atrium systolic 
dimension, lower extremity motor disability, summary physical 
performance score and a six-minute walk test. Predictive validity was 
assessed with follow up looking at cardiovascular mortality, incident 
disability and heart failure related hospitalisations. All criteria suggested a 
similar prevalence of heart failure in the population tested. Framingham 
and Boston criteria were better at correlating with the findings of the 
investigations. The Boston criteria were superior in indicating risk 
adjusted cardiovascular death.  
 
Kim (2006) suggested that the Framingham Criteria was impractical and 
proposed a new modified system The Minnesota Heart Failure Criteria. 
This abridged form of the Framingham Criteria was derived using latent 
class analysis (LCA). LCA is described as a probabilistic approach to 
disease classification that allows for, and can potentially identify more 
precise categories of disease conditions. The authors calculated the 
criteria retrospectively using data from patients who had already been 
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recruited into the Minnesota heart failure study or the Minnesota post-
myocardial infarction study. 
 
Kim (2006) validated their diagnosis of heart failure on the basis of the 
mortality rate by making the assumption that patients with heart failure 
would have a higher mortality rate than patients without the condition 
within a two-year follow up period. The authors stated, ‘in the absence of 
a perfect gold standard, a diagnostic test can be validated by comparing 
its results against a known consequence of a disease.’  
 
The variables were taken from the Framingham Criteria with the addition 
of left ventricular ejection fraction (LVEF). They consisted of: dyspnoea at 
rest or on exertion; pulmonary rales; cardiomegaly; interstitial or 
pulmonary oedema; the presence of a third heart sound; tachycardia; and 
LVEF. A five-class model had a good fit to the observed data. Class 1 
was ‘non-cases’. Class 5 patients almost all had dyspnoea, pulmonary 
rales and cardiomegaly. They were also very likely to have a reduced 
LVEF and a third heart sound. These patients were considered ‘advanced 
heart failure’. This system requires the statistics software SAS© in order 
to calculate which group the patient is most likely to belong to. This 
system does not appear to be practical for use in an emergency setting. 
The link to the required software was not functioning at the time of 
checking (February 2014).  
 
2.2.11 Assessing the Severity of Heart Failure 
 
The New York Heart Association (NYHA) developed a classification of 
patients with heart disease on the basis of the relation between 
symptoms and the amount of effort required to provoke them (Kossman, 
1964). It was originally derived in 1928 but updated and modified in 1994. 
This system was designed for the classification of the severity of the 
condition rather than performing any diagnostic function. Although the 
process of assigning numerical values to subjective findings has obvious 
limitations, this classification is nonetheless useful to grade the severity of 
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the condition thereby allowing comparison of groups of patients, as well 
as describing the condition of the same patient at different times. In 
addition, the NYHA class has proved to be a strong, independent 
predictor of survival in patients with chronic heart failure although it was 
intended for use in patients with known cardiac disease rather than as a 
diagnostic tool. The severity of the patients’ heart failure may be 
symptomatically classified according to the amount of effort needed to  
 produce dyspnoea, as described in  
 
 Table 2-10. 
 
 Table 2-10 NYHA Classification of Heart Failure 
  
Class I No limitation of physical activity 
Ordinary physical activity does not cause undue fatigue, dyspnoea, or 
palpitation. Patients have symptoms only at exertion levels similar to 
those of relatively healthy individuals 
Class II Slight limitation 
Patients with class II disease are comfortable at rest. Ordinary physical 
activity results in fatigue, palpitation, dyspnoea, or angina. Patients 
exhibit symptoms with ordinary exertion. 
Class III Marked limitation 
Although patients are comfortable at rest, less-than-ordinary activity 
leads to symptoms. Patients exhibit symptoms with minimal exertion. 
Class IV Unable to carry out any activity 
without discomfort 
Symptoms of congestive failure are present even at rest. With any 
physical activity, increased discomfort is experienced. 
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2.2.12 Diagnosing Diastolic Heart Failure 
 
Diastolic failure occurs due to the inability of the heart muscle to relax 
fully to allow diastolic filling of the heart. This form of disease is more 
common in elderly patients and, although it presents with similar 
symptoms, it can be more difficult to diagnose, as the echocardiogram 
findings associated with this variation are subtler (Aurigemma et al., 
2001) 
 
Diastolic heart failure is diagnosed when the syndrome of heart failure 
arises in the absence of significant abnormality of left ventricular 
contractile function. These patients are often excluded from heart failure 
trials and so there is less literature available regarding this condition. 
 
Diastole is traditionally divided into four phases: (1) Isovolumic relaxation; 
(2) early diastolic filling; (3) diastasis and; (4) atrial contraction. During 
isovolumic relaxation the myosin and actin cross-bridges within the 
cardiac myocytes must be dissolute. This requires the rapid uptake of 
calcium in order to reduce cytosole levels. This is an active process 
facilitated by the sarcoplasmic reticulum. Some myofilaments may 
maintain the cross-bridges even with a lower calcium concentration. In 
the failing human heart, myofilaments and calcium exchange pumps work 
more slowly which may be responsible for the slowing of left ventricular 
relaxation. 
 
Early diastolic filling begins as the ventricular pressure drops and the 
mitral valve opens. Around 80-85% of the LV filling usually happens at 
this point. Diastasis and the contraction of the atria then occur. The 
effectiveness of the atrial contraction is dependent on the LV compliance 
but also the atrial preload, heart rate, atrial contractility and atrial 
geometry. The atrial contribution may be increased in impaired LV 
function or during exercise. 
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The clinical features of diastolic heart failure cannot be reliably 
differentiated from systolic heart failure. A definitive diagnosis requires 
cardiac catheterisation. Using Doppler echocardiography to measure 
blood velocity across the mitral valve usually gives a characteristic 
appearance with a large E peak representing rapid early diastolic filling 
followed by a smaller A peak during atrial systole as shown in Figure 2-2. 
If LV relaxation slows then the atrial component becomes more important 
and there is reversal of the E/A ratio (van Kraaij et al., 2002). 
 
 
Figure 2-2 Echocardiography Demonstrating Diastolic Dysfunction 
 
The European Study Group on Diastolic Heart Failure has suggested the 
following criteria for the diagnosis of primary diastolic heart failure. 
 
1. Presence of signs or symptoms of congestive heart failure 
2. Presence of normal or mildly reduced left ventricular systolic function 
3. Evidence of abnormal left ventricular relaxation, filling, diastolic 
distensibility and stiffness (Paulus, 1998). 
 
75 
 
2.2.13 Emergency Department Echocardiograms 
 
 
While echocardiography is not routine practice in Emergency 
Departments in the UK, there have been some studies evaluating the 
utility of this test when seeking specific pathology such as pericardial 
effusion (Mandavia et al., 2001; Tayal & Kline, 2003). The value of 
echocardiography in the acute presentation by the Emergency Physician 
to assist in the diagnosis of heart failure has not been assessed.   
 
A major limitation to the introduction of this investigation is the importance 
of operator skill. The individual operator will improve with time and 
experience but will be an issue for the introduction of a new service. 
Other limitations of this intervention are associated with the patient, either 
in terms of comorbidities such as atrial fibrillation or emphysema or as a 
result of body habitus that made the scans more difficult to obtain and 
interpret. The acute nature of the presenting illness in these patients may 
also mean that they are unable to assist with the investigation by 
changing posture or controlling their breathing. Other restraints in using 
this investigation in the Emergency Department environment included the 
service pressure that limited the time available to perform this 
examination. 
 
 
 
2.2.14 Summary 
 
This chapter introduced the rational for the diagnostic tests, findings and 
strategies that are currently used to make the diagnosis of heart failure. 
The reported diagnostic utility of these components demonstrates 
considerable variation in the performance of these variables that may 
depend on the population studied, the acuity of their symptoms and the 
skill and experience of the interpreting clinician. The independence of the 
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available variables, how they perform in isolation or combined with other 
diagnostic variables has not been assessed. 
 
Although various findings are known to be associated with the syndrome 
of heart failure, the individual test or combination of tests that can provide 
a definitive answer early in the patients’ journey has yet to be discovered. 
Scoring systems and diagnostic criteria have been derived but have an 
emphasis on the diagnosis of chronic heart failure, and so may be of 
limited value in the acute setting. 
 
The most recent innovation in this diagnostic field has been the discovery 
of the value of natriuretic peptide levels to aid in the diagnosis of heart 
failure. As this is a novel investigation, not routinely used in the UK 
setting, this variable has been described in further detail in the following 
chapter.  
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Chapter 3 The Natriuretic Peptides 
 
3.1.1 Introduction 
 
Biomarkers, measurable biological markers of a pathological process, 
have established a growing role in modern medical practice over the last 
fifty years. They are used to provide information regarding diagnosis, 
prognosis and response to treatment for a variety of conditions from 
ovarian cancer to renal failure (Jacobs & Bast, 1989; Couchoud et al., 
1999). For the condition of myocardial infarction, the presence of troponin 
has a central role in confirming the diagnosis (O'Gara et al., 2013). 
 
Biomarkers have the greatest utility when they can provide information 
required for clinical decisions. In the condition of the heart failure, where 
there is a clinical need for early and appropriate treatment but no 
objective method for a rapid diagnosis, the potential benefits are 
enormous for any biomarker that can reliably rule in or rule out this 
syndrome. Collinson et al. (2004) have set out a list of criteria for the ideal 
biological marker for cardiac disease. 
 
3.1.2 Characteristics of an ideal marker – from Collinson 
(2004)  
 
1. Well characterised 
2. Completely cardiac specific 
3. Easy to measure accurately and precisely 
4. Stable in storage (although not necessary if ‘point of care’) 
5. Not found in normal circulation 
6. Clinical role defined  
 
Although several potential biomarkers for heart failure and asymptomatic 
ventricular dysfunction have been considered, the natriuretic peptides 
appear the most promising in terms of potential diagnostic value(Jortani 
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et al., 2004). This is due to the rapid and sustained change in natriuretic 
peptide concentration in response to the clinical condition of heart failure. 
It is also relatively stable which makes it easer to measure and there is a 
degree of correlation with the clinical condition of the patient(Tsuji et al., 
1994b).  
 
The natriuretic peptides are well characterised and are mainly produced 
by the cardiac myocytes, especially in the diseased state, although a 
small proportion is produced in other vascular tissue. BNP can easily be 
measured by point-of-care systems and it is known to be relatively stable 
in stored blood (Wu et al., 2004). While natriuretic peptides are found at 
low levels in people with normal cardiac function, high levels always 
suggest a pathological process, although this is not necessarily due to a 
cardiac condition. A recognised issue with the natriuretic peptides is that 
they are synthesized and released in response to cardiac strain from any 
cause, whether this is a result of a primarily cardiac condition or not 
(Bhalla et al., 2004).  
 
Natriuretic peptides are known to be present in higher concentration in 
patients with heart failure and therefore have a potential diagnostic role. 
The cardiac natriuretic peptides consist of atrial natriuretic peptide, brain 
natriuretic peptide and their associated metabolites. Other natriuretic 
peptides such as C-type natriuretic peptide and urodilatin are structurally 
similar and thought to have similar activity but are mainly secreted by 
non-cardiac tissues. The natriuretic peptides have several effects causing 
vasodilation, natriuresis and diuresis, and inhibition of the sympathetic 
nervous system and renin-angiotensin system (Dillingham & Anderson, 
1986; Vesely et al., 1994; Clerico, 2002; Klokkers et al., 2009; Costello-
Boerrigter et al., 2010). They are also likely to have protective effects 
against the processes of ventricular remodelling and endothelial 
dysfunction in association with atherosclerosis (Ahluwalia et al., 2006). 
 
Four distinct natriuretic peptides have been described, (A, B, C and D). 
All have a characteristic 17 amino acid (aa) residue ring formed by an 
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intra-molecular disulphide bridge between 2 cysteine residues (Suga S, 
1992; Daniels, Bhalla, et al., 2006; Bayes-Genis et al., 2007). The amino- 
and carboxyl terminal tails vary between the different peptides, with BNP 
having a 32aa tail (Levin et al., 1998) All exist as pro-hormones that are 
cleaved prior to their release into the circulation (Ozaki et al., 1999; 
Mikkelsen et al., 2007). A visual representation of the structure of this 
molecule is provided in Figure 3-1. 
 
The levels of circulating cardiac peptides are altered by a variety of 
physiological and pathological processes and the levels increase with 
age, female sex, hypertension, pulmonary hypertension, hyperthyroidism, 
renal failure and subarachnoid haemorrhage. The plasma concentration 
of the peptides is also affected by medications such as corticosteroids, 
angiotensin-converting enzyme (ACE) inhibitors and adrenergic drugs 
(Clerico, 2004). 
 
3.1.3 Atrial Natriuretic Peptide 
 
 
Atrial natriuretic peptide (ANP) or atrial natriuretic factor (ANF) was first 
identified by de Bold et al. (1981) although the natriuretic effects resulting 
from atrial stretch were first noticed in a canine model by Henry and 
Pearce (1956).  De Bold (1981) showed that the injection of homogenised 
rat atrial tissue induced diuresis and natriuresis when intravenously 
administered to rats. The presence of granules within the atrial tissue had 
been recognised with the advent of electron microscopy but the purpose 
of these granules had only been postulated upon up until this time. The 
molecular structure was identified and described by the same author 
following further research. 
 
ANP is originally synthesised and released as a pro-form that is cleaved, 
generating a C-terminal ANP and an N-terminal ANP (NT-ANP) 
(Sundsfjord et al., 1988). As the inactive N-terminal section has a longer 
half-life and therefore, a higher plasma concentration, efforts have been 
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made to assess the diagnostic value of NT-ANP in screening for 
ventricular hypertrophy and dysfunction. Studies comparing the 
diagnostic value of this compound with that of the brain natriuretic 
peptides have consistently shown BNP / NT-proBNP to be superior in this 
purpose (Yamamoto et al., 1996; Hammerer-Lercher et al., 2001; Vasan 
et al., 2002; Azzazy & Christenson, 2003; Clerico, 2004). 
 
 
3.1.4 Brain Natriuretic Peptide 
 
 
Brain natriuretic peptide was first isolated from porcine brain by Sudoh et 
al. (1988). It was found to be a potent smooth muscle relaxant and also 
demonstrated hypotensive, natriuretic and diuretic effects when 
administered intravenously to rats.  
 
 
Figure 3-1 Brain Natriuretic Peptide 
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The human BNP gene is located on chromosome 1 (Tamura et al., 1996; 
Levin et al., 1998). BNP regulation appears to take place during gene 
expression. Activation of the BNP gene is required to boost production of 
BNP; it is not stored in granular form within the myocytes unlike atrial 
natriuretic peptide (ANP), but is produced de novo in response to cardiac 
strain. This means that there is not an immediate burst of BNP release in 
response to an exacerbation of the patient’s heart failure but the levels do 
show a response within hours (Yasue et al., 1994; Silver et al., 2004). 
 
BNP is initially formed as a 134 amino acid precursor known as pre-pro-
BNP. Following release of this molecule, it is cleaved by the proteolytic 
enzyme furin to produce proBNP that consists of 108 amino acids. The 
compound is released in bursts and is in turn cleaved by a membrane-
bound serine protease (corin) to produce the active 32aa BNP which 
corresponds to the C-terminal sequence and a 76aa N-terminal fragment, 
NT-proBNP. All 3 components circulate in the plasma and can be 
detected by immunoassay. The molecule is mainly released by myocytes 
although there is probably some released from fibroblasts (Tsunda T, 
2002; Baxter, 2004). NT-proBNP has a longer half-life than BNP (118 
minutes compared to 18 minutes) and is cleared by renal excretion. BNP 
is mainly cleared by proteolysis by peptidases (Wegner et al., 1996; 
Ozaki et al., 1999; McCullough et al., 2003; Wu et al., 2004) although 
BNP levels do correlate with glomerular filtration rates. NT-proBNP levels 
correlate more closely with renal function than BNP (McCullough et al., 
2003; Vesely, 2003; Anwaruddin et al., 2006).  
 
There is a positive correlation between BNP levels and left ventricular 
(LV) end diastolic pressure and an inverse correlation to LV function. The 
main stimulus for BNP secretion appears to be cardiac wall stress as 
ventricular stretch causes increased synthesis and release. There is 
some suggestion that it may be ischaemia within the ventricle walls that 
stimulates the BNP release (Magga J, 1994). Yasue et al. (1994) have 
demonstrated that the secretion of BNP is increased according to the 
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level of dysfunction. The peripheral plasma levels reflect the secretion 
rate from the left ventricle and so allow its use as a marker of left 
ventricular dysfunction (Herman et al., 1990; Yasue et al., 1994; 
Scharhag et al., 2007). 
 
Other neurohormones may modulate cardiac BNP production in a 
paracrine and possibly endocrine way (Harada M 1998). Stimuli such as 
tachycardia and glucocorticoids also contribute to the induction of cardiac 
BNP mRNA in overt heart failure (de Lemos JA, 2003; Collinson et al., 
2004; Apple et al., 2005; Hammerer-Lercher et al., 2010). 
 
The hormone is synthesised in both the cardiac atria and the ventricles, 
although it has been shown that the ventricles produce the majority of this 
compound (Yasue et al., 1994; Boomsma & van den Meiracker, 2001). 
This appears to be especially true for patients with symptomatic heart 
failure. Following a myocardial infarction, BNP production appears to be 
up-regulated to a greater degree than ANP production, possibly due to 
stretch around the infarcted area (Sumida H, 1995). 
 
In subjects with no evidence of heart failure plasma concentrations of NT-
proBNP and BNP are similar. Both peptides are continuously released 
from the heart and are detectable in normal individuals. As BNP has a 
short half-life, of around 20 minutes in blood, levels reflect pulmonary 
capillary wedge pressure (CPWP) changes every two hours. The plasma 
half-life of NT-proBNP is 120 min and so changes in this level reflect 
haemodynamic changes over the last 12h. In patients with left ventricular 
dysfunction, NT-proBNP levels rise relative to BNP levels, with plasma 
concentrations 2-10 times higher than BNP; the mechanism for this is 
unknown (Hunt et al., 1995; Morello et al., 2007). 
 
3.1.5 The Function of Natriuretic Peptides 
 
Three forms of natriuretic peptide cell surface receptors (natriuretic 
peptide receptor NPR-A, NPR-B and NPR-C) mediate the effects of these 
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molecules. Each receptor has a single trans-membrane domain and an 
extracellular binding domain. NPR-A is most abundant in the large blood 
vessels while NPR-B is predominantly found in the brain (Porter et al., 
1990; Yamamoto et al., 1996). The receptor is linked to a c-GMP (cyclic 
guanyl-monophosphate) dependent, signalling cascade that mediates 
most of biological activity (Azzazy & Christenson, 2003; Yap et al., 2004). 
 
BNP causes direct vasodilatation and increases the permeability of the 
vascular endothelium allowing fluid to be shifted into the extravascular 
compartment. It also causes a decrease in sympathetic tone due to 
suppression of central sympathetic outflow; this decreases the sensitivity 
of baroreceptors and suppresses catecholamine release from autonomic 
nerve endings (Vesely, 2003; Apple et al., 2004). 
 
The compound has a direct effect on the kidneys causing an increase in 
the glomerular filtration rate (GFR) by causing dilatation of the afferent 
and constriction of the efferent vessels and allowing relaxation of the 
mesangial cells thereby increasing the surface area for filtration 
(Weidmann et al., 1986; Hobbs et al., 2002). It also inhibits the actions of 
angiotensin II therefore preventing sodium and water reabsorption from 
the proximal tubules. BNP antagonises anti-diuretic hormone (ADH) 
preventing water absorption in the collecting ducts and blocking sodium 
reabsorption in the inner medulla (Zeidel et al., 1988; Apple et al., 2005). 
 
The physiological effects of BNP have been studied by injection into 
intact organism, exposing cells or organs to increased levels, and by the 
genetic design of mice over-expressing BNP or with BNP gene knockout. 
These experiments have shown that BNP binds to natriuretic peptide 
receptor type A causing increased intracellular GMP production (Suga S, 
1992). Biological effects of this include diuresis, vasodilatation, the 
inhibition of renin and aldosterone production and the promotion of 
cardiac and vascular growth (Ogawa et al., 1995; Vasan et al., 2002). 
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Natriuretic peptides are broken down after binding to natriuretic peptide 
receptor C that internalises the peptide before allowing enzymatic 
degradation. The peptides are also lysed within the circulation by 
peptidases, the most studied of which is neutral endopeptidase (NEP) 
(Levin et al., 1998; Campbell et al., 2001) 
 
Table 3-1 Summary of Effects of BNP 
Summary of effects of BNP 
 Vasodilatation 
 Shifts intravascular fluid to interstitium 
 Inhibits renin release from kidney cells 
 Inhibits aldosterone from adrenal cells 
 Inhibits sympathetic tone 
 May have anti-mitogenic properties to modulate growth in 
vascular wall disorders 
 
 
3.1.6 Measuring BNP 
 
Both BNP and NT-proBNP concentrations can be measured by 
immunoassay; various researchers have examined the potential of 
measuring the concentration of these molecules as markers of heart 
failure as described in this section. 
 
Biosite diagnostics introduced an approved test for BNP in 2000. The 
Biosite BNP assay is a point-of-care assay that uses whole blood or 
plasma and produces a result in around 15 minutes. It uses a 
chemiluminescent sandwich immunoassay (Biosite, 2007). There is also 
a micro-particle based immunoassay for BNP available from Abbot 
Laboratories (Jones & Kline, 2003; Silver et al., 2004). 
 
The Roche Diagnostics test (Roche Diagnostics GmbH 2010) measures 
the level of NT-proBNP using an electrochemiluminescent assay. The 
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Roche NT-proBNP assay uses two polyclonal antibodies aimed at 
epitopes on residues 1-21 and residues 39-50. One is labelled with biotin 
and the other with ruthenium complex that bind to NT-proBNP to form a 
sandwich. Detection is by addition of streptavidin labelled micro-particles. 
The complex is then bound via biotin-streptavidin interaction. The assay 
time is approximately 18 minutes. The assays can be run on the Elecsys 
1010, 2010 and E170 machines. All three use the same detection 
technology. The performance accuracy has been calculated as 3.2-2.4% 
from 175-4962ng/l with an analytical range of 5-35000 ng/l. 
 
Collinson et al. (2004) evaluated the performance characteristics 
according to the NCCLS protocol EP-5A. Three sample pools were 
prepared from patients with heart failure with known levels of NT-proBNP 
and measured repeatedly. The precision profile across the entire 
analytical range was tested by analysing eleven samples obtained from 
known cardiac patients and healthy controls measured on each analyser 
with a target number of replicates of ten. 
  
BNP samples in whole blood or plasma are known to be stable for up to 
four hours at room temperature and up to twenty-four hours if 
refrigerated. NT-proBNP samples from plasma are stable for up to three 
days at room temperature or up to one year if frozen (Tsuji et al., 1994a; 
Collinson et al., 2004; Apple et al., 2005; Hammerer-Lercher et al., 2010). 
 
Unlike with ANP, there is no detectable rise in BNP in mild exercise so 
there is no need for the patient to rest for a period before sampling 
although BNP levels are affected by severe exercise, e.g. marathon 
running, even in healthy athletes. This probably equates to moderate 
exercise in a patient with symptomatic heart failure (Anwaruddin et al., 
2006; Herrmann et al., 2007; Scharhag et al., 2007). No evidence has 
been found to demonstrate that BNP levels are affected by posture 
(Boomsma & van den Meiracker, 2001; Harrison et al., 2002). 
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There are several physiological aspects and conditions that are known to 
affect natriuretic peptide levels.  Natriuretic peptide concentrations are 
higher in women than men at all ages (Wieczorek et al., 2002; Wu et al., 
2004; Wang et al., 2006). BNP levels are higher in patients with impaired 
renal function due to decreased renal clearance (McCullough et al., 2003; 
Anwaruddin et al., 2006; Wang et al., 2012). BNP levels are also higher in 
patients with atrial fibrillation (Harrison et al., 2002; Morello et al., 2007). 
BNP levels tend to be lower in obese patients (Struthers, 2000; Daniels, 
Clopton, et al., 2006; Bayes-Genis et al., 2007). Mariano-Goulart et al. 
(2003) have shown that the levels of BNP are higher in patients with 
bilateral ventricular dysfunction compared with isolated left ventricular 
dysfunction as measured using gated blood pool scintigraphy.  
 
The use of diuretics, vasodilators, Angiotensin Converting Enzyme (ACE) 
inhibitors, angiotensin II receptor antagonists and spironolactone all 
decrease BNP concentration. The use of B blockers causes an initial 
increase in BNP as this removes the adrenergic stimulation that acts to 
inhibit BNP release. BNP levels are also elevated in patients with chronic 
respiratory failure with cor pulmonale (Bando et al., 1999; Clerico, 2002). 
Commencing appropriate therapy for heart failure lowers natriuretic 
peptide levels (Devillé et al., 2002; Mikkelsen et al., 2007). 
 
BNP levels are also elevated in patients who have had a pulmonary 
embolism, presumably as a reflection of right ventricular strain. There is 
some evidence that a lower BNP level predicts a lower risk of adverse 
outcome in these patients (Kucher et al., 2003). Patients with terminal 
parenchymal lung disease but with normal left ventricular function do not 
have raised NT-proBNP levels (Schmidt et al., 1977; Goetze et al., 2004). 
 
Other non-cardiac conditions can also be associated with a raised BNP 
concentration. For example, Jones and Kline (2003) described three case 
studies where BNP levels were significantly elevated in patients with 
sepsis, despite normal cardiac function on echocardiography and 
absence of clinical evidence of heart failure. 
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Table 3-2 Summary of Commercially Available Assays (Based on table 
from Silver et al. (2002)) 
Vendor Technology Marker Imprecision Dynamic 
Range 
Cut-off 
(pg/ml) 
Abbot 
Laboratories 
Micro-particle 
enzyme 
immunoassay 
BNP Total %CV 
range 6.5-
9.4 
0-4000 100 
Bayer 
HealthCare 
Diagnostics 
Direct 
chemiluminescent 
sandwich 
immunoassay 
BNP Total %CV 
range 2.3-
4.7 
0-5000 100 
Biosite Inc. Single use 
fluorescence 
immunoassay 
device 
BNP Total %CV 
range 9.9-
12.2 
0-5000 100 
Biosite Inc. Two-site 
chemiluminescent 
immune-
enzymatic assay 
BNP Total %CV 
range 2.1-
6.7 
0-5000 100 
Roche 
Diagnostics 
Electrochemilumi
nescent 
immunoassay 
NT-
proBNP 
Total %CV 
range 3.6-
5.8 
0-35,000 <75y 
125 
>75y 
>450 
 
3.1.7 Optimal Utility of BNP 
 
As BNP levels are known to be higher in patients with ventricular strain, 
this presents the opportunity to use this compound to screen and 
diagnose patients where this finding is expected to be present, for 
example, in cardiac hypertrophy, dysfunction or failure.  
 
The first researchers in this field simply sought to confirm that BNP levels 
could be used to differentiate those with underlying cardiac disease from 
those without. Yamamoto et al. (1996) measured BNP levels in 94 
patients referred for cardiac catheterisation, and 15 people with no known 
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cardiac disease and found that a high BNP level was a good predictor of 
a reduced left ventricular ejection fraction. BNP levels were also 
demonstrated to be higher in patients with respiratory disease with an 
element of cor pulmonale compared to the results in patients with isolated 
pulmonary disease (Bando et al., 1999; Yap et al., 2004). 
 
Groenning et al. (2002) performed a study in 48 patients with a known 
diagnosis of heart failure and found the cardiac size and function, as 
measured using magnetic resonance imaging, could be predicted with 
reasonable accuracy by using NT-proBNP levels. Groenning et al also 
recruited patients aged 50 to 90 years from four randomly selected 
general practitioners in Copenhagen to screen for possible heart failure. 
All of the patients completed a questionnaire covering relevant medical 
history, had an ECG recorded, had blood pressure and pulse measured 
and had blood tests, including NT-proBNP taken. To predict patients with 
a left ventricular ejection fraction of less than or equal to 50%, a cut-off 
value of 41.5 pmol/l of NT-proBNP had a sensitivity of 70% and a 
specificity of 63%. The specificity was improved if a lower ejection fraction 
cut-off was used. 
 
Further research demonstrated that patients with acute decompensated 
heart failure have higher BNP levels than patients with stable, chronic 
heart failure (Sterne & Davey Smith, 2001; Logeart et al., 2002; 
Lainchbury et al., 2003). 
 
Hobbs et al. (2002) investigated the use of NT-proBNP as a screening 
tool for heart failure. They randomly selected 591 patients over the age of 
45 years from four primary care practices. The patients were from four 
cohorts, the general population, patients with a diagnosis of heart failure, 
patients on diuretics and patients at high risk of heart failure. All of the 
patients had a full history, examination and investigations including ECG 
and echocardiography. Using a cut-off value of 36 pmol/l the NT-proBNP 
had a sensitivity of 100% and a specificity of 70% in the general 
population group. In the other groups the sensitivity at this cut-off 
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remained above 90% but the test was less specific. The authors 
suggested using further research to investigate which group of patients 
would benefit from further investigation to confirm heart failure.  
 
Vasan et al. (2002) looked at the value of BNP as a screening tool in the 
Framingham Offspring cohort study. They evaluated 3177 adult patients 
with no history of heart failure and measured BNP levels and performed 
echocardiography in each of the included patients. Patients with renal 
impairment (creatinine ≥ 2.0 mg/dl) or who had inadequate views on 
echocardiogram were excluded. The authors found that although there 
was a correlation between BNP and left ventricular systolic dysfunction 
(LVSD) and left ventricular mass, there was little value demonstrated as a 
screening test. Cut-off values that provided a reasonably high sensitivity 
had a very low specificity and vice versa. Adding the BNP result to a 
model using known clinical risk factors to predict cardiac disease did not 
significantly improve the model. 
 
Lee et al. (2002) demonstrated that BNP levels correlate well with an 
objectively assessed NYHA status in patients with heart failure who were 
managed as outpatients. Wieczorek et al. (2002) performed a larger 
study of 1050 patients whose left ventricular function varied from normal 
to severely impaired. They found that the BNP assay becomes more 
specific with disease severity. Although a direct correlation was found 
between BNP levels and the degree of ventricular dysfunction it was not 
possible to predict NYHA class on the basis of the BNP level as the 
confidence intervals overlapped. 
 
The ‘Breathing Not Properly’ study was a multi-national, international 
study looking at the diagnostic utility of BNP in patients presenting to 
Emergency Departments with acute dyspnoea (Maisel et al., 2002). 1586 
patients were recruited and 744 of these were judged to have acute heart 
failure as the primary cause of their dyspnoea by two cardiologists who 
reviewed all of the data and acted as the reference standard. BNP had a 
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diagnostic accuracy of 83.4% at a cut-off of 100pg/ml and a cut-off of 50 
pg/ml had a negative predictive value of 96%.   
 
 
Rogers et al. (2009) performed a retrospective study on patients who had 
presented to a single centre with acute dyspnoea and had a BNP test 
performed. The authors suggested that different cut-off values should be 
used to diagnose heart failure in patients depending on the presence of 
atrial fibrillation, creatinine levels, BMI and age. 
 
Table 3-3 Factors Affecting Natriuretic Peptide Levels 
Factor  Effect on BNP levels 
Female sex Higher 
Age Increases with age 
Renal impairment Higher 
Obesity Lower 
Atrial fibrillation Higher 
Severe exercise Higher 
Treatment of heart failure Lower 
Right ventricular strain  Higher 
 
3.1.8 Comparing BNP with NT-proBNP 
 
Clerico et al. (2007) performed a literature review after searching for 
published research assessing and comparing the diagnostic roles of BNP 
and NT-proBNP. The authors evaluated the data from fifteen studies 
looking at chronic heart failure and nine studies examining acute heart 
failure and compared the diagnostic utility using the area under the 
receiver operator characteristic (ROC) curve (AUC) and the diagnostic 
odds ratio (DOR). The authors used the random-effects DerSimonian-
Laird method to pool the data for the AUC and the DOR for each 
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biomarker. There were no significant differences between the assay 
performances for the diagnosis of acute or chronic heart failure. 
 
Emdin et al. (2007) compared NT-proBNP and BNP levels in a 
prospective cohort of 820 patients, who all had a confirmed diagnosis of 
heart failure, and 182 healthy controls. The diagnostic utility was 
assessed by measuring the area under ROC curves for the assessment 
of the severity of the heart failure, graded from A to D compared with 
cardiologists blinded to these blood results. NT-proBNP performed 
marginally better than BNP with a significant improvement in the AUC for 
patients graded severity C compared to grade A patients or the controls 
when evaluated against BNP. 
 
Table 3-4 - Characteristics of BNP / NT-proBNP 
 BNP NT-proBNP 
Size 32 amino acids 76 amino acids 
Clearance Mainly endopeptidase Mainly renal 
Half-life 15 – 20 min >1h 
Activity Active Not active 
Stability at room 
temperature 
4h (EDTA tube) 72h 
 
 
3.1.9 Prognostic value of BNP levels 
 
Several studies have looked at the prognostic value of the BNP level, 
both in patients with heart failure and in patients with other conditions 
such as sepsis.  
 
Selvais et al. (1998) published a small study looking at the diagnostic and 
prognostic properties of BNP in patients with heart failure. They found 
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that patients with a high level of BNP had a significantly higher mortality 
rate over a follow up period ranging from 18 months to 2 years. 
 
Morrison et al. (2002) looked at a convenience sample of 325 patients 
presenting with acute dyspnoea. There appears to be an overlap with 
patients recruited for a larger, multicentre study that recruited patients 
with this presentation from this site over the same time period (Maisel et 
al. 2002). The authors followed up the patients at six months, either by 
clinic review, chart review or telephone interviews. End points were 
defined as death, hospital admissions and ED attendances with heart 
failure. A cardiac end point was defined as cardiac death or admission as 
determined by a cardiologist. The authors used ROC curves to determine 
the sensitivity and specificity of BNP in predicting the predetermined end 
points. From their data the authors determined that for the sixty-seven 
patients with a BNP level greater than 480 pg/ml, the probability of a 
cardiac event was 51% compared to a cardiac event rate of 2.5% for 
patients with a BNP level less than 230 pg/ml. The six-month mortality 
rate attributed to heart failure for patients in the high-risk group was 35%. 
 
Groenning et al. (2004) published a study looking at the diagnostic value 
of NT-proBNP in screening a randomly selected population in 
Copenhagen. The authors also examined the prognostic value of this 
biomarker by following up the recruited patients for a median of 805 
(range 60 – 1171) days. Various clinical findings, historical features and 
investigative results were examined using Cox proportional hazards 
analyses. NT-proBNP levels were independent prognostic markers for 
mortality, hospital admission for heart failure and admissions for other 
cardiac causes. Mortality rates were significantly higher for patients with 
an NT-proBNP level greater than 32.5pmol/ l compared to the group of 
patients with a lower result. 
 
Apple et al. (2004) enrolled 399 patients with end-stage renal disease 
(ESRD) who were treated by chronic intermittent haemodialysis in a 
single city in the US. Various blood tests, including NT-proBNP, were 
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performed at enrolment and the patients were followed up for two years. 
99% of the patients had a raised level of NT-proBNP compared to the 
general population, however, if the results were split into tertiles then the 
levels were predictive of mortality. A higher NT-proBNP level was 
associated with a higher mortality rate. 
 
The REDHOT study was a multi-centre study based in ten hospitals in the 
US(Maisel et al., 2004). The patients in this study were recruited if they 
were treated for or admitted with an acute exacerbation of heart failure 
and had a BNP level greater than 100 pg/ml. Higher levels of BNP 
(>200pg/ml) were associated with an increased risk of death or 
congestive heart failure admission or clinic assessment at 90 days.  
 
As part of the Framingham study, Wang et al. (2006) measured ten 
different biological markers in 3209 participants to examine the predictive 
value of each of these tests for primary cardiovascular events or death. 
BNP had the strongest predictive values for death with an adjusted 
hazard ratio of 1.4 per SD in log values. Levels below the cut-off used to 
define heart failure but above the mean were still predictive of a higher 
risk of death during the follow up period.  
 
Anwaruddin et al. (2006) published findings from patients followed up for 
60 days after recruitment for the PRIDE study, which looked at the 
diagnostic value of NT-proBNP for heart failure (Januzzi et al. 2005). NT-
proBNP was found to be the strongest predictor of the sixty-day mortality 
rate with a hazard ratio of 1.61 (95% CI 1.14 – 2.26). 
  
Wang et al. (2012) performed a systematic review and meta-analysis of 
studies that provided information on BNP levels in patients with sepsis. 
Analysing 12 studies with a total of 1,865 patients showed a significant 
correlation between elevated natriuretic peptide levels and mortality with 
an odds ratio of 8.65 (95% CI 4.94 – 15.13). 
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3.1.10 Therapeutic use of exogenous BNP 
 
Due to the physiological properties of natriuretic peptides it was 
postulated that exogenous BNP might benefit patients in acute heart 
failure. Initial trials showed that intravenous exogenous BNP (Nesiritide©) 
decreased pulmonary capillary wedge pressure and provided self-
reported improvement of dyspnoea at three hours post-treatment (Colucci 
et al., 2000; VMAC, 2002) The drug received approval for the treatment 
of acute, decompensated heart failure from the FDA in 2001on this basis. 
 
There were suggestions from meta-analyses of the small trials that 
existed that this treatment may be associated with an increased risk of 
mortality or worsening renal function (Sackner-Bernstein & Aaronson, 
2005; Sackner-Bernstein et al., 2005). The first large randomised trial 
was published in 2011 by O’Connor et al (2011). In this trial 7141 patients 
with acute, decompensated heart failure were randomised to receive 
either a Nesiritide infusion or placebo in addition to standard treatment. 
Overall there was a small and non-significant improvement in outcome in 
terms of dyspnoea; there was no worsening of renal function; there was a 
marked increase in the number of patients having symptomatic and 
asymptomatic episodes of hypotension. The authors did not recommend 
using Nesiritide in the treatment of heart failure. 
 
It has been estimated that $1 billion have been spent on Nesiritide in the 
US healthcare system since the product was licensed (Topol, 2011). 
 
3.1.11 Other Diagnostic Roles for BNP 
 
Campbell et al. (2001) showed that NT-proBNP did not have a useful 
diagnostic role in detecting acute myocardial ischaemia in patients 
presenting to an Emergency Department with chest pain.  
 
As BNP levels rise in response to ventricular strain, this compound has a 
potential prognostic role in the assessment of the severity of pulmonary 
embolism (Klok et al., 2008). 
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3.1.12 Summary 
 
This chapter has introduced the natriuretic peptides and explained the 
potential role that they may have in the diagnosis of heart failure. These 
molecules are only produced by cardiac tissue and the concentration of 
these compounds has been shown to increase in proportion to ventricular 
strain. The natriuretic peptides are relatively stable and simple to 
measure with commercially available kits providing rapid results. Studies 
have been performed to evaluate the diagnostic performance of these 
biomarkers with very promising results. The next chapter examines how 
the optimum combination of the selected diagnostic variables could be 
constructed. 
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Chapter 4 Diagnostics and Decision Rules 
 
4.1.1 Introduction 
 
The successful treatment of patients is reliant on an accurate diagnosis; 
the earlier the appropriate diagnosis is made, the earlier that the correct 
treatment can be commenced and the less likely the application of 
inappropriate treatment.  
 
For some conditions, for example skin wounds, simple recognition is all 
that is required to make a diagnosis; other conditions require greater 
consideration. Several factors are known to influence diagnostic decision-
making and include knowledge, experience, environment and affective 
influences(Croskerry, 2005). 
 
Treatments are often started before diagnoses are confirmed if the risk of 
withholding treatment is considered to outweigh the risk of providing 
unnecessary treatment. In the hypothetical deductive reasoning path a 
selection of potential diagnoses are postulated, and then a series of 
diagnostic hurdles are applied to confirm or refute each of the considered 
conditions. Some authors have suggested that expert clinicians use a 
method of ‘pattern recognition’ (Groen & Patel, 1985; Coderre et al., 
2003). This is where the diagnosis is made on the basis of experience of 
similar cases in the past. This is especially true of conditions such as 
heart failure where there is no gold standard test and the diagnosis is 
made by a combination of signs, symptoms and investigative findings 
(Rutjes et al., 2007).  
 
 
Current cognitive theory suggests that there are two main processes 
involved in decision-making: Type 1 thinking is a rapid, heuristic method 
that is usually correct but is very prone to bias and does not take into 
account aspects such as prior probability of an event; Type 2 thinking is a 
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slower, more reasoned method but takes time to perform and is 
cognitively demanding (Kahnemnan, 2012). 
 
Although, analytical Type 2 consideration would appear to be preferential 
for all diagnostic decisions, the fast-paced and time-pressured 
environment of an Emergency Department does not allow for this to be 
practical.  
 
This is reflected in the fact that most diagnostic errors that occur are not 
through ignorance, where the physician is not aware that a condition 
exists, but due to cognitive errors where the diagnosis is not considered 
(Croskerry, 2013).  
 
The rate of diagnostic errors is difficult to quantify accurately as it is 
difficult to follow up patients who may improve or attend another 
healthcare facility. Croskerry (2005) states that data from autopsy results 
suggests an overall diagnostic error rate of around 40%, and that in a 
third of these cases an autopsy would not have been necessary had the 
correct diagnosis been made and treated at the time of presentation. 
 
4.1.2 Definition of Diagnosis 
 
The Oxford English Dictionary defines diagnosis as ‘the identification of 
the nature of an illness or other problem by examination of the symptoms’ 
(Pearsall, 1998;508). Such a definition of diagnosis carries weight in 
terms of relevant treatment, prognosis and outcome for the patients. 
Misdiagnosis also carries potential maleficence due to both the 
withholding of treatment and potential harm from inappropriate treatments 
intended for other conditions.  
 
4.1.3 The Reference Standard 
 
For conditions such as heart failure, where there is no simple definitive 
finding to rule in, or rule out the condition, an accepted reference 
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standard is a clinical diagnosis made after review of all the available 
information. The ‘Three Wise Men’ method, where three experts in a field 
come to a level of agreement after independently reviewing all of the 
relevant facts, is accepted practice for creating a fair and pragmatic 
reference standard for such decisions where no gold standard for the 
condition exists (Rutjes et al., 2007).  
 
Ideally a reference standard should be applied blind to whichever 
diagnostic test is being assessed in order to reduce the risk of inclusion 
bias. The problem with inclusion bias is that assessing a diagnostic test 
for a condition and using the same test as at least part of the reference 
standard for the condition leads to a circular argument with a test that has 
100% sensitivity and specificity with no capacity for assessing for false 
positive or false negative results.  In this research it has been possible to 
blind the clinicians to novel tests that would not usually form part of their 
diagnostic repertoire, but considered unethical to blind them to the results 
of other tests that they would normally rely upon to make the diagnosis. In 
this research each diagnostic test will only form part of the overall picture 
but it is likely that the inclusion bias will remain.  
 
4.1.4 The Measurement of Outcomes 
 
Outcomes or findings are usually divided into a Boolean choice of true or 
false. In practice, while this may be true of some conditions, for example 
fracture to bones, there are many other conditions where there is a 
continuous spectrum between normal physiological findings and findings 
considered consistent with a diseased state, e.g. blood pressure. Even 
conditions as definitive and uncontroversial as death can arouse some 
debate as to the precise definition (Brenner, 1996). Many medical 
conditions are part of a spectrum where there is a loosely defined central 
zone of normality with the extremes of the condition being considered 
pathological. For example, a pulse rate may be considered abnormal if it 
is of a rate less than sixty or greater than one hundred beats per minute.  
 
99 
 
4.1.5 Normality 
 
If a certain diagnostic test or finding is to signify the diseased state in an 
individual, then there must be a corresponding result or range defined as 
a ‘normal’ finding. The cut-off of what is normal and what is abnormal can 
be defined in many ways. For characteristics with Normal distribution, 
normal values are often defined as within a certain number of standard 
deviations of the population mean. Results may also be considered 
abnormal if they directly result in pathological consequences. The cut-off 
values are usually chosen for practical considerations rather than having 
distinct biological consequences, e.g. a person may be considered to be 
hypertensive if their systolic blood pressure is 151mmHg while a patient 
with a reading of 149mmHg would not require treatment.  
 
This is important for three main reasons: 
 1. Defining a normal range implicitly means that there is at least one 
abnormal range; people with results in this range are then considered to 
be positive for a disease diagnosis.  
2. Dichotomising a test into simply positive or negative results may mean 
excluding useful information.  Often there is a scale of probability where a 
patient with a very high result may have a higher probability of a condition 
than a patient with a result that is just above the normal range. Choosing 
a low cut-off value will mean that both patients will test positive and it may 
be assumed that both patients have the same probability of the disease. 
Choosing a higher cut-off will ignore the fact that the patient with the 
lower result still has a higher probability of the disease than a patient with 
a result in the normal range. 
3. For biological variables there are often two cut-off values, and so the 
relationship with disease should not be assumed to be linear. For 
example, a very high or a very, low body temperature can signify 
significant illness in patients. 
 
A positive test for a patient may mean that they are labelled with a 
disease condition. This may have implications for other areas of their life; 
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there may be stigmata associated with a condition or it may affect their 
prospects of receiving a mortgage or insurance. It can also subject them 
to a further barrage of investigations or instigate life-long treatment. 
Deciding that a patient is disease-negative may also have consequences 
by providing them with false reassurance of their risk of a negative 
outcome and may deny them risk-modifying treatment. 
 
4.1.6 The Diagnosis or ‘Not the Diagnosis’ 
 
In this study, the main intention is to rule-in or rule-out heart failure for the 
presenting patients. By the nature of the inclusion criteria, i.e. adult 
patients presenting due to acute dyspnoea, the study group will be 
distinct from the general population.  All of the included patients will have 
some form of underlying pathology. The ‘not heart failure’ group are likely 
to include a heterogeneous collection of conditions. A diagnostic test that 
is successful in differentiating heart failure from pneumonia may be less 
able to differentiate this condition from pulmonary embolism. There may 
also be one or more underlying comorbidities. Thus, the diagnostic tests 
applied to these patients may have variable success in differentiating the 
individual underlying condition from heart failure due to variety in 
underlying conditions (Thygesen et al., 2007).  
 
Although it is not the focus of this study, all of the patients will need to 
have an accurate diagnosis made of the cause of their symptoms so that 
appropriate treatment can be commenced and the patient can be advised 
appropriately. It is not sufficient just to inform the patient that they do not 
have heart failure as an underlying aetiology. 
 
In medical literature, the majority of papers looking at diagnostic testing 
will concentrate on whether or not a patient has a condition and use 
binary diagnostic test outcomes such as sensitivity, specificity, likelihood 
ratios, and positive and negative predictive values. There is limited work 
looking at the ability of diagnostic procedures to differentiate between two 
or more alternate diagnoses. As patients present due to symptoms that 
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are not normally present within the general population, the question is not 
do they have disease X or no disease, but do they have disease X or 
disease Y. For example, does a patient have ischaemic vs. haemorrhagic 
stroke, ulcerative colitis vs. Crohn’s disease, heart failure vs. COPD 
(Brenner, 1996). 
 
There is usually a spectrum of the severity of a disease or condition. It 
would be reasonable to assume that a patient with severe heart failure, 
with lots of clinical signs due to long-standing disease, will be easier to 
diagnose than the patient with asymptomatic left ventricular dysfunction. 
It is also possible that there may be a synergistic effect when multiple 
pathologies are present in the same patient; for example, the patient with 
mild heart failure may become symptomatic due to a sepsis or anaemia. 
 
There is also limited information about the value of combining tests in the 
diagnosis of disease although this is precisely what we do in practice 
(Irwig et al., 2006). While it may seem intuitive that two positive tests for a 
given patient would mean that the diagnosis is more likely, in fact the 
interpretation of the second test is likely to be less accurate than as the 
clinician will be biased by the findings of the first test. This end diagnosis 
decided by a clinician can depend on the basis of the order that the test 
results become available (Moons & Grobbee, 2002). 
 
Although, in theory, the sensitivity and specificity of a diagnostic test 
should be independent of the prevalence of the target condition there is 
some evidence that this not the case (Willis, 2012). This is another 
potential source of heterogeneity when comparing diagnostic studies 
performed with different populations.  
 
4.1.7 Diagnosis Within Emergency Medicine 
 
The setting of the Emergency Department places considerable 
constraints on the diagnostic process. In the UK setting there is a 
requirement for 95% of all patients to be discharged or admitted within 
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four hours of presentation. This limits the diagnostic investigations to 
those that will return a result within this time. In addition, there is the 
factor that these patients have presented to the emergency setting 
because they are acutely unwell and treatment has to be commenced as 
quickly as possible to improve their condition and outcome, and prevent 
associated complications.  
 
Additional limitations in this setting arise from the equipment available 
and the level of seniority of the medical staff that are available at the time 
of presentation. Investigations that require considerable expertise to 
perform or interpret, are expensive, take a substantial amount of time or 
need specialised equipment are unlikely to be available. Another 
consideration is that most departments aim to provide a consistent 
standard of care twenty-four hours a day but may rely on investigative 
services that may subscribe to more traditional office hours. 
 
 
4.1.8 Measuring Diagnostic Utility 
 
 
Diagnostic tests are used to define whether a particular patient does or 
does not have a particular condition. Assuming that no test is perfect, the 
diagnostic tests are described by two methods to reflect the test 
accuracy. The sensitivity records the proportion of patients who have the 
condition and test positive divided by the total number of patients who 
have the condition, and the specificity measures the proportion of patients 
who do not have the condition and test negative over the total number of 
patients who do not have the condition. Sensitivity is therefore calculated 
only from the patients who have the condition and specificity is calculated 
only from the patients without the condition.  
 
Meta-analysis involves a combination of statistical methods in order to 
summarise the results from more than one study. This can provide 
information about the accuracy of the diagnostic test and also how it is 
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affected by other variables. The advantage of meta-analysis is that by 
combining the data from more than one study can give it greater power 
and hence make estimates that are closer to true values than may be 
gleaned from individual studies. This means that the results of meta-
analysis should be closer to the true performance in the entire population 
of the world compared with individual studies looking at different pockets 
of populations.  
 
Meta-analysis can be beneficial by providing information that can appear 
greater than the sum of its parts but the risks of providing false 
information must be guarded against. Where studies include different 
populations with different prevalence of disease the accuracy of the test 
may be substantially different and combining these studies may 
compound evidence in an artificial way.  
 
Meta-analysis of diagnostic studies is more complex than that of 
intervention studies as there are two summary statistics involved. There 
is also a threshold effect that links the sensitivity of the test with the 
specificity. The statistical methods involved in diagnostic test meta-
analysis have been designed to account for these factors.  
 
There may also be variation in the reference standard for the disease or 
condition that the diagnostic test is looking for. If a perfect reference 
standard existed for a condition then there would be no need to develop 
new ones, so any new diagnostic test must be judged against the older, 
established tests with any inaccuracies or limitations that they may 
encompass. Any variations in the applied reference standard between 
studies may also be reflected in apparent differences in how the 
diagnostic test performs.  
 
Receiver Operator Characteristic (ROC) curves are useful for displaying 
the sensitivity and specificity values of diagnostic tests (Lehr & Pong, 
2010). By comparing various studies for the same diagnostic test in the 
same ROC curve space it is possible to demonstrate if a threshold effect 
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is present. The threshold effect occurs as reducing the threshold for a 
positive test result means that more patients will test positive for that 
condition so sensitivity will increase but specificity, the proportion of 
patients who don’t have the disease who test negative, will decrease. In 
contrast, raising the positivity threshold will decrease sensitivity and 
increase specificity. Plotting the corresponding sensitivity and specificity 
values in ROC space for a test with a variable threshold produces a 
characteristic shoulder-shaped curve as shown in the figure below. 
 
 
Figure 4- Threshold Effect on Summary ROC Curve (Feinstein, 1990) 
 
 
The accuracy of different tests can also be compared using ROC curves. 
This can demonstrate the area under the curve, the optimal diagnostic 
cut-off levels and the Q* point where sensitivity equals specificity. The 
cut-off level can be chosen depending on whether the user wishes to use 
the diagnostic test to rule-in or rule-out a condition, or choose the optimal 
mid-point between these values. 
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Sensitivity analyses are done to explore heterogeneity in the test 
accuracy. The meta-analysis is performed with all the available studies 
and then performed again with certain studies missed out on the basis of 
a defined variable. It may be that the quality of certain studies are 
dubious or are considered to deal with substantially different populations. 
This is not the same as sub-group analysis; this is performed to 
investigate the discovered heterogeneity.  
 
The Cochrane Group advises that meta-analysis involving regression 
modelling may be useful to investigate how poor methodological quality 
can lead to bias in results (Macaskill, 2010).  
 
4.1.9 Reporting of Significance of Findings 
 
In reporting findings in diagnostic studies, the significance of the 
presented results is often represented by using a p value or probability 
value. P values are calculated on the understanding that the null 
hypothesis is correct. It represents the probability of getting a result equal 
to, or more extreme than was actually observed if the null hypothesis is 
true and no effect exists. It does not represent a probability that the null 
hypothesis is incorrect; this can only be calculated by Bayesian methods, 
using likelihood ratios. A major criticism of the use of p values is that a 
large effect in a small study or a small effect in a large study can result in 
the same p value. 
 
Neyman and Pearson (1933) used two hypotheses: the null hypothesis 
and an effect hypothesis. This brings in type I error, finding an effect that 
does not exist and type II error, finding no difference although there is 
one. By concentrating on the p value for a demonstrated effect, this only 
takes account of type I error and does not address any type II error that 
may occur. This is in keeping with the ethical belief that it would be worse 
to give an ineffective treatment with potential side effects and risks than 
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to fail to find a treatment that exists as the effect is too small to be picked 
up or it has not been found by chance. 
 
The p value represents the probability of this particular result happening if 
the null hypothesis is true but does not provide information about the 
likely mean effect or the distribution of the effect. So if a treatment halves 
the one-year mortality rate with a p value of .05 then this tells us that the 
probability of seeing this effect is 1 in 20 if the null hypothesis is true and 
there is no treatment effect on mortality. This may represent an extreme 
outcome of a small but true beneficial effect (Schmidt et al., 1977). 
 
Current theories suggest that the optimal method of reporting results is by 
confidence intervals and likelihood ratios (Goodman, 1999; Sterne & 
Davey Smith, 2001). The use of confidence intervals suggests 
significance if the interval does not cross zero and also conveys some 
idea of the possible distribution of the result. 
 
4.1.10 Models of Decision Making 
 
Thomas Bayes made the first steps to a scientific understanding of 
probability with his theorem which linked the prior or pre-test probability of 
an event or condition with the post-test probability depending on the 
result of another variable such as a diagnostic test(Price, 1763b). This 
has been further refined by the derivation of sensitivity and specificity to 
define the accuracy of diagnostic variables. The understanding of 
diagnostic tests in this way depends on a binary definition of a disease, 
i.e. present or absent, and the binary classification of the diagnostic test 
into positive or negative.   
 
Feinstein (1990) suggests that many clinical decisions are actually 
trichotomous. The author suggests that the results of a test may be used 
as a gold standard of diagnostic evidence, as a contributory factor 
towards a diagnosis or as a surrogate for the diagnosis. In order to 
calculate Bayesian values such as sensitivity and specificity etc., 
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diagnostic variables must have a point defined as true or false. The point 
where the cut-off is made will hugely influence the sensitivity and 
specificity of the test, hence the use of ROC curves to demonstrate this 
and make it easier to choose the optimal value.  
 
Likelihood ratios can also be used to provide information of the utility of 
diagnostic tests but still rely on cut-offs.  Feinstein suggests that in clinical 
practice people apply diagnostic tests into almost certainly present, 
almost certainly absent or maybe. The ‘maybes’ require further 
investigation. This diagnostic uncertainty can be managed within a clinical 
decision rule better than by applying a single diagnostic test as the rule 
can steer the user towards further investigation for the patients who do 
not have a clear cut diagnosis as a result of their initial investigations. 
 
For most diagnoses, all of the available information is combined, with the 
positive and negative findings weighed up by the attending physician to 
formulate a final decision. There is significant scope for variation in the 
tests performed, the interpretation of the results and the weight attributed 
to the findings which all account for the differences in opinion that arise 
when the process is studied (Lok et al., 1998; Joshua et al., 2005).  
 
Medical decision making is known to be a significant source of error and 
this is particularly true of specialties such as Emergency Medicine where 
the clinician is confronted with undifferentiated patients in a time-
restricted environment (Croskerry, 2013). Solutions to avoid cognitive 
errors involve changing systems to decrease reliance on memory, 
relieving time pressures and making tasks easier. 
 
One solution to this is to select the population of interest, the diagnostic 
procedures to be considered and the order in which they should be 
performed by synthesising a clinical decision rule (CDR). 
 
CDRs allow a consistent and logical approach to the application of 
diagnostic testing for conditions where the end-diagnosis is generally 
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made by combining the results of several variables rather than by one 
definitive test result (Phillips, 2010). CDRs are structured around the 
probability of a condition being present in a patient, if specific findings are 
true or false. Evidence suggests that clinicians vary significantly in their 
predictions of post-test probability of a condition even if they are provided 
with information regarding a tests performance (Sox et al., 2009). The 
introduction of CDRs is one way of encouraging a change in practice to 
utilise the available evidence in the optimal fashion (Haynes & Haines, 
1998). 
 
4.1.11 Methodology 
 
 
CDRs are intended as tools to guide physicians in the clinical decision 
making process. This can take the form of decision trees with each 
decision node leading to a ‘branch’ in the tree. They provide either a 
diagnostic probability or a management plan when applied to a particular 
clinical situation. They are generally derived through multivariable 
analysis. As clinical decision rules are designed to directly influence 
patient care it is important that they are safe and robust. They should be 
derived from one group of patients and validated on another group of 
patients, ideally from a different centre, before being applied in 
mainstream practice in order to reduce the risk of overfitting of the data.  
 
The condition or situation that the decision rule is designed to meet must 
be common enough for the creation of the rule to be worthwhile. There 
must be enough confusion, indecision or inconsistency in the 
management of the condition to provide value for the application of the 
clinical decision rule. The rule must be applied in a situation where the 
condition can be confidently diagnosed by the application of simple tests 
or clinical findings. A cumbersome or impractical rule, or one that does 
not address a problem that people come across in daily practice is 
unlikely to be incorporated into clinical practice. It should be perceived as 
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solving a recognised clinical problem rather than creating further 
bureaucracy or paperwork or interfering with clinical independence. 
 
Laupacis et al. (1997) define a clinical prediction rule as a decision-
making tool for clinicians that includes three or more variables obtained 
from the history, physical examination or simple diagnostic tests, and that 
either provides the probability of an outcome or suggests a diagnostic or 
therapeutic course of action.  
 
Stiell and Wells (1999b) described a CDR as a decision making tool that 
is derived from original research and incorporates three or more variables 
from the history, physical examination or simple tests. These authors 
state that there must be a need for the clinical rule in that it must be a 
common condition that is not addressed in a consistent manner.  
 
McGinn et al. (2000) describe a CDR as a clinical tool that quantifies the 
individual contributions that various components of the history, physical 
examination and basic laboratory results make toward the diagnosis, 
prognosis or likely response to treatment in an individual patient.  
 
It is generally agreed that the rule itself should be derived according to 
methodological standards (Stiell & Wells, 1999a). The clinical data should 
be collected according to well-standardized assessment techniques, 
carried out prospectively and recorded on specifically designed forms. 
There should also be a definition of outcome and of reliable predictor 
variables. The rule should make sense in that it should comply in a 
consistent manner with what is already known about the condition and 
there should be a logical order to it. The rule should be sensible. 
(Feinstein, 1987) first described the ‘sensibility’ in the context of CDR 
meaning that it should be clinically reasonable, easy to use and provide a 
course of action. The overall applicability depends on judgement rather 
than any statistical analysis. CDRs that end in prescribed course of action 
rather than estimate of risk of condition are probably better followed by 
treating clinicians. 
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When developing a CDR, investigators identify a number of variables that 
they believe will be useful. Many of these are dropped either because it 
has no predictive value, it has some predictive value on its own but does 
not add predictive value to the rule that is not provided by the other 
variables or because assessment of the variable is too unreliable to justify 
inclusion. 
 
Prospective validation should be completed to ensure robustness of the 
rule. It should be practical to incorporate it into clinical practice. In order to 
be of practical use, the application of the CDR by the physician must be 
able to provide an accurate diagnosis using simple and available tests. 
The clinical findings or tests need to be consistent. The presence of inter-
observer and intra-observer variation should be sought. The outcome 
measure should be clearly defined and assessed blindly to avoid 
observation bias. 
 
The study group must be clearly defined so that physicians know exactly 
who has been involved in the derivation of the rule and which population 
they should apply the CDR to. The setting of the derivation studies also 
needs to be clearly described. A derived rule should also be cost effective 
to apply. If all these factors are present and correct then the message 
needs to be disseminated in order to promote uptake into clinical practice. 
Stiell & Wells (1999) have derived the following six-stage guide to 
developing a clinical decision rule. 
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Six Stages in the Development of a Clinical Decision Rule (Stiell & Wells, 
1999a) 
 
Stage 1. Is there a need for the clinical decision rule? 
Stage 2. Was the rule derived according to methodological 
standards? 
Stage 3. Has the rule been prospectively validated and refined? 
Stage 4. Has the rule been successfully implemented in clinical 
practice? 
Stage 5. Would the use of the rule be cost effective? 
Stage 6. How will the rule be disseminated and implemented? 
 
4.1.12 The Risks of Error 
 
Application of a diagnostic test or decision rule will inevitably apportion 
the wrong diagnosis to some patients. The dangers of mislabelling these 
patients will carry immediate risks for them in that they may receive the 
wrong treatment and fail to receive the correct treatment for their true 
condition. There is also the risk of  ‘labelling’ a patient as having a 
condition, an action can have many effects in terms of their treatments 
and lifestyles and home and relationships. This risk occurs whenever a 
diagnosis is made and is in no way limited to clinical decision rules. The 
application of the clinical decision rule should reduce the risks associated 
with the less experienced clinician by providing clear diagnostic and 
treatment guidance. The guidance can also reduce the risks of the more 
experienced clinician who may make omission errors due to 
overfamiliarity and automation of the management of this condition.  
 
The clinical decision rule can be assessed in terms of its diagnostic 
accuracy against a reference standard like any other diagnostic test. 
Minimum acceptable levels of sensitivity or specificity can be selected to 
ensure sufficient diagnostic utility of a particular model before considering 
incorporating it into clinical practice.  
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4.1.13 The ‘Art’ of Medicine 
 
The application of an accepted pathway can empower the junior clinician 
to be confident in the management of the patient with heart failure in 
terms of treatment and referrals. A theoretical concern with the 
application of clinical decision rules is that it may remove the ‘art’ from 
clinical practice. Research into the utilisation of diagnostic testing in the 
UK National Health Service shows very high levels of variation on a 
regional basis; it is unlikely that such variation is consistent with 
universally applied optimal practice (RightCare, 2013). 
 
By standardising the approach to patients with certain presentations 
using an agreed pathway there is no need for staff to negotiate with ‘gate-
keeping’ staff for access to the diagnostic test in each individual case. 
Setting up the diagnostic pathway and demonstrating that it is based on 
the best available evidence allows the necessary negotiations to be 
carried out at a senior level. This can reduce the number of tests 
performed by removing unnecessary tests that do not provide 
independent new diagnostic information. 
 
4.1.14 Established Clinical Decision Rules 
 
A number of clinical decision rules have been embraced by the 
Emergency Medicine specialty following validation demonstrating a 
consistent, evidence-based approach to different diagnostic quandaries. 
Examples include the Ottawa Ankle Rule which has been used to 
standardise radiological investigation of ankle injuries, Well’s score which 
is used to decide which patients need further investigation for possible 
deep vein thrombosis and the PERC rule which is used to discern when it 
is appropriate to investigate patients for possible pulmonary embolus 
(Stiell & Wells, 1999a; Wells et al., 2006; Kline et al., 2010). 
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4.1.15 Mathematical Techniques to Derive the CDR 
 
Univariate analyses are relatively simple to perform but do not allow 
exploration of the relationship of predictor values with each other and with 
the outcome. In order to account for these relationships multivariate 
statistical approaches such as logistic regression and recursive 
partitioning are used. Potential variables for the multivariate analysis are 
usually screened by assessment of the univariate association with the 
outcome as well as an assessment of the reproducibility of the variable. 
Variables that demonstrate a significant association with the outcome are 
selected for further assessment within a multivariable model. 
 
Recursive partitioning analysis progressively divides patients into 
subpopulations that only include patients with particular outcome. This 
may be appropriate where wish to develop a decision rule with high 
sensitivity. 
 
Logistic regression also predicts likelihood of binary outcome (positive or 
negative) and this is given as log odds that can be used to calculate a 
simple odds ratio. Logistic regression tends to give decision rules with 
higher overall accuracy i.e. better overall classification of all patients but 
possibly with less sensitivity. 
 
Several computer programs have been written to generate decision trees. 
The programs assess all the provided data and variables to decide the 
optimum combination of diagnostic variables and cut-off values using 
three main methods: 
 CHAID (Chi-squared automatic Interaction Detection) - uses 
standard Chi-square tests on cross-tabulation. 
 CRT (Classification and Regression Trees) which use a measure 
of ‘impurity’ based on the ‘gini’ coefficient 
 C5.0 which uses a measure of information gain based on entropy 
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The aim is to create decision nodes that are as different as possible and 
produce sub-populations that are as homogenous as possible. The 
CHAID method handles missing values as a separate category, CRT 
replaces missing values with a value from a surrogate variable closely 
associated with the original variable with the missing value. 
 
Decision trees are not true multivariate models, i.e. they don’t 
simultaneously assess the effect of one variable while controlling for all 
the others but they use different predictors in different branches and 
control for the effect of the preceding variables but only for that particular 
branch of the tree. 
 
End-points can be specified for the decision trees so that the process is 
stopped before over fitting. The stopping decision can be made on the 
basis of the number of available predictors, the number of cases left to 
split, the number of cases in the terminal child nodes or it may be decided 
to synthesise the tree to a predetermined depth. 
 
4.1.16 Validation of the CDR 
 
The initial study should be prospectively validated, as many CDRs do not 
perform as well as predicted when applied in other settings. The reason 
for this may be statistical, due to over-fitting or instability in the original 
model, or may be due to differences in prevalence of disease, the 
threshold of diagnostic criteria or differences in how the CDR is applied.  
 
Bootstrapping involves the removal of the data from a single patient from 
the study, deriving the rule from the rest of the patients and then applying 
this to the first patient and seeing if the rule holds true. This process is 
then repeated in sequence for each patient in the study. This can be used 
as a form of internal validation but is inferior to an independent, 
prospective validation study. 
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Prospective validation should be in new patient group, ideally by a 
different set of clinicians in order to demonstrate the robustness of the 
CDR. Clinicians using the CDR should understand the procedures and be 
confident in the application of the rule. The overall accuracy of the rule in 
the new population should be mapped out in a two-by-two matrix with 
relevant calculations and compared with the original study data. 
 
There should also be measurement of the inter-observer agreement 
regarding the outcome of the CDR providing a value for reliability. 
Centres applying the CDR should be observed to see how effective the 
CDR is in practice, whether it is indeed adopted and how it changes 
practice over a period of time. 
 
 
4.1.17 Application to this Study 
 
The diagnosis of heart failure is complex despite this being a common 
condition there is considerable variation in clinical practice. The end-
diagnosis is derived from a selection of clinical findings and diagnostic 
test results. Patients with this condition would benefit from the derivation 
of a clinical decision rule that allowed a rapid and accurate diagnosis.  
 
Although many symptoms, signs and investigative findings are 
considered to have diagnostic value in defining this condition, the true 
diagnostic weight of each of these elements and the combination of these 
findings remains poorly understood. Early and appropriate treatment 
improves symptomatic relief and is likely to improve outcomes and 
reduce associated health care utilisation and cost.  
 
In order for such a rule to be accepted it would have to be seen as 
making clinical sense, and to perform well in the environment of 
Emergency Medicine. It must be reproducible in application by a mutable 
workforce of variable seniority and experience, and harness available 
diagnostic features that can be interpreted reliably.  
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To demonstrate the reliability and reproducibility of any decision rule 
derived from this study, further validation studies would have to be 
performed with different populations of patients, ideally in independent 
centres. Following this, dissemination of a validated clinical decision rule 
would best be facilitated by publication in peer-reviewed journals. 
 
Having established the potential application for an effective CDR for the 
diagnosis of heart failure, the next stage in the synthesis of the decision 
rule is the selection of predictor variables. The following chapters present 
a systematic review and meta-analysis of diagnostic studies in patients 
presenting to emergency department with symptoms suggestive of heart 
failure. The intention was to assess the utility of all potential predictor 
variables and then use meta-analytic techniques to select those with the 
optimal diagnostic value for consideration in the CDR.  
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Chapter 5 Meta-analysis of Diagnostic 
Studies 
 
 
5.1.1 Introduction 
 
In order to select which variables have the greatest diagnostic utility, and 
to be able to define summary statistics of their diagnostic performance, 
meta-analysis of the potential predictor variables from the studies 
included in the systematic review was necessary.  
 
Meta-analysis is essentially the analysis of analyses. Glass (1976) coined 
the term in 1976, although the concept and process existed before this. 
The intentions behind meta-analysis are two-fold: the first intention is to 
enable a summary or review of various studies of the same subject, with 
a method other than that of a simple narrative; the second intention is to 
produce an answer to a clinical dilemma which may be greater than the 
sum of its parts. Meta-analysis may also facilitate explanation of observed 
heterogeneity between different studies (Trikalinos et al., 2012). 
 
Meta-analysis is the aggregation of results from multiple studies. Each 
study has ‘weight’ corresponding to its precision, which is estimated by 
the variance. The weight of a study is equivalent to one under the power 
of the variance. The general formula for meta-analysis the global 
outcome (D) expressed as a weighted mean.  
 
For interventional studies the size of effect of the selected intervention 
can be measured by a chosen outcome. The outcomes values of multiple 
studies can then be combined while weighting the results according to 
relevant factors, for example, the size of the study. Meta-analysis 
methods for looking at diagnostic tests, rather than treatments, are less 
well established in the literature. The rationale, however, is similar: to 
summarise the information in a valid way and to provide information on 
the factors affecting the estimates. The validity of the estimates is 
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dependent on the absence of publication bias, the absence of bias due to 
poor quality of the selected studies and that belief that the meta-analysis 
estimates are generalisable in a useful way. 
 
In diagnostic studies or screening studies the outcome is more complex 
than interventional studies as there are two components to consider, 
namely sensitivity and specificity. Moreover, sensitivity and specificity are 
not independent of each other but usually have a negative correlation, 
whereby increasing the threshold of a diagnostic test increases the 
sensitivity but decreases the specificity of the test. (Jones & Athansiou, 
2009; Sousa & Ribeiro, 2009; Willis & Quigley, 2011; Begum et al., 2012). 
This is described as a threshold effect. The threshold may be explicit, 
where different cut-off values are chosen deliberately, or implicit, where 
different cut-offs are applied due to some degree of subjectivity or there is 
an unrecognised variability in the way that the test is performed. 
 
Meta-analysis of diagnostic studies is a developing field and there is no 
unanimous agreement as to the best method to use (Riley et al., 2007). 
Although it is possible to perform meta-analysis on the sensitivity and 
specificity of the test individually, there are theoretical reasons and 
modelled examples that demonstrate better results when a combined 
method is performed (Leeflang, Moons, et al., 2008).  
 
5.1.2 Threshold Effect 
 
Most diagnostic tests will have a positivity threshold to dichotomise 
patients into condition positive or condition negative. The threshold may 
be explicit or latent. For example one study may classify patients over 
185cm in height as tall, while another study may ask the attending 
physician to choose tall patients; the explicit threshold should mean 
greater consistency but this is not always possible when assessing 
patients for more subjective findings, for example, pulmonary oedema. 
There may also be an implicit threshold where the difference in applied 
thresholds is not apparent between different studies (Harbord et al., 
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2008). Reducing a positivity threshold will tend to increase the number of 
patients who test positive, increasing the true positive and false positive 
proportions. This, in turn, increases the sensitivity but decreases the 
specificity of the test. 
 
It is possible to use a Spearman correlation coefficient to examine the 
relationship between sensitivity and specificity for all of the included 
studies. In studies where the threshold exists, the diagnostic odds ratio 
will remain approximately constant for all the given sensitivity and 
specificity values and there will be a strong negative correlation between 
them. When plotted on a ROC plane, a threshold effect will provide a 
symmetrical, curvilinear line (Irwig et al., 2002). In examining the values 
of the selected studies for the presence of a threshold effect, it is 
important to observe how far the plotted study points are from the 
summary ROC curve rather just than how far they are from each other. 
 
5.1.3 Heterogeneity 
 
Statistical heterogeneity, usually referred to as simply heterogeneity, is 
defined as the variation between studies that is considered to be beyond 
random effect. It results from the differences in study design, conduct, 
patients, procedures, outcome measurements and other difference that 
may be difficult to predict or measure.  Heterogeneity is a recognised 
feature of systematic review of diagnostic studies as between-study 
heterogeneity is widespread for all measures of diagnostic accuracy 
(Higgins & Thompson, 2002). It is important to have an idea of the level of 
heterogeneity present in order to understand the influence of this on the 
results of the meta-analysis (Devillé et al., 2002). The presence of 
heterogeneity can be tested for statistically using a chi-square test, or 
Fisher’s exact test for smaller numbers of studies. The power of this test 
tends to be low (Deeks, 2001).  
 
An impression of the level of heterogeneity present can be obtained by 
examining the appearance of the summary ROC curve. The presence of 
120 
 
a threshold effect affects the diagnostic odds ratios to the extent that a 
smooth curve will be seen, often described as resembling a shoulder 
(Cochran, 1954). Studies with marked differences in the study 
populations or results will be plotted far from the ROC curves. The basic 
method of examining a forest plot of sensitivity and specificity with 95% 
confidence intervals is also a reasonable method of assessing 
heterogeneity.  
 
Estimating the between-study variance is done as part of a random 
effects meta-analysis. The variance can be used to describe the extent of 
variability but can be difficult to interpret as it is quantified on the scale of 
the log-odds ratio. 
 
Cochran’s Q test, also known as Cochran’s chi-square test, is a way of 
indicating the extent of heterogeneity with a p-value indicating the extent 
of variability between studies (Hardy & Thompson, 1998). This test does 
have some limitations: it has a low statistical power when meta-analyses 
include few studies and it may also detect clinically unimportant 
heterogeneity in the presence of many studies (Higgins & Thompson, 
2002). 
 
H is the square root of the chi-square for heterogeneity statistics divided 
by its degrees of freedom. It describes the relative excess in Q over its 
degrees of freedom. R is the ratio of the standard error of the mean from 
the random effect meta-analysis to the standard error of a fixed effect 
meta-analytic estimate. It describes the inflation in the confidence interval 
for a summary estimate under a random effect model compared with a 
fixed effect model. 
 
An inconsistency (I2) score is a measure of the variation across studies 
due to their heterogeneity. Higgins and Thompson (2002) described I2 as 
the percentage of total variability in the estimates that is due to 
heterogeneity between studies rather than sampling error (Ioannidis et 
al., 2008). I2 is a transformation of the H that describes the proportion of 
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total variation in study estimate that is due to heterogeneity, that is, the 
variation that is not due to chance. I2 is given as a value between 0 and 
100%. This number also reflects the number of studies within the 
analysis. Confidence intervals can be calculated for this variable.  
 
An advantage of I2 over Q is that it can allow comparisons between meta-
analyses of different sizes. It has been suggested that I2 values of 25%, 
50% and 75% are evidence of low, moderate and high heterogeneity, 
respectively. However, while the I2 index and its 95% confidence intervals 
are helpful in expressing quantitative values, decisions should not be 
based entirely on these results (DerSimonian & Laird, 1986). Ioannidis et 
al. (2008) recommend that the interpretation of heterogeneity in a 
systematic review still needs consideration of the clinical and 
methodological diversity between studies.  
 
5.1.4 Random Effects Model 
 
The procedures in the calculation can either use fixed effect models or 
random effect models. Fixed effect models assume that the available 
studies all give an estimate of the same effect so that the estimated 
effects can all be considered as part of the same distribution. This 
method is only reliable for models with low heterogeneity. 
 
The random effects model does not assume that all of the patients in the 
selected studies come from the same population. Each study is 
considered to have its own population, and each population, its own 
means. Therefore, variability of the estimate may have two sources, 
variation within the study and variation between different studies. The 
DerSimonian-Laird method is used to calculate this (Moses et al., 1993). 
 
If the test for statistical heterogeneity has a significant result then the 
random effects model should be used. Some statisticians argue that the 
random effects model should always be used in meta-analysis, as in the 
absence of significant heterogeneity, the results are almost identical to 
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fixed effect model, while there is general agreement that the fixed effect 
model should not be used in the presence of significant heterogeneity. 
Heterogeneity is to be expected in the results of test accuracy studies 
thus random effects models are required to optimally describe the 
variability in the test accuracy. 
 
5.1.5 Methods of Meta-analysis of Diagnostic Studies 
 
Moses et al. (1993) proposed a method of meta-analysis that has 
received some acceptance in the field of medical statistics (Irwig et al., 
2002). Their approach utilises diagnostic odds ratios (DOR) as a method 
of unifying the sensitivity and specificity that can be used even in the 
presence of a threshold effect. The DOR represents the odds of a 
positive test result in patients with a target condition compared to the 
odds of a positive test result in patients without the condition. The DOR 
expresses how much greater the odds of having the disease are for the 
people with a positive test result than for the people with a negative test 
result. It is a single measure of diagnostic test performance that combines 
both likelihood ratios. Using the log of the odds or the logit values of the 
DOR it is possible to construct a line describing the relationship between 
these values and then transform the values back to create a summary 
Receiver Operating Characteristic (ROC) curve (Glas et al., 2003). This 
curve describes the diagnostic odds ratio (DOR) over a range of 
corresponding sensitivity and specificity values. The DOR is calculated by 
the following equation: 
 
 
 
The DOR is a useful indicator of a diagnostic tests utility as it is a single 
value, making it easier to visualise and perform statistical calculations. 
The disadvantage is that it is not possible to weight for true positive and 
false positive results separately{Moses 1993}. The first step is to convert 
the true positive results (TPR) and false positive results (FPR) to their 
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logistic transformations. The logit of the TPR is the logarithm of the TPR 
divided by one minus the TPR. The logit of the FPR is calculated in the 
same manner. To account for any cells that contain zero or one, 0.5 is 
added to all the cells in the two by two tables for each study. Two 
equations are involved: 
 
S = logit (TPR) + logit (FPR)  
D = logit (TPR) – logit (FPR).  
 
S is the sum of the two transforms and is related to how often the test is 
positive, which is related to the test threshold. D is the difference between 
the two transforms and is a measure of how well the test discriminates 
between the two populations of disease positive and disease negative 
patients. 
 
Generally, TPR and FPR are inversely related. The main factor affecting 
these variables is the threshold. The relationship between D and S is 
estimated using a linear model (least squares regression): 
 
D = bS + i 
 
Once the slope and intercept of the transformed line is known it can be 
back-transformed. Since DK is the log-odds ratio of the kth study, a 
summary of D (by equally weighted mean, weighted mean or median) 
can provide reasonable estimate of the power of the test.  
 
As this method involves regression analysis it is susceptible to influence 
from extreme outliers. If a test is being used with the intention of 
confirming that a patient really has a condition, then the area of interest 
will be the part of the curve with high specificity. If some included studies 
involve results with low specificity and high sensitivity this may influence 
the data even though that cut-off point has little to do with how the test 
would be used in clinical practice. Moses et al. (1993) therefore 
recommend that only studies that lie within a clinically determined 
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“relevant range” should be used (Deeks, 2001). The authors also 
recommend that the curve not be extended beyond the plotted study 
points. They concede that reducing the size of the curve in this way will 
inflate the apparent accuracy of the index test but state that the bias is 
not large. 
  
The area under the curve (AUC) is equal to the probability that if two 
individuals are chosen at random and one has the condition and the other 
doesn’t have the condition, the diseased individual will have a higher test 
result than the non-diseased. It is also an average sensitivity over the 
entire range of specificity and vice versa. In symmetric ROC curves all 
points have a common DOR. In asymmetric curves the DOR varies with 
the threshold. 
 
In a summary ROC curve, individual studies are plotted in ROC space. In 
this study the plotted studies have been scaled by sample size with the 
height representing the number of patients with disease (precision 
sensitivity) and the width representing the number of patients without the 
disease (precision specificity). 
 
Unfortunately there are some limitations of this technique. This method 
does not supply summary values for sensitivity or specificity. It is possible 
to calculate the sensitivity and specificity for any point on the ROC curve 
that is produced, but these values may not be represented in the original 
data (Gatsonis & Paliwal, 2006; Leeflang, Deeks, et al., 2008). There are 
also assumptions made about the relationship between the sensitivity and 
the specificity that may not hold true. The threshold effect may be 
negated to some degree by selecting the point where the ROC curve 
intersects with a line drawn to illustrate where the sensitivity is equal to 
specificity but this approach is only appropriate for homogenous data 
(Walter, 2002). This technique also fails to allow for variation in the 
prevalence of the disease in the included studies (Leeflang, Moons, et al., 
2008). 
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Other criticisms include the fact that sampling variability in the individual 
studies is not taken into account and that there is an underestimation of 
test accuracy due to zero cell corrections (Moses et al., 1993). Zero cell 
corrections, where 0.5 is added to every cell, are necessary so that 
logarithmic calculations can be performed even if no there are no patients 
in one of the categories without causing an error. 
 
5.1.6 Bivariate Analysis 
 
An alternative method of meta-analysis has been described by Kardaun 
and Kardaun (1990).  Bivariate analysis overcomes some of the 
shortcomings of the method described by Moses et al. (1993) (Reitsma et 
al., 2005). In the method described by Kardaun and Kardaun (1990) the 
assumption is made that there is Normal distribution of both the sensitivity 
and specificity around a mean, following logit transformation. A random 
effects model is used to incorporate unexplained variability in the 
analysis. It is assumed that there is a negative correlation between the 
two values and this is incorporated into the analysis as a single model. 
The combination of two normally distributed outcomes, the logit 
transformed sensitivities and specificities and the acknowledgement of a 
possible correlation between them leads to bivariate normal distribution. 
The studies are weighted so that those with a more precise estimate of 
sensitivity or specificity are given a higher weight in the analysis. The 
bivariate model is then analysed using linear mixed model techniques.  
 
One advantage of this method is that it provides summary values of 
sensitivity and specificity together with confidence intervals (Lau et al., 
1998). Covariates can be added to the bivariate model to allow further 
analysis. There are issues with using a random effects model, it does not 
explain any heterogeneity that is present and it may provide a more 
conservative level of statistical significance than fixed effect models 
(Trikalinos et al., 2012). 
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The distributions of the logarithm of the likelihood ratios are 
approximately normal and so it is possible to calculate confidence 
intervals for these values. The distribution for the diagnostic odds ratio is 
also approximately normal and the standard error and confidence interval 
of the DOR can be calculated. 
 
5.1.7 Hierarchical Summary ROC Curve Method 
 
A third model for meta-analysis of diagnostic tests is the Hierarchical 
Summary ROC curve method (HSROC). This method is similar to the 
bivariate method but instead of allowing for the variability of the sensitivity 
and specificity of the test includes parameters for the scale and accuracy 
of the studies. This method produces identical results to the bivariate 
method unless covariates are added to explore between-study 
heterogeneity. While both methods allow the introduction of covariates to 
examine the effects of other factors on the diagnostic performance of the 
test under examination the bivariate method allows the direct evaluation 
of the effect on the sensitivity or specificity while the HSROC method 
allows evaluation of the effect on accuracy or threshold parameters.  
 
5.1.8 Likelihood Ratios 
 
Likelihood ratios are a useful tool to describe the application of diagnostic 
tests to a given population. A positive likelihood ratio is calculated by 
dividing the proportion of patients with a positive result who really have a 
condition (true positive) by the proportion of patients with positive results 
who do not have the condition (false positive) (Sackett et al., 2002). This 
can also be represented by dividing the sensitivity of a test by one minus 
the specificity of the test.  
 
A negative likelihood ratio is the proportion of patients with a false 
negative result over the proportion of patients with a true negative result. 
This is the equivalent of one minus the sensitivity divided by the 
specificity.  
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Likelihood ratios have the advantage of being independent of the 
prevalence of the disease condition. They can be used to calculate the 
post-test odds for a given population from pre-test odds when a 
diagnostic test is applied. The only issue with their use is the need to 
convert the probability of a condition into the odds of a condition before 
applying the likelihood ratio. Odds represent the ratio of a positive result 
against a negative result, while probability represents the proportion of 
positive results over the total population. Probability is a more intuitive 
method of description though odds have more useful mathematical 
properties.  
 
Use of a Fagan nomogram makes working with likelihood ratios easier to 
use as approximate values can be obtained simply by drawing a straight 
line through the pre-test probability and the likelihood ratio to read off an 
approximate post-test probability (Fagan, 1975). 
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Figure 5- Fagan Nomogram (By Mikael Häggström [Public domain], via 
Wikimedia Commons) 
 
5.1.9 Selected Methods of Meta-analysis 
 
The first stage of the meta-analysis was the calculation of the summary 
statistics for the selected predictor variable from each study that provided 
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information about it. The sensitivity and specificity were calculated for that 
diagnostic variable. Forest plots were compiled providing graphical 
representation of the tests performance as the first stage in the 
examination of the data. This allowed visual assessment of the degree of 
variability between studies. The confidence intervals were also calculated 
and displayed for the sensitivity and specificity. 
 
Positive and negative likelihood ratios (LR) were derived from the 
sensitivity and specificity. 
 
𝐿R+=Se𝑛/1-𝑆𝑝𝑒𝑐.                         𝐿𝑅−=1−𝑆𝑒𝑛/𝑆𝑝𝑒𝑐. 
 
Likelihood ratios express how much more frequent the respective result is 
among subjects with disease than among patients without disease. These 
were used to calculate the diagnostic odds ratio (DOR). 
 
𝐷O𝑅= LR+/𝐿𝑅−  
 
The DOR expresses how much greater the odds of having the disease 
are for the people with a positive test result than for the people with a 
negative test result. It is a single measure of diagnostic test performance 
that combines both LRs and so incorporates both sensitivity and 
specificity.  
 
There is an important extra source of variation in diagnostic studies, as 
compared with treatment studies, and that is the use of different 
thresholds to define positive and negative results. To explore this source 
of variation the sensitivity and specificity were plotted on a ROC plane. In 
the presence of a threshold effect it is expected that the points will show a 
curvilinear pattern. Calculating the Spearman correlation coefficient 
between sensitivity and specificity can also test for a threshold effect. If 
the threshold effect exists an inverse correlation appears (Devillé et al., 
2002; Bewick et al., 2004). 
 
130 
 
For the next stage, overall test accuracy indexes were calculated as the 
weighted average of these summary statistics. These were plotted in 
ROC space using the MetaAnalyst software. In the presence of 
considerable heterogeneity between the studies the differences were 
reported rather than providing a pooled estimate. Where there were 
studies that were obvious outliers, reasons for the heterogeneity were 
sought. In the presence of marked heterogeneity it is reasonable to 
assume that they are substantial differences in the population or the 
diagnostic test between the included studies. These studies were 
excluded from the meta-analysis and the effects of their exclusion on the 
results examined. 
 
For variables where the meta-analysis was considered appropriate, in 
that there were sufficient numbers of studies available that displayed a 
reasonable level of homogeneity or heterogeneity attributable to a 
threshold effect then meta-analysis was carried out. MetaDisc© software 
was used to summarise the data from each study in a Summary ROC 
Curve. This allowed the exploration the homogeneity of the studies 
graphically and statistically, and computation of the summary statistics 
and their confidence intervals.  
 
In the presence of significant diagnostic threshold variation among 
studies, the best summary of study results may be a ROC curve rather 
than a single point. The shape of the ROC curve depends on the 
underlying distribution of test results in patients with and without the 
disease. 
 
The confidence intervals of sensitivity and specificity were calculated 
using the F distribution method to compute the exact confidence limits for 
the binomial proportion (Leemis & Trivedi, 1996; Friedman & Popescu, 
2003).  
 
As meta-analyses often include small numbers of studies, the power of 
both tests G2 and Q, is low so they are poor at detecting true 
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heterogeneity among studies as significant. An alternative approach is to 
quantify the effect of heterogeneity is the I2 index that describes the 
percentage of total variation across studies that is due to heterogeneity 
rather than chance (Higgins, 2003; Bewick et al., 2004).  
 
5.1.10 Methods Used 
 
MetaDiSc 1.4 software was used to examine the heterogeneity of the 
selected studies. The number of patients included, the prevalence of the 
target condition and the sensitivity and specificity for each variable in 
each study were entered allowing the calculation of the Spearman 
coefficient and I2 values (Zamora et al., 2006). The bivariate analysis was 
performed using Meta-Analyst software (Wallace et al., 2009). This 
provided the overall summary point for each selected variable and the 
data regarding logit values for sensitivity, specificity and the covariate 
were entered back into the RevMan software to produce the summary 
ROC curve and summary point figure for each selected variable.  
 
5.1.11 Summary 
 
This chapter explained the statistical methods used for the meta-analysis 
of the diagnostic variables taken from the systematic review. There was 
also an exploration of alternative methods and justification for the 
methods chosen. The following chapter presents the results of the 
systematic review and the assessment of all of the possible diagnostic 
variables gleaned from the literature. 
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Chapter 6 Systematic Review and Meta-
analysis 
 
6.1.1 Scope 
 
In order to select the optimum variables for the synthesis of the clinical 
decision rule an exhaustive search of the relevant literature was 
performed. The intention was to find all available data pertaining to the 
question: ‘For adult patients presenting to an emergency setting, with 
acute dyspnoea, which diagnostic tests can be used to confirm or refute 
this diagnosis?’ 
 
The methods for the systematic review were in accordance with current 
guidance. An open literature search was performed to minimise the risk of 
missing relevant studies. Pertinent studies were included and critically 
appraised to assess their quality. Any variables that were included in the 
selected studies that may have some utility in the diagnosis of heart 
failure were examined, and the relevant data extracted. Data from each 
study was used to compile two-by-two tables in order to calculate the 
sensitivity and specificity and this was combined for each variable to 
assess its diagnostic utility. The data was then examined further by 
creating forest plots and summary ROC curves for each group of 
variables. Variables that appeared to have reasonable diagnostic value 
were further scrutinised, and where appropriate, meta-analysis was 
performed in order to summarise the overall diagnostic utility for that 
particular variable.  
 
This chapter summarises the literature search, the selection process for 
relevant diagnostic papers, the quality of the selected papers and the 
summary data for the selected variables from the studies. The selected 
variables are grouped by their diagnostic utility and a summary of the 
findings is presented at the end of the chapter. 
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6.1.2 Literature Search 
 
 
A search was originally performed in August 2009 of the Medline and 
EMBASE databases using Ovid interface.  The literature search was 
optimised in order to minimise the risk of missing relevant studies.  
The literature search is detailed in appendix 1. Filters were not applied to 
minimise the risk of excluding relevant studies (Wilczynski & Haynes, 
2005; Leeflang, Deeks, et al., 2008). 
Two readers (KMJ and CJF) assessed all the titles and abstracts and all 
relevant papers were accessed and read in detail by CJF. The literature 
search was repeated in January 2014 by CJF to look for further data. 
 
Additional searches were carried out using GoogleScholar © using the 
terms “heart fail$” and “diagnos$” looking at the first one hundred hits.  
 
The references of selected papers were also examined to look for any 
further relevant studies. Lead authors were contacted by email to ask if 
there was any further unpublished data available. Grey literature was also 
searched for using the DevonAgent © software with the search strategy: 
(“heart failure” OR adhf) AND (acute OR new OR decompensated) AND 
diagnos* 
258 unique results were obtained from 7064 results.  
 
Two further grey literature websites were also checked: 
www.mediondatabase.nl and the North West Grey Literature website 
(www.fade.nhs.uk). 
 
The papers were critically appraised to assess quality and the data 
extracted and entered into the Review Manager (RevMan 5.1) software 
downloaded from the Cochrane collaboration (Cochrane, 2012). This 
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software provides a structure for quality assessment, data reporting and 
basic data analysis.  
 
6909 papers were identified using the EMBASE search and 5633 papers 
were identified using the OVID search in 2009. In the repeat search in 
2014, EMBASE and OVID were searched in combination. This identified 
21,852 papers that were searched back until 2008. From this selection 
forty-nine papers were included and forty-one papers were excluded. The 
included studies are detailed in Section 6.1.12 and summarised in 
Appendix IV; the excluded papers are detailed, with the reasons for 
exclusion in Section 6.1.14.  
A diagram of the format recommended by the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) group shows the 
results of the literature search in Figure 6-1. 
 
 
 
Figure 6-1 PRISMA Diagram of Literature Search 
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6.1.3 Risk of Bias 
 
The New Oxford Dictionary of English defines ‘bias’ in a statistical context 
as ‘a systematic distortion of a statistical result due to a factor not allowed 
for in its derivation’ (Pearsall, 1998;169). Given the number of studies, the 
number of patients, the number of settings and the number of variables 
involved in this analysis it is inevitable that some degree of bias will be 
present. The forms of bias considered relevant for this study have been 
detailed in Table 6-1. While some degree of bias is accepted as 
inevitable, steps have been taken to minimise the effects whenever 
possible, and to at least openly acknowledge its presence in other areas.  
 
While it is very likely that publication bias, where studies with positive 
findings are more likely to be published than those with negative findings, 
there are no universally accepted or validated methods to assess for 
publication bias in diagnostic studies (Irwig et al., 2002). Research has 
suggested that smaller studies are more likely to have more positive 
results and that the best method of reducing publication bias in diagnostic 
studies is by including as many studies as possible (Song et al., 2002).  
  
An attempt has been made to avoid selection bias by involving two 
people in the selection process and defining clear, transparent inclusion 
criteria prior to beginning the search. The possibility of extractor bias has 
been reduced by having the process of data recording repeated 
independently by a second reader for each included study. Arrangements 
were made for a further independent reader to assess the literature in the 
event of any disagreement between these two readers.  
 
The inclusion dates and settings for each of the studies were examined 
and cross-referenced to try to avoid multiple publication bias and multiple 
use of the same subject bias. 
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Reporting bias, where the authors look at many variables but only report 
the optimal results, may also be present (Macaskill, 2010). 
Recording error bias, where data in the original study has been 
accidentally recorded incorrectly is unavoidable given the number of 
studies and patients involved. The overall effect is unlikely to be 
significant as any accidental errors are as likely to increase as decrease 
any effect. 
 
Other biases that may exist include geographic biases. There may be 
different disease aetiology and prevalence and different diagnostic 
thresholds in different countries, or even different regions within the same 
country. 
 
Incorporation bias will be present in the findings of the analysis for 
several of the variables. As there is no single diagnostic test for heart 
failure the reference standard is usually created by a combination of 
various findings. For novel diagnostic tests such as BNP or NT-proBNP 
where this test does not form part of standard practice, it is ethical to 
withhold the result of this test from the treating physician. For standard 
diagnostic tests, for example, the chest x-ray, which has an established, 
essential role in forming a diagnosis for the breathless patient, it is not 
ethical to withhold this information from the treating physician. As a result 
of this bias, a circular process will be present where the same diagnostic 
feature is used to make and confirm the diagnosis and then found on 
subsequent analysis to have a significant diagnostic role. This form of 
bias is recognised but considered unavoidable in this field (Sackett et al., 
2002). 
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Table 6-1 Different Forms of Bias 
Type  When? Under/over estimate? 
Patients  
Spectrum bias Included patients do not 
represent intended 
spectrum of severity of the 
condition 
Depends on difference 
between targeted and 
included spectrum. 
Selection bias When eligible patients are 
not enrolled consecutively 
or randomly. 
Usually leads to 
overestimation. 
Index test  
Information bias 
 
Index test results 
interpreted with knowledge 
of the reference standard 
or with different information 
than would be known in 
practice 
Usually leads to 
overestimation 
Reference Standard 
Misclassification Reference standard does 
not correctly classify 
patients with the target 
condition 
Depends on whether both 
tests make the same 
mistakes 
Partial verification bias Set of patients are 
identified with a second or 
third reference standard, 
especially if this depends 
on the index test 
Usually leads to 
overestimation 
Incorporation bias Index test is incorporated 
in reference standard 
Overestimation 
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Disease progression Patients condition changes 
between applying index 
test and the reference 
standard 
Over or underestimation 
depending on change in 
patient’s condition 
Information bias 
 
 
 
  
When the reference 
standard is interpreted 
knowing the index test 
results 
Usually overestimation 
Data analysis  
Excluded data  Uninterpretable or 
intermediate test results 
and withdrawals not 
included 
Usually overestimation 
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6.1.4 Inclusion and Exclusion Criteria 
 
The two readers (CJF & KMJ) used the following criteria to guide the 
selection of papers to consider for inclusion. 
 
Table 6-2 Inclusion Criteria 
Inclusion Criteria 
Prospective, diagnostic study 
Set in an emergency department or acute care    
environment 
Breathlessness the main presenting complaint. 
Adult patients. 
Reasonable reference standard. 
Heart failure the target condition. 
Prospective studies 
 
 
Table 6-3 Exclusion Criteria 
 Exclusion Criteria 
Inappropriate inclusion criteria e.g.  >75 years only 
Inappropriate reference standard. 
Inappropriate exclusion criteria. 
Not possible to calculate sensitivity / specificity from data 
provided. 
Poor quality. 
 
 
6.1.5 The Reference Standard 
 
Choosing a reference standard for the diagnosis of heart failure is 
difficult. There is no universally agreed definition of heart failure and no 
accepted gold standard tests. Some guidance exists regarding reviews of 
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diagnostic tests in this situation (Deeks, 2001; Irwig et al., 2002; Gatsonis 
& Paliwal, 2006). A combination of different diagnostic tests is a 
legitimate end-point in the absence of a gold standard. Clinical opinion 
appeared the reasonable choice to make as a reference standard. It is 
chosen as the reference standard for most of the included studies and it 
is also a practical method that reflects real life. Physicians have to make 
diagnostic and therapeutic decisions about patients who may have heart 
failure based on the available information in daily practice. 
 
A decision was made that the optimal reference standard should be the 
opinion of two or more physicians, after reviewing of all the diagnostic 
evidence available including response to treatment and post-mortem 
results if applicable. Studies with a less rigorous reference standard such 
as the review of one physician or the review of echocardiogram results 
have also been included. Echocardiogram results have a high correlation 
with the clinical diagnosis of heart failure although this is not perfect and 
the interpretation of this investigation still involves some degree of 
subjectivity.  
 
Where the reference standard is sub-optimal, the studies have been 
included in the initial assessment of the data for the particular diagnostic 
test. For diagnostic tests that appear to have demonstrated useful 
diagnostic utility, the contribution of the poorer quality studies to the 
overall results has been examined.  A recommended technique is 
sensitivity analysis, whereby instead of simply excluding poorer quality 
studies, they are initially included and then their contribution to the 
analysis result is assessed (Hui & Zhou, 1998). 
 
The threshold of the positivity for the reference standard will vary 
between studies in addition to the threshold that is explicitly applied to the 
diagnostic test. This will also affect the diagnostic accuracy of the test 
and needs to be examined as a source of heterogeneity during the 
analysis of the data. 
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Hui and Zhou (1998) make the point that most studies treat the gold 
standard as though there was conditional independence while this is 
often not the case. In a condition where there is a spectrum of disease, 
severe cases are unlikely to be missed by any test, while in the least 
severe cases the patients may test negative on more than one test. The 
diagnostic value of a test may also vary with the pre-test probability of a 
condition in some situations. 
                                                                                                                       
6.1.6 Methods 
 
An assessment of each included study and all of the diagnostic data 
provided by it was entered into the RevMan 5.1 software for diagnostic 
systematic reviews downloaded from the Cochrane Collaboration website 
(Cochrane, 2012). This software allows the storage and basic analysis of 
the available data and also provides a framework for the summary and 
quality assessment of each study. 
 
The data from each included study was entered by the lead researcher 
and verified independently by another researcher (RB, DH, SC, KMJ, BF, 
JB or TB). Data consisted of any information pertaining to the diagnosis 
of heart failure where it was possible to create a two-by-two table and 
calculate sensitivity and specificity for the variable. Most papers provided 
data about more than one diagnostic variable although often the primary 
intention of the paper was to compare one or more diagnostic tests 
against the reference standard. On the occasions when a novel 
diagnostic test was being investigated the index test was often blinded; 
for established variables the results were usually known and often 
incorporated as part of the basis of the reference standard. 
 
6.1.7 Extraction of Information 
 
Data was taken directly from the study papers and entered into the 
RevMan Software. This allows the diagnostic data to be entered either as 
raw patient numbers or as sensitivity, specificity, prevalence and total 
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number of patients. This software was then used to compile forest plots 
for each diagnostic variable from all the studies that provided information 
about it. Where explicit positivity thresholds were present, the same 
threshold was used for each of the combined test results. For variables 
where the threshold was less objective the issue has been addressed in 
the accompanying text. To reduce the risk of extractor bias or error a 
second reader was asked to read a selection of the chosen articles and 
perform the data extraction and quality assessment. A total of seven 
readers were involved in addition to the main researcher, each reading a 
selection papers to independently assess the quality and extract the 
necessary data (RB, DH, SC, KMJ, BF, JB and TB). The results available 
from the independent readers were compared with the lead researcher 
results and any differences settled by discussion. 
 
6.1.8 Assessment of Quality 
 
 
The quality of each study has been assessed using the QUADAS (Quality 
Assessment of Diagnostic Accuracy Studies) system (Whiting et al., 
2003). This system has been designed specifically to assess quality in 
systematic reviews of diagnostic studies and has been validated by the 
authors (Whiting et al., 2006). A summary of this system is presented in 
Appendix III. However, any scoring system requires some level of 
subjectivity so there remains a possibility of a quality score bias. In an 
effort to counter this effect, two researchers assessed the quality of each 
of the included studies independently and summarised the quality 
assessment on a table derived from the QUADAS criteria.  
 
Scoring systems such as QUADAS are useful as a method of assessing 
and displaying the quality of the included studies but the use of these 
systems still requires some degree of subjectivity. While individual 
aspects of quality can be demonstrated to affect diagnostic accuracy, the 
overall quality scores produced by scoring systems such as QUADAS, or 
even the stratification of studies into high or low quality, has not been 
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shown to be of value (Hui & Zhou, 1998). A recommended strategy is to 
examine the role of individual aspects of quality and how this affects the 
analysis of the diagnostic utility of the variable. 
 
 
6.1.9 Data Presentation 
 
The data for each variable has been summarised using a forest plot and 
a summary receiver operator characteristic (SROC) curve. Coupled forest 
plots allow the simultaneous display of sensitivity and specificity from 
each study along with the 95% confidence intervals. The study identifier 
and numbers of true positive, false positive, false negative and true 
negative values are provided for each included study. This method allows 
concise display of the diagnostic information provided by each study for 
the relevant variable. The graphic display of the forest plot allows the 
presence of heterogeneity to be observed directly although it can be more 
difficult to discern a threshold effect. 
 
A summary ROC curve has been presented for each of the diagnostic 
variables to display the results of the included studies. This allows 
visualisation of any clustering of results, threshold effects or outlying 
studies in the analysis. Each analysis was examined to see if a threshold 
effect was apparent by visual examination of the calculated ROC curve. 
The information provided by the summary ROC curve is discussed for 
each of the included variables. 
 
 
6.1.10 Selection of Variables for Meta-analysis 
 
Sensitivity is a measure of the proportion of patients who truly have the 
condition who are found to be positive on application of the diagnostic 
test of interest. A test of that has high sensitivity can have a useful role in 
ruling out the condition for patients who have a negative test result.  
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Specificity is a measure of the proportion of patients who do not have the 
condition and who test negative for the condition. This measure is very 
useful in that tests with a high specificity can be used to rule in the 
condition in patients for whom the diagnostic test is positive.  
 
The intention of this research is to create a decision rule to rule-in and 
rule-out heart failure therefore it needs to involve variables with 
reasonable sensitivity and specificity. Tests such as JVP are very specific 
and can rule-in the condition but have low sensitivity. Other variables 
such as a history of hypertension are sensitive but not specific. 
 
Youden’s Index is a method of examining a variables diagnostic merit 
(Youden, 1950). Adding the sensitivity result to the specificity result, and 
subtracting one from this figure obtains Youden’s Index value. The 
perfect test would score one; tests that score less than zero have little 
diagnostic value. For example, a diagnostic test with a sensitivity of 0.8 
and a specificity of 0.6 would have a Youden’s Index score of 0.4 (0.8 
+0.6 -1.0). Although Youden’s Index provides a rather crude measure of 
diagnostic accuracy it was decided that variables that failed to score 
greater than 0.4 in at least one included study should be excluded from 
further analysis. The intention was to concentrate on variables that had a 
reasonable sensitivity and specificity. A score of 0.4 corresponds with the 
equivalence of a sensitivity and specificity of 70%. 
 
Variables that scored less than 0.4 on Youden’s Index but had very high 
specificity for heart failure were also investigated further. These tests 
were considered to be potentially useful, as a positive result would mean 
that a patient had a high likelihood of having heart failure. The 
disadvantage is that these findings are present in only a few patients so 
are likely to have a limited role in a diagnostic pathway. Information 
regarding the positive likelihood ratio associated with the presence of 
these clinical signs was also provided. 
 
6.1.11 Included Studies 
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Forty-four studies were included, derived from forty-eight papers with a 
total of 15,496 original patients. Table 6-4 provides basic information 
about the included studies. A summary of the each study is also provided 
in Appendix IV. Table 6-5 displays the quality assessment of each of the 
included studies. Figure 6-2 displays the number of patients in each study 
against the prevalence of heart failure in that study.  
 
 
 
Figure 6-2 Study Size Versus Prevalence For Included Studies 
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Table 6-4 – Included Papers  
Author / Year Country Total Patients Prevalence of HF Recruitment dates Notes 
Ababsa et al. 
(2005) 
France 86 58.1% ? Dates unclear 
Alibay et al. 
(2005) 
France 160 37.5% 6/2003 - 1/2004  
Barcarse et al. 
(2004) 
US 98 58.2% 6/2001- 4/2002  
Bayes-Genis 
et al. (2004) 
Spain 100 (11excl.) 58.4% 4/2002 - 2/2003  
Boldanova et 
al. (2010) 
Austria 452 49.3% 5/2001-4/2002.  Same patient group as 
Mueller C (2005) 
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Choi et al. 
(2007) 
Korea 1040 36.3% 10/2004 -10/2005  
Chung and 
Hermann 
(2006) 
Australia 143 50.3% ? Dates unclear 
Collins, 
Lindsell, 
Peacock, 
Eckert, et al. 
(2006) 
US 343 (96 excl.) 38.7% 9/2003 - 6/2004  
Collins et al. 
(2009) 
International 995 41.5% 3/2006 - 10/2006  
Coste et al. 
(2006) 
France 699 60.0% 9/2003 - 2/2005  
Davis et al. 
(1994) 
New Zealand 52 61.5% ? Dates unclear 
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Fleischer et al. 
(1997) 
New Zealand 123 31.7% 11/1994 - 1/1995  
Garcia (2013) US 44 36.3% 4/2010 – 8/2010  
Gargani et al. 
(2008) 
 
Italy 149 81.9% 11/2004 – 3/2006  
Gegenhuber et 
al. (2006) 
Austria 251 54.6%  Patients from Mueller 
(2005) 
Green et al. 
(2008) 
US 592 34.0%  Patients from Januzzi 
(2005) 
Huang et al. 
(2006) 
Taiwan 92(12 excl.) 55.4% 1/2005-10/2005  
Januzzi et al. 
(2005) 
US 599 35.0% 4 months? Duration unclear 
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Jourdain et al. 
(2002) 
France 125 67.0% 7/2001 -10/2001  
Kang et al. 
(2006) 
Korea 69 81.2% 11/2003-5/2004  
Klemen et al. 
(2009) 
Slovenia 546 43.6% 1/2005 – 6/2007  
Knudsen, 
Omland, 
Clopton, et al. 
(2004) 
International 880(706 excl.) 50.8%  As per Maisel (2002) 
Lainchbury et 
al. (2003) 
New Zealand 205 34.0% ? Dates unclear 
Lakhdhar et al. 
(2013) 
Tunisia 30 56.6% 1/3/2010 – 20/6/2010  
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Liteplo et al. 
(2009) 
US 94(6 excl.) 42.6% 12/2006-6/2007  
Lo et al. (2007) Taiwan 52 (8 excl.) 38.5% ? Dates unclear 
Logeart et al. 
(2002) 
France 163 (72 excl.) 70.6% 6/1999-6/2001  
Lokuge et al. 
(2010) 
Australia 612 (87 excl.) 44.8% 8/2005 – 4/2007  
Maisel et al. 
(2002) 
International 1586 47.0% 4/1999-12/2000  
Maisel et al. 
(2010) 
International 1641 34.6% 3/2007-2/2008  
McCullough et 
al. (2002) 
International 1538 (48 excl.) 47.0%  As per Maisel (2002) 
Miller et al. 
(2012) 
US 89 39.3% 1/9/2008 – 30/4/2009 3 patients excluded due to 
poor views. 
151 
 
Moe et al. 
(2007) 
Canada 
(multi-centre) 
500 (34 excl.) 46.0% 12/2004-12/2005  
Morrison et al. 
(2002) 
US 321 42.0% 6/1999-6/2000  
Mueller, Frana, 
et al. (2005) 
Austria 293 52.5% 10/2003-2/2004  
Mueller et al. 
(2004) 
Switzerland 452 48.0% 5/2001 – 4/2002  
Nazerian et al. 
(2010) 
Italy 145 44% 1/2007-3/2007  
Parrinello et al. 
(2008) 
Italy 292 58.9% 12/2004 - 12/2006  
Potocki et al. 
(2010) 
Switzerland 287 54% 4/2006 – 3/2007  
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Prosen et al. 
(2011) 
Slovenia 218 59.2% 7/2007 – 4/2010  
Ray and Lefort 
(2006) 
France 514 43.0% 2/2001- 9/2002  
Reichlin et al. 
(2010) 
Switzerland 743 51%  Patients taken from Mueller, 
C (2005) and Potocki (2010) 
studies. 
Robaei et al. 
(2011) 
Australia 68 40% ? Dates unclear 
Seronde et al. 
(2013) 
France 336 48.8% June 2009? Dates not given in studies 
but on clinicaltrials.gov. 
Acute dyspnoeic 
subpopulation data provided 
separately in paper. 
Shah et al. 
(2009) 
US (Multi-
centre) 
412 35.7% 5/2003 - 12/2006  
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Singer et al. 
(2009) 
US (Multi-
centre) 
301 30.2% 2005  
Villacorta et al. 
(2002) 
Brazil 70 51.4% 4/2001-7/2001 
 
 
 
Wang et al. 
(2010) 
Taiwan 84 58.3% 6/2005 – 9/2006  
6.1.12 Assessment of Quality 
 
The following table provides the summary assessment of quality for all of the 
included papers. The summary of the assessment is based on the QUADAS 
scoring system for diagnostic studies. Blank rows occur where the authors 
have reported on another aspect of a study that has already been assessed 
under the primary authors.  
Table 6-5 Quality Assessment of Included Papers 
Author / Year 
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Ababsa   
(2005) 
? ? + + +   + + +  
Alibay et al. 
(2005) 
? ? + + + + - - + ? ? 
Barcarse et al. 
(2004) 
- + + + + + + + + + + 
Bayes-Genis 
et al. (2004) 
+ + + + + + - + + - + 
Choi (2007) + + + + + + + + + ?  
Chung  (2006) + ? ? + ? - + - + ? ? 
Collins  (2006) + + + + + + + + + + + 
Collins  (2009) + + + + + + + + - + + 
Coste  (2006) + + + + + + + + + + + 
Davis (1994) ? + + + + ? - - +  + 
Fleischer  
(1997) 
+ - + + + + + - + + + 
Garcia (2013) ?  + + +  + + +  - + + + 
Gargani (2008) ? + + + + +  + + + + 
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Gegenhuber 
(2006) 
- + + + + + + + + + - 
Green  (2008) + + + +  -  + + + + 
Huang  (2006) + + ? + + + + + + - + 
Januzzi  
(2005) 
+ + + + + + + + + + + 
Jourdain 
(2002) 
? + + + + + +  + ?  
Kang (2006) + ? + + + + +   + + 
Klemen (2009) + ? + ? + + ? + +  ? 
Knudsen 
(2004) 
+ + + + + +     + 
Lainchbury  
(2003) 
+ + + + + + - +   + 
Liteplo (2009) + + + + + + + ? + + + 
Lo  (2007) ? + ? + + + + + ? + ? 
Logeart (2002) + + + + + + - + +  + 
Maisel (2002) + + + + + + +  + + + 
Maisel (2010) + + + + + + + + + + + 
McCullough 
(2002) 
 
 
          
Miller (2011) + + + + + + + - + + + 
Moe (2007) + + + +  - - + + + + 
Morrison 
(2002) 
+ + + + + + +  + + + 
Mueller, 
Gegenhuber, 
et al. (2005) 
- + + + + + + - + + + 
Mueller C 
(2005) 
+ + + + + - + - + + + 
Nazerian 
(2010) 
+  + + +  + + + + + +  + 
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Parrinello  
(2008) 
+ + + + + + - + + + + 
Potocki (2010) + + + + + + +  + + +  + 
Prosen (2011) + ? + + +  + - +  + 
Ray (2006) + ? + +   + + + + + 
Reichlin (2009)            
Robaei (2011) + + + +  - - + + + + 
Seronde 
(2013) 
+ + + - - -   +   
Shah (2009) + + + + + + + + + + + 
Singer (2009) ? ? + ?  ? + ? ?  + 
Villacorta  
(2002) 
+ + + + + + + + + + + 
Wang (2010) + + + + + + + + + ? + 
 
 
6.1.13 Excluded Studies 
 
Table 6-6 describes the characteristics of excluded studies and details the 
reasons for their exclusion. 
 
Table 6-6 Excluded Papers 
Study Reason for Exclusion 
Behnes et al. (2009) 
 
Recruited patients with acute dyspnoea and/or 
peripheral oedema. Unable to separate results to look 
at diagnostic function in dyspnoeic patients only. 
Berdagué et al. (2006) 
 
Only selected patients over the age of 70y and 
excluded patients in whom they could not decide on a 
clear diagnosis. 
157 
 
Chenevier-Gobeaux et al. 
(2005)  
Reference standard of two ‘urgentists’ in the 
Emergency Department not acceptable.  
Cinar et al. (2012) Only recruited dyspnoeic patients where the 
Emergency Physician had diagnostic uncertainty and 
informed them of the result of the novel test within 30 
– 60 minutes to assess if that altered their diagnosis.  
Collins, Lindsell, Peacock, 
Eckert, et al. (2006)  
 
Patients already included in Collins, Lindsell, Peacock, 
Hedger, et al. (2006). 
Dao et al. (2001) 
 
Subset of patients from Morrison et al. (2002) paper. 
deFilippi et al. (2007) 
 
Breaks patient data into those with renal impairment 
and those without and then provides cut-off values of 
BNP and NT-proBNP for these groups but doesn't 
provide overall values for all patients and not enough 
data provided to calculate this.  
 
Dieplinger et al. (2009) Data for tests with independent diagnostic utility for 
heart failure already presented in Maisel et al. (2005)  
and Gegenhuber et al. (2006) papers.  
el Mahmoud et al. (2006) Only looked at patient over 75y age so not 
representative sample. 
Eckstein et al. (2012) Includes patients from study by Potocki (2010) & 
Reichlin (2010). Divides patients into those with AF 
and without and looks at diagnostic performance of 
NT-proBNP and MR-ANP in these groups. 
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Eurlings et al. (2012) Prognostic but not diagnostic study. 
Gillespie et al. (1997)  
 
Patients had already been admitted to hospital. 
Gruson et al. (2008)  
 
Patients presenting with chest symptoms, so included 
chest pain etc. not just dyspnoea. 
 
Havelka et al. (2011) Reference standard was discharge diagnosis as 
entered by a primary care physician. 
Jang et al. (2010) Reference standard was a radiologist interpretation of 
chest x-ray. 
Jang et al. (2012a) Same study as Jang et al. (2010) 
Jang et al. (2012b) Same study as Jang et al. (2010) 
Januzzi et al. (2006) 
 
Patients already included in individual studies. 
Javadzadeh et al. (2008)  
 
Included patients with dyspnoea and others presenting 
with chest pain. 
Jose et al. (2003) Used combination of patients presenting acutely and 
those with chronic shortness of breath either 
presenting to the emergency department or referred to 
outpatients.  
Leuppi et al. (2005)  Looked at patients presenting with chest symptoms, 
not just dyspnoea. 
Malas et al. (2003)  
 
Excluded patients with both cardiac and respiratory 
disease from the study retrospectively. 
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Marantz et al. (1990) Poor reference standard. Applied modified scoring 
system in ED to patients as reference standard. ECG 
and CXR only performed at the discretion of the 
attending physician so full reference standard not 
consistently applied to all patients. 
 
McCord et al. (2005)  Subgroup analysis of patient group reported in 
Knudsen, Omland, Clapton, et al. (2004) 
 
McNamara and Cionni 
(1992) 
 
Excluded patients from the study retrospectively so 
that only patients with either heart failure or COPD 
were included. 
Mendez Bailon et al. 
(2007)  
 
Recruitment methods unclear. NT-proBNP measured. 
No mention of blinding. Reference standard is 
application of Framingham criteria by GPs plus echo 
data if available, not clear at what point this was 
carried out. Little in the way of inclusion or exclusion 
criteria mentioned, not clear if patient group part of 
another study. 
 
Mueller and Laule-Kilian 
(2004)  
Randomised patients to have BNP test or not and then 
looked to see if this altered outcomes. Not diagnostic 
test. Data from clinical and investigative findings from 
same study included as Mueller, Frana, et al. 
(2005)paper.  
 
Mueller-Lenke et al. (2006) Sub-group analysis of (Mueller, Frana, et al., 2005) 
study in patients who had chest x-ray in emergency 
department which was reported by a radiologist.  
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Pascual Figal et al. (2005)  Selected 70 out of 1267 patients who presented with 
acute dyspnoea whom the investigators felt may have 
heart failure but may have had another diagnosis.  
Peacock et al. (2006)  
 
No reference standard applied. Asked ED physicians if 
they thought the patient had heart failure then provided 
information from a bio-impedance reading and 
recorded how many clinicians altered their diagnosis. 
 
Ray et al. (2004)  
 
Data included in Ray et al. (2006) paper. The 
diagnostic result of BNP is taken from this paper and 
included in the analysis but referenced as the 2006 
paper as this included most of the information about 
this study.  
 
Ray et al. (2005)  
 
Patients already included in the Ray and Lefort (2006) 
paper. The diagnostic result of NT-proBNP is taken 
from this paper and included in the analysis but 
referenced as the 2006 paper as this included most of 
the information about this study.  
 
Rogers et al. (2009) 
 
Retrospective analysis of patients who had a BNP 
checked, not patients presenting with heart failure. 
 
Sanz et al. (2006) No reference standard provided. Not clear how or 
when diagnosis of heart failure made. Seems to 
assume presence of AF confirms cardiac cause of 
dyspnoea. No patient demographics. No time scale 
provided for when tests were taken etc. 
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Schneider et al. (2009)  
 
Not diagnostic study. Patients randomised to have 
BNP tested or not tested and looked at outcomes in 
these two groups. 
 
Shah et al. (2012) Data derived from PRIDE study by Januzzi et al. 
(2005). 
Strunk et al. (2006) 
 
Sub-group analysis of Maisel et al. (2002) study.  
Studler et al. (2008) Sub-group analysis of Mueller and Laule-Kilian (2004) 
study.  
 
Styron et al. (2009) 
 
Not diagnostic study, retrospective cohort. Looked at 
patients who had had an echo performed and then 
compared their LV ejection fraction with their systolic 
BP to look to see if there was any correlation.  
 
van der Burg-de Graauw 
et al. (2009) 
Not clear who made the diagnosis of heart failure or at 
what stage in the patient journey. A definitive diagnosis 
was made using all available data including an NT-
proBNP level and then looked to see if the NT-proBNP 
result made a difference. Cannot calculate final 
diagnosis from available results. Other factors such as 
COPD, hypertension, ECG, age, glucose and clinical 
judgement were of value on stepwise logistic 
regression but only odds ratios provided. 
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van Kimmenade et al. 
(2006) 
 
Further analysis of PRIDE study by Januzzi et al. 
(2005). Looking at other biomarkers but nothing added 
diagnostically, suggest may have a role in predicting 
adverse outcomes. 
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Systematic Review 
 
The literature search is detailed in the preceding sections. Duplicates and 
papers that were not diagnostic studies or had no relevance to the diagnosis 
of acute heart failure on the basis of their title were excluded leaving 500 
papers that were reviewed at greater depth. Ninety papers were selected 
from these on the basis of the inclusion and exclusion criteria detailed in the 
following section. From this selection forty-nine papers were included and 
forty-one papers were excluded. The included studies are detailed in Section 
6.1.12 and summarised in Appendix IV; the excluded papers are detailed, 
with the reasons for exclusion in Section 6.1.14. 
 
Forty-four articles were selected that provided information about the diagnosis 
of heart failure in the breathless patients in an acute setting. The articles were 
derived from thirty-eight studies. Data regarding forty diagnostic variables was 
present in the selected articles. Some of the papers presented different 
information from the same study. If relevant, the articles have been listed 
separately although it is made clear in the text that the patients were from the 
same study. Articles dealing with studies that did not provide original 
diagnostic information of diagnostic value were excluded. One author, Ray, 
provided relevant information pertaining to the same study over three articles 
(Ray et al., 2004; Ray et al., 2005; Ray & Lefort, 2006). For the sake of 
simplicity data derived from these three articles has been referenced to as 
Ray et al. (2006). 
 
BNP was measured in a number of studies and information was provided 
about twenty-nine different cut-off levels. Twenty-nine different cut-off values 
were also available for NT-proBNP. Several studies provided several cut-off 
values with a sensitivity and specificity for each, or data such that these 
values could be calculated. In the absence of any statistical method of 
combining the data for the different cut-off values from all the different 
studies, this data was discarded. Cut-offs corresponding to the manufacturers 
recommendations were selected for further analysis and are detailed at the 
relevant sections in the results section. 
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A coupled forest plot has been produced for each variable, and where 
appropriate, a summary Receiver Operating Characteristic (ROC) curve has 
been calculated. Further analysis has been performed for variables that 
demonstrate significant diagnostic value including meta-analysis where 
appropriate. Each included study is represented by a square plotted in the 
ROC space, the size of the square is proportionate to the size of the study 
and hence the weight it carries in the analysis. Where summary values have 
been plotted they are shown as a solid black circle.  
 
6.2 Variables with Little Diagnostic Value 
 
6.2.1 Absence of History of Asthma 
 
As patients with asthma tend to present with acute dyspnoea, a previous 
diagnosis with this condition could suggest that this is more likely to be the 
cause of the patients’ breathlessness than a coincidental occurrence of acute 
heart failure. Three studies provided information about the history of asthma 
in a total of 1,596 patients presenting to emergency departments with acute 
dyspnoea. They demonstrate the absence of a history of asthma is sensitive 
for the correct diagnosis of heart failure but has very poor specificity. 
 
 
 
Figure 6-3 Forest Plot of History of Asthma 
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Figure 6-4 Summary ROC Curve for Absence of History of Asthma 
  
 
6.2.2 Presence of an Abnormal Electrocardiogram 
 
There are no specific changes on an electrocardiogram (ECG) that are 
diagnostic of heart failure but cardiac disease is associated with both ECG 
changes and heart failure and it has been suggested that heart failure is an 
unlikely diagnosis in the presence of a completely normal ECG (Mant et al., 
2010). Two studies looked at this factor, determining whether the ECG 
appeared within normal limits or was abnormal (without defining what 
abnormalities were present) in 1,321 patients. Although an abnormal ECG 
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was suggestive of heart failure it did not obtain a useful level of diagnostic 
utility as demonstrated in the following figures. 
 
 
Figure 6-5 Forest Plot for Abnormal Electrocardiogram 
 
Figure 6-6 Summary ROC Curve for Abnormal Electrocardiogram 
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6.2.3 History of Smoking Tobacco 
 
Smoking is a major risk factor for the development of ischaemic heart disease 
but also for COPD. Four studies examined this risk factor in a total of 2249 
patients. The four studies providing data about this risk factor have discordant 
results and do not suggest any diagnostic role for this variable. 
 
Figure 6-7 - History of Tobacco Smoking 
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Figure 6-8 Summary ROC Curve - History of Tobacco Smoking 
6.2.4 Hypertension 
 
Twenty-two studies provided information about the diagnostic value of a 
history of hypertension in predicting patients with heart failure. A total of 9,360 
patients were included. The sensitivity and specificity of this condition as a 
predictor of heart failure was very variable in the different studies; this may 
reflect different definitions of hypertension, different levels of screening within 
the population, different thresholds for commencing treatment or genuine 
population differences. While there was a tendency for patients with a history 
of hypertension to have heart failure this did not translate into any useful 
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diagnostic criteria in any individual study. The overall diagnostic utility for this 
finding, as presented by the summary ROC curve, was poor. The calculated 
values, forest plot and summary ROC curve are provided below.  
 
 
Figure 6-9 Sensitivity and Specificity of Hypertension as a Predictor of Heart 
Failure 
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Figure 6-10 Summary ROC Curve - History of Hypertension 
6.2.5 History of a cough 
 
Patients with heart failure may complain of the presence of a cough although 
this is usually due to respiratory conditions. Six papers looked at this 
symptom in a total of 2,514 patients. As can be seen from the forest plot in 
Figure 6-11 and the summary ROC curve in Figure 6-12, the presence of a 
cough suggests a non-cardiac cause for the patient’s dyspnoea but the 
sensitivity and specificity for absence of a cough are not high enough to have 
a useful diagnostic role. 
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Figure 6-11 Sensitivity and Specificity of History of Cough 
 
Figure 6-12 Summary ROC Curve – History of Cough 
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6.2.6 History of Orthopnoea 
 
Thirteen studies provided information about the presence of orthopnoea 
derived from 5,757 patients. This symptom, a sensation of increased 
breathlessness on lying flat, is thought to occur because of increased venous 
return in this position (O'Connor, 2005). There is considerable heterogeneity 
in the results as can be seen from the table and forest plot provided below 
this text. A summary ROC curve demonstrates the distribution of the data in 
Figure 6-14. 
 
 
Figure 6-13 Forest Plot – Presence of Orthopnoea 
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Figure 6-14 Summary ROC Curve – Presence of Orthopnoea 
 
The data was entered into Meta-DiSc that provided the following information 
about the heterogeneity of the diagnostic odds ratios. 
 
Heterogeneity chi-squared = 27.54 (d.f. = 12) p=0.006 
Inconsistency (I2) = 56.4 
 
Estimate of between-study variance (Tau-squared) = 0.0727 
 
Analysis of Diagnostic Threshold 
 
Spearman Correlation Coefficient: 0.883 p value = 0.002 
 
174 
 
Meta Analyst analysis 
 
Specificity = 0.801 (95% CI 0.705 − 0.875) 
Sensitivity = 0.404  (95% CI 0.365 − 0.590) 
Positive Likelihood Ratio = 2.03 
Negative LR = 0.74 
 
 
The pattern of distribution of points suggests a possible threshold effect. The 
summary point and wide dispersion of the included study outcomes suggest 
that the test does not have sufficient diagnostic accuracy to consider as part 
of an optimal diagnostic strategy. 
 
 
 
6.2.7 Absence of Fever 
 
Fever is usually associated with an infective process so it may be assumed 
that the presence of pyrexia would suggest an infective cause of the patient’s 
dyspnoea rather than heart failure. Four studies provided information about 
this finding in 1723 patients. This finding demonstrated good sensitivity but 
poor specificity as shown in Figure 6-15 and Figure 6-16. 
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Figure 6-15 Forest Plot for Absence of Fever 
 
Figure 6-16 Summary ROC Curve for Absence of Fever 
 
6.2.8 History of Nocturnal Cough 
 
The presence of a nocturnal cough is thought to be associated with heart 
failure due to the worsening of respiratory compromise on becoming 
recumbent (Irwin & Madison, 2000). Three studies looked at this symptom in 
a total of 686 patients. From the variable and poor sensitivity and specificity 
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values and the summary ROC curve it can be seen that this aspect of the 
history has no diagnostic utility. 
 
 
Figure 6-17 Forest Plot of History of Nocturnal Cough 
 
Figure 6-18 Summary ROC Curve for History of Nocturnal Cough 
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6.2.9  The Use of Diuretics 
 
Loop diuretics have long been used as a treatment for heart failure to attempt 
to reduce fluid overload. Thiazide diuretics are added as a second-line 
treatment for heart failure and are also used in the treatment of hypertension, 
a known risk factor for developing heart failure. It is reasonable to assume 
that patients displaying symptoms consistent with heart failure may be 
commenced on diuretics, and so to examine the data for a correlation. There 
were five studies, involving a total of 3,670 patients, which provided this 
information.  
 
 
Figure 6-19 Forest Plot - Patients Using Diuretics 
 
178 
 
 
Figure 6-20 Summary ROC Curve - Patients Using Diuretics 
 
Only one study, Januzzi et al. (2005), had a sensitivity of 56% and a 
specificity of 84%. This provided the best diagnostic predictive value of the 
five studies. This variable is likely to be associated with a medical history of 
heart failure, but could be considered a proxy for the diagnosis, as this is the 
main indication for commencing this treatment.  
 
 
6.2.10 Use of ACE Inhibitors 
 
 
Patients are prescribed angiotensin converter enzyme inhibitors for treatment 
for hypertension and as treatment for heart failure. It is reasonable to assume 
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that there may be a correlation between the patients receiving this treatment 
and the presence of heart disease leading to acute failure. Two studies 
provided this information as derived from 748 patients. This data shows 
reasonable specificity but poor sensitivity for acute heart failure. This is 
unlikely to be independent of a previous diagnosis of heart failure but may be 
considered a proxy marker. The positive likelihood ratio derived from the 
summary sensitivity and specificity from the available studies is 2.2, the 
negative likelihood ratio was 0.79.  
 
 
Figure 6-21 Forest Plot for the Use of ACE Inhibitors 
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Figure 6-22 Summary ROC Curve for the Use of ACE Inhibitors 
  
6.2.11 Use of ARB Medication 
 
Angiotensin-receptor blocker (ARB) medication is primarily used in the 
treatment of heart failure and hypertension, particularly for patients who 
cannot tolerate the side effects of ACE inhibitors. As with ACE inhibitors, 
patients who are receiving this treatment may be expected to be more likely 
to have heart failure than patients who are not receiving them. One study 
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provided information about the use of the treatment in presenting patients and 
showed reasonable specificity but poor sensitivity. This corresponded with a 
PLR of 1.38 and a NLR of .86. 
 
 
Figure 6-23 Forest Plot for Use of ARB Medication 
6.2.12 Presence of Peripheral Oedema 
 
Oedema due to venous congestion, secondary to a failing heart, may be 
present in the lower limbs, the abdomen or the sacral area. Various other 
conditions can also cause this condition. Twenty studies (8,171 patients) 
assessed this sign as a predictor of heart failure. While there was some 
association between the presence of peripheral oedema and the end-
diagnosis of heart failure, in patients presenting with acute dyspnoea, the 
results demonstrated significant variability and failed to show real diagnostic 
value as shown in Figure 6-24 and Figure 6-25.  
 
 
Figure 6-24 Sensitivity and Specificity - Presence of Peripheral Oedema 
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Figure 6-25 Summary ROC Curve - Peripheral Oedema 
Examining the data regarding the presence of peripheral oedema for the 
diagnosis of heart failure only one study, Chung et al. (2009), provided a 
Youden's index greater than 0.4.  
 
Analysis using MetaAnalyst provided the following data: 
 
Specificity = 0.797  (95% CI 0.760 − 0.832) 
Sensitivity = 0.467 (95% CI 0.399 − 0.540) 
PLR = 2.30  
NLR = 0.67 
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This test does not have sufficient sensitivity or specificity to provide useful 
diagnostic information for the diagnosis of heart failure in isolation but may 
have value if combined with other, more sensitive variables. 
 
6.2.13 Presence of Dyslipidaemia 
 
The presence of a raised cholesterol level is associated with an increased risk 
of ischaemic heart disease and so could be associated with the presence of 
heart failure. Three studies provided information about this condition in 1,753 
patients. These small studies demonstrate a reasonable specificity, although 
with wide confidence intervals, but a low sensitivity. 
 
 
Figure 6-26 Forest Plot - History of Dyslipidaemia 
6.2.14 The Presence of Rales 
 
The sudden opening of small fluid-filled airways is thought to cause the 
presence of ‘rales’, crepitations or crackles during inspiration that are audible 
on auscultation of the lung fields (Forgacs, 1978). The presence of pulmonary 
oedema with oedematous small bronchi is thought to cause the late opening. 
Similar findings can be found in patients with pulmonary fibrosis. Nineteen 
studies examined this clinical finding and presented data derived from 7,731 
patients. There is considerable variation in the study findings with a tendency 
towards reasonable specificity, but limited sensitivity. 
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Figure 6-27 Sensitivity and Specificity of Presence of Rales 
 
Figure 6-28 Summary ROC Curve - Presence of Rales Presence of Rales 
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This data was entered into Meta-DiSc and the following results were 
obtained. 
 
Heterogeneity chi-squared = 44.82 (d.f. = 17) p = 0.000 
Inconsistency (I2) = 62.1% 
Estimate of between-study variance (Tau-squared) = 0.0872 
 
Data from MetaAnalyst 
 
Specificity = 0.736 (95% CI 0.656 − 0.802) 
Sensitivity = 0.591 (95% CI 0.509 − 0.670) 
PLR = 2.34 
NLR = 0.56 
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Figure 6-29 Summary ROC Curve - Presence of Rales 
Although the data appears to be skewed by three studies that appear to be 
out-lying on the SROC chart, eliminating these studies from the analysis did 
not improve the diagnostic utility of this test. The summary point suggests that 
this finding has limited diagnostic utility. 
 
6.2.15 Presence of Wheeze 
 
The presence of a polyphonic expiratory wheeze is usually considered to be 
due to narrowing of small airways (Forgacs, 1978). This clinical finding is 
suggestive of asthma or chronic obstructive pulmonary disease but can also 
be present in patients with heart failure. In the results of the search nine 
papers provided information about the presence of wheeze from 5,274 
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patients. It can be seen that from the forest plot in Figure 6-30 and the 
summary ROC curve in that the absence of wheeze is suggestive of a cardiac 
cause for the patient’s symptoms.  
 
  
 
Figure 6-30 Sensitivity and Specificity of Absence of Wheeze 
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Figure 6-31 Summary ROC Curve - Absence of Wheeze 
Bayes-Genis et al. (2004), demonstrated good specificity and sensitivity for 
this clinical finding but in the other studies it had unremarkable diagnostic 
value and there was marked heterogeneity in the results. This single study 
was an outlier on the summary ROC curve, and following its exclusion, 
absence of wheeze showed poor diagnostic utility overall.  
 
6.2.16 Patient Taking Beta Antagonist Medication 
 
Beta antagonists or beta-blocker drugs have been shown to improve long-
term survival in patients with heart failure and reduce the damaging 
remodelling that can occur in the failing heart (Krum et al., 1995). The 
beneficial effects are thought to be due to down-regulation of the sympathetic 
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nervous system response(Packer, 1995b). Patients are also commenced on 
beta antagonists as treatment for hypertension, itself a significant risk factor 
for the development of heart failure. It may be reasonable to assume that 
patients who are taking this class of medication are more likely to present with 
heart failure. Six studies provide information about whether 4,007 patients 
were receiving this treatment prior to their attendance, the data is 
summarised in Figure 6-32.  
 
 
Figure 6-32 Forest Plot for Patients Taking Beta-blockers 
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Figure 6-33 Summary ROC Curve for Patients Taking Beta-blockers 
 
The summary ROC curve in Error! Reference source not found. suggests 
some diagnostic value from knowing if a patient has been prescribed this form 
of medicine.  
The data was entered into Meta-DiSc that provided the following information 
about the heterogeneity of the diagnostic odds ratios. 
 
Heterogeneity chi-squared = 16.45 (d.f. = 5) p=0.006 
Inconsistency (I2) = 69.6% 
 
Estimate of between-study variance (Tau-squared) = 0.0805 
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Meta Analyst analysis 
 
Specificity = 0.765  (95% CI 0.692 − 0.835) 
Sensitivity = 0.571  (95% CI 0.441 − 0.692) 
Positive Likelihood Ratio = 2.43 
Negative LR = 0.56 
 
This result suggests that this variable has some diagnostic value although the 
performance is skewed by a single study, Gargani et al. (2008). This finding is 
unlikely to have diagnostic value independently of a positive medical history 
of heart failure, as this would be a common reason to commence a patient on 
this form of medication.  
 
 
6.2.17 History of Chronic Obstructive Pulmonary Disease 
 
 
Patients with a history of Chronic Obstructive Pulmonary Disease (COPD), 
also known as Chronic Obstructive Airway Disease (COAD), may present in a 
similar fashion to patients with heart failure, as they tend to have periods of 
exacerbation and remission of their symptoms that includes breathlessness. 
The clinical picture is further confused as they share some common risk 
factors and indeed, often co-exist. The distinction between the two conditions 
is likely to affect clinical out-come as the treatments for each condition are 
very different. Starting inappropriate treatment on the basis of an incorrect 
diagnosis is likely to be at best ineffectual, and at worst may cause harm. As 
the condition of COPD tends to have intermittent episodes of exacerbation, a 
previous diagnosis of this condition could be assumed to make heart failure 
less likely to be the cause of the patient symptoms. Fifteen studies including a 
total of 6,989 patients provided data about a previous diagnosis of COPD. 
The summary ROC curve of this data is shown in Error! Reference source 
not found. This demonstrates that there is likely to be an association with a 
history of COPD and a cause other than heart failure for patients presenting 
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with acute dyspnoea. The results are variable and may reflect differences in 
prevalence of COPD within the recruited population.  
 
 
Figure 6-34 Forest Plot - History of COPD 
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Figure 6-35 Summary ROC Curve No History of COPD 
  
 
Only one study, Klemen et al. (2009) demonstrated high levels of sensitivity 
and specificity. The other included studies demonstrated little overall 
diagnostic value and this is shown by the relatively flat ROC curve. This study 
was carried out in a pre-hospital setting although all of the patients were 
subsequently admitted to hospital. This may mean that it represents a 
different population from the other studies. However, eliminating this study 
still leaves marked heterogeneity between the studies that would not appear 
to be explained by a positivity threshold effect. With the exception of the 
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single excluded study, there does not seem to be any significant diagnostic 
value to this historical variable. 
 
 
6.2.18 History of Ischaemic Heart Disease 
 
Twenty-four studies provided information about a history of ischaemic heart 
disease. This category was taken to include all patients described as having 
ischaemic heart disease or a history of myocardial infarction or angina. A total 
of 9,902 patients were included in this analysis. The calculated values for 
sensitivity and specificity from each study are provided in Figure 6-36. There 
is considerable variation that suggests a significant degree of heterogeneity 
within the studies. Constructing a summary ROC curve demonstrates an 
approximate curved shape overall that may suggest a threshold effect as 
shown in Figure 6-37. It is reasonable to expect a threshold effect due to 
variations in the definition of ischaemic heart disease. No studies provided a 
sensitivity or specificity high enough to suggest a diagnostic role for heart 
failure.  
 
 
Figure 6-36 Sensitivity and Specificity of IHD as a Predictor of Heart Failure 
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Figure 6-37 Summary ROC Curve – IHD 
 
6.3 Variables with Limited Applicability 
 
Five variables achieved a Youden’s Index of 0.4 or greater suggesting at least 
reasonable diagnostic utility but have been excluded from further analysis on 
the basis that they are not generally available and could not be incorporated 
into standard emergency medicine practice without specific training or 
equipment.  
 
One study, Lo et al. (2007), looked at impedance cardiography and another 
study, Parrinello et al. (2008), examined bioelectrical impedance. While these 
studies had impressive results suggesting useful diagnostic function, each 
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investigation is represented by single study representing novel technology 
that is not routinely available in emergency departments. Therefore, the 
usefulness of the method clinically is limited. 
 
A study by Gegenhuber et al. (2006), demonstrated good sensitivity and 
specificity for mid-range proANP but the assay for this potential biomarker is 
not available for use in emergency departments, and even in the reported 
study it was not superior to BNP or NT-proBNP.  
 
Two studies, Gargani et al. (2008) and Liteplo et al. (2009), looked at the use 
of ultrasound and in particular, the presence of ‘B’ lines or comets, to detect 
pulmonary oedema. While these studies had promising results with high 
specificity and reasonable sensitivity, they used slightly different techniques 
and cut-off values to define a positive result and are therefore not suitable for 
combination for further analysis. As the presence of ultrasound becomes 
more ubiquitous in emergency departments it may have a diagnostic role in 
the future but cannot be recommended as part of a decision pathway at the 
current time. 
 
6.3.1 Impedance Cardiography 
 
One study examined the use of impedance cardiography to diagnose heart 
failure in the breathless patient. In this process a small current is passed 
through the patient’s thorax and the changes in current are used to calculate 
aortic blood volume and flow over time. This data can be used to calculate 
stroke volume and cardiac index. The study involved 52 patients. The results 
of this study are promising but the interpretation needs to be cautious due to 
the small size of the study. 
 
 
Figure 6-38 Forest Plot for Impedance Cardiography 
6.3.2 Bioelectrical Impedance Analysis 
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The measurement of bioelectrical impedance can be carried out non-
invasively using an impedance plethysmograph. This passes an electric 
current through specified areas of the body and measures the impedance to 
the current flow. The associated theory is that increased body water due to 
fluid overload will decrease the bio-impedance. A study by Parrinello et al. 
(2008) has looked at the diagnostic utility of this and has provided diagnostic 
d ata for two cut-off values. 
 
 
Figure 6-39 Forest Plot for Bioelectrical Impedance Analysis 
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Figure 6-40 ROC Curves for Bioelectrical Impedance Analysis 
 
This is very suggestive of significant diagnostic utility but was based on a 
single study that was used to derive the cut-off values for this diagnostic test. 
The technique used appears to be relatively simple and is non-invasive but it 
is not standard practice in the hospital setting and validation would be 
required before advocating this practice.  
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6.3.3 Acoustic Third Heart Sound 
 
 
Two papers, by the same authors, Collins, Lindsell, Peacock, Hedger, et al. 
(2006) and (Collins et al., 2009), have looked at the utility of electronically 
recording the presence of a third heart sound in the diagnosis of heart failure. 
The equipment uses microphones to record the heart sounds while recording 
the patient’s electrocardiograph. The auscultation of the heart sounds is 
analysed along with the electrocardiograph using a computer algorithm and 
these are combined to provide a diagnosis. The two studies involved a total of 
1,338 patients. 
 
 
Figure 6-41 Forest Plot of Acoustic Third Heart Sound 
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Figure 6-42 Summary ROC Curve for Acoustic Third Heart Sound 
The studies suggest that there is good specificity for this test, especially 
compared with standard auscultation, but further validation is required. 
 
6.3.4 Mid-regional pro-Atrial Natriuretic Peptide 
 
Gegenhuber et al. (2006) explored the diagnostic value of ’N’ terminal pro-
Atrial Natriuretic Peptide (NT-proANP) for the condition of acute 
decompensated heart failure using an immunoassay that was targeted at the 
mid-regional epitopes of this molecule, this was also used by Maisel et al. 
(2010). The data from these studies appear promising but further examination 
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and validation of this test is required before widespread clinical use could be 
advocated.  
 
 
Figure 6-43 Forest Plots for MR-proANP 
 
Figure 6-44 ROC Curves for MR-proANP 
 
6.3.5 Use of Ultrasound 
 
The presence of extra fluid within the lung tissue causes linear artefacts to be 
present when using ultrasound to scan lungs. These artefacts are referred to 
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as ‘B’ lines or ‘ultrasound lung comets’. The presence of these have been 
demonstrated to correspond with NYHA functional class and signs on chest x-
rays in-keeping with pulmonary oedema (Jambrik, 2004; Frassi et al., 2007). 
Two studies, Gargani et al. (2008) and Liteplo et al. (2009), involving 243 
patients, reported on this finding as shown in Figure 6-45 and Figure 6-46. 
 
 
Figure 6-45 Forest Plot for Performance of Ultrasound 
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Figure 6-46 Summary ROC Curve for Performance of Ultrasound 
6.4 Variables with High Specificity 
 
Ten variables had very high specificity but low sensitivity. This means that this 
finding dramatically increases the likelihood of heart failure although the 
absence of this variable does not rule the condition out. Only a small 
proportion of the patients in each study had the variable present so the 
clinical utility remains limited. Summary points have been calculated using 
bivariate meta-analysis and the positive likelihood ratios calculated for each 
variable.  
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6.4.1 History of Paroxysmal Nocturnal Dyspnoea 
 
This symptom is described in textbooks as being pathognomonic of heart 
failure. The patient typically describes waking at night with a sudden feeling of 
acute dyspnoea one to two hours after lying down. It is considered that this is 
due to increased venous return when the patient maintains a supine position 
(O'Connor, 2005). Eight studies provided information about this symptom that 
was derived from 2,639 patients as shown in Figure 6-47.  
 
  
 
Figure 6-47 Sensitivity and Specificity PND 
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Figure 6-48 Summary ROC Curve PND 
 
The following results were obtained from Meta-DiSc: 
 
Heterogeneity chi-squared = 10.68 (d.f. = 7) p=0.153 
Inconsistency (I2) = 34.5 
Estimate of between-study variation (Tau-squared) = 0.0432 
 
Despite the moderate inconsistency score the summary ROC curve displays 
a distribution that would be consistent with a threshold effect.  
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Bivariate meta-analysis using MetaAnalyst software provided the following 
summary point: 
 
Sensitivity = 0.409 (95% CI 0.316 – 0.511) 
Specificity = 0.816 (95% CI 0.697 – 0.900) 
 
Although some studies suggested high specificity for this variable, the 
summary point suggests limited diagnostic value, and that is reflected in an 
overall positive likelihood ratio value of 2.28. 
 
6.4.2 Presence of diabetes 
 
Having diabetes increases the risk of developing cardiac disease. Sixteen 
studies with a total of 5,861 patients provided information about a history of 
diabetes in patients with heart failure. This provided reasonable specificity but 
poor sensitivity for the presence of heart failure as illustrated in Figure 6-49 
and Figure 6-50. 
 
 
Figure 6-49 Forest Plot of Presence of Diabetes 
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Figure 6-50 Summary ROC Curve of Presence of Diabetes 
After collating the data into Meta-DiSc software the following results were 
obtained: 
 
Heterogeneity chi-squared = 36.07 (d.f. = 14) p=0.001 
Inconsistency (I2) = 61.2% 
Estimate of between-study variation (Tau-squared) = 0.1187 
 
This suggests moderate heterogeneity and the studies appear widely 
distributed when their descriptive variables are plotted in ROC space. 
Bivariate meta-analysis using MetaAnalyst software provided the following 
summary point: 
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Sensitivity = 0.310 (95% CI 0.244 – 0.382) 
Specificity = 0.783 (95% CI 0.724 – 0.834) 
 
This suggests that although some studies have a very high specificity, the 
overall value does not provide sufficient specificity to conclude that a patient 
definitely has heart failure. The positive likelihood ratio of 1.42 confirms this. 
 
6.4.3 Patients with Atrial Fibrillation 
 
 
Atrial fibrillation, where there is chaotic and uncoordinated depolarisation of 
the cardiac atria, can occur at any age but is more common as patients 
become older. There are a wide variety of causes but the commonest 
aetiology is as a result of ischaemic heart disease (Lip et al., 1995). If atrial 
fibrillation occurs in isolation, it may be well tolerated, but in the presence of a 
heart that is already compromised in some way, it can predispose the patient 
to the clinical manifestations of heart failure. Eight studies provided 
information about the presence or absence of atrial fibrillation in 1,996 
patients. Although there is reasonable specificity associated with this finding 
the sensitivity is poor as shown in Figure 6-51. 
 
 
Figure 6-51 Forest Plot for Presence of Atrial Fibrillation 
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Figure 6-52 Summary ROC Curve for the Presence of Atrial Fibrillation 
 
Analysis of the data using Meta-DiSc software provided the following results: 
 
Heterogeneity chi-squared = 16.66 (d.f. = 6) p = 0.011 
Inconsistency (I2) = 64.0% 
Estimate of between-study variation (Tau-squared) = 0.2197 
 
Bivariate analysis using MetaAnalyst software provided the following 
summary point: 
Sensitivity = 0.286 (95% CI 0.199 – 0.381) 
Specificity = 0.871 (95% CI 0.750 – 0.955) 
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As with the other variables already discussed in this section, although this 
variable demonstrates reasonable specificity, suggesting a positive diagnosis 
of heart failure as the cause of the patient’s symptoms if it is present, the 
absence of atrial fibrillation does not rule out the possibility of heart failure. 
The positive likelihood ratio for this variable was 2.22.  
 
6.4.4 History of Renal Impairment 
 
There is an association between renal disease and cardiac disease and these 
two conditions also share many of the same risk factors such as diabetes and 
hypertension. Ten studies have looked at the existence of renal dysfunction 
and presentation with acute dyspnoea in 5,873 patients. There is some 
variation in the definition of renal impairment. One study, Choi (2007), was 
from Korea and had a very low prevalence of renal impairment compared to 
the other studies, the definition of renal impairment in this paper was not 
provided.  This study was the only one to demonstrate specificity greater than 
95% but had a sensitivity of almost zero and therefore did not provide any 
useful diagnostic information.  
 
 
Figure 6-53 Forest Plot - Renal Impairment 
 
211 
 
 
Figure 6-54 Summary ROC Curve - Renal Impairment 
The data provided from Meta-DiSc was as follows: 
 
Heterogeneity chi-squared = 18.38 (d.f. = 8) p=0.019 
Inconsistency (I2) = 56.5% 
Estimate of between-study variation (Tau-squared) = 0.0922 
 
This suggests significant heterogeneity although most of the study summary 
points lie close to the estimated summary ROC curve. Bivariate meta-analysis 
provided the following results: 
 
Sensitivity = 0.299 (95% CI 0.157 – 0.484) 
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Specificity = 0.907 (95% CI 0.849 – 0.947) 
 
Even with this high specificity this variable does not provide conclusive 
evidence of heart failure as the sensitivity becomes very low as the specificity 
improves. The positive likelihood ratio calculated from the overall summary 
point is 3.22. 
 
6.4.5 Presence of a raised Jugular Venous Pressure 
 
The jugular venous pressure (JVP) can be estimated by examining the patient 
for the venous pulsation within the internal jugular vein. This vein is in direct 
continuation with the right atrium and so provides a measure of the pressure 
within it. The presence of a failing heart will usually lead to a raised jugular 
venous pressure though other conditions, for example superior vena cava 
obstruction can also cause this. The pressure can be measured invasively or 
can be approximated by lying the patient down at 45˚ and seeing if the jugular 
venous waveform can be visualised in the internal jugular vein. Although this 
test is useful when the waveform is visible, it is often difficult to discern in the 
acute unwell patient who is likely to be tachycardic, tachypnoeic and may not 
tolerate lying at this angle. Nineteen studies, with a total of 7,877 patients, 
examined the utility of this clinical finding. As can been seen in the forest plot 
in Error! Reference source not found., the test has good specificity but poor 
sensitivity as a marker for acute decompensated heart failure.  
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Figure 6-55 Forest plot for presence of raised JVP 
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Figure 6-56 Summary ROC Curve for presence of raised JVP 
 
Analysis of the data using Meta-DiSc produced the following results: 
Heterogeneity chi-squared = 27.62 (d.f. = 17) p = 0.056 
Inconsistency (I2) = 37.4% 
Estimate of between-study variation (Tau-squared) = 0.0563 
 
This suggests a low level of heterogeneity. 
 
Bivariate analysis provided the following results: 
Sensitivity = 0.341 (95% CI 0.276 – 0.412) 
Specificity = 0.920 (95% CI 0.889 – 0.945) 
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This corresponds to a positive likelihood ratio of 4.26 so the presence of 
clinically high JVP is very suggestive of heart failure, though as the specificity 
is below 95% it is not advisable to use this result in isolation.  
 
6.4.6 Presence of a Cardiac Murmur 
 
Heart murmurs are audible due to the turbulent flow of blood through the 
heart. Although some heart murmurs are benign and can be a normal finding 
in young patients, the presence of other murmurs suggests valvular disease, 
the presence of abnormal foramen within the heart or abnormal flow rate over 
a normal valve. Detecting heart murmurs can be difficult in a noisy 
environment, especially with an acutely unwell and tachypnoeic patient. 
Auscultation of the heart for the presence of murmurs can be enhanced by 
special manoeuvres or by breath holding; neither of these may be possible in 
the acutely decompensated patient. Six studies were found which looked at 
the presence or absence of audible heart murmurs in a total of 3,327 patients. 
The results of these studies are shown in Figure 6-57 and Figure 6-58 with 
the bivariate meta-analysis results shown in Figure 6-59. 
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Figure 6-57 Forest Plot for Presence of Heart Murmur 
 
Figure 6-58 Summary ROC Curve for the Presence of a Heart Murmur 
 
Analysis of the data using Meta-DiSc provided the following results: 
 
Heterogeneity chi-squared = 5.58 (d.f. 4) p = 0.233 
Inconsistency (I2) = 28.3% 
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Estimate of between-study variance (Tau-squared) = 0.0283 
This suggests moderate heterogeneity. Bivariate meta-analysis presented the 
following summary point: 
Sensitivity = 0.279  (95% CI 0.219 – 0.351) 
Specificity = 0.912 (95% CI 0.870 – 0.943) 
 
This provides a positive likelihood ratio of 3.2 and, although the presence of a 
murmur is strongly suggestive of a diagnosis of heart failure, it is not 
sufficiently specific to rule confirm this condition as an isolated finding.  
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Figure 6-59 Summary ROC Curve Heart Murmur with Bivariate Meta-analysis 
Data 
 
6.4.7 Troponin Levels 
 
Troponin is a very specific cardiac marker, forming part of the contractile 
mechanism in the cardiac myocytes that is released into the circulation 
following cell death. Levels tend to be higher in patients with some degree of 
cardiac dysfunction and this may provide prognostic information (Felker et al., 
2012). A prospective study has shown that troponin levels are raised in 
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around 50% of patients who present with acute decompensated heart failure 
and a further 20% develop a troponin rise during their admission 
(Gheorghiade et al., 2005). Three studies looked at this biomarker in 1,258 
patients. As can be seen with reference to Figure 6-60 and Figure 6-61, this 
test is very specific but has poor sensitivity for the diagnosis of heart failure. 
 
Figure 6-60 Forest Plot for Troponin Rise 
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Figure 6-61 Summary ROC Curve for Troponin Rise 
Pooling the available data using MetaAnalyst software provided the following 
values: 
 
Sensitivity = 0.408 (95% CI 0.234 - 0.629) 
Specificity = 0.908 (95% CI 0.802 - 0.970) 
 
Again, this finding is strongly suggestive of heart failure with a positive 
likelihood ratio of 4.4, but the presence of a high troponin level does not 
confirm the diagnosis by itself. Other advantages of this test include its 
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ubiquity in the UK Emergency Department setting, the objectivity of the test 
and the fact that it is rapidly available.  
 
6.4.8 Hepato-jugular Reflux 
 
The hepato-jugular reflux is elicited by pressing in the right upper quadrant of 
the abdomen and observation to record any rise in jugular venous pressure. 
This was first described by Rondot (1898) as a diagnostic test for heart failure 
but subsequent studies have not confirmed its diagnostic value (Singh & 
Haider, 1973). Two studies with a total of 500 patients provided data about 
this clinical test. The results are provided in Figures 6-62 and 6-63. 
 
 
Figure 6-62 Forest Plot for Hepato-jugular Reflux 
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Figure 6-63 Summary ROC Curve for Hepato-jugular Reflux 
Pooled results suggest a very good degree of specificity in the small 
proportion of patients who had the positive finding with poor sensitivity. 
Results pooled using Meta-DiSc as shown: 
 
Sensitivity = 0.164 (95% CI 0.119 - 0.217) 
Specificity = 0.939 (95% CI 0.903 - 0.965) 
Positive Likelihood Ratio = 2.69 
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6.4.9 Presence of a Third Heart Sound 
 
The presence of a third heart sound occurs in early diastole and is though to 
be due to abnormal ventricular filling. It is usually a pathological finding 
though it can be normal in young adults and during pregnancy. The finding is 
suggestive of heart failure. Twelve studies included the presence of this factor 
and the resulting data is derived from 6,072 patients.  The resulting forest plot 
and summary ROC curve demonstrate that this test is extremely specific but 
has low sensitivity for the diagnosis of heart failure. 
 
 
Figure 6-64 Forest Plot - Presence of Third Heart Sound 
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Figure 6-65 Summary ROC Curve - Presence of Third Heart Sound 
In contrast with many of the other variables examined, the amount of 
statistical heterogeneity was minimal as is reflected in the following results: 
 
Heterogeneity chi-squared = 4.34 (d.f. 9) p = 0.888 
Inconsistency (I2) = 0.0% 
Estimate of between-study variance (Tau-squared) = 0.000 
 
Bivariate meta-analysis provided the following summary point: 
 
Sensitivity = 0.100 (95% CI 0.070 – 0.138) 
Specificity = 0.985 (95% CI 0.973 – 0.993) 
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Although the specificity of this test is excellent, the sensitivity is very poor, in 
keeping with the very low incidence of this clinical sign and so the diagnostic 
value is limited despite a likelihood ratio of 6.66.  
An example is provided to put this result in context: if this test were applied to 
a population of 1,000 patients with a prevalence of heart failure of 40% then 
the following results would be obtained.  
 
Table 6-7 - Example Data for Third Heart Sound -1 
 Heart Failure Not Heart Failure Totals 
3rd Heart Sound 40 9 49 
No 3rd Heart 
Sound 
360 591 951 
Totals 400 600 1000 
 
Therefore nine out of the forty-nine patients would not have acute heart failure 
despite having an audible third heart sound. However, if the patients are 
subjected to a diagnostic process that increases the prevalence or pre-test 
probability of heart failure to 70% then a positive finding becomes much more 
useful for ruling the condition in as shown below.  
 
Table 6-8 Example Data for Third Heart Sound - 2 
 Heart Failure Not Heart Failure Totals 
3rd Heart Sound 70 5 75 
No 3rd Heart 
Sound 
630 295 925 
 700 300 1000 
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6.4.10 Presence of a Fourth Heart Sound 
 
The fourth heart sound is thought to be due to the increased non-compliance 
of the ventricle walls in the presence of heart failure. On contraction of the 
atria, the extra blood causes a sudden increase in pressure rather than 
volume, and this usually signifies abnormal cardiac function. Four studies 
derived data about this finding from 2,258 patients. As with the presence of a 
third heart sound, this clinical finding was highly specific for heart failure but 
demonstrated poor sensitivity as shown in Figure 6-66 and Figure 6-67. 
 
 
Figure 6-66 Forest Plot for Presence of Fourth Heart Sound 
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Figure 6-67 Summary ROC Curve for the Presence of a Fourth Heart Sound 
Using Meta-DiSc software to analyse the available data the following results 
were obtained: 
 
Heterogeneity chi-squared = 3.18 (d.f. 3) p = 0.364 
Inconsistency (I2) = 5.8 % 
Estimate of between-study variance (Tau-squared) = 0.0207 
 
Pooling of the data provided the following summary point: 
 
Sensitivity = 0.037 (95% CI 0.026 – 0.052) 
228 
 
Specificity = 0.983 (95% CI 0.975 – 0.989) 
 
As with the presence of third heart sound there is little statistical 
heterogeneity between the reported studies but an excellent specificity is 
linked to a very poor specificity which limits the diagnostic utility of this finding 
and this is reflected in a positive likelihood ratio of 2.18. 
 
6.5 Variables with Good Diagnostic Value 
 
6.5.1 History of Heart Failure 
 
 
Given that heart failure rarely resolves entirely, that acute exacerbations are 
not associated with a 100% mortality rate and that it tends to follow a course 
of remission and exacerbation, it is not surprising that having a history of 
heart failure in the past, predicts further episodes in the future. The utility of 
this variable as a diagnostic tool is limited in the patient presenting with 
dyspnoea for the first time, but in patients with numerous admissions for heart 
failure in the past, the pre-test probability of heart failure would be expected to 
be substantially higher than that of the general population. Twenty-three 
studies examined this historical variable in 9,080 patients. The findings are 
displayed in Figure 6-68.  The studies suggest that the history of heart failure 
is a reasonably specific finding for diagnosing heart failure although there is 
greater variation in the reported sensitivity. 
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Figure 6-68 Sensitivity and Specificity of a History of Heart Failure 
 
Figure 6-69 Summary ROC Curve - History of Heart Failure 
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Analysis of heterogeneity using Meta-DiSc software provided the following 
information: 
 
Heterogeneity chi-squared = 122.50 (d.f. = 22) p = 0.000 
Inconsistency = 82.0% 
Estimate of between-study variance (Tau-squared) = 0.3163 
(Added ½ to any cells with zero). 
 
MetaAnalyst provided the following bivariate meta-analysis results. 
 
Mean specificity = 0.864 (95% CI 0.819 − 0.903) 
Mean sensitivity = 0.514 (95% CI 0.431 − 0.600) 
 
The overall result suggests reasonable specificity although the results of the 
sensitivity are more variable and limit the overall diagnostic value. Marked 
statistical heterogeneity is present although the distribution in ROC space 
suggests a threshold effect.  
 
Two studies are outliers on examining the summary ROC curve Shah (2009) 
and Chung (2006). The reason for this discrepancy is not obvious. In the 
Shah (2009) study 32.4% of the group of patients who were judged not to 
have acute decompensated heart failure had a history of heart failure. 
Excluding both of these studies from the analysis did not improve the 
heterogeneity scores and did not markedly improve the diagnostic utility: 
 
Heterogeneity chi-squared = 54.02 (d.f. = 20) p=0.000 
Inconsistency = 63.0% 
Estimate of between-study variance (Tau-squared) = 0.1190 
(Added ½ to any cells with zero). 
 
Overall estimated data by Meta-Analyst for data with two studies excluded: 
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Specificity = 0.880 (95% CI 0.845 – 0.911) 
Sensitivity = 0.512 (95% CI 0.420 – 0.610) 
 
As may have been expected, the test is specific as patients who have been 
diagnosed with heart failure before are more likely to present this condition, 
than patients who have never been diagnosed with this malady. The low 
sensitivity may be due to a significant number of patients presenting with 
decompensated heart failure as an initial presentation. There may be some 
bias in applying the reference standard to this group, as patients with a known 
history of heart failure may be more likely to receive this as an end diagnosis.  
 
6.5.2 Clinical Opinion 
 
Information regarding ‘clinical opinion’ was available from nine studies. In 
order to be included the clinical opinion had to be the opinion of the treating 
physician, recorded while the patient was still in the emergency department.  
The opinion needed to be based on the historical, clinical and investigative 
findings that would usually be available at that point in time. Data from eleven 
studies, where the clinician has indicated that it was highly likely or more than 
80% likely that the patient had heart failure, has been included. A total of 
5,357 patients were involved in these studies. One study, Lo (2007), is an 
obviously outlier on the summary ROC curve as shown in Figure 6-71, with 
values far different from the other studies. The other studies follow a 
reasonably smooth curve that would be consistent with a ‘threshold’ effect.  
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Figure 6-70 Forest Plot of Clinical Opinion 
 
 
 
Figure 6-71 Summary ROC Curve - Clinical Opinion 
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Although the individual components that make up clinical opinion may have 
be shown to have limited diagnostic value, clinical opinion overall is 
reasonably accurate. There is considerable variation, and as may be 
expected with such a subjective variable, the pattern of distribution of the 
results in ROC space is strongly suggestive of a threshold effect. 
 
Entering the data and an analysis using Meta-DiSc software provided an 
inconsistency score (I2) of 66.9%, suggesting a high level of heterogeneity. It 
can be seen on the summary ROC curve that one study, Lo (2007), is an 
obvious outlier. The study involved a low number of patients selected as a 
convenience sample with wide confidence intervals and lies far from the 
summary curve compared with the other studies. 
 
Excluding this study improves the I2 score to 57.3%, which remains 
reasonably high, although this score does not account for heterogeneity due 
to the positivity threshold effect. A revised summary ROC curve, excluding Lo 
2007, demonstrates that the lie of the plotted studies is similar the SROC 
curve suggesting a threshold effect. 
 
Bivariate meta-analysis using MetaAnalyst software and excluding Lo (2007) 
provides the following summary point: 
 
Sensitivity = 0.603 (95% CI 0.483 – 0.713) 
Specificity = 0.919 (95% CI 0.852 - 0.965) 
 
It may be difficult to apply this result directly to clinical practice due to the 
subjectivity involved, but examination of the data is useful. It is reassuring 
that, overall, clinical opinion is a reasonably good test of whether or not a 
person has heart failure. It has to be borne in mind that this variable closely 
resembles the reference test that has been applied for these studies and will 
be based on many of the same findings. 
 
In addition to the inter-observer and intra-observer variation that is likely to 
exist with such a subjective criteria, there is also the consideration of the 
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spectrum of the disease; there may be greater discrepancy in the diagnoses 
for patients with mild or moderate symptoms compared with patients with 
severe heart failure.  
 
6.5.3 Presence of Cardiomegaly on the Chest X-ray 
 
The presence of cardiomegaly can be suggested by a widening of the cardio-
thoracic ratio on a posterior-anterior chest film. The normal width of the 
cardiac shadow is generally defined as less than 50% of the internal thoracic 
wall when measured at the widest point. An increase in the size of the cardiac 
shadow on x-ray is suggestive of heart failure in the symptomatic patient. The 
cardiac shadow can be measured either on a physical film or on computer 
image and a ratio between the cardiac shadow and the thoracic diameter can 
be calculated. The estimate of cardiac size is much less reliable on anterior-
posterior (AP) films as the heart is further away from the radiation source and 
so projects a larger shadow. Unfortunately, as patients with acute dyspnoea 
are often too unwell to be transferred to the radiology department, they tend 
to have a portable radiograph that can only be performed as an AP film.  Ten 
studies have looked at this investigative finding in a total of 3,194 patients. 
The summaries of the findings from these studies are presented in Figure 
6-72 and Figure 6-73. 
 
 
Figure 6-72 Sensitivity and Specificity Presence of Cardiomegaly 
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Figure 6-73 Summary ROC Curve - Presence of Cardiomegaly 
 
The data extracted from the studies was analysed using Meta-DiSc software. 
The following results were obtained suggesting marked heterogeneity. 
 
Heterogeneity chi-squared = 52.89 (d.f. = 8) p = 0.000 
Inconsistency (I2) = 84.9% 
Estimate of between-study variance (Tau-squared) = 0.4114 
 
The study Huang (2006) is a notable outlier on the summary ROC curve. The 
study involved small numbers of patients and has wide confidence intervals. 
The study was set in Taiwan and excluded over ten per cent of potentially 
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eligible patients due to poor echocardiography windows. Exclusion of this 
study allowed calculation of the following results: 
 
Heterogeneity chi-squared = 43.85 (d.f. = 7) p=0.000 
Inconsistency (I2) = 84.0% 
Estimate of between-study variance (Tau-squared) = 0.3527 
 
This still suggests significant heterogeneity between the studies although the 
plotted results do not appear to stray too far from the summary ROC curve on 
visual inspection. The next obvious outlier is Chung (2006). The inclusion 
criteria for this included patients with severe dyspnoea and whom the 
attending physician felt needed admission to hospital. This suggests that this 
study population may have been a subgroup of the patients who attended 
hospital with acute dyspnoea, and different from the other study populations 
in this respect. However, elimination of this study did little to improve the 
estimated heterogeneity. 
 
The best diagnostic result was obtained in the Knudsen (2004) study. This is 
a subgroup analysis from a larger study, Maisel (2002), in which patients who 
had their chest x-ray reported by a radiologist while in the emergency 
department. It is possible that selection bias occurred in this population as the 
process by which this occurred it is not clear from the study description. 
 
Heterogeneity chi-squared = 27.75 (d.f. = 5) p = 0.000 
Inconsistency (I2) = 82.0% 
Estimate of between-study variance (Tau-squared) = 0.2650 
 
Bivariate meta-analysis was performed using MetaAnalyst software on the 
available data excluding Huang 2006 and provided the overall summary point: 
 
Sensitivity = 0.640 (95% CI 0.554 – 0.718) 
Specificity = 0.75 (95% CI 0.652 – 0.825) 
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The studies do not provide information about whether the x-rays were taken 
as AP or PA films. Excluding the Knudsen (2006) study makes the summary 
point slight less diagnostic as shown: 
 
Sensitivity = 0.617 (95% CI 0.540 – 0.688) 
Specificity = 0.736 (95% CI 0.616 – 0.833) 
 
The presence of cardiomegaly may be suggestive of chronic heart failure, 
rather than an acute episode but given the remitting and relapsing nature of 
this condition, there is likely to be some diagnostic value of the recognition of 
this finding. This is reflected in the summary result. This long period that is 
required to develop this feature may mean that it is not be independent of 
other variables, such as a history of a previous diagnosis of heart failure.  
 
 
6.5.4 Oedema on Chest X-ray 
 
Chest x-rays are performed on almost all patients presenting to emergency 
departments due to shortness of breath. The investigation is fast, portable, 
rapid, non-invasive, and painless and can help, not only with the diagnosis of 
heart failure, but can also aid in the diagnosis of other conditions, such as 
pneumonia or pneumothorax. Pulmonary oedema develops in heart failure 
due to the increased pulmonary venous pressure causing increased 
hydrostatic pressure leading to capillary leakage. This process was first 
described by Starling (1896). Fluid first tends to accumulate around the 
pulmonary vessels with blurring of their appearance on x-ray, subsequently 
Kerley lines and sub-pleural effusions develop. This is referred to as 
interstitial pulmonary oedema. Further increases in pressure result in fluid 
filling the alveoli which causes diffuse opacity of the lower parts of the lungs 
or occasionally the peri-hilar regions (Gluecker et al., 1999). Two studies 
specified whether interstitial oedema or alveolar oedema was present on the 
x-ray; the other studies just had a section for general pulmonary oedema. 
Theses studies have been considered together for the purposes of this 
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analysis. Twelve studies involving 4,162 patients reported on this finding. The 
results are shown in Figure 6-75  
 
Figure 6-74 Presence of pulmonary oedema on chest x-ray 
 
Figure 6-75 Forest Plot - Presence of Pulmonary Oedema on CXR 
Analysis of the data using Meta-DiSc provided the following analysis 
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Heterogeneity chi-squared = 17.54 (d.f. = 11) p = 0.093 
Inconsistency (I2) = 37.3% 
Estimate of between-study variance (Tau-squared) = 0.0791 
 
All of the studies apart from Kang (2006) appear to follow the estimated 
summary ROC curve suggesting a positivity threshold effect. In the study 
reported by Knudsen et al (2004), in which the chest x-rays were reported by 
radiologists in the emergency department, rather than the attending 
physician, there was higher specificity than the other studies.  This study still 
lay close to the summary ROC curve as it demonstrate a relatively low 
sensitivity. The study by Kang et al (2006) was set in Korea and involved a 
small number of patients. The results suggested very good specificity and 
reasonable sensitivity but with very wide confidence intervals. Exclusion of 
this study provided the following results: 
 
Bivariate meta-analysis of the data using MetaAnalyst software provided the 
following overall estimates: 
 
Sensitivity = 0.543 (95% CI 0.412 – 0.667) 
Specificity = 0.890 (95% CI 0.819 – 0.940) 
 
This demonstrates reasonably good specificity with moderate sensitivity. 
Although this finding does not demonstrate a definitive diagnostic role in 
isolation, it may have value as part of a diagnostic pathway.  
 
 
6.5.5 Cephalisation of Vessels on Chest X-ray 
 
Pulmonary vascular congestion occurs as a result of impaired pumping by the 
left ventricle, which leads to increasing left atrial pressure, which leads, in 
turn, to pulmonary hypertension. In a person with normal cardiac and 
pulmonary function the blood flow within the lungs is not distributed evenly. 
Due mainly to gravity, the blood tends to be present in the lower vessels with 
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a reduction in relative perfusion of the upper lung compared with the lower 
lung. In pulmonary hypertension this pattern of distribution is lost as the 
pressure increases and the upper lobe vessels dilate as a result. This may be 
visible on viewing a chest x-ray due to the relative dilatation of the upper lung 
vessels. Four studies examined this investigative finding in 1,633 patients as 
summarised in Error! Reference source not found. and Figure 6-78. 
 
 
Figure 6-76 Sensitivity and Specificity of Cephalisation of the Vessels on CXR 
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Figure 6-77 Summary ROC Curve for Cephalisation of Vessels 
 
Analysis of the four studies for heterogeneity using Meta-DiSc provided the 
following results: 
 
Heterogeneity chi-squared = 3.59 (d.f. = 3) p=0.309 
Inconsistency (I2) = 16.4% 
Estimate of between-study variance (Tau-squared) = 0.0233 
 
This shows relatively low heterogeneity. Two of the studies, Morrison (2002) 
and Knudsen (2004), show data from the same centre although one of the 
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authors has confirmed in correspondence that there was no overlap in 
recruited patients (Schwam, 2004). 
 
Meta-analysis of the results using Meta-Analyst provided the following results. 
 
Sensitivity = 0.603 (95% CI 0.368 – 0.797) 
Specificity = 0.894 (95% CI 0.751 – 0.967) 
 
Applying the resultant data to RevMan software provided the following 
summary ROC curve suggesting that the finding may have a diagnostic role. 
The finding is unlikely to be independent of the presence of pulmonary 
oedema on the x-ray. 
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Figure 6-78 Summary ROC Curve with Bivariate Data Cephalisation Vessels 
 
6.5.6 Brain Natriuretic Peptide 100 pg/ml 
 
 
Nineteen studies provided information about a total of 27 different cut-off 
values for Brain Natriuretic Peptide (BNP) with several studies providing data 
at various cut-off thresholds. There was also more than one type of BNP 
assay used. For this analysis the value of 100pg/ml as a cut-off was chosen 
as this is the level recommended by both Biosite Inc. and Abbott Laboratories 
to rule out heart failure. These manufacturers produce the assays have been 
used in the vast majority of the published studies. A total of sixteen studies 
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provided information about this threshold for BNP derived from 7,659 patients 
as shown in Figure 6-79 and Figure 6-81. This cut-off point was deliberately 
chosen in order to rule-out heart failure and has therefore been chosen to 
maximise sensitivity. The sensitivity is correspondingly high in all of the 
selected studies, though the specificity is more variable.  
 
 
 
 
 
Figure 6-80 Summary ROC Curve - BNP 100 pg/ml 
 
 
 
 
 
Figure 6-79 Forest Plot - Brain Natriuretic Peptide 100pg/ml 
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Figure 6-81 Summary ROC Curve for BNP 100pg/ml 
 
The majority of studies used the Biosite assay while two studies, Mueller 
(2005) and Ababsa (2005), used the Abbot Laboratories assay. Testing for 
heterogeneity provided the following results: 
 
Heterogeneity chi-squared = 69.24 (d.f. = 14) p = 0.000 
Inconsistency (I2) = 79.8% 
Estimate of between-study variance (Tau-squared) = 0.5360 
 
Eliminating studies on the basis of size, assay used or various measures of 
quality failed to significantly reduce the inconsistency score. This variation 
246 
 
may be due to the variety in the cut-off value of the applied reference 
standard. There is no obvious correlation between the prevalence of heart 
failure in the studies and the level of specificity of the test. 
 
 
Figure 6-82 - Prevalence of Heart Failure Versus Specificity for BNP Studies 
Bivariate meta-analysis of this data gave the following results: 
 
Sensitivity = 0.958 (95% CI 0.939 – 0.974) 
Specificity = 0.608 (95% CI 0.499 – 0.707) 
 
 
Six of the studies included the BNP result as part of the reference standard. 
Analysis of the studies where BNP did not form part of the reference standard 
was also performed. This analysis estimated lower heterogeneity and actually 
improved sensitivity. 
 
 
Heterogeneity chi-squared = 21.84 (d.f. = 8) p = 0.005 
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Inconsistency (I2) = 63.4% 
Estimate of between-study variance (Tau squared) = 0.2146 
 
Sensitivity = 0.965 (95% CI 0.948 – 0.979)  
Specificity = 0.551 (95% CI 0.441 – 0.652) 
  
 
6.5.7 Brain Natriuretic Peptide 400 pg/ml 
 
 
The cut-off recommended by Biosite Inc. to rule in heart failure is 400 pg/ml. 
Six studies, involving 2,564 patients were found to provide data about this 
value as illustrated in Error! Reference source not found. and Figure -6-84. 
As this cut-off value was chosen to maximise specificity it is unsurprising that 
the specificity of this test is excellent, although the sensitivity also remains 
reasonable at this threshold. 
 
 
Figure 6-83 Forest Plot for BNP with 400 pg/ml Cut-off 
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Figure -6-84 Summary ROC Curve - BNP 400 pg/ml 
 
 
Analysis of this data using Meta-DiSc provided the following estimates: 
Heterogeneity chi-squared = 42.53 (d.f. = 5) p = 0.000 
Inconsistency (I2) = 88.2% 
Estimate of between-study variance (Tau-squared) = 0.9784 
 
Meta-analysis of the data using MetaAnalyst software provides the following 
summary point: 
 
Sensitivity = 0.771 (95% CI 0.664 – 0.865) 
Specificity = 0.927 (95% CI 0.850 – 0.975) 
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This would suggest significant heterogeneity although this is not apparent on 
looking at the summary ROC curve. The I2 score is considered to exaggerate 
the level of heterogeneity when a small number of studies are used (Hardy & 
Thompson, 1998). 
 
The obvious outlying study in terms of specificity is Chung et al (2006). The 
inclusion criteria for this study included severe dyspnoea that the attending 
physician felt necessitated hospital admission; this may have been a different 
population from the other studies that included all attenders with acute 
dyspnoea.  
 
Excluding this study from the estimate of heterogeneity failed to improve the 
estimated level of statistical heterogeneity as shown: 
 
Heterogeneity chi-squared = 38.71 (d.f. = 4) p = 0.000 
Inconsistency (I2) = 89.7% 
Estimate of between-study variance (Tau-squared) = 1.0959 
 
Excluding the Chung (2006) study improved the specificity as shown: 
 
Sensitivity = 0.761 (95% CI 0.640 – 0.873) 
Specificity = 0.950 (95% CI 0.916 – 0.979) 
 
6.5.8  ‘N’ Terminal proBNP (NT-proBNP) 
 
 
NT-proBNP also has two cut-off levels recommended by Roche Diagnostics 
who are the main manufacturers of this assay. Patients with levels below 300 
pg/ml are considered very unlikely to have acute heart failure and patients 
with levels greater than 1800 pg/ml are considered very likely to have acute 
heart failure. Patients with levels in between these two values are considered 
to have moderate likelihood of acute heart failure. Three studies provided 
data about the cut-off value of 300 pg/ml and a further study, Mueller (2005), 
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provided data from the cut-off value of 292 pg/ml, which has been included in 
this group. This data represents very high sensitivity as demonstrated in 
Error! Reference source not found..  
 
Figure 6-85 Forest Plot Using NT-proBNP Cut-off Value of 300 pg/ml 
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Figure 6-86 Summary ROC Curve for NT-proBNP with Cut-off Value of 300 
pg/ml 
Only four studies provide information about this cut-off level. Meta-analysis is 
not appropriate with so few studies. Pooling of the data provides an 
approximate summary value. The data was pooled using Meta-DiSc software 
to give the following results: 
 
Pooled sensitivity = 0.981 (95% CI 0.968 – 0.990) 
 
Pooled specificity = 0.575 (95% CI 0.539 – 0.610) 
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The manufacturers also recommend a higher cut-off value of 1800 pg/ml. No 
studies were found that used this cut-off value to rule-in the condition of heart 
failure but one study used 2000 pg/ml, Klemen (2009) and a further study, 
Lainchbury (2003), used a cut-off of 240 pmol/l which is equivalent to 2029.7 
pg/ml and these have been grouped together for the purpose of the analysis. 
This cut-off provides good sensitivity and specificity as displayed in 
Figure 6-87 and Figure 6-88. 
Figure 6-87 Forest Plot Using NT-proBNP with Cut-off Value of 2000 pg/ml 
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Figure 6-88 Summary ROC Curve Using NT-proBNP with Cut-off Value of 
2000 pg/ml 
Only two studies provided information about this cut-off. The results have 
been pooled using Meta-DiSc software. 
 
Pooled sensitivity = 0.838 (95% CI 0.792 – 0.877) 
 
Pooled specificity = 0.825 (95% CI 0.781 – 0.864) 
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6.6 Discussion 
 
“Mankind always sets itself only such problems as it can solve; since, looking 
at the matter more closely, it will always be found that the task arises only 
when the material conditions for its solutions already exist or at least are in 
the process of formation." - Karl Marx (1859) 
 
A summary of the optimum diagnostic variables is provided in Table 6-9. It 
can be seen from the results of the meta-analysis that the natriuretic peptides, 
BNP and NT-proBNP, are superior to any other individual diagnostic test and 
even appear to out-perform the clinical assessment by the attending 
physician. 
 
Although a search of the literature dating back to 1950 was performed, the 
majority of papers concerning the diagnosis of heart failure have been 
published since the discovery of BNP, suggesting that the difficulties in 
making this diagnosis were not acknowledged, at least in medical literature, 
until this superior test was discovered. 
 
The variables tend to perform well in terms of either sensitivity or specificity, 
with the perfect diagnostic test that is both sensitive and specific, remaining 
elusive. The use of upper and lower cut-off values for the natriuretic peptides, 
optimised for specificity and sensitivity respectively, bypass this issue to some 
extent, but still leave a zone of intermediate risk. Unfortunately, there is some 
evidence that this zone overlaps with the region of clinical diagnostic 
uncertainty (Schwam, 2004). 
 
Having selected the strongest candidates for inclusion in a clinical decision 
rule (CDR) and having derived summary values to represent their diagnostic 
performance it would appear to be a simple process to combine the sensitive 
and specific tests to derive a robust CDR. Unfortunately, by examining each 
of the tests in isolation there is no assessment of the independence of the 
tests. In order to derive the optimum combination of diagnostic variables to 
synthesise the CDR, individual patient data must be used so that it is possible 
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to perform multivariable analysis and assess the utility of the potential 
components in this situation. 
 
6.6.1 Summary of Findings 
 
Table 6-9 Summary Table - Diagnostic Utility of Selected Variables 
Diagnostic 
Variable 
Summary 
Sensitivity 
Summary 
Specificity  
Positive 
Likelihood 
Ratio (LR+) 
Negative 
Likelihood 
Ratio (LR-) 
History of HF 0.514 (95% 
CI 0.431 − 
0.600) 
0.864 (95% 
CI 0.819 − 
0.903) 
 
2.02 0.23 
Clinical 
Opinion 
0.603 (95% 
CI 0.483 – 
0.713) 
0.919 (95% 
CI 0.852 - 
0.965) 
6.94 0.43 
Large cardiac 
shadow on 
CXR 
0.640 (95% 
CI 0.554 – 
0.718) 
0.75 (95% CI 
0.652 – 
0.825) 
2.76 0.5 
Pulmonary 
oedema 
0.543 (95% 
CI 0.412 – 
0.667) 
0.890 (95% 
CI 0.819 – 
0.940) 
4.47 0.53 
Cephalisation 
of vessels 
0.603 (95% 
CI 0.368 – 
0.797) 
0.894 (95% 
CI 0.751 – 
0.967) 
5.69 0.44 
BNP 100 
pg/ml 
0.958 (95% 
CI 0.939 – 
0.974) 
0.608 (95% 
CI 0.499 – 
0.707) 
2.15 0.05 
BNP 400 
pg/ml 
0.771 (95% 
CI 0.664 – 
0.865) 
 
0.927 (95% 
CI 0.850 – 
0.975) 
12.79 0.29 
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NT-proBNP 
300 pg/ml 
0.981 (95% 
CI 0.968 – 
0.990) 
0.575 (95% 
CI 0.539 – 
0.610) 
2.55 0.03 
NT-proBNP 
2000 pg/ml 
0.838 (95% 
CI 0.792 – 
0.877) 
0.825 (95% 
CI 0.781 – 
0.864) 
4.79 0.20 
Impaired 
Renal 
Function 
0.299 (95% 
CI 0.157 – 
0.484) 
0.907 (95% 
CI 0.849 – 
0.947) 
2.82 0.81 
Raised JVP 0.341 (95% 
CI 0.276 – 
0.412) 
 
0.920 (95% 
CI 0.889 – 
0.945) 
 
4.52 0.75 
Presence of 
heart murmur 
0.279  (95% 
CI 0.219 – 
0.351) 
0.912 (95% 
CI 0.870 – 
0.943) 
3.30 0.77 
Raised 
Troponin 
0.408 (95% 
CI 0.234 - 
0.629) 
0.908 (95% 
CI 0.802 - 
0.970) 
3.31 0.78 
Hepato-
jugular Reflux 
0.164 (95% 
CI 0.119 - 
0.217) 
0.939 (95% 
CI 0.903 - 
0.965) 
2.69 0.89 
Presence of 
3rd HS 
0.100 (95% 
CI 0.070 – 
0.138) 
0.985 (95% 
CI 0.973 – 
0.993) 
6.56 0.91 
Presence of 
4th HS 
0.037 (95% 
CI 0.026 – 
0.052) 
0.983 (95% 
CI 0.975 – 
0.989) 
2.18 0.98 
 
 
6.6.2 Limitations of the Systematic Review 
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The search has designed to be as open and inclusive as possible to ensure 
that no studies concerned with the diagnosis of acute heart failure in the 
Emergency Department setting were missed. Publication bias in diagnostic 
studies is an unknown quantity (Song et al., 2002). It is very likely to exist, as 
the same pressures that encourage the publication of positive results for 
interventional studies apply to diagnostic studies but this matter has not been 
studied. The publication bias for interventional trials has been quantified by 
the requirement to register the trials before they commence but no such 
registers have been created for the diagnostic studies. The paucity of new 
data generated by the grey literature search did not suggest a wealth of 
unpublished material.  
 
It was recognised that the quality of the included studies was variable. The 
decision was made not to exclude studies directly on the basis of poor quality 
but to assess the impact of these studies on the sum of knowledge and 
explore the effects of including these studies.  
 
Likewise it was recognised that considerable heterogeneity exists even in 
studies purporting to study the same variable, with the same threshold, in the 
same population. This is to be expected given the lack of an objective 
reference standard and variations in definitions and populations that are likely 
to exist in a variety of geographic and social environments. Heterogeneity has 
not been grounds for exclusion of studies and the possible reasons for its 
presence and the effects on the results have been explored in the analysis. 
 
Most of the variables that have been examined may also form part of the 
reference standard. The results of this inclusion bias are difficult to ascertain. 
In theory, if a certain variable were to be considered pathognomonic for a 
diagnosis, then the presence a positive finding would confirm both the 
diagnosis and the importance of this variable for making the diagnosis. In 
practice, none of the variables examined demonstrated this degree of 
diagnostic certainty, and the only variables that approached this optimal 
performance, the natriuretic peptides, retained this diagnostic utility even 
when the blinding was in place. 
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It was recognised that the ideal clinical decision rule, combining several 
independent predictor variables, which each demonstrated good diagnostic 
utility, was unlikely to be attained.  
 
The variation in the applied reference standards for the included studies is 
likely to be one of the sources of heterogeneity in this review. In the absence 
of a recognised gold standard all that can be done is to acknowledge that this 
is not ideal. The quality of the reference standards used was considered as 
part of the inclusion criteria for the selected studies, and the reference 
standard applied has been considered in attempting to explain apparent 
heterogeneity. Information about the reference standard used has been 
provided for each of the included studies so that the reader can make an 
informed interpretation of the provided analysis. This is a pragmatic solution 
as, in real-life practice, the diagnosis has to be made and treatment initiated, 
often with less evidence than is available in these studies. While hindsight 
allows greater clarity of vision, these patients require immediate treatment, 
and the challenge is to ensure that the immediate treatment is also the 
optimal treatment.  
 
One issue with this review is that the tests are being examined and analysed 
in isolation; this does not reflect clinical practice. It has been suggested that 
diagnostic tests perform better in combination than they do individually (Irwig 
et al., 2006). The variable of clinical opinion overcomes this to some degree, 
although this will also have inclusion bias due to the similarity this will bear to 
the end-diagnosis. If a patient is confidently diagnosed as having heart failure 
in the emergency department and the specific treatment for this condition is 
commenced and continued then this may influence the end-diagnosis even 
when the person making the end-diagnosis is blinded to the documented 
opinion of the emergency physician.  
 
Another limitation of this systematic review is that it does not assess the 
independence of the diagnostic variables. This information is essential if one 
intends to create a diagnostic pathway as it optimises the value of each 
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applied diagnostic test. One would also like to know how the diagnostic 
variables perform in combination as it there may a synergistic effect where 
the combined tests perform better than would be expected from combining 
their individual utility values.  
 
6.6.3 Limitations of Brain Natriuretic Peptide 
 
A recognised problem with the use of the natriuretic peptide levels is the 
presence of a diagnostic ‘grey area’. A very low result rules out heart failure 
with excellent sensitivity and a very high level of BNP has sufficient specificity 
to confirm the diagnosis with confidence. This leaves a range of results 
between these two cut-off values where the diagnostic power is less 
definitive, although it still compares well with any other individual diagnostic 
test. The two studies that provide data about both cut-off values, Choi (2007) 
and Logeart (2002), had around 25% of the included patients in this 
diagnostic grey zone. Maisel (2002) presents a ROC curve for the BNP at 
various thresholds that is shown in Figure 6-89. This demonstrates that even 
with values in the middle of the diagnostic ‘grey-zone’ there is still reasonable 
sensitivity and specificity. A diagnostic pathway could use a range of values 
rather than just a positive or negative dichotomy in order to maximise the 
information provided by this result.  
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Figure 6-89 ROC Curve and Data for BNP Taken From Maisel 2002 
BNP and NT-proBNP are cleaved from the same molecule and so should be 
created in the same proportion at the same time. In fact NT-proBNP levels 
rises more than BNP in the acute setting. This is probably due to differences 
in the clearance method with NT-proBNP being eliminated by renal clearance 
while BNP is broken down by endo-peptidases. The diagnostic utility of these 
molecules is very similar as can be seen by combining ROC curves for BNP 
at 100 pg/ml and NT-proBNP at 300 pg/ml as shown in Figure 6-90. The 
summary ROC curves are almost identical. These variables are unlikely to be 
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independent, as the values would be expected to correlate with each other in 
any particular patient.  
 
There are known limitations for the use of brain natriuretic peptide as a 
marker for acute heart failure; levels are known to be affected by age, renal 
function, obesity, sex and other conditions that can cause ventricular strain 
such as pulmonary embolism. These factors are explored in more detail in 
Chapter 3 of this thesis. The reasons for false positive results were not 
documented or explained in the included studies although it may be due to 
patients having with some degree of cardiac failure even if this is not the 
primary cause for their attendance. As a high BNP level is a significant 
predictor of all-cause mortality, it is probably prudent to recommend 
admission and further investigation of these patients, even if heart failure is 
not felt to be the cause of their symptoms (Hammerer-Lercher et al., 2010). 
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Figure 6-90 Summary ROC Curve Comparing BNP 100 pg/ml data against 
NT-proBNP 300 pg/ml data 
 
6.6.4 Other Reviews of the Literature 
 
Other systematic reviews examining the diagnosis of heart failure have been 
conducted, although these have been concerned with the diagnosis of chronic 
heart failure and so have not been in the Emergency Department setting. 
Issues that have previously been explored have been concerned with the 
selection of appropriate patients for further elective investigation and 
specialist referral. 
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Khunti et al. (2000) looked performed a systematic review of the available 
literature in order to assess the value of clinical and historical findings in 
confirming a diagnosis of left ventricular systolic dysfunction in patients 
presenting in a primary care setting. The authors concluded that although 
some symptoms and signs were suggestive of heart failure, there were no 
findings conclusive enough to make a firm diagnosis without further 
investigation such as ECG or echocardiogram. Significant findings were the 
presence of dyspnoea, ankle swelling, a history of myocardial infarction, 
hypertension or angina, raised JVP, oedema, abnormal apical pulse, basal 
crepitations and a baseline pulse between 90 – 100 bpm.  
 
Fonseca et al. (2004) looked at a random selection of 6300 patients over the 
age of 25 to examine the prevalence of heart failure within the population of 
Portugal. Patients who were suspected of having heart failure underwent 
chest radiography, ECG, blood tests and an echocardiogram. 17% of the 
patients were excluded, as an echocardiogram could not be performed. In this 
sub-group of selected patients, an abnormal ECG had a sensitivity of 80% 
and a specificity of 40%. An abnormal chest x-ray had sensitivity of 57% and 
a specificity of 78%.  The most sensitive components of chest x-ray 
abnormality were the presence of cardiomegaly and an enlarged 
cardiothoracic ratio (>0.50). Pulmonary vessel cephalisation and lung 
interstitial oedema had a sensitivity of 18%.  
 
Craig et al. (2005) performed a Health Technology Assessment examining 
the use of natriuretic peptides in the investigation of patients with suspected 
heart failure. The authors performed a literature review and cost effectiveness 
assessment for the use of natriuretic peptide measuring in patients in primary 
care and in the acute setting.  The main recommendations for the use of 
natriuretic peptide testing were as a rule-out test for General Practitioners 
who were not confident in ECG interpretation and in the acute setting where 
there remained diagnostic uncertainty.  
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Davenport et al. (2006) carried out a systematic review and meta-analysis to 
assess the accuracy of natriuretic peptides and ECG in the diagnosis of left 
ventricular systolic dysfunction. The authors selected studies using nuclear 
studies or echocardiography as a reference standard to confirm the 
dysfunction. The authors found that while ECG, BNP and NT-proBNP tended 
to be sensitive tests for heart failure there remained considerable variation in 
the published data. The specificity results tended to be lower and were even 
more heterogeneous for all three tests. The authors also found that combining 
BNP and ECG findings did not improve the diagnostic value beyond that of 
the individual tests. 
 
Clerico et al. (2007) performed a systematic review and meta-analysis of 
studies comparing the diagnostic utility of BNP with that of NT-proBNP for 
patients with either chronic or acute heart failure. The authors included and 
analysed 15 studies concerned with diagnosing patients with chronic heart 
failure, and 9 studies examining the relative diagnostic values in patients with 
acute heart failure. The authors did not find any significant difference between 
the two compounds in terms of their diagnostic value. The diagnostic odds 
ratio (DOR) for the condition of chronic heart failure for BNP was 8.44 (95% 
CI 4.66 – 15.30) versus 23.36 (95% CI 9.38 – 58.19) for NT-proBNP; for 
acute heart failure the respective DORs were 16.46 (95% CI 10.65 – 25.43) 
and 18.61 (95% CI 12.99 – 26.65).  
 
Mant et al. (2010) et al performed a systematic review and meta-analysis 
examining the diagnosis of heart failure within primary care on behalf of the 
Health Technology Assessment programme. The patient population used in 
this analysis is significantly different to the patients presenting to the 
Emergency Department in terms of the acute onset of the condition. The 
investigations available to the General Practitioner may be more limited and 
there will usually be a greater delay in receiving the results of these tests. The 
authors found that dyspnoea had high sensitivity but poor specificity for the 
diagnosis of heart failure, while a history of myocardial infarction, orthopnoea, 
oedema, cardiomegaly, added heart sounds and hepatomegaly all had high 
specificity but low sensitivity. The recommendation was that patients with 
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dyspnoea and a history of myocardial infarction, basal crepitations or ankle 
oedema should be referred for echocardiography. In patients without these 
findings, a natriuretic peptide level should be checked and depending on 
certain cut-offs which vary depending on the patient’s sex and the presence 
or absence of ankle oedema, a decision should then be made about whether 
the patient requires echocardiography. BNP and NT-proBNP were found to 
be of equivalent diagnostic value.  
 
The emergency department attracts a different population of patients than 
those attending their family doctor and these patients are more likely to 
represent the more severe end of the disease spectrum. Patients presenting 
with an acute onset of symptoms may not have had time to develop the 
stigmata of chronic heart failure. It may also be difficult to obtain a history of 
recent events or past medical history in the acutely unwell, dyspnoeic patients 
and it is unlikely that the Emergency Physician will have any prior knowledge 
of the patient. On the other hand, there is greater accessibility for tests and 
investigations with results available in minutes or hours rather than days or 
weeks. 
 
6.6.5 Application of Study Findings 
 
In the consideration of the patient with undifferentiated acute dyspnoea, the 
patient still needs to be assessed in the traditional manner with regards to 
history taking, examination and the relevant investigations performed, 
although it is now possible to estimate the diagnostic utility of each of the 
components with regards to the diagnosis of heart failure. Individual 
components can be combined to produce a more definitive post-test 
probability to confirm or refute the diagnosis of heart failure. 
 
It remains important to define the aetiology of the patients’ symptoms and so, 
investigations that may impart information suggesting diagnoses other than 
heart failure should be continued. Informing a dyspnoeic patient that their 
symptoms do not arise from heart failure is likely to provide little comfort if an 
alternative diagnosis cannot be provided.  
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Although the systematic review and meta-analysis suggest that the natriuretic 
peptides bear significant diagnostic promise, questions that remain 
unanswered include which group of patients, and at what stage in the 
diagnostic pathway, should these tests be used? 
 
 
6.6.6 The Need For Original Research 
 
A further study was felt to be necessary to confirm the findings of the 
systematic review in a prospective study in the UK setting, thus allowing a 
wide range of potential diagnostic variables to be reliably collected and then 
analysed. This would allow determination of the independence of the 
variables and facilitate the derivation of a clinical decision rule to guide 
clinicians towards an optimal and consistent diagnostic route. The methods 
and data analysis for the clinical study are presented in the next chapter. 
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Chapter 7 Original Diagnostic Study 
 
7.1 Introduction 
 
7.1.1 Research Background 
 
The intention of this research was to devise a clinical decision rule for the 
diagnosis of heart failure, confirming or refuting its presence in patients 
presenting to an Emergency Department due to acute breathlessness. The 
rule had to be applicable to patients in the United Kingdom setting and only 
incorporate information that is routinely available at the time of patient’s 
attendance in an Emergency Department. 
  
7.1.2  Considerations for this Study 
 
In order for the research to be applicable to clinical practice it was important 
to use the clinical findings and parameters that would be readily available in 
most emergency departments in the UK. As these decisions are currently 
made in clinical practice in the emergency setting everyday, a pragmatic 
approach to this study was considered appropriate. The clinical decisions 
have to be made quickly as it benefits the patient to have rapid and 
appropriate treatment started as soon as possible.  
 
In order to confirm the diagnosis in this study, each patient had an 
echocardiogram performed as part of the reference standard. This is not 
standard practice in UK Emergency Medicine although the use of general 
ultrasound has become more commonplace in UK departments and has 
recently been added to the College of Emergency Medicine Curriculum (CEM, 
2014). This means that most departments in the UK have access to an 
ultrasound machine that is capable of at least limited echocardiography views 
and trainees with a potentially transferrable skill set. Other studies have 
examined the use of Emergency Department echocardiography in the 
assessment of patients with acute coronary syndrome (Mohler et al., 1998). 
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Although natriuretic peptides are used in the diagnosis of acute heart failure 
in some European and US centres, BNP and NT-proBNP testing do not form 
part of current standard practice in the UK setting. It was therefore considered 
reasonable to keep the attending physician blind to these investigation results 
for the purposes of this study.  
 
High sensitivity Troponins now form part of the standard investigations for 
Acute Coronary Syndrome (ACS) but the utility of this test for the diagnosis of 
heart failure remains unknown. As this does not form part of current practice, 
it was considered reasonable to perform this test without informing the 
attending physician of the result. The cardiologists providing the reference 
standard were also blinded to these data in order to assess the absolute utility 
of these variables without bias.  
 
7.2 Methods 
 
7.2.1 Setting 
 
This study was carried out in a large city-centre emergency department in a 
university teaching hospital that had around 175,900 emergency attendances 
per year during the duration of the study (HSCIC, 2011). The department staff 
levels at the time of this study consisted of ten Consultants, nine middle-
grade doctors (Specialist Registrar or equivalent) and two Clinical Research 
Fellows with part-time clinical commitment. 
 
Ethical approval was obtained through the local National Health Service 
(NHS) Research Ethics Committee as detailed in Appendix III.  
 
The patients were recruited on a convenience basis between the start of 
March 2008 and the end of June 2009. Physicians working in the Emergency 
Department, including the lead researcher, recruited patients. The recruiting 
physicians were all either middle-grade doctors or consultants.  
 
Roche Diagnostics provided the sample kits for the NT-proBNP testing 
without cost.  Biosite provided the meter required to perform the point of care 
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testing for BNP without cost (Triage Meter Pro with Census Data 
Management Software). The appropriate testing kits were purchased from 
Biosite.  
 
 
 
7.2.2 Inclusion/Exclusion criteria 
 
The inclusion criteria for patients presenting to the emergency department 
consisted of a primary complaint of dyspnoea in patients who were aged 50 
years or older at the time of recruitment. It was not necessary for patients to 
be admitted to hospital to be included.  
 
This age cut-off was chosen as it was considered unlikely for patients below 
this age to present with decompensated heart failure in the UK setting (Cowie 
et al., 1999). Younger patients are much less likely to have heart failure and 
those with heart failure are likely to be known to have a cardiac condition and 
present less of diagnostic conundrum. The condition is so uncommon in 
patients of this age group that the prevalence rate is likely to be below the 
sensitivity of any feasible clinical decision rule.  
 
Patients were excluded from the study if the attending physician suspected an 
acute myocardial infarction, if they had renal dysfunction to the point of 
requiring dialysis, if there was another obvious cause for the dyspnoea such 
as trauma, or if they were unable to give informed consent.  
 
Patients with renal failure requiring dialysis were excluded as both renal 
dysfunction and dialysis are known to affect the levels of BNP and NT-
proBNP and the measured levels may have been more reflective of the timing 
of dialysis than any acute disease process (Wahl et al., 2004). There is an 
important, though incompletely understood, relationship between impaired 
renal function and acute or decompensated cardiac failure and so a 
significant proportion of patients with acute heart failure have some degree of 
renal impairment. Excluding all patients with renal impairment would have 
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excluded a significant proportion of patients with heart failure and so the 
assessment of the utility of these markers in real clinical practice would have 
been compromised. Renal impairment is known to affect NT-proBNP and 
troponin levels and to a lesser extent BNP and so it was important to quantify 
this and how it affected the diagnostic utility in this population 
 
The inclusion criteria were chosen in order to select the group of patients 
where there remained a quandary as to whether the patients’ symptoms are 
due to heart failure. It was not necessary for patients to be admitted to 
hospital to be considered for inclusion in this study though the majority of 
patients were not discharged from the Emergency Department.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7-1 Inclusion / Exclusion Criteria 
Inclusion Criteria 
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 Patient ≥ 50 years of age 
 Primary complaint of acute dyspnoea 
 
Exclusion Criteria 
 Suspected AMI 
 Previous inclusion in this study 
 Trauma 
 Renal impairment requiring dialysis 
 Obvious cause of dyspnoea that is not 
heart failure e.g. pneumothorax 
 Unable to communicate in English 
 
 
 
 
7.2.3 Informed Consent 
 
 
Informed consent was obtained using two separate consent forms provided in 
Appendix IV: one form documented consent to participate, the other form was 
for consent to provide and gift a blood sample. The ethics committee 
stipulated that two separate forms be used. In the event that the patient was 
too unwell to give written consent at the time of attendance, permission had 
been granted by the ethics committee to proceed on the basis of verbal 
consent until the patient was well enough to give written consent (Coats, 
2006). This occurred with two patients who verbally confirmed that they were 
willing to take part in this research project and completed written consent the 
day after admission, when more stable.  
 
Patients were presented with an information sheet with contact details for the 
lead investigator and a letter was sent to the patient’s GP informing them that 
their patient had consented to take part in this trial.  
 
7.2.4 Blood Sampling 
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Two blood samples were taken from each patient on attendance in addition to 
the blood samples required by the attending physician. Blood samples were 
taken into Becton, Dickinson and Company Vacutainer® containers. One 
sample was taken into a tri-potassium EDTA tube and used for the point-of-
care BNP test in a Biosite meter within a few minutes being drawn. The other 
sample was taken into a tube containing a polymer gel and clot activator. This 
sample left for several minutes until the clot had formed and was then spun 
using a Heraceus Sepatech Labofuge 200 centrifuge at 3000 rpm for seven 
minutes. The serum was then drawn off using a pipette and labelled and 
frozen at -20C. The frozen samples were used for batch analysis for NT-
proBNP using the Roche (Elecsys) machine and kit. 
 
The frozen blood samples were also tested for High Sensitivity Troponin T to 
assess the potential diagnostic utility of this. This test was also performed on 
the Roche (Elecsys) machine using kits provided by Roche.  
 
All included patients had bloods taken to measure urea and electrolyte levels 
and a full blood count. Any other blood tests including standard troponin T, C 
Reactive Protein, D-dimer, INR, glucose and arterial blood gases were 
performed at the discretion of the attending physician. All included patients 
underwent an electrocardiogram and had a chest x-ray performed. The 
majority of patients had a chest x-ray performed in the radiology department 
but, in patients that the attending physician felt that were too unwell or 
unstable to be transferred there, a portable chest x-ray was performed in the 
emergency department. The majority of patients, therefore, had posterior-
anterior films while the minority of less stable patients had anterior-posterior 
films taken within the Emergency Department.  
 
 
7.2.5 Recording of Patient Data 
 
 
The patient’s demographic details, clinical history, current medications and 
examination findings were recorded on a standardised sheet by the attending 
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doctor and then this sheet was included as part of the patients’ medical 
records. A copy of this sheet is included in Appendix V. This form was 
incorporated as part of the patient’s medical clerk-in as well as providing data 
collection for this study. 
 
The attending doctor was also asked to comment on the results of the chest 
x-ray, interpret the ECG and provide a clinical impression of whether or not 
this patient had heart failure. An anonymised copy of the ECG was made and 
stored with the patient details for presentation to the cardiologists. 
 
The patients were also asked to provide a score from 1 to 10 to represent 
their dyspnoea when at its worst. At the beginning of the study, patients were 
also asked to fill in a visual analogue scale consisting of a 10cm line ranging 
from, ‘not breathless’ to ‘extremely breathless’. The use of the visual 
analogue scale was abandoned during the study as many patients found the 
concept difficult to understand, and were unable to complete it. The scoring 
system was then used alone. The use of a numerical score for dyspnoea has 
been validated as being correlated to the respiratory rate, oxygen saturation, 
heart rate and systolic blood pressure in a study by (Saracino et al., 2008). 
There is also some evidence of a relationship with pulmonary congestion as 
assessed by ultrasound and natriuretic peptide levels (Weber et al., 2014). 
Relevant details from patients’ medical history, clinical examination findings 
and the results of investigations carried out within the emergency department 
were entered into a database produced compiled within SPSS 18 © (SPSS, 
2008). Analysis was subsequently performed on this data using SPSS© and 
other software.  
 
Patient data was checked for up to three years following their original 
attendance in order to obtain data on re-attendance and subsequent 
procedures or events. The final discharge diagnosis as recorded in the 
medical notes was also obtained from the recorded patient discharge letter 
where available. 
 
7.2.6 Echocardiography 
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All patients had echocardiography performed within forty-eight hours of their 
attendance of the emergency department. In the original design of the study 
the intention was that this should be performed within seventy-two hours of 
the patient’s attendance. This time period was selected on the advice of the 
cardiologist (RK) who felt that there was unlikely to be significant changes to 
the cardiac function within this time period. In practice, this was performed 
within a few hours of attendance in all but two cases when the study was 
performed the following day. 
 
Echocardiography was performed using a Siemens Acuson X300 ultrasound 
machine with the P4-2 cardiac transducer and the supplied cardiac software. 
For each patient the intention was to record short and long axis para-sternal 
views with M-mode measurements of the left ventricle and valves. Apical four, 
five and two chamber views were also obtained. Colour Doppler flow was also 
recorded where possible and pulsed and continuous wave Doppler was used 
to record blood flow across the mitral and tricuspid valves. This data was 
presented anonymously to the cardiologists and contributed to the reference-
standard. 
 
In almost all of the patients, the lead researcher performed the 
echocardiogram. In one patient a cardiology registrar had already performed 
an echocardiogram and recorded his findings in the notes prior to the patient 
being recruited. Other patients went on to have echocardiography performed 
by the echocardiogram technicians or cardiologists while in-patients. When 
this occurred the results were made available for consultants making the final 
diagnosis in the form of a report. 
 
 
7.2.7 Brain Natriuretic Peptide 
7.2.7.1 Biosite Triage Kit 
 
The Triage® BNP test is a point of care test that uses fluorescence 
immunoassay for the quantitative measurement of BNP. This takes the form 
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of a specific cartridge with the test reagents incorporated. Several drops of 
EDTA anti-coagulated blood were added to the cartridge, using a calibrated 
pipette, before it was inserted into the triage meter. The concentration of BNP 
is calculated by the amount of fluorescence. Murine BNP monoclonal 
antibodies and BNP polyclonal antibodies are labelled with fluorescent dye. 
The test takes around 15 minutes to produces a result. The meter printed out 
the result of the assay but this was not viewed until after the patients 
management had been decided. The results were not made available to the 
receiving team if the patient had been referred, or to the attending physician. 
In patients recruited by the main researcher the results were not examined 
until all of the appropriate paperwork had been completed and the patient 
referred or discharged. In one case this led to the failure to obtain a BNP 
result as the blood sample was discarded before the results were reviewed, 
and there had been an error with the processing of this sample.  
 
The Triage meter was tested using a quality control device on every day that 
the machine was used. Specimens are measurable using the Triage meter for 
concentrations ranging from 5 pg/ml to 5,000 pg/ml (Biosite, 2007). Linear 
regression analysis of data derived from measuring known concentrations of 
BNP in healthy volunteers plasma show that the assay is linear throughout 
the measurable range. 
 
The lowest detectable concentration distinguishable from zero was 
determined by using a zero calibrator 20 times using 3 lots of reagent and 5 
different meters on 5 days. The average 95% confidence interval was less 
than 5 pg/ml. Haemoglobin, lipid, triglycerides or bilirubin concentrations were 
not shown to affect BNP levels. The haematocrit was also varied between 
27% and 51% with no significant effect. A wide variety of drugs have been 
tested at normal therapeutic concentration with no effect on measuring the 
BNP concentration. 
 
Various proteins and peptides were checked, including angiotensin I, II and 
III, and C-type natriuretic peptide with no significant interference on measured 
BNP levels. Average within day and total precision were determined using the 
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ANOVA model. The CV was between 9 and 12%. A comparison study was 
performed on EDTA whole blood vs. plasma. The correlation data shows r2 = 
0.9878, y = 0.925x+13.439. 
 
The manufacturers state that there are no statistically significant changes in 
BNP concentration associated with hypertension, diabetes or chronic, 
obstructive pulmonary disease (Maeda et al., 1998). 
 
In this study the lead researcher performed all of the samples analyses. The 
results were available within fifteen minutes of the sample being entered to 
the point-of-care machine. The machine provided a result on a digital display 
and a printout from an integrated printer. The results were collected after the 
patient had left the department.  
 
 
 
 
7.2.8 ‘N’ Terminal pro-Brain Natriuretic Peptide 
 
The concentration of NT-proBNP was measured using the Roche Elecsys 
proBNP II assay. This assay contains two monoclonal antibodies that 
recognise epitopes in the N-terminal part of the proBNP molecule. One of the 
antibodies is labelled with ruthenium, the other with biotin. The complex then 
binds to micro-particles coated with streptavidin. The micro-particles are then 
separated from the solution by using a magnetic electrode. Application of a 
voltage to the electrode then induces a chemiluminescence that is measured 
to provide a concentration value.  
 
The measurement range for this assay is 5 to 35000 pg/ml (0.6-4130 pmol/l). 
The Intermediate Precision coefficient of variation (CV) was 4.6% for a 
solution of concentration 44.0 pg/ml and 3.8% for a solution with 
concentration of 33606 pg/ml. There were no specific cross-reactions with 
various tested compounds including aldosterone, angiotensin II, BNP, 
endothelin, NT-proANP, renin or urodilatin (Roche, 2010). 
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The collected samples were stored in a freezer within the laboratory and then 
analysed as a single batch at the end of the study.  
 
 
7.2.9 High Sensitivity Troponin ‘T’ 
 
High sensitivity Troponin T was measured using the Roche Elecsys 2010 
analyser. The assay uses two monoclonal antibodies directed against two 
epitopes on the central portion of human cardiac troponin T. One of the 
antibodies is attached to ruthenium and the other is bound to biotin. After the 
initial incubation streptavidin micro-particles are added to form a solid 
complex. The complexes are separated from the solution using a magnetised 
electrode. A voltage is passed to the electrode to cause electroluminescence 
that is measured to calculate the concentration of troponin T.  
 
The range that can be measured using this assay is 3 to 10,000 ng/l. The 
lowest concentration with a CV less than 10% was 13 pg/l. The 
manufacturers found no interference on testing with 52 commonly used 
pharmaceuticals. Falsely low readings can occur in the presence of 
haemolysis when the haemoglobin level is greater than 0.1g/dl. 
 
The high sensitivity troponin test was performed on the batch of frozen 
samples after the recruitment phase of this study was concluded.   
 
7.2.10 The Reference Standard 
 
Two independent cardiologists reviewed all of the relevant historical data, 
clinical findings and investigations including chest x-rays and the recorded 
echocardiography to provide the reference standard for this study. A study 
number identified the patients. The ECGs were provided as photocopies of 
the original ECGs with identifying data obscured. A summary of the attending 
physician’s interpretation of the ECG was also provided. The chest x-rays 
were provided as high-definition jpeg files along with a simplified reporting of 
the emergency physician’s interpretation and the radiologist report was also 
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included where this was available. The cardiologists remained blind to the 
BNP, NT-proBNP and HS-TnT results. The cardiologists decided if the patient 
had definite, possible or no heart failure. 
 
In the event of disagreement, a third senior physician was available in order 
to allow a majority decision. 
 
7.3 Statistical Methods 
 
7.3.1 Sample Size 
 
In creating a diagnostic model, all variables that have been hypothesised on 
theoretical grounds or have been shown in previous research to be 
confounders of the relationship being studied should be considered. It has 
been recommended that researchers should err on the side of including 
potentially important variables but should not include extraneous ones. Where 
there is significant overlap in the diagnostic information provided by two 
variables it is recommended that only one should be selected for inclusion in 
the model.  
 
Given the limitations of working with a finite number of outcomes within the 
population studied, some limitation in the number of considered variables is 
necessary. If the number of variables included in the model synthesis is too 
large relative to the number of outcomes of interest within the study 
population then there is a high probability of associations arising by chance; 
these events would lead to false conclusions and may obscure the true value 
of other variables. There has to be some selection of variables on the basis of 
clinical sensibility and demonstrable utility in order to enable the production of 
a useful model (Concato et al., 1993). 
 
Cepeda (2003) used Monte Carlo simulations on a fabricated study to 
compare logistic regression with propensity scores. This study looked at 
comparing logistic regression and propensity scores in terms of bias, 
precision, empirical coverage probability, empirical power, and robustness 
279 
 
when the numbers of events are low relative to the numbers of confounders. 
In logistic regression, as the number of events per confounder increased, the 
magnitude of the bias decreased. Four or less events per confounder gave 
large bias; seven or more events per confounder gave a level of bias close to 
zero. The strength of the association of exposure with outcome did not have a 
clear effect on the amount of bias. Other authors have recommended a ratio 
of around ten to one with a minimum sample size of one hundred (Peng & al, 
2002). 
 
7.3.2 Estimation of Sample Size 
 
Wasson et al. (1985) stated in their landmark paper on the applications and 
methodological standards of clinical prediction rules, that there should be at 
least five patients for each predictive finding in the rule. Other authors have 
used mathematical modelling to suggest that at least seven patients should 
be used for each decision node in the rule (Laupacis et al., 1997).  A decision 
rule incorporating five predictive variables would therefore require twenty-five 
to thirty-five patients with the target condition. Assuming a prevalence of heart 
failure of at least 35% in the recruited population, based on the studies from 
the systematic review, meant that a minimum sample size of one hundred 
patients was required.  
 
 
 
 
7.4 Selection of Variables 
 
 
In order to create a clinical decision rule the first stage was to consider which 
variables demonstrated diagnostic utility.  
 
The decision of how many variables to include depends on the intended 
outcome of the research. If the purpose of the research is to explore 
explanatory roles then all potential variables should be included. As the main 
reason for the creation of this model is for diagnostic purposes, then only 
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those variables that enable accurate predictions should be used. In addition 
to this, a smaller number of included variables makes the decision rule more 
practical to use and easier to remember. 
 
Although statistical software, such as SPSS ©, has optional automatic 
variable selection settings there are limitations associated with their 
application. Methods include forward stepwise selection, backwards deletion, 
and best subset. For stepwise selection, the variable with the strongest 
association with the out-come is selected first, followed by the next strongest 
and so on until all the variables related to the outcome, at a significance level 
set by the investigator, are entered into the model. Any variable entered in the 
model that does significantly add to the outcome decision is deleted. For 
backward deletion, the reverse process occurs and the variable with the 
weakest association is removed first and so on.  
 
Setting a fixed level of significance for individual variables to allow entry into 
the model introduces a risk of eliminating variables that are weak when tested 
individually but significant in combination. Another problem is that if two 
variables are similar, the model will exclude the one with the poorer statistical 
characteristics although this variable may have more clinical significance. A 
third issue is that some investigations, for example chest x-ray, will be 
performed in almost all patients with this presentation regardless of the 
diagnostic utility for the condition of heart failure, as findings may be 
pathognomonic of other conditions; if there is some diagnostic utility for heart 
failure, even if other variables are stronger, then this should not be 
disregarded. 
 
It is for these reasons that automated methods were not used in the variable 
selection and for each of the considered variables the decision was based on 
performance in the univariate analysis, the clinical relevance and practicality 
of the model and in consideration of its relationships with the other variables.  
 
Three separate methods were used to shortlist the most useful candidates for 
a clinical decision rule. The first method was simply selecting the variables 
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that had proved most useful in the systematic review of the relevant literature 
and considering the meta-analysis that had been performed. The second 
method was to use Random Forest® software to produce an ordinal list of 
diagnostic variables.  
 
The third method was by using univariate logistic regression analysis for each 
of the potential variables; the Wald test significance was used to select the 
variables for further analysis. A value of 0.1 was chosen rather than the 
conventional 0.05 in order to minimise the risk of missing variables with useful 
diagnostic roles that were not apparent in isolation.  
 
7.4.1 Random Forests® 
 
Random Forests® is software created by Salford Systems. This software 
provides a robust method for selecting the optimal predictors from a selection 
of variables for a given, binary target outcome. The software is based on the 
CART decision tree algorithms and Breiman’s ‘Bagger’ bootstrap aggregation 
(Breiman et al., 1995). The software works by randomly selecting around 
two/thirds of the potential cases and then randomly selecting a chosen 
number of variables. The researcher selects the number of variables to be 
chosen at random but it is recommended that the initial number should be 
approximately the square root of the total number of variables. The optimal 
decision tree using the selected variables and cases is then produced. The 
intention is to provide a weakly predictive tree. The tree is then assessed to 
see which of the variables have the greatest predictive value within that tree. 
This process is then repeated numerous times and the findings regarding 
which variables have had the greatest predictive value are combined for all of 
the trees. Due to the double randomisation, all of the trees produced are 
unique and will tend to be quite different. The combination of information from 
a large number of different trees has been shown to be more useful than 
combining data from software systems designed to produce the ultimate 
unique tree and the problems of over-fitting of the data are avoided. The 
results have been verified by predicting data from samples from very large 
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data bases and this method was found to be more reliable than neural 
networks, solo decision trees, logistic regression or support vector machines. 
 
For nodes where there is a selection of highly significant splitter variables 
there will be a significant improvement in the model. For nodes where only 
weak variables are available the best selected will add little to the overall 
value of the tree. Although the same splitter may be chosen as potential 
splitters for variable nodes this is unlikely to happen; for example if you have 
100 potential variables and the software randomly chooses 10 of these then 
the chances of the same variable being chosen again is .1 *.1 = 0.01 or one 
in a hundred. 
 
If a variable with a strong predictive value is selected then it is likely that this 
will be chosen as the most powerful selector compared with the other nine 
variables. This should become apparent over multiple repetitions of the 
analysis model.  
 
Each tree produced will be the optimal tree given the selected variables so no 
tree will actually produce misleading results, but any of these trees would be 
expected to perform less well than the optimum tree which would combine the 
best performing variables from the entire data set.  
 
The different trees are combined through a voting or averaging process. The 
double random choices in the process mean that the trees will be 
substantially different from each other. This, paradoxically, actually improves 
the results of combining the trees. Other software which tries to predict the 
ultimate tree based on the available data tends to produce very similar trees 
and so the combination of these trees provides little new information and 
does not avoid the risks of over-fitting. Combining weaker models actually 
provides a stronger combined model. As each tree is independent then there 
is no over-fitting of data. Each tree provides a small amount of useful 
information towards the complete model. Genuine patterns will be discovered 
on repeated occasions by various trees while accidental patterns will be 
‘washed out’ by the averaging out of the results (Friedman & Popescu, 2003). 
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7.4.2 Logistic Regression 
 
Logistic regression is a useful way of describing the relationship between one 
or more independent variables (e.g. age, sex etc.) and a binary response 
variable expressed as probability; for example, the probability of a patient 
having heart failure (Peng & al, 2002). 
 
Logistic regression allows the prediction of a discrete outcome from a set of 
variables that can be continuous, discrete, dichotomous, or a mix of any of 
these types. Discriminant analysis can only be used with continuous 
variables. No assumption is made about the distribution of the variables used 
in the logistic regression model (Chappell & Fine, 2010).  
 
The goal of logistic regression is to correctly predict the category of outcome 
for the individual case using the most parsimonious model. The system can 
also be used to explore the strength of relationships of the included variables.  
 
The basic assumption is that for every increase in a unit of the predictor 
variable the odds of the outcome are multiplied by a factor (the odds ratio of 
the predictor) and that the effect of several variables is the multiplicative 
product of their individual effects. This should be confirmed by plotting a 
graph of the logit of the probability in order to confirm a linear relationship 
(Anderson, 2005). If the relationship is not close to linear it may be more 
appropriate to transform the data before applying the logistic regression. 
 
If the binary outcome of an event is plotted against a continuous variable that 
is associated with the outcome then the chart appears as follows: 
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Figure 7-1 Binary outcome associated with a continuous variable 
Mapping the probability or odds of a dichotomous outcome against a continuous 
event produces a ‘S’ shaped curve. 
 
 
Figure 7-2 Probability of a binary outcome associated with a continuous 
variable 
 
In order to perform logistic regression, the probabilities are converted to odds, 
and then the natural logarithm of each value is used to transform the data to 
resemble a straight line. Obtaining a straight line allows the relationship 
between the variables to be plotted and the relationship can be described 
using the simple equation:  
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ln (b) = ax + c.   
 
This process resembles simple linear regression but unlike linear regression 
the least sum of squares cannot be used to calculate the best fitting line. 
Instead, for each chosen value of the variable, the probability of the event is 
calculated. Then the maximal probability value is found given the measured 
outcome. There is an assumption of binomial distribution of the probability 
value. The position of the line is calculated using the values of the 
probabilities of the outcomes that are closest to the maximum probability 
value. The logit is then converted back into odds by using the exponential 
function (Bewick et al., 2004). 
 
All of the variables were examined using univariate logistic regression to test 
for significance and all variables that had a probability value of less than 0.1 
were considered further. Continuous variables were examined for correlation, 
and for pairs of variables, which demonstrated very significant correlation, 
only one of the variables was chosen. This is because the logistic regression 
model is constructed with the assumption that the variables are independent. 
 
7.4.3 Wald Statistic 
 
The Wald statistic is a test of the significance of each coefficient in the model. 
Dividing the coefficient by the standard error of the coefficient and squaring 
the result calculates the Wald statistic. This statistic has a chi-squared 
distribution. The significance of the test is calculated by comparing the effect 
against the null hypothesis. The reliability of the Wald statistic is questionable, 
especially in smaller samples. If the significance of the Wald statistic is 
significant i.e. less than 0.05, then the predictor is accepted as being useful 
and included in the model (Bewick et al., 2004). 
 
7.5 Creation of the Decision Rule 
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Following the selection of the relevant components of the decision rule, the 
intention was to combine them in the optimum manner. The following 
methods were used to create decision rules: multivariable logistic regression; 
classification and regression tree software (CART); manual decision tree 
creation; scoring systems and consideration of the individual variables that 
provided the maximal diagnostic utility in this population. 
 
7.5.1 Multivariable logistic regression analysis 
 
Multivariable analysis is used to determine the unique contributions of various 
factors to a single event or outcome. Multivariable analysis is necessary for 
diagnoses such as heart failure where there are numerous risk factors, 
aetiologies and signs and symptoms associated with the pathological 
condition. In these circumstances it is impossible to isolate individual 
variables from surrounding confounding variables in vivo. While it is relatively 
simple to conduct a trial where patients are randomised to exposure or 
avoidance of a single pharmaceutical agent, the same process cannot be 
applied to genetic factors, environmental exposure or lifestyle choices.  
 
While univariate analysis can suggest an association, the relationship 
between this factor and the disease process can be difficult to tease out in the 
presence of cofounding factors. An example provided by (Katz, 2003) is that 
males in low-income groups are more likely to smoke and more likely to have 
cardiovascular disease. The cause and effect relationship is much more 
difficult to prove than the association. In fact, both poverty and smoking are 
independent risk factors for cardiovascular disease but are confounding 
factors for each other.  
 
Although it is relatively easy to stratify an analysis to take account of a small 
number of variables, for example sex or age, attempts to control for many 
variables leads to dividing the data set into smaller and smaller subgroups. 
The use of multiple, small subgroups increase the likelihood of introducing 
random findings that can become amplified by the analysis.  
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Multivariable analysis allows for adjustment for confounding factors in order to 
demonstrate an independent relationship. When using multivariate analysis or 
stratified analysis is used it is important to remember that adjustment can only 
be performed for measured variables; results may still be confounded by 
other known and unknown factors that have not been measured. 
 
7.5.2 Limitations of Logistic Regression 
 
One limitation is that certain variables may be excluded despite a strong 
predictive value as another variable has a greater predictive power e.g. NT-
proBNP may have an inferior predictive power in the presence of BNP. 
Excluding the inferior variable leads to a less adaptable model in the event 
that the superior variable result was not available (Steyerberg et al., 2000). 
 
It is also difficult to recognise interactions between variables; for example, 
there may be a synergistic effect between two variables where the 
combination of both variables has a much greater effect on the out-come than 
would be predicted by a simple summation. 
 
It may also be difficult to demonstrate non-conformity to a linear gradient; 
although the association is recognised, the true relationship between the 
variable and the outcome may be over simplified by the logistic regression 
equation.  
 
Logistic regression does not allow for the same outcome to occur to the same 
person, more than once during the follow up period (Peng & al, 2002). It is 
possible to use generalised estimating equations to adjust for this but this has 
not been performed in this study; patients were not included in this study a 
second time even if they re-attended with the same symptoms. The patients 
were followed up and re-attendances to this hospital were recorded.  
 
7.5.3 Assessing the logistic regression model 
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Goodness of fit of the logistic regression model can be calculated using the 
technique described by (Lemeshow & Hosmer, 1982). The statistic is 
produced by creating ten ordered groups of subjects and compares the 
number that are actually in each group, the observed number, with the 
number predicted by the logistic regression model, the expected number. The 
test statistic is a chi-square statistic and a good model will be non-significant 
(p > 0.05) as there will be no significant difference between the observed and 
predicted number values. The ordered groups are selected on the basis of the 
predicted probability for the selected patients so that the first group will have a 
predicted probability of the studied outcome of less than ten per cent, and the 
next group would have a predicted probability of between ten and twenty per 
cent and so on (Hosmer et al., 1991). 
 
 
 
7.5.4 Summary of CART analysis 
 
The purpose of classification trees is to discriminate between whether or not a 
categorical outcome is true, based on various parameters. The analyses are 
performed via tree-building algorithms that determine a set of if-then logical 
conditions allowing accurate classification of the included cases. The 
predictor variable data can be nominal, ordinal or scale. A growing method 
must be selected (Lewis & Stevens, 1991). 
 
CART analysis divides the entire database into two using one variable. The 
tree examines every eligible predictor for its splitting power (measured by one 
of several mathematical criteria) and, for non-categorical data, examines each 
potential value of the variable, to create a database partition using the best 
performing predictor. The best splitter for a node is found by an exhaustive 
examination of every eligible splitter at that node and every node is searched 
in the same way. Splitting is carried out until it is no longer possible due to 
lack of data or a pre-specified stopping point. 
 
The basic process of CART can be described as four steps: 
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• Specifying the criteria for predictive accuracy 
• Selecting splits 
• Determining when to stop splitting 
• Selecting the ‘right-size’ tree 
 
CRT uses surrogates for missing values of independent variables. 
Essentially, if a particular variable is missing for a case then the next best 
predictor is used instead in its place for that particular case. A list of the most 
commonly used substitute predictors is provided with the production of the 
tree. 
 
Advantages of CART analysis include the fact that the interpretation of the 
results is usually simple. This makes it simple to apply and to explain. There 
is no implicit assumption that the underlying relationships between the 
predictor variables and the dependent variable are linear or even that they are 
monotonic. The methods allow for many potential predictors and interactions. 
 
7.5.5  Growing Methods 
 
The production of the decision tree results from the process of recursive 
partitioning. There are a variety of methods of performing this process; the 
commonest ones are CHAID, a method used to calculate the optimal 
predictors in a top-down approach, and the use of the Gini coefficient in 
calculating the ‘purest’ nodes (Kass, 1980). 
 
CHAID - Chi-square Automatic Interaction Detection. At each step the 
independent variable with the strongest interaction with the dependent 
variable is chosen. Categories of each predictor are merged if they are not 
significantly different with respect to the dependent variable. The exhaustive 
form examines all possible splits for each independent variable.  
 
The Gini coefficient is used to measure impurity of the nodes. A terminal node 
in which all the cases have the same value for the dependent variable is a 
homogenous ‘pure’ node. One advantage of this growing method is that the 
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nodes are split in a binary fashion while the CHAID method may split 
variables at multiple levels. 
 
7.5.5.1 Classification and Regression Trees 
 
The same approach can be applied to regression problems where optimal 
cut-off levels are determined from continuous variables in order to predict 
outcomes most accurately. 
 
A major issue when applying CART analysis to real data is deciding when to 
stop splitting. With background random noise due to variation within the 
sample, classifying every individual in a study will result in over-fitting and the 
resulting tree is unlikely to be applicable to another sample of the population. 
The basic principle is to cease splitting when the splits do not add significant 
improvement to the prediction of the target outcome. 
 
The optimal method is to derive the tree from one set of observations and 
then check it against a second, independent group of observations. There are 
techniques to ensure that the created tree is more robust if a validation set of 
data is not available.  
 
The intention of CART algorithms is to achieve the best possible predictive 
accuracy. Operationally the most accurate prediction is defined as the 
prediction with the minimum costs. The notion of costs was developed as a 
method of generalising the idea that the best prediction has the lowest 
misclassification rate. In most applications the cost is measured in terms of 
proportion of misclassified cases or variance. The need for minimising costs, 
rather than just the proportion of misclassified cases, arises when some 
predictions that fail are more catastrophic than others. For example, it would 
be much worse to miss an early diagnosis of lung cancer than over diagnose 
the incidence of ankle sprains. 
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7.5.5.2 Selecting Splits 
 
The second step consists of selecting the splits on the predictor variables that 
are used to predict membership in classes of the categorical dependent 
variables or to predict values of the continuous dependent variable. In 
general, the split at each node will be found that will generate the greatest 
improvement in predictive accuracy. This is usually measured with some type 
of node impurity measure that provides an indication of the relative 
homogeneity of cases in the terminal nodes. If all the cases in each terminal 
node show identical values then the node impurity is minimal, homogeneity is 
maximal and prediction is perfect (for the provided sample that has been used 
in this analysis, but perhaps not for a further independent sample). 
 
There are several impurity measures: The Gini index, Chi-square of G-
square. The Gini index of node impurity is the measure most commonly 
chosen for classification-type problems. As an impurity measure it reaches a 
value of zero when only one class is present at a node. With priors estimated 
from class sizes and equal misclassification costs, the Gini measure is 
computed as the sum of products of all pairs of class proportions for classes 
present at the node and it reaches maximum value when class sizes at the 
node are equal (Mingers 1988}. The Chi-square measure is similar to the 
standard Chi-square value computed for the expected and observed 
classifications (with priors adjusted for the misclassification cost) and the G-
square measure is similar to the maximum-likelihood Chi-square. For 
regression-type problems, a least-squares deviation criterion is automatically 
used.  
7.5.5.3 Stopping splitting 
 
Two options are available, a minimum number or a fraction of objects. One 
method to control splitting is to allow splitting to continue until all terminal 
nodes are pure or contain no more than a specified number of cases. The 
other option is to allow splitting to continue until all terminal nodes are pure or 
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contains no more cases than a specified minimum fraction of the sizes of one 
or more classes. 
 
 
7.5.6 Naïve Bayes Analysis 
7.5.6.1 Bayes’ Theorem 
 
Bayes’ theorem relates to the probability of a given event, and how this is 
affected by the results of other variables (Price, 1763a). The probability of an 
event, A, can be estimated how many times this event occurs when a trial is 
carried out N times. That is: 
 
𝑷𝒓𝒐𝒃 (𝑨) =
𝑵𝑨
𝑵
 
 
For a certain event, probability would equal one, for an impossible event, the 
probability would be zero. For all other events, as N approaches infinity, the P 
should approach the true probability of the event result.  
 
If B is a variable that affects the probability of event A occurring then it is 
possible to study the probability of event A when B is also true. 
 
𝑷𝒓𝒐𝒃 (𝑨|𝑩) =
𝑵(𝑨 ∩ 𝑩)
𝑵𝑩
 
 
Where ‘𝑨 ∩ 𝑩’ represents the intersection of the two events. 
By dividing both the numerator and denominator by N, the equation includes 
the probability of each component. 
 
𝑷𝒓𝒐𝒃 (𝑨|𝑩) =
𝑷(𝑨 ∩ 𝑩)
𝑷(𝑩)
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The probability of the intersection, where A and B are both true, can be seen 
to be equivalent to the probability of A if B is true, multiplied by the probability 
of B. This is also true for the probability of event B occurring when A is true. 
 
𝑷(𝑨|𝑩)𝑷(𝑩) = 𝑷(𝑨 ∩ 𝐁) = 𝑷(𝑩|𝑨)𝑷(𝑨) 
 
This can be rearranged to create the formula derived from Bayes’ theorem: 
 
𝑷(𝑩|𝑨) =
𝑷(𝑨|𝑩)𝑷(𝑩)
𝑷(𝑨)
 
 
This can be applied to diagnostic queries on the basis of clinical findings. For 
example if it is known that the 30% of patients presenting to an Emergency 
Department with shortness of breath have heart failure, that 20% of patients 
having a chest x-ray in the department have pulmonary oedema present and 
that 50% of patients with known heart failure have pulmonary oedema 
changes on their chest x-ray then it is possible to predict the probability that a 
patient with pulmonary oedema on chest x-ray will have a final diagnosis of 
heart failure. 
 
P(A) = probability of pulmonary oedema 
P(B) = probability of acute heart failure 
P(A|B) = probability of pulmonary oedema in patients with acute heart failure 
P(B|A) = probability of heart failure in patient with pulmonary oedema 
 
𝑷(𝑩|𝑨) =
𝟎. 𝟓 ∗ 𝟎. 𝟑
𝟎. 𝟐
 
 
Thus, in a patient with acute breathlessness, with pulmonary oedema present 
on the chest x-ray, the probability of a final diagnosis of heart failure would be 
0.75. 
 
Once the data has been collected on a patient population with a given 
condition it is usually relatively simple to retrospectively calculate the 
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proportion of patients who had a given symptom or sign at the time of 
attendance. By calculating how the probability of the target condition is 
affected by each independent variable and multiplying these factors together 
it is possible to combine this information to calculate the probability of the 
target result from the available data. If the data is not available for a particular 
variable for a patient then the result can still be calculated with the available 
data. 
 
This process assumes that the included variables are independent, for 
example, in determining whether or not a fruit was an apple, questions may 
be asked about the colour and the diameter of the object. In the consideration 
of the clinical features of a medical diagnosis, the relevant variables are rarely 
independent; hence the term ‘Naïve’ or ‘Simple’ Bayes analysis. However, 
despite the theoretical limitations of this technique, the results are far more 
accurate than would be predicted, especially in the derivation of decision 
rules where there are relatively few cases and many potential variables 
(Domingos & Pazzani, 1996).  
 
Laplacian correction, named after the French mathematician Pierre-Simon 
Laplace, who developed Bayes’ theory, simply means that 1 is added to each 
variable (Deakin, 1981). This overcomes the problem that may arise if there 
were zero incidences of a result. This would provide a probability of zero, 
which when multiplied with the other probabilities would result in an overall 
value of zero no matter how likely the other variables were. By adding one to 
each variable the effect on the likelihood will not be affected by much but the 
risk of the zero probability will not arise.   
 
Using Naïve Bayes analysis has advantages over decision tree analysis as all 
of the included variables are used to inform the final diagnosis. The full 
spectrum of the variable can also be used in the decision process rather than 
having to choose a cut-off value to dichotomise the results into positive or 
negative. Also, the decision process works well with missing variables; the 
same decision tool could also contain alternative variables such as BNP and 
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NT-proBNP. The decision tool also allows a probability or likelihood ratio to be 
calculated rather than a simple Boolean result. 
 
Možina et al. (2004) have developed a nomogram for use with Bayes’ 
method. This allows visualisation of how the included variables contribute 
towards the end diagnosis. It also allows the application of simple decision 
tools to be used without the need for a calculator or computer. Applying a 
straight edge to the variable on the nomogram gives a value from zero to one 
hundred, adding the results for each available variable gives a total that has a 
corresponding probability value. An example is provided in Figure 7-3. 
 
 
Figure 7-3 Example Using a Nomogram for Naive Bayes' Analysis 
7.5.6.2 The Standard Error 
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The standard error (SE) is a measure of how close the sample mean is likely 
to be to the true population mean while the standard deviation is a description 
of how widely scattered value in a sample are. For larger samples the SE can 
be used to estimate the 95% confidence intervals, as the SE will 
approximately equal the standard deviation (SD). The sampling distribution of 
the mean has the SD which is the square root of the SD (squared) /n where n 
is the number in the sample. A 95% confidence interval for a large sample 
can be calculated as the mean ± 1.96*SE 
 
 
 
7.5.6.3 The Chi-Square Test 
 
The Chi-squared statistic is calculated using a two-by-two table. The 
observed outcomes are compared with expected outcomes. For example: 
 
 Death No death Totals 
 
Treatment 5 45 50 
 
No treatment 20 30 50 
 
 
While the expected table, if the chosen treatment had no effect, would look 
like this: 
 
 Death No death Total 
 
Treat 12.5 37.5 50 
 
No treat 12.5 37.5 
50 
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The value of the expected result is subtracted from the observed result, the 
difference is squared and then this result is divided by the expected value. 
The squaring of the results means that positive and negative differences are 
considered equivalently and also that larger differences are amplified while 
small differences are less significant. When this is performed for all the cells 
in a table a Chi-square value is obtained. This can be read from a table of 
distribution (or software used) to give an estimate of the probability of this 
event depending on the number of degrees of freedom present. 
 
If Z is a standard Normal variable with a mean of 0 and a standard deviation 
and variance of 1 then the value formed by Z2 follows the Chi-squared 
distribution with 1 degree of freedom. As the number of variables increases 
the distribution tends to Normal. The expected value of Z squared is the 
variance of Z. The expected value of Z is zero so E(Zsq)=1. The expected 
value of chi squared with n degrees of freedom is thus n. The variance is VAR 
(chi-squared)=2n. The square root of the chi-square is the square root of n-
0.5 and has variance 0.5. If the data is from a Normal sample then the sample 
mean will follow a normal distribution and the sample variance will be from a 
chi-squared distribution times the sigma squared over (n-1). If the value of n 
is greater than twenty then the distribution of the sample standard deviation is 
approximately normal (Bland, 2000). 
 
The strength of an association between two qualitative variables can be 
difficult to measure, but it is easy to test the null hypothesis, i.e. that there is 
no relationship between them. This is done using the Chi-square test for 
larger samples. The chi-square test does not test the strength of an 
association, it merely indicates if the probability that the null hypothesis is true 
(Bland, 2000). 
 
7.5.6.4 Variance 
 
The variance is the average squared difference from the mean.  
E.g. For the number of heads after two tossed coins: 
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0 is 1 unit from the mean and happens a quarter of the time. 
1 is 0 units from the mean and happens half the time. 
2 is 1 unit from the mean and happens a quarter of the time. 
Variance = (0-1)(0-1)*1/4 + (1-1)(1-1)*1/2 +(2-1)(2-1)*1/4 
  = 1/4 +1/4 
  = 0.5 
The square root of the variance is the standard deviation (sigma). 
 
 
 
7.5.6.5 Normal Distribution 
 
Standard Normal distribution has a mean of 0 and a standard deviation of 1. 
Tables provide values for the area under the curve. For systems where a 
random variable is derived by a factorial equation then the distribution tends 
not to be Normal. This is often the case for biological systems where the 
variable is dependent on several steps e.g. for production of a substance via 
several enzyme steps. Usually in these situations log transformation will 
provide Normal distribution. The random variable is then described as having 
Lognormal Distribution. The data can be transformed using logarithms to 
perform calculations and then transformed back. 
 
There are a few ways of checking if a variable has normal distribution. One of 
them is to use a statistics program to construct a ‘q-q’ plot. This involves 
placing all of the variable results in order of size and then using approximation 
to calculate the probability that a value will be less than z for the ith 
observation (of n) z. 
If Standard Normal points are plotted against the observed values there 
should be a straight line if the variable has Normal distribution, otherwise will 
obtain a curve. 
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7.5.6.6 Recursive Partitioning 
 
In recursive partitioning, a question is asked of a data set which divides the 
data into two groups (partitioned) and then each of the ‘children’ groups is 
asked a new question and so on (recursive). The questions are decided by 
calculating what would optimise the purity of the groups. There also needs to 
be some stopping criteria. This may by a specified branch level, purity of the 
nodes or the minimum number of cases in the terminal nodes. 
 
7.5.6.7 Sampling distributions 
 
If there is a population with n of around 100 then it is possible to estimate 
values by taking ten samples of 4 from the 100, at random. This will give an 
approximate mean but the standard deviation of the estimate is small 
compared with the actual population standard deviation. The standard 
deviation of the sample is called the Standard Error (SE) of the estimate. The 
true mean is likely to be within one SE of the sample mean and is unlikely to 
be more than two SE away from it. With large samples the estimates are 
likely to be accurate predictions of the population values.  
 
 
 
 
7.5.7 Summary 
 
This chapter has introduced the methods used for the prospective diagnostic 
study with a focus on the novel investigations used. The methods used in the 
analysis of the results and the intended techniques for derivation of the 
clinical decision rule have also been explored. 
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Chapter 8 Results and Analysis 
 
8.1 Patient Characteristics and Classification 
 
One hundred and five patients with heart failure were recruited, as a 
convenience sample, between the start of March 2008 and the end of June 
2009. All of the patients presented to a single Emergency Department with 
acute shortness of breath as their main presenting complaint. Forty-three 
patients (41%) were male and sixty-two were (59%) female. 
 
The lead researcher recruited 48 of the patients, 2 were recruited by 
Emergency Department (ED) consultants, 37 by ED registrars, 9 by ED senior 
house officers and 9 by the receiving medical officers. 
 
The mean age of the patients was 72 years, the age range of the patients 
varied from 52 years to 93 years. Three patients declined to participate in the 
study and no further data was recorded regarding these patients. 
 
The mean duration of symptoms prior to attendance was 6.25 days; the 
median duration was 3.12 days. The range of this period extended from one 
hour to six weeks. Only nineteen patients (18.1%) were aware of having a 
prior diagnosis of heart failure although forty-five patients (42.9%) were 
receiving regular diuretics. The patient characteristics and final diagnostic 
classification as defined by the study reference standard are provided in 
Table 8-3.  
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Table 8-1 - Patient Characteristics and Classification 
 All Patients Definite Heart 
Failure 
Possible Heart 
Failure 
Not Heart 
Failure 
Total Number 105 31 28 46 
Male (%) 43 (41%) 13 (41.9%) 14 (48.3%) 16 (35.6%) 
Mean Age 71.8 years 74.3 years 73.5 years 69.0 years 
Median Age 72 years 76 years 72 years 69 years 
Standard 
Deviation 
10.5 9.0 8.9 11.8 
Range 52 – 93 years 56-88 years 56-89 years 52 – 93 years 
Admitted 98 (93.3%) 30 (96.8%)  26 (89.7%) 42 (93.3% ) 
Length of stay 
(LOS) 
    
Mean LOS 12.4 days 11.6 days 16.3 days 10.3 days 
Median LOS 8 days 11 days 8 days 8 days 
Standard 
Deviation LOS 
14.8 8.6 21.1 13.1 
Range LOS 0 – 76 days 0 – 35 days 0 – 76 days 0 – 59 days 
Died during 
admission 
6 4 1 1 
Died within 30 
days of 
admission 
6 4 0 2 
Died within 1 
year of 
admission 
11 6 
 
2 3 
Re-attended 
within 30 days 
25 7 6 12 
Previous 
diagnosis of 
heart failure 
(%) 
19 (18.0%) 13 (41.9%) 4 (13.7%) 2 (4.4%) 
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Figure 8-1shows the breakdown of the patient population by reference 
standard provided by the reviewing cardiologists with the discharge 
diagnoses provided to the patient’s general practitioner. This diagnosis was 
taken from the discharge letter written at the time of the patient’s discharge 
from hospital. Normal practice in this institution is for the discharge letter to be 
written by a junior doctor. In twenty-four cases, either no discharge letter was 
written or no specific discharge diagnosis was made within the letter. 
 
Attendance to hospital with acute dyspnoea was associated with high 
admission rates and significant lengths of stay. There was also a significant 
mortality rate, most marked in the patients who were considered to have 
definite heart failure. Almost a quarter of the included patients re-attended this 
hospital within thirty days of their initial attendance.  
 
All patients had a primary complaint of acute dyspnoea in order to be included 
in the study but other respiratory symptoms were recorded. These symptoms 
are provided in Table 8-2 with a breakdown by reference standard diagnosis.  
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Figure 8-1 Reference Standard and Discharge Diagnoses 
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Table 8-2 Reported Symptoms 
Symptoms All Patients Definite Heart 
Failure 
Possible 
Heart 
Failure 
Not Heart 
Failure 
Chest pain 36 (34.3%) 12 (38.7%) 5 (17.2%) 18 (40.0%) 
Cough 61 (58.1%) 11 (35.5%) 18 
(62.1%) 
32 (71.1%) 
Orthopnoea 52 (49.5%) 17 (54.8%) 15 
(51.7%) 
20 (44.4%) 
PND 41 (39%) 17 (54.8%) 13 
(44.8%) 
11 (24.4%) 
Wheeze 61 (58.5%) 12 (38.7%) 21 
(72.4%) 
28 (62.2%) 
Productive cough 26 (24.7%) 3 (9.7%) 6 (20.7%) 17 (37.8%) 
 
The historical features of the patient were those provided to the physician at 
the time of attendance rather than from other sources such as medical 
records. These are recorded in Table 8-3.  
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Table 8-3 – Patient Historical Features 
Historical 
features 
All Patients Definite 
Heart 
Failure 
Possible 
Heart 
Failure 
Not 
Heart 
Failure 
Previous heart 
failure 
19 (18.1%) 13 
(41.9%) 
4 
(13.8%) 
2 (4.4%) 
Angina 20 (19%) 5 
(16.1%) 
6 
(20.7%) 
9 
(20.0%) 
Myocardial 
infarction 
17 (16.2%) 8 
(25.8%) 
4 
(13.8%) 
5 
(11.1%) 
Diabetes 25 (23.8%) 6 
(19.4%) 
10 
(34.5%) 
9 
(20.0%) 
Hypertension 28 (26.7%) 12 
(38.7%) 
8 
(27.6%) 
8 
(17.8%) 
Smoker (current 
or ex) 
 70 
(66.7%) 
18 
(58.1%) 
21 
(72.4%) 
31 
(68.9%) 
Current Smoker 30 (28.6%) 8 
(25.8%) 
8 
(27.6%) 
14 
(31.1%) 
Chronic 
obstructive 
pulmonary 
disease 
44 (41.9%) 8 
(25.8%) 
9 
(31.0%) 
27 
(60.0%) 
Cancer 17 (16.2%) 5 
(16.1%) 
5 
(17.2%) 
7 
(15.6%) 
Asthma 23 (21.9) 5 
(16.1%) 
8 
(27.6%) 
10 
(22.2%) 
Raised 
cholesterol 
71 (67.6%) 18 
(58.1%) 
19 
(65.5%) 
34 
(75.6%) 
Previous stroke 9 (8.6%) 2 (6.5%) 4 
(13.8%) 
3 (6.7%) 
Pacemaker 
fitted 
5 (4.8%) 4 
(12.9%) 
1 (3.4%) 0 
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Cardiac 
Resynchroniser 
Therapy 
5 (4.8%) 1 (3.2%) 1 (3.4%) 3 (6.7%) 
ICD fitted 0 0 0 0 
CABG 12 (11.4%) 6 
(19.4%) 
4 
(13.8%) 
2 (4.4%) 
 
All of the patient’s current medications were recorded at the time of 
recruitment and any medications that were considered to be relevant to 
respiratory or cardiac disease were included as diagnostic variables. These 
medications are listed in Table 8-4. 
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Table 8-4 Current Medications 
Medications All Patients Definite Heart 
Failure 
Possible 
Heart 
Failure 
Not Heart 
Failure 
Home oxygen 8 (7.6%) 3 (9.7%) 2 (6.8%) 3 (6.7%) 
Loop Diuretics 37 (35.2%) 18 (58.1%) 11 
(37.9%) 
8 (17.8%) 
Inhalers 58 (46.4%) 15 (48.4%) 15 
(51.7%) 
28 
(62.2%) 
Aspirin 25 (23.8%) 7 (22.6) 9 
(31.0%) 
9 (20.0%) 
Clopidogrel 8 (7.6%) 3 (9.7%) 2 (6.9%) 3 (6.7%) 
Beta-blockers 22 (21.0%) 11 (35.5%) 7 
(24.1%) 
4 (8.9%) 
ARB 14 (13.3%) 7 (22.6%) 5 
(17.2%) 
2 (4.4%) 
ACE Inhibitors 25 (23.8%) 10 (32.3%) 5 
(17.2%) 
10 
(22.2%) 
Calcium 
antagonists 
22 (21.0%) 6 (19.4%) 7 
(24.1%) 
9 (20.0%) 
Nicorandil 3 (2.9%) 1 (3.2%) 1 (3.4%) 1 (2.2%) 
Digoxin 5 (4.8%) 3 (9.7%) 1 (3.4%) 1 (2.2%) 
Warfarin 15 (14.3%) 9 (29.0%) 2 (6.9%) 4 (8.9%) 
Nitrates 15 (14.3%) 5 (16.1%) 5 
(17.2%) 
5 (11.1%) 
Proton-pump 
inhibitor 
32 (30.5%) 12 (38.7%) 9 
(31.0%) 
11 
(24.4%) 
Statin 46 (43.8%) 18 (58.0%) 9 
(31.0%) 
19 
(42.2%) 
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The patients’ observations as recorded on arrival to the department and 
clinical signs picked up during the clinical examination are recorded in Table 
8-5. 
 
Table 8-5 Clinical Signs and Observations 
Signs All Patients Definite Heart 
Failure 
Possible 
Heart 
Failure 
Not Heart 
Failure 
Raised JVP 14 (13.3/%) 9 (29.0%) 2 (6.9%) 3 (6.7%) 
Peripheral 
Oedema 
15 (14.3%) 9 (29.0%) 5 
(17.2%) 
1 (2.2%) 
Temperature 
(Mean) 
36.7 (Range 
33.8 - 39.1, SD 
.92) 
36.7 (33.8-
38.7, SD ±1.0) 
36.4 
(35.3 – 
38.6, sd 
.64) 
36.9 (34.0 
-39.1, SD 
.94) 
Normal heart 
sounds 
90 (85.7%) 23 (74.2%) 25 
(86.2%) 
42 
(93.3%) 
Systolic Blood 
pressure (Mean) 
138.8 (n=102, 
80 – 204, SD 
26.0) 
144.3 (92-
204, SD 30.1) 
142.3 (96 
– 201, sd 
25.9) 
133.0 (80 
– 183, SD 
22.3) 
Cyanosis 3 (2.9%) 1 (3.2%) 1 (3.4%) 1 
Respiratory rate 
(Mean) 
23.0 (Range 12 
– 40, SD 6.47) 
24.6 (14-40, 
SD 7) 
22.6 (16 
– 40, sd 
5.85) 
22 (12 – 
36, SD 
6.34) 
Crepitations 53 (50.4%) 19 (61.3%) 15 
(51.7%) 
19 
(42.2%) 
Heart Rate 
(Mean) 
99.2 (28 – 197, 
sd 26.1) 
98.5 (55-152, 
SD 27.5) 
96.5 (56 
– 140, sd 
20.8) 
101.5 (28 
– 197, 
28.3) 
 
All of the relevant investigations for each patient were recorded. The results 
are presented as total number with a positive result for dichotomous variables 
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or as the mean result for the group for continuous variables. The results are 
presented in Table 8-6. 
Table 8-6 Results of Investigations 
Investigations All Patients Definite Heart 
Failure 
Possible 
Heart 
Failure 
Not Heart 
Failure 
BNP (Mean) 386.591 (5.0 – 
3450, SD 628.2) 
843.8(Range 
14.2 – 3450, 
SD 853.5) 
311.1 (6.3 
– 2790, 
SD 529.7)  
115.1 (5.0 
– 721, SD 
156.4) 
NT-proBNP 
(Mean) 
464.3 (Range 
1.1 – 5811, SD 
993.2) 
1145.9 (Range 
11 – 5811, SD 
1581.3) 
276.9 (5.1 
– 1292, 
SD 373.8) 
107.6 
(Range 
1.19 -1061, 
SD 196.7) 
Cardio-thoracic 
Ratio (Mean) 
0.574 (Min 0.36, 
max 0.94, SD 
0.1) 
.6328 (Min .37, 
max .82, SD  
.0959) 
.601 (min 
.41 - .94, 
SD .101) 
.520 ( .355 
- .693, SD 
.077) 
Pulmonary 
oedema 
14 (13.3%) 10 (32.3/%) 3 (10.3%) 1 (2.2%) 
Upper lobe 
diversion present 
21 (20%) 13 (41.9%) 5 (17.2%) 3 (6.7%) 
HS-Troponin 55.30 (3.0 - 
757.4,SD 109.8) 
90.8 (10.5- 
757.4, SD 
153.8) 
50.8 (3.0 
– 469.1, 
SD 91.1) 
33.3 (3 -
395.7, SD 
74.4) 
Pulmonary 
oedema present 
on CXR 
14 (13.3%) 7 (22.6%) 5 (17.2%) 2 (4.4%) 
D-dimer (Mean) 665.2 (n=25, 
Range 5- 5740, 
SD 1281.8) 
320.0 (n=7, 
Range 185 – 
760, SD 200.5) 
952.5 
(n=8, 5 – 
5470, SD 
1942.1) 
677 (n=10, 
range 115 
– 3820, SD 
1120.3) 
Lactate (Mean) 1.71 (n=55, 
Range .6 -9.3, 
SD 1.58) 
2.18 (n=14, 
range .7 - 9.3, 
SD 2.2) 
1.44 
(n=15, .7 -
4.7 SD 
1.0) 
1.62 (n=26, 
.6 – 7.5, 
1.45) 
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C-Reactive 
protein (Mean) 
47.9 (n=95, 
Range 3 – 365, 
SD 74.49) 
44.1 (n=26, 
range 3 – 365, 
SD± 83.3) 
37.8 
(n=26, 3 – 
248, SD 
63.5) 
55.8 (n=43, 
3 – 324, 
SD 75.4) 
Urea (Mean) 7.67 (n=105, 
range 1.9 – 
25.9, SD 3.78) 
9.8 (5.3 – 25.9, 
SD±4.9) 
7.53 (3.1 
– 15.9, 
SD 2.91) 
6.3 (1.9 – 
13.3, SD 
2.65) 
WCC (Mean) 10.9  (n=103, 
range 1.1 – 
28.3, SD 4.85) 
10.66 (4.5 – 
23.6, SD±5.06) 
10.4 (3.8 
– 28.3, 
4.93) 
11.4 (1.1 – 
23.7, SD 
4.71) 
Est. GFR (Mean) 64.3 (n=103, 
range 15 – 91, 
SD 21.33) 
50.87 (15 – 90, 
SD± 19.21) 
66.5 (19 – 
90, SD 
21.9) 
72.25 (18 -
91 SD 
18.05) 
Creatinine 
(Mean) 
98.5 (n=103, 
range 39 -351, 
SD 51.0) 
122.71 (63 -
351, SD 
61.393) 
96.8 (39 – 
226, SD 
45.0) 
82.7 (39 – 
297, SD 
39.9) 
 
Table 8-7 compares the opinion of the attending clinician with the reference 
standard provided by the cardiologists. 
 
Table 8-7 Clinical Opinion 
 All Patients Definite Heart 
Failure 
Possible 
Heart 
Failure 
Not heart 
failure 
Clinician 
Impression 
Definite HF 
24 (22.9%) 16 (51.6%) 7 
(24.1%) 
1 (2.2%) 
Clinician 
Impression 
Possible HF 
33 (31.4%) 10 (32.3%) 11 
(37.9%) 
12 
(26.7%) 
 
 
8.1.1 Echocardiograms 
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As discussed in Chapter 2, there were limitations in the success of the 
application of this investigation in the Emergency Department environment. 
Despite these constraints, some idea of whether left ventricular function was 
completely normal or was impaired to some degree, was obtained in the 
majority of patients. In some cases the results were not interpretable due to 
the mentioned factors. 
 
In this study the echocardiograms were electronically stored and then 
reviewed by two cardiologists. The quality of the echocardiograms were 
considered good in 28 patients (26.6%), adequate in 31 patients (29.5%), 
suboptimal in 34 patients (32.3%) and missing or interpretable in 12 patients 
(11.4%). Even in the echocardiograms where the view was considered 
suboptimal, it was possible for the cardiologists to comment on their 
impression of global left ventricular function 
 
 
 
8.2 Examination of Data 
 
8.2.1 Random Forest Variables 
 
8.2.1.1 Random Forests Results 
 
This was performed using a selection of 9, 5 and 18 variables from a potential 
selection of 89 variables.  
 
The output from the software shows a running relative error rate for the model 
in Figure 8-2. When the class weights are balanced the overall error rate is a 
simple average of the error rates in each class. The parallel coordinate graph 
shows the twenty-five records with the highest likelihood of a positive result 
and the twenty-five with the highest probability of a negative result. Eligible 
predictors can be selected or excluded to see how the model is affected.  
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The error rate is initially high then gradually improves as more and more 
models are added to the forest. Eventually the error rate plateaus as the 
model cannot be improved any further.  
 
Gini is the measure of how much the split has improved the purity of the two 
resulting classes. The scores for all the variables are cumulated for all the 
generated trees and then standardised by giving the best variable a score of 
100; the actual numbers attributed only provide information about that model 
and so cannot be used to compare different models. 
 
The Standard method of validating the results involves ‘scrambling’ a variable 
cut-off value and then seeing how this affects the model. If a model is not 
affected much then the particular variable is obviously not that important. This 
is, again, recoded to have a value between zero and one hundred.  
8.2.1.2 Cross Validation 
 
The sample is divided into numerous subsamples or folds. Tree models are 
generated excluding the data from each subsample in turn. The first tree is 
based on all the cases except those in the first sample fold, the second tree is 
based on all the cases except those in the second sample fold and so on. For 
each tree the misclassification risk is estimated by applying the tree to the 
subsample excluded in its generation. A positive number, valued between 2 
to 25 is used and the higher the number, the fewer cases are excluded for 
each tree model. Cross validation produces a single final tree model. The 
cross-validated risk estimate for the final tree is calculated as the average of 
the risks for all the trees. 
 
Random Forest analysis was performed using the Salford Systems CART 
analysis software (Breiman et al., 1995). All potential variables were entered 
into the equation and the variables were ranked in order of importance by Gini 
analysis. Continuous variables tend to be ranked more highly than categorical 
variables, as there is the potential to use different cut-offs in order to provide 
the optimum split of the selected group data. 
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One thousand RandomForest trees were created using nine potential 
predictor variables at each node and with a minimum of two cases per parent 
node. The following variables were ranked in terms of importance as shown in 
Table 8-8. 
Table 8-8 Variables Ranked by RandomForest 
Variable Score 
Cardiac Size 100 
Cardio-thoracic Ratio 59.80 
Urea 49.36 
NT-proBNP 40.87 
BNP 36.54 
Clinical Heart Failure 16.56 
Creatinine 13.62 
Troponin 11.83 
Age 11.58 
Diastolic Blood Pressure 9.13 
Estimated GFR 7.91 
Platelet Count 7.75 
Potassium 7.02 
Ankle Oedema 6.87 
Loop Diuretic 6.73 
Dyspnoea Score 5.74 
Upper Lobe Diversion 5.55 
Productive Cough 3.39 
CRP 3.90 
Cough 3.39 
Pulmonary Oedema 3.25 
History of Heart Failure 2.71 
Respiratory Rate 2.60 
pH 2.35 
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The selected variables have considerable overlap with the variables that 
demonstrated significance on univariate analysis. This analysis identifies the 
variables that tend to have the greatest significance in the majority of the 
decision trees created but does not compile a single summary decision tree 
and so the variables selected cannot be assumed to be independent of each 
other. 
 
The model provides a graphic representation of the overall error rate as 
shown in Figure 8-2. The summary model had an overall sensitivity of 95% 
with a specificity of 48%.  
 
 
 
Figure 8-2 - Overall Error Rate for Random Forest Model 
 
 
8.2.2 Univariate Analysis 
 
The patient data was entered into the SPSS software to allow further analysis 
(SPSS, 2008). The diagnostic importance of each of the variables was 
examined using univariate analysis against the provided clinical reference of 
possible or definite heart failure. All of the data with a Wald significance value 
of less than or equal to 0.1 were examined further, these variables are 
highlighted in the table for clarity. The results are displayed in Table 8-9. 
Systolic Blood Pressure 2.18 
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Table 8-9 - Results of Univariate Analysis 
Variable 
 
B S.E. Wald Sig. Exp(B) 95% CI for Exp(B) 
Lower Upper 
Sex .394 .405 .945 .331 1.483 .670 3.282 
Cardiac size (xr) .008 .004 3.571 .059 1.008 1.000 1.016 
Cardio-thoracic 
ratio 
13.356 3.185 17.581 .000 631534.50
0 
1227.5
83 
3.249E8 
Age (years) .047 .020 5.570 .018 1.048 1.008 1.090 
Duration 
symptoms 
.000 .000 .069 .793 1.000 1.000 1.000 
Chest pain -.030 .265 .013 .910 .970 .578 1.630 
Orthopnoea .278 .199 1.947 .163 1.320 .894 1.951 
Hx diabetes .165 .233 .500 .479 1.179 .747 1.861 
Home oxygen .107 .357 .089 .766 1.112 .552 2.240 
Loop diuretic 1.504 .471 10.202 .001 4.5 1.788 11.325 
On diuretics .941 .356 7.007 .008 2.563 1.277 5.144 
On inhalers NS       
PND 1.128 0.432 6.810 .009 3.091 1.324 7.214 
Wheeze -.298 .402 .550 .458 .742 .337 1.633 
Hx of HF 2.140 .778 7.566 .006 8.500 1.850 39.005 
Hx of MI .693 .574 1.460 .227 2.00 .650 6.157 
Hx of Angina .108 .500 .046 .830 1.114 .418 2.968 
Hx of CABG 1.459 .802 3.307 .069 4.300 .893 20.709 
Hx of COPD -1.333 .418 10.180 .001 .264 .116 8.607 
Hx CVA .442 .736 .360 .549 1.556 .367 6.588 
Hx of asthma -.032 .476 .005 .946 .968 .381 2.462 
Hx HTN .838 .476 3.096 .079 2.312 .909 5.884 
Clopidogrel .248 .760 .107 .744 1.282 .289 5.686 
Aspirin .417 .476 .768 .381 1.518 .597 3.858 
Beta-blocker 1.529 .597 6.567 .010 4.615 1.433 14.867 
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AR Blockers 1.699 .794 4.581 .032 5.467 1.154 25.901 
Ca Antagonist .139 .489 .081 .776 1.149 .440 2.997 
Digoxin 21.036 1797
4.847 
.000 .999 1.367E9 .000 . 
Nitrates .237 .362 .427 .513 1.267 .623 2.575 
PPI .497 .446 1.244 .265 1.644 .686 3.937 
Warfarin .872 .623 1.961 .161 2.391 .706 8.102 
ACE inhib .044 .134 .109 .741 1.045 .803 1.360 
Statin .257 .314 .666 .414 1.293 .698 2.394 
Inhaler -.190 .158 1.440 .230 .827 .607 1.128 
Smoker -.192 .171 1.271 .259 .825 .591 1.153 
Alcohol intake -.108 .290 .140 .709 .897 .508 1.585 
Temperature -.417 .230 3.293 .070 .659 .420 1.034 
O2 Sats in air -.077 .053 2.062 .151 .926 .834 1.028 
Pulse -.006 .008 .604 .437 .994 .979 1.009 
Systolic BP .016 .008 3.804 .051 1.016 1.000 1.033 
Diastolic BP .028 .012 5.287 .021 1.029 1.004 1.054 
Fine Creps .981 .456 4.618 .032 2.667 1.090 6.524 
Raised JVP 1.145 .684 2.799 .094 3.143 .822 12.020 
Cyanosis .417 1.241 .133 .737 1.517 .133 17.273 
Ankle oedema 2.595 1.056 6.033 .014 13.391 1.689 106.169 
Respiratory rate .040 .032 1.576 .209 1.041 .978 1.108 
Q waves ECG .537 .412 1.694 .193 1.710 .762 3.838 
ECG rhythm .065 .083 .623 .430 1.068 .907 1.256 
Dyspnoea score -.019 .097 .039 .844 .981 .811 1.187 
Sodium -.002 .041 .003 .958 .998 .921 1.081 
Potassium .714 .375 3.621 .057 2.043 .979 4.265 
Urea .257 .084 9.482 .002 1.294 1.098 1.524 
Creatinine .016 .006 6.478 .011 1.016 1.004 1.029 
Est. GFR -.034 .011 9.799 .002 .967 .946 .987 
Hb .005 .094 .003 .954 1.005 .836 1.209 
WCC -.038 .042 .852 .356 .962 .887 1.044 
317 
 
Platelets -.004 .002 4.394 .036 .996 .992 1.000 
Glucose -.010 .043 .057 .811 .990 .910 1.077 
D-dimer .000 .000 .001 .969 1.000 .999 1.001 
CRP -.003 .003 .870 .351 .997 .992 1.003 
PO2 -.024 .028 .697 .404 .977 .924 1.032 
pCO2* .338 .196 2.983 .084 1.402 .955 2.057 
Bicarbonate -0.29 .077 .147 .701 .971 .835 1.129 
pH -8.727 4.281 4.154 .042 .000 .000 .715 
Base XS .004 .061 .004 .948 1.004 .891 1.132 
Lactate .076 .179 .181 .670 1.079 .760 1.532 
BNP .004 .001 11.068 .001 1.004 1.002 1.006 
HS-TnT .005 .003 2.422 .120 1.005 .999 1.011 
NT-proBNP .003 .001 9.417 .002 1.003 1.001 1.006 
Age (years) .047 .020 5.570 .018 1.048 1.008 1.090 
Prod cough 1.236 .475 6.778 .009 3.440 1.357 8.722 
Pulm oedema* 2.499 1.059 5.571 .018 12.170 1.528 96.939 
Upper lobe 
diversion 
1.792 .661 7.355 .007 6.000 1.644 21.904 
Auscultation Only fine crepitations achieved significance 
ECG axis  .577 .387 2.220 .136 1.780 .834 3.802 
ECG ST segment -.239 .516 .214 .643 .788 .287 2.164 
ECG conduct Only LBBB achieved significance 
ECG T waves 1.109 .480 5.329 .021 3.031 1.182 7.771 
ECG LVH .577 .387 2.220 .136 1.780 .834 3.802 
Clinical Impress 3.309 1.046 10.014 .002 27.351 3.524 212.313 
ECG Conduction .681 .304 5.027 .025 1.976 1.089 3.582 
 
 
8.2.3 Correlation Analysis 
 
As the first step for the multivariate analysis a correlation table was compiled 
of all of the continuous variables that reached significant levels according to 
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Wald’s test in the univariate analyses. Pearson’s test was used to look for 
significant correlation as shown in Table 8-10. 
Table 8-10 - Correlations of Selected Continuous Variables 
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Correlations 
 
CT 
ratio BNP 
NT-
proBNP 
Cardia
c 
diamet
er Urea Cr EGFR 
Pota
ss. Age  pH 
pCO
2 Plts 
Syst. 
BP 
Diast. 
BP Temp. 
CT 
ratio 
 
 
Pearson 
Correlatio
n 
1 .264** .188 .719** .305** .179 -.287** .157 .261** -.193 .338* -.135 .214* .239* -.206* 
Sig. (2-
tailed) 
 
.009 .063 .000 .002 .080 .005 .146 .009 .180 .016 .188 .036 .019 .042 
N 99 98 98 99 99 97 96 87 99 50 50 97 96 96 98 
BNP Pearson 
Correlatio
n 
.264** 1 .877** .288** .350** .332** -.314** .275** .203* -.109 -.065 -.155 -.036 .091 -.159 
Sig. (2-
tailed) 
.009 
 
.000 .004 .000 .001 .001 .008 .039 .435 .638 .121 .719 .367 .109 
N 98 104 103 98 104 102 101 91 104 54 54 102 101 101 103 
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NT-
proBN
P 
Pearson 
Correlatio
n 
.188 .877** 1 .235* .393** .385** -.315** .237* .218* -.059 -.181 -
.265** 
-.150 .021 -.126 
Sig. (2-
tailed) 
.063 .000 
 
.020 .000 .000 .001 .024 .026 .670 .189 .007 .133 .838 .206 
N 98 103 104 98 104 102 101 91 104 54 54 102 101 101 103 
Wides
t 
cardia
c 
diamet
er 
Pearson 
Correlatio
n 
.719** .288** .235* 1 .315** .281** -.250* .167 .160 -
.289* 
.175 -
.292** 
.188 .292** -.104 
Sig. (2-
tailed) 
.000 .004 .020 
 
.001 .005 .014 .121 .113 .042 .225 .004 .067 .004 .309 
N 99 98 98 99 99 97 96 87 99 50 50 97 96 96 98 
Urea Pearson 
Correlatio
n 
.305** .350** .393** .315** 1 .748** -.683** .201 .276** -.238 -.162 -
.216* 
-.116 -.104 -.073 
Sig. (2-
tailed) 
.002 .000 .000 .001 
 
.000 .000 .055 .004 .080 .236 .028 .245 .296 .461 
N 99 104 104 99 105 103 102 92 105 55 55 103 102 102 104 
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Creati
nine 
Pearson 
Correlatio
n 
.179 .332** .385** .281** .748** 1 -.847** .290** .214* -.156 -.236 -
.299** 
-.008 .025 -.057 
Sig. (2-
tailed) 
.080 .001 .000 .005 .000 
 
.000 .005 .030 .260 .086 .002 .934 .807 .572 
N 97 102 102 97 103 103 102 91 103 54 54 101 100 100 102 
Estim
ated 
GFR 
Pearson 
Correlatio
n 
-
.287** 
-.314** -.315** -.250* -.683** -
.847** 
1 -
.221* 
-.279** .146 .301* .275** -.025 .034 .014 
Sig. (2-
tailed) 
.005 .001 .001 .014 .000 .000 
 
.036 .004 .297 .028 .006 .803 .737 .886 
N 96 101 101 96 102 102 102 90 102 53 53 100 99 99 101 
Potas
sium 
Pearson 
Correlatio
n 
.157 .275** .237* .167 .201 .290** -.221* 1 .003 -
.274* 
.206 .106 .085 .141 -.109 
Sig. (2-
tailed) 
.146 .008 .024 .121 .055 .005 .036 
 
.976 .049 .143 .318 .429 .186 .305 
N 87 91 91 87 92 91 90 92 92 52 52 91 89 89 91 
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Age in 
years 
Pearson 
Correlatio
n 
.261** .203* .218* .160 .276** .214* -.279** .003 1 -.078 -.239 .015 -.067 -.058 -.093 
Sig. (2-
tailed) 
.009 .039 .026 .113 .004 .030 .004 .976 
 
.571 .079 .883 .502 .559 .349 
N 99 104 104 99 105 103 102 92 105 55 55 103 102 102 104 
pH Pearson 
Correlatio
n 
-.193 -.109 -.059 -.289* -.238 -.156 .146 -
.274* 
-.078 1 -.123 .028 -.247 -.192 .093 
Sig. (2-
tailed) 
.180 .435 .670 .042 .080 .260 .297 .049 .571 
 
.370 .843 .071 .163 .504 
N 50 54 54 50 55 54 53 52 55 55 55 54 54 54 54 
pCO2 Pearson 
Correlatio
n 
.338* -.065 -.181 .175 -.162 -.236 .301* .206 -.239 -.123 1 .142 .298* .077 -.207 
Sig. (2-
tailed) 
.016 .638 .189 .225 .236 .086 .028 .143 .079 .370 
 
.306 .029 .582 .133 
N 50 54 54 50 55 54 53 52 55 55 55 54 54 54 54 
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platele
ts 
Pearson 
Correlatio
n 
-.135 -.155 -.265** -.292** -.216* -
.299** 
.275** .106 .015 .028 .142 1 .038 -.089 -.031 
Sig. (2-
tailed) 
.188 .121 .007 .004 .028 .002 .006 .318 .883 .843 .306 
 
.706 .376 .758 
N 97 102 102 97 103 101 100 91 103 54 54 103 100 100 102 
Systoli
c BP 
Pearson 
Correlatio
n 
.214* -.036 -.150 .188 -.116 -.008 -.025 .085 -.067 -.247 .298* .038 1 .598** -.057 
Sig. (2-
tailed) 
.036 .719 .133 .067 .245 .934 .803 .429 .502 .071 .029 .706 
 
.000 .569 
N 96 101 101 96 102 100 99 89 102 54 54 100 102 102 101 
Diasto
lic BP 
Pearson 
Correlatio
n 
.239* .091 .021 .292** -.104 .025 .034 .141 -.058 -.192 .077 -.089 .598** 1 -.220* 
Sig. (2-
tailed) 
.019 .367 .838 .004 .296 .807 .737 .186 .559 .163 .582 .376 .000 
 
.027 
N 96 101 101 96 102 100 99 89 102 54 54 100 102 102 101 
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Temp
eratur
e 
Pearson 
Correlatio
n 
-.206* -.159 -.126 -.104 -.073 -.057 .014 -.109 -.093 .093 -.207 -.031 -.057 -.220* 1 
Sig. (2-
tailed) 
.042 .109 .206 .309 .461 .572 .886 .305 .349 .504 .133 .758 .569 .027 
 
N 98 103 103 98 104 102 101 91 104 54 54 102 101 101 104 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
In order to allow the decision pathway to include only variables that 
display independent diagnostic utility the data was examined to identify 
the most obvious dependent factors. Variables with significant correlation 
were examined in terms of their significance on univariate analysis and 
their contribution to the model in combined logistic regression. This led to 
the elimination of Cardiac Size in favour of Cardio-thoracic ratio (CTR), 
NT-proBNP in favour of BNP, estimated Glomerular Filtration (GFR) rate 
in favour of Urea and Systolic Blood pressure (SBP) in favour of Diastolic 
blood pressure (DBP).  
 
The remaining continuous variables (CTR, BNP, DBP, Urea, Potassium, 
Age, pH, Platelet count and Temperature) were added to a logistic 
regression equation using the Enter Method in SPSS. Age, Platelet count 
and Temperature were then eliminated from the model, as they did not 
add any significant improvement. Although pH had been a significant 
diagnostic variable on univariate analysis it was excluded it at this 
juncture, as it had only been performed on only a few of the patients. 
There were two reasons for this exclusion; the small number samples 
means that the analysis is less reliable and the investigation is likely to 
have been applied selectively in patients who are considered more 
unwell.  
 
Performing the logistic regression analysis again with the reduced 
number of variables led to the removal of the potassium level and the 
diastolic blood pressure, as they did not add any significant value to the 
model. This left urea, BNP and the cardiothoracic ratio as the continuous 
variables in the equation. 
 
The categorical data that had been significant on univariate analysis were 
then added to the logistic regression equation. Most of the categorical 
data was in the form of a simple dichotomy that could be positive or 
negative, for example a history of heart failure; other questions had 
multiple potential results, for example the diuretic used category was 
divided into the various types of diuretics that patients were taking. In the 
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later case the individual components were examined to see if they 
achieved significance, for example, the use of loop diuretics was 
positively associated with an end-diagnosis of heart failure while the use 
of thiazide diuretics did not achieve significance for this diagnosis. 
 
The list consisted of: Loop Diuretic use, Paroxysmal Nocturnal Dyspnoea 
(PND), History of Heart Failure (HxHF), History of Coronary Artery By-
pass Graft (HxCABG), History of Chronic Obstructive Pulmonary Disease 
(COPD), History of Hypertension (HxHBP), Use of Beta Blocker, Use of 
Angiotensin Receptor Blocker (ARB), presence of fine crepitations, 
Raised Jugular Venous Pulse (JVP), Ankle Oedema, Presence of 
Productive Cough, Pulmonary Oedema, Electrocardiogram (ECG) 
Conduction abnormalities, Presence of T wave abnormalities on ECG 
and Presence of Upper Lobe Diversion (ULD).  
 
The binary logistic regression equation was then run repeatedly using the 
Enter method in SPSS. Following each calculation, the categorical 
variables that added the least to the model were removed and the 
process repeated. The presence of upper lobe diversion or cephalisation 
of vessels on the chest x-ray did not add anything significant to the model 
in the presence of the pulmonary oedema variable and so were removed.  
 
The final model contained the following variables: Urea, Cardio-thoracic 
ratio, Brain Natriuretic Peptide, Loop Diuretic, Presence of Pulmonary 
Oedema and Clinical Impression of Heart Failure. The presence of 
pulmonary oedema was the least significant factor in the equation but 
was included as a positive finding of pulmonary oedema is highly 
predictive of an end-diagnosis of heart failure. 
 
Although the presence of pulmonary oedema was consider as a binary 
variable for the purposes of this decision pathway it is recognised that the 
condition exists as a spectrum ranging from normal to grossly 
oedematous. It is reasonable to assume that severe pulmonary oedema 
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is likely to be less subjected to inter-observer disagreement and more 
pathognomonic for heart failure. 
 
Table 8-11 - The Logistic Regression Model 
Variables in the Equation 
 
B S.E. Wald df Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Step 
1a 
ratio 9.314 3.664 6.463 1 .011 11095.4
50 
8.443 1458084
2.456 
bnp .002 .001 2.651 1 .103 1.002 1.000 1.004 
ur .170 .117 2.128 1 .145 1.186 .943 1.490 
loopdiur(
1) 
1.492 .631 5.591 1 .018 4.446 1.291 15.316 
clinhf(1) 1.581 1.180 1.795 1 .180 4.862 .481 49.149 
pulmoed
(1) 
1.407 1.567 .807 1 .369 4.084 .189 88.017 
Constan
t 
-7.362 2.180 11.405 1 .001 .001 
  
Variable(s) entered on step 1: ratio, bnp, ur, loopdiur, clinhf, pulmoed. 
S.E. = Standard Error, df = degrees of freedom, Sig. = Significance, Exp(B) = 
Exponential function of B 
 
It can be seen on examining the data in Table 8-11, that only the Cardio-
thoracic ratio and the history of use of a loop diuretic achieve significance 
in terms of the Wald statistic. This is due to the chosen variables still 
having some degree of overlap in their association with the diagnosis of 
heart failure despite each being highly significant on univariate analysis. 
This is predictable as all of these variables are likely to be present in the 
patient with classical heart failure and the variables are related to each 
other in causing this condition. There is also the risk of the inclusion bias, 
as, with the exception of the BNP level, the cardiologists are likely to have 
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considered these variables in providing the diagnosis for use as the 
reference standard. Given the significance of each of these factors on 
univariate analysis, it would seem appropriate to include all of them in the 
logistic regression equation. This also adds robustness to the model 
although a slightly different equation would be required if any of the 
variables are missing; for example, a patient with a missing BNP value 
would not have the same risk of heart failure as a patient with a BNP 
value of zero. 
 
The Hosmer-Lemeshow Test demonstrated a good fit of the model. The 
test statistic was 0.595 with 8 degrees of freedom indicating that there 
was no significant difference between the probability results predicted by 
the model and the actual results recorded. 
 
To apply the logistic regression equation in practice means using the 
following equation: 
 
Log [p/(1+p)] = -7.362 + [9.314*CTR] + [.002 * BNP] + [.170*Urea] + 
[1.492*Loop Diuretic] + [1.581*Clin HF] + [1.407*pulm oedema] 
 
Where p is the probability of heart failure. The data from the first five 
patients has been placed in Table 8-12 to demonstrate the calculated 
probabilities and how this compares with the reference standard applied. 
Figure 8-3 shows the ROC curve for the application of this logistic 
regression equation on this data set. The area under the curve for this 
equation was 0.817 (95% confidence 0.713 to 0.902). Table 8-13 shows 
the values of sensitivity and (1- specificity) that result from accepting 
different values of probability as cut-off values for defining whether a 
patient is considered to have heart failure. These values are the 
coordinates that are used to create the ROC curve in Figure 8-3. 
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Table 8-12 - Probability of Heart Failure for Five Patients Calculated 
Using the Logistic Regression Equation 
Patient 
ID 
CTR Urea Pulm. 
Oedem
a 
Clinica
l HF 
BNP Loop 
Diureti
c 
Pred. 
Prob. 
Ref. 
Stand. 
1 .50 5.4 0 0 146.0 0 18.2% Not  
2 .61 7.1 0 0 40.1 0 39.3% Not 
3 .59 6.4 0 0 74.6 1 69.2% Poss. 
4 .54 4.2 0 0 78 0 18.3% Not 
5 .74 9.4 0 1 639 1 99.5% Definite 
 
 
Figure 8-3 - ROC Curve Logistic Regression Equation 
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Area Under the Curve 
Test Result Variable(s): Predicted probability 
Area Std. Errora Asymptotic Sig.b 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
.817 .043 .000 .731 .902 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
Std. Error = Standard Error, Asymptotic Sig.= Asymptotic Significance. 
 
Figure 8-4 - AUC Logistic Regression 
Table 8-13 Coordinates of ROC Curve for LR Equation 
Positive if ≥ Sensitivity 1 - Specificity 
0.025 1.00 0.95 
0.179 0.945 0.52 
0.944 0.473 0.04 
1.000 0.218 0.02 
 
Testing of the logistic regression method was carried out using the leave-
one-out method. In this method the equation is generated using all of the 
patients except one and then the equation is applied to the remaining 
patient. This process is repeated for every patient included in the study 
and the overall performance of the generated equations assessed. This 
resulted in an area under the curve of 0.8181 with a sensitivity of 0.7833, 
specificity of 0.6889 and a Brier value of 0.3517. 
 
8.2.4 Scoring System Derived from the Logistic 
Regression Equation 
 
Moon et al. (2002) have suggested a method of deriving a simple scoring 
system from logistic regression in order to make the application of the 
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equation easier without electronic support. The authors suggest rounding 
the value of the regression coefficient and multiplying by ten to provide a 
score for each variable in the equation.  
 
Log [p/(1+p)] = -7.362 + [9.314*CTR] + [.002 * BNP] + [.170*Urea] + 
[1.492*Loop Diuretic] + [1.581*Clin HF] + [1.407*pulm oedema] 
 
Multiplying the B values for each factor by 10 and then rounding gives the 
following values: 
Loop diuretic  =  15 
Clinical HF  = 16 
Pulm oedema = 14 
CTR    =  10 for every .1 (100 for 1) 
Urea   =  2 for every mg 
BNP   = 2 for every 100 
 
Applying this to the first five patients from my data set would give the 
following result: 
 
Table 8-14 - Scoring System Derived from Logistic Regression Equation 
Pt 
ID 
CTR Urea Pulm 
Oed 
Clin 
HF 
BNP Loop 
Diuretic 
Score Ref. 
Stand. 
1 .50 5.4 0 0 146.0 0 64 Not  
2 .61 7.1 0 0 40.1 0 75 Not 
3 .59 6.4 0 0 74.6 1 88 Possible 
4 .54 4.2 0 0 78 0 63 Not 
5 .74 9.4 0 1 639 1 122 Definite 
 
Even with rounding up values and using approximations this equation is 
still complicated to use and the result is more difficult to interpret than a 
simple percentage probability. Although the score results show 
correlation with the probabilities calculated by the logistic regression 
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equation, as shown in Figure 8-5 this method does not appear to confer 
any major advantage compared with using the original logistic regression 
equation.  
 
 
Figure 8-5 LR Model Compared Against Scoring System 
 
8.2.5 Classification and Regression Tree Analysis 
 
The method described by Breiman et al. (1995) was used in this analysis. 
The results were of limited value due in part to the relatively small study 
sample population and the nature of the clinical application. 
 
Trees were created using all of the variables, the variables that were 
significant on univariate analysis, the variables selected for the logistic 
regression model, the variables selected by the RandomForest software 
and the variables selected from the systematic review and meta-analysis.  
 
There were several problems with the automated tree production; 
selection of the variables, the order that the variables were utilised, 
multiple cut-off values for the same variable and limitation of some 
variables to distal portions of the tree. 
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In clinical practice it makes sense to apply the broadest and least 
invasive investigative tools earlier and apply tests with more specific 
results only in selected groups of patients. For example, all patients 
presenting to an Emergency Department with acute breathlessness will 
have chest auscultation performed, where as only a selection of these 
patients, in whom the attending physician considers at risk of heart 
failure, may benefit from a BNP test.  
 
The software is applied only to compare the diagnosis of heart failure with 
the diagnosis of ‘not heart failure’ but this second group is extremely 
heterogeneous. Diagnostic tests such as ECG or chest x-ray may 
produce findings that are pathognomonic for other conditions and 
therefore rule-out heart failure by being specific for the other cause. 
 
Another issue was that some aspects of the produced trees did not make 
clinical sense. For example, patients with a certain level of troponin or 
higher were deemed to be in the high-risk group for heart failure. While 
patients in the lower group were dichotomised again, further down the 
tree, on the basis of their troponin level but in this instance the patients 
with the lower level were considered to be the high-risk group for heart 
failure.  
 
The depth of the tree could be controlled either by the number of 
branches, the number of patients in the end-nodes or the purity of the 
end-nodes but no optimal level was obtained. This may result from the 
high number of potential variables and the relatively low number of 
patients, but had the consequence that the predictive value of the model 
was directly related to the complexity of the model. Trees that had a very 
good predictive model were very large, cumbersome, limited in sound 
theory and over-fitted the data. When the trees were limited by controlling 
the number of variables or nodes, the simpler trees did not demonstrate 
diagnostic utility greater than that of the individual components. This may 
also be related to the lack of independence between the end variables. 
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The fourth issue was the need to split continuous variables to define high 
or low risk groups. This essentially discarded potentially useful data. For 
example, while a patient with a BNP value of greater than 150 pg/ml is 
more likely to have heart failure than a patient with a value less than this, 
a patient with a BNP value of over 1500 pg/ml is much more likely to have 
this condition than a patient with a value of 151 pg/ml. This was partially 
overcome where the same variable was used at different nodes with 
different thresholds but this made of a cumbersome and complicated tree. 
 
Another issue in applying the trees is a result of the dichotomous nature 
of the nodes; for example, a patient could be classified as lower risk on 
the basis of the initial variable, e.g. BNP and no other variable would then 
be considered. On some trees it was possible for a patient to have a BNP 
level of 300pg/ml and be classified as low risk on the first node despite a 
previous history of heart failure, cardiomegaly and pulmonary oedema on 
the chest x-ray, on-going diuretic use and an abnormal ECG. 
 
Despite trying many different variations of included variables and tree-
growing methods, it was not possible to synthesise a clinically useful 
decision tree from the available data. 
 
8.2.6 Manual Classification Tree 
 
Attempts were made to create a decision tree manually using Orange 
software, open-source data-mining software (Demšar et al., 2013). This 
software can be used to synthesize a decision tree automatically or can 
allow the user to choose the variables, select the cut-off values, control 
the order of the decision nodes and decide the depth of the tree or any 
combination of these methods. 
 
Various efforts were made to create decision trees varying from 
completely automated to completely manual. Various data sets were 
used; the complete data set, variables that had been selected by the 
automatic tree synthesis, variables with significant univariate analysis 
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results, variables selected by the systematic review and meta-analysis, 
variables selected by the Random Forest software and the variables 
selected from the logistic regression model. 
 
Despite experimenting with every possible setting the same issues arose 
as when the CART analysis was performed: trees that provided excellent 
levels of sensitivity, specificity, or both were huge, cumbersome and over-
fitted; while honing down the trees to contain only the variables selected 
as having the greatest utility produced trees with diagnostic utility no 
better than their individual components. 
 
An example of a manual decision tree is shown in Figure 8-6. The pie 
charts represent the proportion of patients with an end-diagnosis of heart 
failure in red, and the proportion of patients with an end-diagnosis of not 
heart failure in blue. This particular model had a sensitivity of 82.1% and 
a specificity of 75.0% as shown in Table 8-15 and as such added little to 
the diagnostic performance of the individual variables.  
 
Table 8-15 - Diagnostic Performance of Manual Decision Tree 
 HF Not HF Totals 
 
Test +ve 46 10 56 
 
Test -ve 10 30 40 
 
Totals 56 40 96 
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Figure 8-6 Example of Manual Decision Tree Created Using Orange 
Software (Demšar et al., 2013) 
 
8.2.7 Naïve Bayes Analysis 
 
Naïve Bayes analysis was performed using Orange software (Demšar et 
al., 2013). The first analysis was performed with all the variables that 
achieved significance on univariate analysis and demonstrated 
independence on correlation analysis. 
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The included continuous variables were: cardiothoracic ratio, BNP, urea, 
age, temperature, potassium, diastolic blood pressure, pH and platelets. 
The discrete variables included were: use of loop diuretics, paroxysmal 
nocturnal dyspnoea, a history of heart failure, a history of CABG, a history 
of COPD, a history of hypertension, use of a Beta blocker, use of an 
ARB, presence of fine crepitations, presence of a raised JVP, a 
conduction abnormality on ECG, T wave inversion on ECG and the 
presence of upper lobe diversion.  
 
When this system is used to its full potential it classifies all of the included 
patients correctly. Where the system dichotomises each of the variables, 
selecting the optimum cut-off point for continuous variables to have a 
positive or negative influence, the overall sensitivity is 0.7333, specificity 
is 0.844 and the area under a ROC curve is 0.8359 with a Brier value of 
0.4147. This was estimated using the leave-one-out analysis.  
 
 Heart Failure  Not Heart 
Failure 
 
 
Test +ve 44 16 60 
 
Test –ve 7 38 45 
 
 51 54 105 
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Figure 8-7 ROC Curve for Naive Bayes Analysis of Variables Significant 
on Univariate Analysis 
 
The analysis was repeated using the first ten variables ranked in the 
RandomForest analysis.  The Naïve Bayes analysis produced a decision 
tool with a sensitivity of 0.750, a specificity of 0.711, an AUC of 0.851 and 
a Brier value of 0.3851. The variables used were: cardiac size, 
cardiothoracic ratio, urea, NT-proBNP, BNP, clinical heart failure, 
creatinine, troponin, age and diastolic blood pressure.  
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Figure 8-8 ROC Curve for Bayes Analysis using First Ten Variables from 
RandomForest Analysis 
The Naïve Bayes Analysis was also performed for the six variables that 
were found to perform best in the logistic regression equation. With a 
limited number of variables considered it is feasible to use the full volume 
of information provided by them rather than simple dichotomise each 
variable into the best-performing positive or negative result. This can be 
performed using a computer but can also be described using a 
nomogram. Drawing a straight vertical line from the result of each 
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available variable provides a score. Totalling the scores for all of the 
available variables provides a probability value. The results of this 
decision tool have been completed for the first patient in the trial as an 
illustration in Figure 8-9. Performing this provides 100% sensitivity and 
specificity for the patients included. 
 
 
Figure 8-9 Naive Bayes Analysis Nomogram Applied to Patient 1 Results 
 
Performing leave-one-out analysis demonstrates a more realistic 
estimation of the performance. In this process, the optimal scoring values 
for each of the variables are calculated based the results of all of the 
patients bar one, the rule is then applied to the single remaining patient 
and it is recorded whether or not this is correct. This process is then 
applied repeatedly missing out each patient in turn until the analysis has 
been performed missing out each patient in turn.  
342 
 
 
This resulted in sensitivity of 0.816, specificity of 0.667, AUC of 0.8274 
and a Brier score of 0.3907 as shown in Figure 8-10. 
 
 
 
Figure 8-10 ROC Curve for Variables Selected by Logistic Regression 
when Naive Bayes Analysis performed using 'Miss-One-Out' analysis 
In order to obtain a more realistic idea of how this decision rule would 
function in real life a random selection of the patients were chosen to 
derive the rule. The patients were divided into a derivation group (70%) 
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and a validation group (30%).  The rule derived again had 100% 
sensitivity and specificity for the derivation group if the rule was 
completely applied. For the patients within the derivation group using the 
‘leave-one-out’ analysis the sensitivity was 0.833, the specificity 0.7500, 
the AUC 0.8802 and the Brier statistic 0.3150.  
 
 
When this rule was applied to the validation group the sensitivity result 
decreased to 0.66 and the specificity was 0.69 as shown in  
Table 6.10.  
Table 8-16 Results of Decision Tool on Validation Group 
Pt 
ID 
CTR Oed Loop BNP Urea Clin 
Imp 
Final 
Diag 
NB Prob 
4 0.533142 0 1 295 9 1 0 1 0.99 
11 0.524334 0 1 23.8 8.2 0 1 0 0.28 
15 0.411386 0 1 10.9 7.2 0 1 0 0 
20 0.600845 1 1 15.8 3.3 1 1 1 1 
21 0.489349 1 1 411 7.5 1 0 1 1 
22 0.73969 1 0 549 7.6 1 1 1 1 
25 0.3704 0 0 162 7.5 0 1 0 0 
30 0.62047   0 354 5.9 0 1 0 0.45 
34 0.355315 0 0 259 8.7 1 0 0 0.01 
35 0.556744 1 0 166 6.9 1 0 1 1 
36 0.683598 1 0 1280 8.5 1 1 1 1 
37 0.507344 0 0 15.9 4.1 0 0 0 0.01 
40 0.622122 1 1 370 9 1 1 1 1 
47     0 2680 5.3 1 1 1 0.98 
49 0.685531 1   193 5.7 1 1 1 1 
53 0.437447   0 146 3.4 0 0 0 0 
57 0.456707   0 12.7 2.2 0 0 0 0 
59 0.611252   1 90.4 1.9 0 0 0 0.13 
62 0.418732   0 25 9.4 0 1 0 0.01 
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66 0.462505   0 6.1 5.2 0 0 0 0 
67 0.619351   1 1680 12 1 1 1 1 
68   0 0 27.3 5.7 0 1 0 0.05 
71 0.607582   1 118 7.7 1 1 1 0.9 
81 0.5   0 1290 6.6 1 1 1 0.91 
85 0.447697   0 143 6.5 0 0 0 0 
91 0.578213   1 106 4.9 1 1 1 0.55 
92     0 28.9 7.7 0 0 0 0.14 
94 0.601588   0 30 7.9 0 1 0 0.16 
97 0.454202   0 85.9 3.5 0 0 0 0 
99 0.640744   1 3450 7.2 1 1 1 1 
100 0.692517   0 83.7 8 0 0 1 0.66 
 
 
 
8.2.8  Application of the Framingham Criteria 
 
The Framingham criteria for heart failure have been derived from the 
Framingham study to aid in the diagnosis of heart failure (McKee et al., 
1971). The criteria are listed in Table 8-17. The majority of these criteria 
are available from the data recorded from the patients included in this 
trial. Central venous pressure, hepato-jugular reflux, weight loss over five 
days and vital capacity were not recorded. 
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Table 8-17 Framingham Criteria for Heart Failure 
  
 Paroxysmal Nocturnal Dyspnoea 
 Neck vein distension 
 Rales 
 Radiographic cardiomegaly 
 Acute pulmonary oedema 
 S3 gallop rhythm 
 Increased central venous pressure  
 (>16cm H2O at right atrium) 
 Hepatojugular reflux 
 Weight loss >4.5kg in 5 days response to treatment 
 
Minor criteria  
 Bilateral ankle oedema 
 Nocturnal cough 
 Dyspnoea on ordinary exertion 
 Hepatomegaly 
 Pleural effusion 
 Decrease in vital capacity by 1/3 from maximum               
 recorded 
 Tachycardia (>120bpm) 
 
The application of the available criteria from the Framingham study 
resulted in the data shown in Table 8-18. This results in a sensitivity value 
of 79.7% and a specificity of 60.9%.  
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Table 8-18 Application of Framingham Criteria to Included Patients 
 Ref. Stand. +ve Ref. Stand. -ve  
Framingham score +ve 47 18 65 
Framingham score -ve 12 28 40 
Totals 59 46 105 
Ref. Stand = Reference Standard 
 
Applying the Boston scoring systems, as shown in Table 8-19, gives the 
results shown in Table 8-20. 
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Table 8-19 Boston Criteria for Heart Failure 
Criterion Point value 
Category 1: history  
Rest dyspnoea 4 
Orthopnoea 4 
Paroxysmal Nocturnal Dyspnoea 3 
Dyspnoea walking on flat 2 
Dyspnoea while climbing 1 
Category II: physical examination 
Heart rate abnormality (1pt 91-110bpm, 
2 pts >110bpm) 
1 or 2 
JVP (2 pts if >6cmH2O, 3 pts >6cm H2O 
and hepatomegaly) 
2 or 3 
Lung crackles (1pt basilar, 2pts more 
than basilar) 
1 or 2 
Wheezing 3 
Third heart sound 3 
Category III: chest radiography 
Alveolar pulmonary oedema 4 
Interstitial pulmonary oedema 3 
Bilateral pleural effusion 3 
Cardiothoracic ratio > 0.50 3 
Upper zone flow redistribution 2 
Pts = Points 
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Table 8-20 Application of Boston Criteria to Study Patients 
Boston 
Criteria 
Not HF Possible HF Definite HF 
Low 3 1 0 
Mod 9 3 5 
High 34 25 25 
 
This translates into a sensitivity of 98.3% but a specificity of 6.7% if 
moderate to high probability Boston score is compared with possible or 
definite heart failure on clinical opinion. 
 
8.2.9 Performance of Individual Variables 
 
Certain variables were consistently identified by the different selection 
methods to have reasonable diagnostic utility when applied as a single 
diagnostic test. By altering the cut-off threshold for the continuous 
variables it is possible to manipulate the test to provide the required level 
of sensitivity or specificity.  
 
8.2.9.1 Cardiothoracic Ratio 
 
The cardiothoracic ratio (CTR) could not be calculated in six patients. 
This was due to lung pathology such as pulmonary effusions, which 
obscured the cardiac border although this also demonstrated the likeliest 
aetiology of the patients’ symptoms and so provided a diagnosis. A ROC 
curve of the CTR against the reference standard of possible or definite 
heart failure is shown in Figure 8-11. This provided an area under the 
curve of .792 (95% confidence interval .703 -.881). Table 8-21 shows 
various cut-off values and the corresponding sensitivity and specificity 
results illustrated in the ROC curve. 
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It can be seen from this table that using a cut-off of ≥.49 for the CTR 
would provide a sensitivity of 94.6% and a specificity of 37.2% (Positive 
Likelihood Ratio (PLR) 1.51 and Negative Likelihood Ratio (NLR) .14). 
Alternatively, this measurement could be used as a specific diagnostic 
test by using a cut-off value of .65 resulting in a sensitivity of 33.9% with a 
specificity of 95.3% (PLR of 7.29, NLR .69). 
 
 
 
Figure 8-11 Receiver Operating Characteristic (ROC) Curve for 
cardiothoracic ratio for Possible/Definite Heart Failure 
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Area Under the Curve 
Test Result Variable(s):Cardiothoracic ratio 
Area Std. Errora Asymptotic Sig.b 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
.792 .046 .000 .703 .881 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
 Std. Error = Standard Error, Asymptotic Sig. = 
Asymptotic Significance 
 
Figure 8-12 AUC for CT ratio 
Table 8-21 Coordinates for Cardiothoracic Ratio ROC Curve 
Positive if ≥ Sensitivity 1 - Specificity 
0.3629 1.00 0.953 
0.4995 0.946 0.581 
0.6249 0.429 0.047 
0.6975 0.143 0.000 
 
 
8.2.9.2 Brain Natriuretic Peptide 
 
BNP performed well as a diagnostic test over a range of values as can be 
seen on the ROC Curve in Figure 8-13. The area under the curve is .749 
(95% confidence interval .655 to .843). Lowering the threshold did not 
provide sensitivity sufficient to rule-out the condition unless it was 
reduced to such a point that only a few patients were included in the 
analysis. Raising the cut-off to 400 pg/ml provided a sensitivity of 43.3% 
and a specificity of 90.9% (PLR 4.77, NLR.62). Raising the threshold 
further to 600 pg/ml provided an improved rule-in performance with a 
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sensitivity of 30.0% but a specificity of 97.7% (PLR 13.2, NLR .95). The 
sensitivity and specificity values associated with the various potential cut-
off values are listed in Table 8-22. 
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Figure 8-13 Receiver Operating Characteristic Curve (ROC) BNP for 
Definite / Probable Heart Failure 
Area Under the Curve 
Test Result Variable(s):Brain Natriuretic Peptide 
Area Std. Errora Asymptotic Sig.b 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
.749 .048 .000 .655 .843 
The test result variable(s): BNP has at least one tie between the positive 
actual state group and the negative actual state group. Statistics may be 
biased. 
Std. Error = Standard Error, Asymptotic Sig. = Asymptotic Significance 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
 
Table 8-22 - Diagnostic Performance of BNP 
Cut-off value 
(pg/ml) 
Sensitivity 
(%) 
Specificity 
(%) 
Positive 
Likelihood 
Ratio 
Negative 
Likelihood 
Ratio 
100 73.3 68.2 2.3 .76 
400 43.3 90.9 4.77 .62 
600 30.0 97.7 13.2 .95 
 
 
Table 8-23 Coordinates for ROC Curve for BNP 
Positive if greater 
than: 
Sensitivity 1 - Specificity 
6.2 1.000 0.955 
11.250 0.950 0.864 
482.00 0.400 0.045 
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906.5 0.217 0.000 
 
8.2.9.3 Urea 
 
Urea performed less well than CTR or BNP with a smaller AUC of .712 
(95% Confidence Interval .612 to .813) as shown in Figure 8-14. Although 
cut-offs could be chosen that have sufficient sensitivity or specificity to 
rule-out or rule-in the condition of heart failure they are at the extremes of 
the range of distribution of this variable and so are only applicable to a 
small proportion of presenting patients.  
 
Table 8-24 - Diagnostic Utility of Urea as a Single Variable 
Cut-off 
Value 
Sensitivity Specificity PLR NLR 
4.5 mg/l 95.0 24.4 1.26 .20 
12.8 mg/l 11.7 97.8 5.25 .90 
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Figure 8-14 – Receiver Operating Characteristic Curve for Urea for 
Diagnosis of HF 
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Area Under the Curve 
Test Result Variable(s):Urea 
Area Std. Errora Asymptotic Sig.b 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
.712 .051 .000 .612 .813 
 
The test result variable(s): Urea has at least one tie between the positive 
actual state group and the negative actual state group. Statistics may be 
biased. 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
Std. Error = Standard Error, Asymptotic Sig. = Asymptotic Significance 
Figure 8-15 Area Under the Curve for Urea 
 
Table 8-25 Coordinates for ROC Curve for Urea 
Positive if greater than: Sensitivity 1 – Specificity 
2.650 1.00 0.933 
4.550 0.950 0.756 
12.750 0.133 0.044 
13.350 0.117 0.000 
 
8.2.9.4 Clinical Impression of Heart Failure 
 
The overall clinical impression of heart failure performed well in this study 
in terms of the specificity of this test. The sensitivity was 30.0%, the 
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specificity was 97.7%, the positive likelihood ratio was 13.2 and the 
negative likelihood ratio was 0.72. 
 
8.2.9.5 Presence of Pulmonary Oedema 
 
The presence of pulmonary oedema was also a specific finding for this 
data set. The sensitivity was 20.0%, the specificity of 95.5%, the positive 
likelihood ratio was 4.5 and the negative likelihood ratio was 0.84. 
 
8.2.9.6 Use of Loop Diuretic 
 
The use of a loop diuretic is likely to be a proxy marker for a previous 
diagnosis of heart failure. The other main indication for the prescription of 
this class of drugs is hypertension, itself a risk factor for developing heart 
failure. The sensitivity of the use of a loop diuretic as a predictor for heart 
failure was 38.3%, specificity was 81.8%, positive likelihood ratio was 
2.75 and negative likelihood ratio 0.61. 
8.2.9.7 NT-proBNP 
 
NT-proBNP also performed well as a diagnostic test over a range of 
values. The ROC Curve is presented in Figure 109. The area under the 
curve was 0.756 (95% Confidence Interval 0.663 to 0.849). NT-proBNP 
performed in a very similar manner to BNP in that while it was possible to 
choose a cut-off value that was sensitive enough to rule-out the condition, 
the specificity at this level was so poor that there was little practical 
benefit. Choosing a cut-off value of 500pg/ ml, well below the 
recommended value of 1800 pg/ml, was sufficiently specific to rule the 
condition in as shown in Table 8-26  
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Table 8-26 - Diagnostic Value of NT-proBNP 
Cut-off 
Value 
Sensitivity Specificity PLR NLR 
7 pg/ml 93.5% 4.8% 1.35 .98 
300 pg/ml 46.7% 88.6% 4.33 .60 
500 pg/ml 31.2% 95.3% 6.70 .72 
1800 pg/ml 13.7% 100% Inf .86 
 
 
Figure 8-16- Receiver Operating Characteristic Curve for NT-proBNP 
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Area Under the Curve 
Test Result Variable(s):NT-proBNP 
Area Std. Errora Asymptotic Sig.b 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
.756 .048 .000 .663 .849 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
Std. Error = Standard Error, Asymptotic Sig. = Asymptotic Significance 
 
 
Table 8-27 Coordinates for ROC Curve for NT-proBNP 
Positive if greater 
than: 
Sensitivity 1 - Specificity 
4.505 1.00 0.932 
7.825 0.950 0.909 
452.45 0.333 0.045 
1077.5 0.183 0.000 
 
 
 
8.2.9.8 Upper Lobe Diversion 
 
Upper lobe diversion or cephalisation of the vessels on chest x-ray was 
found to be a useful diagnostic feature for heart failure but was out-
performed by the presence of pulmonary oedema in this study population. 
The sensitivity of this test was 30.0%, the specificity was 93.3%, the 
positive likelihood ratio was 4.5 and the negative likelihood ratio was 
0.75. 
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8.2.9.9 Combining the variables 
 
CTR, BNP, NT-proBNP, presence of pulmonary oedema on chest x-ray 
and clinical impression all demonstrate sufficient specificity to be used to 
rule-in heart failure. The presence of any of these individual features has 
specificity greater than 95%.  
 
Table 8-28 - Summary Table for Individual Variables With High Specificity 
for Heart Failure 
Variable Sensitivity 
(95% 
Confidence 
Interval) 
Specificity 
(95% 
Confidence 
Interval) 
Likelihood 
Ratio 
Positive 
Likelihood 
Ratio 
Negative 
Cardiothoracic 
Ratio ≥ 0.65 
35.1% (23.0 – 
49.0%) 
95.4% (83.2 
99.2%) 
7.74 0.68 
BNP ≥ 600 
pg/ml 
30.5% (19.5 – 
44.0 %) 
97.7% (86.7 
99.8%) 
13.7 0.71 
NT-proBNP ≥ 
500 pg/ml 
31.1% (20.2 -
41.4%) 
95.4% (83.2 – 
99.2%) 
6.85 0.72 
Pulmonary 
Oedema 
20.0% (11.2 – 
32.9%) 
95.5% (83.6 – 
99.2%) 
4.5  0.84 
Clinical 
Impression  
38.3% (26.3 – 
51.8%) 
97.8% (86.7 – 
99.8%) 
17.25 0.63 
Urea ≥ 12.8 
mg/l 
13.3% (6.0 
25.0%) 
95.6% (85.6 – 
99.2%) 
3 0.91 
 
These variables can be combined so that for any patients who have any 
two or more of these variables present, the specificity of this finding 
approaches 100%. This is illustrated in a STARD (STAndards for the 
Reporting of Diagnostic accuracy studies) diagram as recommended by 
the Cochrane group in Figure 8-17. 
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Table 8-29 Combining Specific Variables (Number of patients with both 
variables positive / Number of patients diagnosed as not having heart 
failure) 
 CTR BNP NT-
proBNP 
Pulmonary 
Oedema 
Clinical 
Impression 
Urea 
CTR  9 / 0 7 / 0 7 / 0 10 / 0  3 / 0 
BNP   15 / 1 3 / 0 11 / 0 4 / 0 
NT-
proBNP 
   3 / 0 11 / 0  4 / 0 
Pulmonary 
Oedema 
    5 / 0  0 / 0  
Clinical 
Impression 
     7 / 0 
Urea       
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Figure 8-17 STARD Diagram For Patients with Variables Specific For the 
Diagnosis of Heart Failure 
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Table 8-30 Summary of Variables with High Sensitivity for the Absence of 
Heart Failure 
Variable Sensitivity 
(95% 
Confidence 
Interval) 
Specificity 
(95% 
Confidence 
Interval) 
Likelihood 
Ratio 
Positive 
Likelihood 
Ratio 
Negative 
CTR ≤ 0.49 37.2% (23.4 
– 523.3%) 
94.4% (83.6 
– 98.6%) 
6.7 0.67 
Urea ≤ 4.5 
mg/l 
22.2% (11.8 
– 37.5%) 
95.0% (85.3 
– 98.7%) 
4.4 0.81 
BNP ≤ 11.2 
pg / ml 
13.7 % (5.7 
– 28.0%) 
94.9% (84.9 
– 98.7%) 
2.7 0.9 
NT-proBNP ≤ 
20 pg/ml 
34.1% (20.9 
– 50.0%) 
83.3% (71.0 
– 91.2%)  
2.0 0.8 
 
By selecting low cut-offs for these variables, the specificity for the 
absence of heart failure approach 95%. Combining these variables meant 
that there improved this specificity but the numbers of patients with any 
two of these variable values was very small.  
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Table 8-31 Combining Variables Sensitive for Ruling Out Heart Failure 
(Number of patients with both variables positive / Number of patients 
diagnosed with heart failure) 
 CTR ≤ 
4.9 
Urea ≤ 
4.5 
NT-
proBNP ≤ 
20 pg/ml 
BNP ≤ 
11.2 
pg/ml 
CTR ≤ 4.9  5 / 0  8 / 2 4 / 1 
Urea ≤ 4.5 mg/l   4 / 2 0 / 0  
NT-proBNP ≤ 20 pg/ml    6 / 3  
BNP ≤ 
11.2 
pg/ml 
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Figure 8-18 STARD Diagram for Patients With Variables Specific for the 
Diagnosis of Not Heart Failure 
 
8.2.10 Summary 
 
Certain variables were found to have the maximal utility whichever 
method was used to derive them. Other findings, such as the presence of 
a nocturnal cough, that have been traditionally considered useful in the 
diagnosis, were found to be of little value. Diagnostic tools using the 
selected variables performed as well as strategies that included all of the 
potential variables.  
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Despite this, it was not possible to derive a decision tree, using either 
automatic or manual methods that could usefully be derived and applied 
to this data set to confirm or refute the diagnosis of heart failure. The 
optimal tree structures synthesised did not adding any significant value to 
the initial clinical impression. 
 
Other methods to derive a decision tool were used. Logistic regression 
utilises the full range of continuous variables without the need to 
dichotomise the results into positive or negative. The Naïve Bayes 
method shares these advantages and can still be used even if there are 
unknown variables for the included patients. Both of these methods allow 
all of the selected variables to inform the diagnosis; one disadvantage of 
decision trees is that a patient may be diagnosed on the basis of the first 
node, even if every other result suggests the opposite diagnosis. 
 
Logistic regression resulted in an equation that delivered a good degree 
of accuracy though was complicated and cumbersome to use. Using the 
Naïve Bayes method resulted in a similar equation though this could be 
applied using a nomogram in order to simplify the technique without 
losing efficacy. Both of these methods were likely to be subject to 
overfitting as testing the equations using ‘Leave-one-out’ sampling or 
splitting the data into derivation and validation samples resulted in much 
less impressive figures.  
Finally, by identifying two or more positive variables that were specific for 
the presence of heart failure, it was possible to derive a method that 
approached 100% specificity for this condition. Unfortunately, neither 
using the variables and cut-off values specific for the presence of heart 
failure, nor those specific for the absence of heart failure, provided 
methods sensitive enough to reliably rule out this condition although it 
could certainly be considered less likely.  
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Chapter 9 Discussion And Conclusions 
 
9.1.1 Introduction 
 
 
In the introduction to this thesis, there was exploration of the issues 
around the diagnosis of acute decompensated heart failure. Evidence 
was provided to show the significant prevalence of this condition and the 
devastating impact on the lives of the individuals affected, their families 
and carers, and the population at large. There was an introduction to the 
difficulties associated in making this diagnosis; namely that this condition 
lacks a standardised definition, can present with a wide range of 
symptoms of variable severity and that there are several potential 
aetiologies. 
 
In the following chapters, the strengths and limitations of the various 
modalities used to confirm or refute this diagnosis were addressed and 
the potential role for natriuretic peptides was presented. The limitations in 
current practice and potential benefits of an evidence-based, clinical 
decision rule were raised in Chapter 5. 
 
The main ambition of this thesis was to derive a clinical decision rule that 
could be applied in the Emergency Department setting and assist 
clinicians in diagnosing patients with acute, decompensated heart failure. 
To this end a systematic review of all literature relevant to the diagnosis 
of heart failure in an Emergency setting was undertaken. Meta-analysis of 
the data derived from the systematic review was performed to rank and 
quantify the diagnostic utility of the potential predictor variables assessed.  
 
The second part of this thesis consisted of an original diagnostic study 
carried out to obtain individual patient data to allow multivariable analysis 
to be performed. This was to assess the independence of potential 
diagnostic variables and to select the optimum combination and order of 
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these to synthesise the optimal clinical decision rule. Various techniques 
were explored for the selection of the variables, and several methods 
were used to derive a clinical decision rule. 
 
9.1.2 Findings of the Thesis 
 
The systematic review of the literature and the meta-analysis allowed 
ranking of the performance of all reported potential diagnostic variables in 
terms of their diagnostic utility. This brought to the fore the diagnostic 
elements with potential for inclusion in a CDR while allowing the variables 
with limited utility to be excluded from consideration.  
 
These variables were found to have the greatest diagnostic utility:  
 A history of heart failure 
 Clinical opinion 
 Presence of cardiomegaly on chest x-ray 
 Presence of pulmonary oedema on a chest x-ray 
 Cephalisation of the vessels on a chest x-ray 
 BNP levels  
 NT-proBNP levels 
 
Variables with poor predictive value, or very variable reported results 
included features such as a history of orthopnoea, the presence of 
peripheral oedema, a history of COPD or a history of ischaemic heart 
disease. 
 
From the original diagnostic study, analysis using RandomForest 
software produced a similar selection of variables with the greatest 
diagnostic value: 
 Cardiomegaly on chest x-ray 
 Renal function 
 NT-proBNP 
 BNP 
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 Clinical opinion 
 History of heart failure 
 
The diagnostic utility of the variables was also assessed using univariate 
logistic regression and correlation analysis that also produced a similar 
list of variables: 
 Use of loop diuretics 
 Clinical opinion 
 Pulmonary oedema on chest x-ray 
 Cardiomegaly on chest x-ray 
 Renal function  
 BNP 
 
Attempts were made to construct a simple but robust CDR using the data 
from the original diagnostic study by a variety of methods: 
 Multivariable logistic regression 
 Scoring system derived from logistic regression 
 CART analysis 
 Manual generation of a classification tree 
 Bayesian analysis 
 Combination of individual variables 
 
The above methods were used with all potential variables, the variables 
selected by the systematic review, the variables selected using logistic 
regression and the variables selected using the RandomForest analysis.  
 
Decision pathways with excellent diagnostic utility that were synthesised 
were over-fitted, large, cumbersome and impractical to use. Simpler and 
more practical rules failed to improve diagnostic utility significantly over 
the performance of the original components. 
 
The finding of two or more of the individual variables specific for heart 
failure approached 100% specificity for this condition. Although variables 
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were found that had high sensitivity for this condition, no combination of 
these could be produced that could be reliably used to rule this condition 
out.  
 
 
9.1.3 The Implications of These Findings 
 
This thesis has demonstrated that certain findings are useful in the rapid 
assessment of patient with acute dyspnoea when determining if this 
patient has heart failure. It also highlights some variables that have 
limited utility despite traditional teaching that would suggest otherwise. 
 
The patient who has acute dyspnoea with severe pulmonary oedema, a 
raised JVP, a third heart sound and a high BNP does not form a 
diagnostic quandary; the patient who has ambiguous results for one 
variable is more likely to have ambiguous findings for all of the variables. 
This reflects the spectrum of the condition.  
 
This also raises the question of the value of adding natriuretic peptide 
levels into the diagnostic equation. As this is a new diagnostic test 
involving laboratory time and equipment there is a cost involved which is 
not necessarily justified by the marginal diagnostic benefits. Introduction 
of a novel test also needs explicit guidance to prevent the overuse of the 
test that can result in over-investigation and over-diagnosis if used 
inappropriately. And, unlike other investigations such as chest x-ray, the 
information that the natriuretic peptide levels produce is almost solely 
related to the presence or absence of cardiac strain.  
 
On the other hand, point-of-care systems allow a rapid result to be 
available, which is objective and reliable. This makes it easy to 
incorporate into a diagnostic pathway without making assumptions about 
the skills or experience of the person interpreting it. Mueller et al. (2006) 
provided some evidence that the introduction of this test is cost-effective.  
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9.1.4 Reliability and validity of the selected variables 
 
There is little published literature to assess the reliability of clinical signs, 
for cardiac disease, or for any other conditions. Studies that have 
assessed the presence of the third heart sound or the presence of a 
raised JVP have found a level of agreement that is as likely to have 
occurred by chance (Lok et al., 1998; Cowie et al., 1999). 
 
The interpretation of chest x-rays fares little better with poor reliability 
score (Gatt, 2003). This remains the case even when performed by 
experienced radiologists (Robinson et al., 1999; Fox et al., 2001). This 
would suggest an advantage to an objective measurement such as the 
cardiothoracic ratio although there is the obvious disadvantage that this 
feature will be relatively fixed and will not vary in the presence of an acute 
exacerbation. 
 
 
9.1.5 Strengths and Weakness of the Systematic Review 
 
An extensive systematic review was performed with a deliberately open 
literature search. Two readers (CJF & KMJ) reviewed the literature 
search independently and selected which papers to obtain on the basis of 
the title and abstract. The selected papers were obtained in electronic or 
paper form and the quality and relevance assessed. CJF and a panel of 
seven other readers then assessed papers that were felt to be of 
sufficient quality, and provide relevant information. Each reader 
independently extracted the relevant data and made an assessment of 
the quality of the paper based on the QUADAS format. 
 
Due to the period of time that had elapsed between this literature search 
and the writing up of this thesis the same search was repeated in 2011 to 
elicit any further evidence that had been published in the elapsed interval. 
Due to restrictions in time this evidence has been selected and the data 
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extracted by a single reader (CJF). Allowing for two independent readers 
to assess the evidence reduces the risk of selection or interpretation bias 
by the single reader. Although, new data was added to this thesis, this did 
not change any of the outcomes or conclusions.  
 
9.1.6 Meta-analysis of the Selected Variables 
 
Due consideration was applied to the methods used in the meta-analysis. 
Although there is no universal agreement as to the optimum method for 
novel technique of diagnostic study meta-analysis, there was a significant 
amount of literature supporting the bivariate method. This method has 
also been used in other published diagnostic meta-analyses within 
medical literature (Vasan et al., 2002; Scal, 2005; Willis, 2012). The 
methods used allowed assessment of the available data and exploration 
of any heterogeneity found.  
 
Use of bivariate analysis allowed the production of summary data with 
confidence intervals for the variables with diagnostic potential. The 
production of this allowed the distinction to be made for the diagnostic 
variables as to sensitive, specific, both or neither. The most relevant 
variables were highlighted and other variables without diagnostic value 
were removed from consideration. 
 
The selection of the most important variables was useful as it confirmed 
the value of the variables in my original research by independently 
selecting the same variables and predicting similar diagnostic utility. 
 
9.1.7 Strengths of the Original Diagnostic Study 
 
The original diagnostic study that was performed as part of this thesis did 
have some positive features. It was a prospective study with appropriate 
and transparent inclusion and exclusion criteria that were relevant and 
justified. The study had a reasonable reference standard consisting of the 
review of all available results by two cardiologists including the recorded 
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echocardiograms. It also afforded the blinded assessment of both point-
of-care BNP, and laboratory-based NT-proBNP measurements in the UK, 
Emergency department setting. 
 
 A wide selection of potentially useful variables were prospectively 
collected and recorded on a specific form. Follow up data in terms of 
readmissions and mortality of the patients was also recorded.  
 
9.1.8 Weaknesses of the Original Diagnostic Study 
 
There were also significant weaknesses inherent in this study.  The 
original intention of the study was to be at least twice as large but this 
was not possible due to two reasons. There was a delay in commencing 
the study while the department procured a suitable echocardiogram 
machine. The second issue was due to a national restructuring of the 
training system for Emergency Medicine that meant the lead investigator 
had to take on full-time clinical commitments. The research position was 
then continued on a part-time basis around a busy full-time clinical job. 
 
A major shortcoming of this study is that it was a single site study. This 
was necessary for pragmatic reasons given that the research project was 
dependent on a single investigator with clinical commitments. In the event 
of developing a useful clinical decision rule, validation should be 
performed at multiple centres separate to the one that was involved in the 
derivation study. 
  
The recruitment of patients was done on a convenience basis. This was 
for pragmatic reasons as the study relied on the principal investigator 
being available and free of clinical duties to perform the 
echocardiography and to handle the preparation of the blood samples. 
This introduces the potential of selection bias although every effort to 
recruit every potential patient possible. The majority of patients were 
obtained during a two-month research secondment when the lead 
investigator was free of clinical duties.  
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Another opportunity to strengthen this study would have been to use a 
more experienced technician or cardiologist to record the 
echocardiograms. Again, a pragmatic reason was behind this although it 
was also useful to assess the value of training an emergency physician 
with this skill.  
 
9.1.9  Development of the Clinical Decision Rule 
 
Attempts to derive a simple but robust clinical decision rule to aid the 
diagnosis of heart failure in the acutely breathless patient in the 
Emergency Department setting revealed that it was difficult to do. The 
condition is common, has serious consequences and the current 
diagnostic process is variable and based on little evidence, suggesting 
that a clinical decision rule would have been useful. However, the end 
diagnosis and most of the diagnostic tests involved in obtaining it 
incorporate some degree of subjectivity that made defining consistent 
rules challenging.  
 
The only way to achieve very high sensitivity or specificity using a clinical 
decision rule was by deriving a large, cumbersome decision system that 
was demonstrably over-fitted to the available data. The alternative was to 
provide a selection of specific variables, the finding of two or more being 
associated with a very high specificity for this condition.  
 
While there are certainly weaknesses with the study that was used to 
attempt to derive the rule, as have been discussed in the previous 
section, I do not think that these reasons are the primary reason behind 
the failure to derive the rule for the following reasons: 
 
1. The variables with the greatest diagnostic utility derived from the 
original study were similar to those found from the systematic 
review of the medical literature. 
2. The reference standard was reasonable. 
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3. The diagnostic performances of the selected variables were similar 
in both the original research and the results of the meta-analyses. 
4. The number of patients with the target condition was adequate to 
derive a decision rule with a selected number of variables included 
in the model. 
5. Application of the other published scoring systems for heart failure 
to the original data did not provide any better results than the 
diagnostic strategies synthesised within this thesis. 
 
There are several factors with the condition of acute, decompensated 
heart failure that make the derivation of a clinical decision rule in the 
emergency setting difficult to the degree of unlikely: 
 
a. There is no agreed gold standard for this condition.  
b. The mechanism for decompensation of heart failure remains 
poorly understood and it is likely that there is more than one. 
c. The onset of heart failure tends to be insidious rather than a fixed 
time-event so dynamic changes in biological markers are less 
useful.  
d. The subjectivity in the diagnosis and the interpretation of many of 
the diagnostic findings. 
e.  The association between heart failure and age raises the difficulty 
in distinguishing normal findings in an ageing human from a 
diseased state. 
 
9.1.10 Recommendations for Further Research 
 
Although the concentration of natriuretic peptides was could be applied to 
cut-offs as a diagnostic tool, it did not significantly outperform other 
variables, including clinical opinion. However, there may still be clinical 
benefits if the use of natriuretic peptides improves the speed of diagnosis 
and therefore reduces the time to commencement of appropriate 
treatment.  
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Clinicians may also be positively guided in the interpretation of more 
subjective investigations, such as chest x-ray, in the light of known 
natriuretic peptide levels. This increased confidence may influence the 
speed and aggression with which clinicians treat this condition. 
 
A prospective diagnostic trial in the UK setting where patients were 
randomised to either have, or not have, a natriuretic peptide level 
measured could provide answers to these queries. The cost-effectiveness 
of introducing this into clinical practice could also be assessed. 
 
9.1.11 Conclusion 
 
In the diagnosis of acute decompensated heart failure, chest x-ray 
findings, natriuretic peptides and clinical opinion have been verified as 
providing the optimal diagnostic role in making this diagnosis. Other 
variables, some of which have been traditionally taught as being 
consistent with heart failure have been shown to have little diagnostic 
utility.   
 
It has been shown that the combination of certain specific variables can 
be considered pathognomonic for heart failure though ruling the condition 
out appeared more difficult despite some of the variables demonstrating 
high sensitivity. Although natriuretic peptides demonstrated diagnostic 
worth, they did not improve the diagnosis making process beyond the 
combination of other variables.  Further evidence is of improvement in 
clinical outcomes would be required before recommending the routine 
use of natriuretic peptides in the diagnosis of this condition. 
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Chapter 10 Appendices 
 
10.1 Appendix I - Literature Search 
 
10.1.1 EMBASE Search 
  
Database: EMBASE <1980 to 2009 Week 35> 
Search Strategy: 
-------------------------------------------------------------
------------------- 
1     medical history taking.mp. or exp anamnesis/ (106585) 
2     (clinical adj3 assessment).af. (33653) 
3     (signs adj3 symptoms).af. (29489) 
4     (clinical adj3 evaluation).af. (37241) 
5     (clinical adj3 examin$).af. (74107) 
6     (clinical adj3 finding$).af. (39521) 
7     (physical adj3 evaluat$).af. (2969) 
8     (physical adj3 finding$).af. (5062) 
9     (physical adj3 assess$).af. (4055) 
10     (aetiological adj4 features).af. (70) 
11     (etiological adj4 features).af. (131) 
12     xray.af. (213) 
13     x-ray.af. (144097) 
14     radiogra$.af. (186110) 
15     roentgenogra$.af. (8432) 
16     (medical adj3 history).af. (11760) 
17     (physical adj3 exam$).af. (83665) 
18     electrocardiogra$.af. (90138) 
19     ecg.af. (31088) 
20     ekg.af. (1834) 
21     (natriuretic adj peptide$).af. (16359) 
22     NTproBNP.af. (74) 
23     NT-proBNP.af. (1206) 
24     NTpro-BNP.af. (9) 
25     BNP.af. (4120) 
26     (biological adj3 marker).af. (36305) 
27     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 
or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 
or 22 or 23 or 24 or 25 or 26 (773600) 
28     acute$.af. (576780) 
29     emergen$.af. (171867) 
30     urgent.af. (17360) 
31     decompensat$.af. (7586) 
32     sudden.af. (48954) 
33     or/28-32 (773709) 
34     (heart adj3 fail$).af. (111653) 
35     (heart adj3 dysfunction$).af. (1968) 
36     (heart adj3 insufficien$).af. (620) 
37     (cardiac adj3 insufficien$).af. (1541) 
38     (cardiac adj3 fail$).af. (10043) 
39     (cardiac adj3 dysfunction$).af. (5141) 
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40     (ventric$ adj3 dysfunction$).af. (12614) 
41     (ventric$ adj3 fail$).af. (15799) 
42     (ventric$ adj3 insufficien$).af. (288) 
43     (systolic adj3 dysfunction).af. (4242) 
44     (systolic adj3 fail$).tw. (1286) 
45     (diastolic adj3 fail$).af. (1005) 
46     (diastolic adj3 dysfunction).af. (3925) 
47     hf.af. (11728) 
48     lvf.af. (427) 
49     adhf.af. (105) 
50     adcf.af. (4) 
51     ccf.af. (688) 
52     chf.af. (7792) 
53     (pulmonary adj3 edema).af. (7466) 
54     (pulmonary adj3 oedema).af. (1912) 
55     breathless$.af. (2180) 
56     dyspnoea.af. (4411) 
57     dyspnea.af. (41738) 
58     (short$ adj3 breath).af. (2938) 
59     sob.af. (270) 
60     or/34-59 (184624) 
61     27 and 60 and 33 (11802) 
62     di.fs. (1433897) 
63     predict$.tw. (510452) 
64     specificity.tw. (195785) 
65     or/62-64 (1975218) 
66     61 and 65 (7074) 
67     limit 66 to human (6909) 
 
10.1.2 Ovid MEDLINE Search 
 
Database: Ovid MEDLINE(R) <1950 to August Week 4 2009> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     medical history taking.mp. or exp Medical History Taking/ (15741) 
2     (physical adj3 exam$).af. (55686) 
3     (clinical adj3 assessment).af. (18036) 
4     (signs adj3 symptoms).af. (36461) 
5     (clinical adj3 evaluation).af. (39223) 
6     (clinical adj3 examination).af. (27277) 
7     (clinical adj3 findings).af. (45839) 
8     (physical adj3 evaluation).af. (1748) 
9     (physical adj3 findings).af. (5685) 
10     (physical adj3 assessment).af. (1910) 
11     aetiological features.af. (26) 
12     etiological features.af. (47) 
13     xray.af. or exp X-Rays/ (13757) 
14     radiogra$.af. (201299) 
15     roentgenogra$.af. (16905) 
16     electrocardiogra$.af. (169539) 
17     ecg.af. (37470) 
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18     ekg.af. (4219) 
19     natriuretic peptide.mp. or exp Natriuretic Peptides/ (21237) 
20     NTpro-bnp.af. (8) 
21     NT-proBNP.af. (1191) 
22     exp Natriuretic Peptide, Brain/ or BNP.af. or exp Biological Markers/ 
(448302) 
23     or/1-22 (1057279) 
24     (heart adj3 fail$).af. (101414) 
25     (heart adj3 dysfunction$).af. (1964) 
26     (heart adj3 insufficien$).af. (1251) 
27     (cardiac adj3 dysfunction$).af. (5506) 
28     (cardiac adj3 insufficien$).af. (4023) 
29     (cardiac adj3 fail$).af. (13517) 
30     (ventric$ adj3 dysfunction$).af. (25378) 
31     (ventric$ adj3 fail$).af. (6272) 
32     (ventric$ adj3 insufficien$).af. (598) 
33     (systolic adj3 fail$).af. (1415) 
34     (systolic adj3 dysfunction).af. (4079) 
35     (diastolic adj3 fail$).af. (989) 
36     (diastolic adj3 dysfunction).af. (3861) 
37     hf.af. (11656) 
38     lvf.af. (494) 
39     adhf.af. (172) 
40     adcf.af. (2) 
41     ccf.af. (709) 
42     chf.af. (7880) 
43     (pulmonary adj3 oedema).af. (2436) 
44     (pulmonary adj3 edema).af. (17607) 
45     breathless$.af. (2394) 
46     dyspnea.af. (24763) 
47     dyspnoea.af. (4926) 
48     (short$ adj3 breath).af. (3253) 
49     sob.af. (446) 
50     or/24-49 (188573) 
51     (acute or emergen$ or urgen$ or decompensat$ or sudden).af. (990218) 
52     50 and 51 and 23 (10634) 
53     limit 52 to "diagnosis (sensitivity)" (5633) 
 
379 
 
10.2 Appendix II - QUADAS questions 
 
1 Was the spectrum of patients representative of the patients who will receive the 
test in practice? (spectrum) 
2 Were selection criteria clearly described? (selection criteria) 
3 Is the reference standard likely to correctly classify the target condition? 
(reference standard)*  
4 Is the time period between reference standard and index test short enough to be 
reasonably sure that the target condition did not change between the two tests? 
(disease progression bias)*  
5 Did the whole sample or a random selection of the sample, receive verification 
using a reference standard of diagnosis? (partial verification)  
6 Did patients receive the same reference standard  
regardless of the index test result? (differential verification)  
7 Was the reference standard independent of the index test (i.e. the index test did 
not form part of the reference standard)? (incorporation bias)  
8 Was the execution of the index test described in sufficient detail to permit 
replication of the test? (index test execution)  
9 Was the execution of the reference standard described in sufficient detail to 
permit its replication? (reference standard execution)  
10 Were the index test results interpreted without knowledge of the results of the 
reference standard? (test review bias)  
11 Were the reference standard results interpreted without knowledge of the 
results of the index test? (reference standard review bias)  
12 Were the same clinical data available when test results were interpreted as 
would be available when the test is used in practice? (clinical review bias)*  
13 Were uninterpretable/ intermediate test results reported? (uninterpretable test 
results)  
14 Were withdrawals from the study explained? (withdrawals) 
(Whiting et al., 2006) 
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10.3 Appendix III – Ethical Approval 
 
Bolton Local Research Ethics Committee 
Room 181, Gateway House 
Piccadilly South 
Manchester  M60 7LP 
 
Telephone: 01612372585  
Facsimile: 01612372383 
12 September 2005 
 
Private & Confidential 
Dr C J Ferguson, Clinical Research Fellow 
Department of Emergency Medicine 
Manchester Royal Infirmary 
Oxford Road 
MANCHESTER 
M13 9WL 
 
 
Dear Dr Ferguson 
 
Full title of study: Creation of a Clinical Decision Rule for the Diagnosis 
and Management of Heart Failure within Emergency 
Medicine involving the use of B Natriuretic Peptide  
REC reference number: 05/Q1409/53 
 
Thank you for your response to the Committee’s request for further 
information on the above research and for submitting revised 
documentation. 
 
The further information has been considered on behalf of the Committee 
by the Vice Chair. 
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Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical 
opinion for the above research on the basis described in the application 
form, protocol and supporting documentation as revised. 
 
However, the Committee has not yet been notified of the outcome of any 
site-specific assessment (SSA) for the research site taking part in this 
study.  The favourable opinion does not therefore apply to any site at 
present.  I will write to you again as soon as one Local Research Ethics 
Committee has notified the outcome of a SSA.  In the meantime no study 
procedures should be initiated at sites requiring SSA. 
 
Conditions of approval 
 
The favourable opinion is given provided that you comply with the 
conditions set out in the attached document.  You are advised to study 
the conditions carefully. 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is 
as follows: 
 
Document Version Date 
Application  4.1 23 May 2005 
Investigator CV K Mackway-Jones  20 May 2005 
Investigator CV C J Ferguson  20 May 2005 
Protocol   4 20 May 2005 
Summary/Synopsis   1
.
2 
20 May 2005 
GP/Consultant Information Sheets   2 12 May 2005 
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Participant Information Sheet   2 02 September 2005 
Participant Consent Form Gifting 3 02 September 2005 
Participant Consent Form  3  
 
Management approval 
 
The study should not commence at any NHS site until the local Principal 
Investigator has obtained final management approval from the R&D 
Department for the relevant NHS care organisation. 
 
Membership of the Committee 
 
The members of the Ethics Committee who were present at the meeting 
are listed on the attached sheet. 
 
Notification of other bodies 
 
The Committee Administrator will notify the research sponsor that the 
study has a favourable ethical opinion. 
 
Statement of compliance  
 
The Committee is constituted in accordance with the Governance 
Arrangements for Research Ethics Committees (July 2001) and complies 
fully with the Standard Operating Procedures for Research Ethics 
Committees in the UK.  
 
05/Q1409/53                 Please quote this number on all 
correspondence 
 
With the Committee’s best wishes for the success of this project, 
 
Yours sincerely 
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10.4 Appendix IV – Consent Form 
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10.5 Appendix V – Clinical Details Form 
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10.6 Appendix VI – Characteristics of the 
Natriuretic Peptides 
 
BNP and NT-proBNP have skewed distribution in common with many 
biological variables. The log transformation of these values does have 
normal distribution.  
 
 
Figure 10-1 Frequency Histogram of BNP 
 
 
 
389 
 
 
Figure 10-2 Frequency Histogram of Log BNP 
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Figure 10-3 Normal P-P Plot for Log BNP 
 
BNP and NT-proBNP demonstrate correlation with a Pearson Correlation 
value of 0.951 with a significance of 0.000.  
 
BNP correlates with age, correlation coefficient of 0.424 with 2-tailed 
significance of .000, considered significant at the 0.01 level. 
 
I did not find any significant difference in mean BNP values dependent on 
sex using the Mann-Whitney U test (Significance  = 0.251). The same 
was true for NT-proBNP with a significance level of 0.151. 
 
There was a significant correlation for BNP with age (Spearman’s Rho 
Correlation Coefficient of 0.424 and a significance of 0.000.  The same 
was true with NT-proBNP CE of 0.474 and significance of 0.000.  
 
There was a negative correlation for NT-proBNP with estimated GFR with 
a CC of -0.429 and a significance of 0.000.  For BNP this was -0.459 and 
0.000.  
 
The values of NT-proBNP were significantly higher in the patients who 
subsequently died using the Mann-Whitney U test (significance .006). 
The same was true of BNP with a significance level of 0.022.  
 
For male patients the mean BNP level was 475.3 (95% CI 255 – 695) 
with a median value of 166.000. For female patients the mean level was 
324.7 (95% CI 182 – 467) with a median of 95.2. 
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Figure 10-4 BNP Values by Sex of Patients 
For male patients the mean NT-proBNP level was 616.2 (95% CI 246 – 
986) with a median value of 124.7.  
For female patients the mean NT-proBNP levels was 361.3 (95% CI 150 
– 572) with a median value of 56.6. 
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Figure 10-5 NT-proBNP Values by Patient Sex 
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10.7 Appendix VI – Summary of Included Studies  
 
Ababsa 2005 
Clinical Features - Acute dyspnoea as the primary complaint. 
Setting - A single emergency department in Pontoise, France. Time period not 
specified. 
Participants - 86 adult patients with mean age of 66 years (Range 38 to 94 
years). 36 female: 50 male patients. Excluded patients with severe renal 
impairment. 
Study Design - Selection method for patients not clear. 
Target condition - Heart failure. 
Reference standard - The opinion of two cardiologists. Mentions that treating 
clinicians were unaware of BNP results, not clear if cardiologists blinded. 
Index and comparator tests - BNP was measured using AxSYM BNP kit by 
Abbot laboratories. All specimens assayed immediately on arrival at laboratory. 
Used results to determine optimal levels to rule-in and rule-out heart failure. 
Follow up - Not mentioned. 
Funding - Abbot Laboratories provided BNP assay kits. 
Notes - Data provided as sensitivity, specificity, PPV, NPV and +LR for certain 
cut-off values. I have calculated best fitting numbers but it does not match the 
figures exactly. Mentions that treating clinicians were unaware of BNP results -
not clear if cardiologists blinded. 
 
Alibay 2005 
Clinical features - Patients presenting with acute dyspnoea 
Setting - A single emergency department in Paris, France between June 2003 
and January 2004. 
Participants - 160 patients. Mean age 80.1 ± 13.5 years (range 16-98 years). 84 
female: 76 male patients. 60 patients diagnosed with heart failure. 
Study design - Convenience sample?  
Target condition - Heart failure. 
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Reference standard - Two cardiologists using all data including ECG, 
echocardiography, CXR and response to treatment based on the European 
Cardiology Society (ESC) guidelines. 
Index and comparator tests - BNP levels were measured. The coefficient 
variation was 10.3% at low end, 29.1 pg/ml and 15.2% at high end, 5,000pg/ml. 
Biosite Kit. NT-proBNP was also used. The coefficient variation was 5% at 
380pg/ml, 4.4% at 8700 pg/ml and 5% at 13,000pg/ml. Roche Elecsys. 
Follow up - Not clear. 
Funding - Not stated. 
Notes - Little demographic data provided. 
 
Barcarse 2004 
Clinical features - Adult patients with acute dyspnoea. Excluded patients who 
clearly had another cause of dyspnoea. 
Settings - Patients presenting to the Veterans Association Hospital, San Diego, 
USA between June 2001 and April 2002. 
Participants - 98 male patients. Mean age 64.6 ± 1.2y. 
Study design - Convenience sample. All patients had BNP test done followed by 
non-invasive haemodynamic monitoring by Impedance Cardiography. The 
attending physician was told if the BNP level was greater than 100pg/ml upon 
request. Biosite kit. 
Target condition - Heart failure. 
Reference standard - The reference standard was a single cardiologist who 
reviewed all the patient data apart from the ICG result and determined if the 
patient had heart failure.   
Index and comparator tests- Impedance cardiography. 
Follow up - Patients were followed up for 90 days with regard to cardiac deaths, 
readmissions, ED visits within 90 days in patients with BNP >100pg/ml. 
Disclosures - Kits for BNP testing provided by Biosite Inc. BioZ device loaned 
by Cardiodynamics for ICG monitoring. Dr Maisel is a consultant for Biosite 
Inc. 
Notes - Compared BNP and CI by using ROC curves. 
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Bayes-Genis 2004 
Clinical features - Adult patients presenting with shortness of breath as the most 
prominent complaint. 
Settings - One emergency department at a hospital in Barcelona, Spain between 
April 2002 and February 2003. 
Participants - 100 patients recruited, six died before diagnosis confirmed and 
five withdrew from the study. Mean age 71 years, range 40-80 years. 54 males: 
35 females. 
Study design - Prospective study with consecutive recruitment. Bloods were 
taken for NT-proBNP testing on arrival.  
Target condition - Heart failure. 
Reference standard - The reference standard was two cardiologists opinions, 
following review of the patient notes. The cardiologists were blinded to the NT-
proBNP results. 
Index and comparator tests- Patients had an echocardiogram as an index test, 
spirometry, pulmonary volumes and blood gases. Left ventricular dilatation 
(LVEDD>55mm) and LVEF <45% were used as criteria for systolic LV 
dysfunction. Left ventricular hypertrophy and LVEF >45% with inversion or 
pseudo-normalisation of E/A ratio identified diastolic LV dysfunction.  
Follow up - Patients reviewed at 7 days after admission. 6 patients died before 
confirmation of diagnosis and 5 patients withdrew from the study. 
Disclosures: Drs Bayés-Genis, Santaló-Bel, Zapico-Muñiz and Ofdóñez-Llanos 
received honoraria from Roche Diagnostics for conferences. Roche Diagnostic 
provided the reagents for the study. 
Notes - Stated that recruited consecutive patients but only 100 patients recruited 
in 11 months. 
 
Boldanova 2010 
 
Further write up of Mueller 2005 paper but includes data about the diagnostic 
accuracy of the clinical diagnosis of heart failure and BNP while recorded in the 
emergency department.  
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Choi 2007   
Clinical features - Adult patients presenting because of dyspnoea. Excluded 
patients with history of trauma, cardiopulmonary resuscitation or patients who 
had been transferred from other hospitals. 
Settings - Emergency departments in Korea from October 2004 to October 2005. 
Participants - 1040 patients. 582 male: 458 female. Mean age 63 years, 
Study design – consecutive? Prospective study.  
Target condition - Heart failure. 
Reference standard - The reference standard was an echocardiogram performed 
by two echo-cardiologists blind to the BNP result. The criteria for systolic 
dysfunction were LVEF <50% or the inner diameter of the left ventricle at 
diastole was  >5.2cm or global hypokinesia was detected. The criteria for 
diastolic dysfunction was an E-wave / A-wave ratio of <1 and the deceleration 
time was >240ms or the E/A ratio was >1.5 and the deceleration time <150ms. 
Index and comparator tests- BNP (Biosite Triage) was the index test. Collected 
blood on arrival, stored in EDTA tubes prior to analysis. Also looked at 
concurrent medical conditions. 
Follow up - Until discharge from hospital.  
Disclosures - None mentioned. 
Notes - Korean hospital, mentions emergency departments in pleural but doesn't 
state which hospitals or how many. 
Chung 2006 
Clinical features - Adult patients with acute dyspnoea whom the attending 
emergency physician felt required hospital admission. Exclusion criteria included 
AMI (including NSTEMI), unstable angina, or renal failure requiring dialysis.  
Setting - Single emergency department in Sydney, Australia. Recruitment period 
not stated. 
Participants - 143 patients. Mean age 79±10 years. 63 male: 80 female patients. 
Study design - The emergency physician assessed the patient and then had to 
give a likeliest diagnosis as to acute heart failure, heart failure but another 
precipitation condition or no heart failure. The ED physician was then told the 
BNP and offered the opportunity to change their mind.  
Target condition - Heart failure. 
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Reference standard - A single cardiologist who was aware of all the medical 
notes, investigations and BNP result. 105 patients had an echocardiogram, LVEF 
was assessed on a visual estimate. 
Index and comparator tests- BNP was the Biosite Triage fluorescence 
immunoassay kit. 
Follow up - Until discharge? 
Disclosures - Study supported by untied grant from Servier Australia. Biosite 
P/L lent the authors the BNP measuring device. 
Notes - 
 
Collins 2006 
Clinical features -  Adult patients who presented with signs or symptoms of 
heart failure (dyspnoea, extremity oedema, fatigue) and who had an ECG 
requested by the attending physician. 
Settings - Four emergency departments in the US between September 2003 and 
June 2004. 
Participants - 439 patients were recruited in total. The first 17 were part of a 
pilot study. Of the remainder, 343 were included in the study. Main reasons for 
exclusion were failure to get heart sound data recorded successfully, patients 
were also excluded if the heart sound could not be analysed (S3: ventricular 
rhythm/tachycardia, heart rate >115, PR interval <120ms; S4: all of the S3 
excluders plus junctional rhythm, ventricular pacing, atrial fib/flutter/tachy). 
Excluded if an ECG had been performed and over 1h had passed since receiving 
vasodilators or diuretics. Median age 61 years. 230 female : 209 male patients. 
Study design - Prospective convenience sample. 
Target condition - Heart failure. 
Reference standard - 2 senior cardiology fellows blinded to BNP and heart 
sound data. 
Index and comparator tests- Looked at diagnostic value of electronically 
detected 3rd heart sound and physician detected 3rd heart sound. Also 
electronically detected S4. 
Follow up - 30 day follow up by telephone. 
Disclosures - The original data collection for the database was paid for by 
Inovise Medical Inc. Drs Collins and Lindsell received honoraria from Inovise 
Medical Inc. Dr Peacock has received research support and is a consultant for 
Inovise Medical, Inc. and received research support and honoraria from Biosite, 
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Inc. Dr Storrow received research support from Inovise Medical, Inc. and Biosite 
Inc. and honoraria from Biosite, Inc. 
Notes - Large proportion of patients not analysed because of missing or 
uncollectable data. 
Collins 2009 
Clinical features - Patients aged over 39 years presenting to EDs with acute 
dyspnoea. Excluded patients with dialysis dependent renal impairment or 
patients where there was another obvious cause. 
Settings - 7 centres in USA, 1 in Switzerland and 1 in Taiwan between March 
and October 2006. 
Participants - 995 patients included. Excluded 70 patients as no acoustic 
cardiography S3 determination and 11 patients as no criterion standard diagnosis. 
Median age 60 years (range 40 to 95 years). 547 male : 448 female patients.  
Study design - Convenience sample.  Acoustic cardiography carried out by 
study personnel. ED data collected prospectively: demographics, medical history, 
physical examination, ECG findings as documented by the attending ED 
physician. Laboratory tests, CXR reported by radiologist and echo reported by a 
cardiologist were obtained from the medical records. After history and 
examination but before any diagnostic test results were available, the treating 
physician had to use a VAS to document the likelihood of acute decompensated 
heart failure. The attending physician was then presented with the acoustic 
cardiography printout, which incorporates an ECG and a computer generated 
diagnosis, and then repeat the VAS score. The score was repeated again, once all 
the other investigations were back. 
Target condition - Heart failure 
Reference standard - The opinion of 2 cardiologists at each centre who 
reviewed all the data apart from the acoustic cardiography. Not clear if they were 
blinded to each other. 
Index and comparator tests- Index test was acoustic cardiography. 
Follow up - Followed up to 90 days by telephone. 
Disclosure - Inovise Medical Inc. funded the study including provision of 
acoustic cardiography devises and sensors, providing study support for patient 
enrolment and data management and assisted with device training for study 
personnel. 
Notes - Acoustic cardiography software did not analyse data if the heart rate was 
>115. 
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Coste 2006 
Clinical features - Adult patients with acute dyspnoea presenting to three 
hospitals as emergencies 
Settings - Three hospitals in Pontoise, Clichy and Boulogne between September 
2003 and February 2005. 
Participants - 699 consecutive patients. Mean age 72.8 ± 14.3 years. 477 male : 
222 female patients. 
Study design - Standardised clinical examination. Bloods taken before any 
therapeutic intervention. 
Target condition - Heart failure. 
Reference standard - 2 cardiologists who used all results except BNP. 
Index and comparator tests- Bloods taken into a vial containing potassium 
EDTA and then immediately assayed using the triage BNP test. (Biosite 
Diagnostics). Mean confidence limit of the analytical sensitivity <5ng/L (95% CI 
0.2-4.8 ng/L). 
Follow up - Followed up until discharge. 
Disclosures - None stated. 
Notes - Cannot calculate sensitivity / specificity from data provided. 
 
Davis 1994 
Clinical features - Patients with acute dyspnoea. Patients were recruited after 
clinical examination to exclude obvious pneumonia, pulmonary embolus or 
pneumothorax. 
Settings - One hospital in New Zealand. 
Participants - 52 patients. 31 female : 21 male patients. Mean age 74 years 
(range 49 − 89 years). 
Study design -  
Target condition - Heart failure. 
Reference standard - Committee of physicians and a radiologist decided end-
diagnosis. 
Index and comparator tests- Measured routine bloods, had chest x-ray and 
blood gases. also measured ANP, BNP and endopeptidase. Within-assay 
coefficients of variation were 5% for ANP and 3.2% for BNP. LVEF 
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radionuclide scanning done with General Electric 400T gamma camera linked to 
a GE Star 2 computer. The CV for LVEF varies from 5-7.5% over the range of 
35-75%. All results reviewed retrospectively by a committee of physicians for a 
decision on the final diagnosis. 
Follow up - Follow up was attempted after a few days to repeat the tests. This 
was not possible in 5 patients who had died and 6 patients who were discharged 
prior to follow up. 
Disclosures - None stated. 
Notes -  
 
Fleischer 1997 
Clinical features - Patients requiring admission due to acute dyspnoea. 
Settings - One hospital in New Zealand recruited between November 1994 and 
January 1995. 
Participants - 123 patients. Mean age 68.3 years (range 23 − 90 years). 54 
female : 69 male patients. 
Study design - Patients had a blood sample taken within 24 hours of admission. 
All patients also had a chest x-ray. 
Target condition - Heart failure.  
Reference standard - The discharge diagnosis.   
Index and comparator tests - BNP levels were measured on admission and 
were usually available within 24h of attendance. The results were made available 
to the treating clinician at that time with information explaining that levels 
greater than 49 pg/ml were suggestive of heart failure. 
Follow up - Until discharge. 
Disclosure - Supported in part by the Health Research Council and the National 
Heart Foundation of New Zealand. 
Notes - Poor reference standard. Small numbers. Developed own assay for BNP 
so may not be directly comparable to commercial assays. 
 
 
Gargani 2008 
Clinical features - Inclusion criteria were presence of dyspnoea at admission, 
venous blood sample for NT-proBNP taken on day of admission, assessment of 
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ultrasound lung comets within 4h of the NT-proBNP assay, no diuretic therapy 
between the two measurements 
Settings -  . Patients admitted to the Cardiology and Pneumonology Division of 
the Institute of Clinical Physiology in Pisa between November 2004 and March 
2006. 
Participants - 149 consecutive patients. Mean age 71±11 years. 51 female : 98 
male patients. 
Study design -  Although patients were described as consecutive over 100 
patients were excluded, often because the emergency physician did not notify the 
sonographer, so it is essentially a convenience sample. No exclusion criteria 
given.  Peripheral venous blood was collected from each patient on admission. 
Blood samples were collected in polypropylene tubes containing aprotonin and 
ethylene diamine tetra acetic acid then analysed by electro-chemiluminescence 
sandwich immunoassay (ECLIA) method for NT-proBNP using an Elecsys 2010 
analyser from Roche Diagnostics. Plasma samples were centrifuged for 15min at 
4C then stored at -20C in polypropylene tubes until assay. The coefficient for 
inter and intra-assay precision is 4%. 
Every patient had an ultrasound chest of the anterior and lateral chest walls, with 
a total of 28 sites examined. The total number of comets seen was recorded 
giving the 'comet score'. A score of ≤5 was considered normal. Intra and inter-
observer variability of assessments are 5.1% and 7.4% in their institution. 
The patients also echocardiograms done with the LV volumes and EFs measured 
according to the modified biplane Simpson's method and adjusted for body 
surface area. Diastolic function was determined from the pattern of mitral and 
pulmonary venous flow velocity by pulsed Doppler. Diastolic dysfunction was 
staged as absent, mild, moderate or severe. 
Target condition - The target condition was heart failure (prevalence 81.9%).  
Reference Standard - The standard reference was the opinion of two 
cardiologists who were blinded to the ULC and NT-proBNP results. A third 
expert was around for cases where there was disagreement. 
Index and comparator tests- The index test was the presence of ultrasound 
comets on ultrasound examination of the chest. NT-proBNP was used as a 
comparator test. 
Follow up - Not clear. Presumably until discharge when all relevant 
investigations had been carried out. 
Disclosures - Supported by Institute of Clinical Physiology, National Research 
Council and a research grant from the Clinica “Montevergine”. 
 Notes - Very high level of heart failure compared with other studies, 122 out of 
149 patients felt to have heart failure. 
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Gegenhuber 2006 
Clinical features and settings -Same patients as in Mueller 2005 paper. 
Excluded patients with STEMI and non-STEMI and trauma 
Participants - Patients presenting to the St. John of God Hospital in Linz, 
Austria.  All patients presenting between October 2003 and February 2004 were 
recruited. 
Study design -  
Target condition and reference standard - The target condition was heart 
failure (prevalence 54.6%). 
Index and comparator tests- All patients were examined and had blood taken 
for BNP and NT-proBNP. Estimated GFR by Cockcroft and Gault formula. The 
echo and classification of the patients had to be done within 3 days of the 
patients’ attendance. The classification was done before the NT-proBNP and 
BNP results were made available. Set up to compare BNP and NT-proBNP but 
kept samples for further analysis. These samples were then used to look at mid-
range proANP. 
Follow up -  
Notes -  
 
 
Green 2008 
Clinical features and settings - 
Participants -  
Study design -  
Target condition and reference standard - 
Index and comparator tests- Study designed around NT-proBNP 
Follow up -  
Notes - Further analysis of Januzzi (PRIDE) study but looking at clinical opinion 
though hard work to extract. 
 
Huang 2006 
Clinical features - Adult patients with main complaint of dyspnoea.  Exclusion 
criteria were AMI, trauma, other obvious cause of dyspnoea e.g. pneumothorax.  
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Also excluded patients with poor echocardiographic windows, which was 12 out 
of 104 potential patients. 
Settings - Tertiary medical centre from Jan-Oct 2005. 
Participants - Identified 104 patients and recruited 92 of these. Mean age 72.3 
years. 45 male : 47 female patients. 
Study design - Prospective. 
Target condition - The target condition was heart failure (prevalence 55.4%). 
Reference standard - The opinion of 2 cardiologists blinded to the patients 
tissue Doppler echocardiography and BNP levels. Diagnosis based on the 
Framingham and NHANES criteria. In the event of a disagreement between the 
cardiologists a 3rd cardiologist was brought into the discussion. The decision 
was made as to whether patients had acute heart failure or not. 
Index and comparator tests- The index test was tissue Doppler 
echocardiography. Not clear when the echo was performed. Patients also had 
BNP checked if the attending physician requested it. BNP assayed on an AzSYM 
analyser from Abbott laboratories. Echocardiography was carried out by a 
cardiologist using a System V, GE-Ving Med Sound AB machine with a 3.5-
MHz multiphase array probe. Used pulsed Doppler to record trans-mitral and 
aortic flow in the apical 4 chamber view. Tissue Doppler velocities were 
acquired at the septal and lateral mitral annular sites of the left ventricle form the 
apical 4-chamber view with a spectral pulse-wave pattern. The studies were then 
analysed by and echocardiographer blinded to all clinical details. Mitral inflow 
data included peak early diastolic and peak late diastolic velocities, E:A ratios 
and the deceleration time of early diastolic flow. The tissue Doppler peak early 
diastolic velocities at the septal and lateral mitral annular sites were measured 
and the E:Ea ratios were calculated from the average of the septal and lateal Ea 
due to the optimal accuracy of this approach in patients with regional wall 
abnormalities. 
Follow up - Until discharge. 
Disclosure - None declared. 
Notes - BNP only performed if requested by the attending physician so data from 
this not included although the index test and reference standard were blinded to 
the result. 
Calculated the E:Ea ratio, i.e. the peak early diastolic mitral inflow against the 
peak early diastolic inflow at the septal and lateral mitral annular sites but used 
different cut-offs for patients with ejection fractions above or below 50%.  
 
 
Januzzi 2005 
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Clinical features - Patients over 21 years presenting with acute dyspnoea. 
Exclusion criteria creatinine > 2.5 mg/dl, chest trauma, ST elevation or 
depression >0.1mV, >2h after intravenous loop diuretics and unblinded 
natriuretic peptide level measurement. 
Settings - Massachusetts General Hospital, Boston over a 4 month period. 
Participants - 600 patients recruited, 1 withdrew consent. Mean age 62.4 years. 
305 male : 295 female patients. 
Study design - Clinical characteristics, signs, symptoms, medical history, 
medications, results of diagnostic test in the ED, x-ray and standard blood tests. 
Another blood sample was taken for NT-proBNP following measurement. 
Target condition and reference standard - The target condition was heart 
failure (prevalence 35%). States that study cardiologist reviewed all results 
including the 60 day phone call. Doesn't state how many cardiologists were 
involved. 
Index and comparator tests- Blood samples taken after recruitment and frozen 
at -80C. 
Follow up - 60 day follow up on every patient. Attempts made to contact each 
patient and a chart review undertaken to see if any clinical events had taken place 
since the index presentation. 
Disclosure - Supported by a grant from Roche Diagnostics. 
Notes -  
 
Jourdain 2002 
Clinical features - Adult patients presenting with a primary complaint of acute 
dyspnoea. 
Settings - One emergency department in France. 
Participants - 125 patients recruited, 115 analysed. Mean age 71.4 years.  
Study design - All patients had BNP checked on arrival. Attending physicians 
blind to results. End diagnosis by cardiologists, also blind to BNP. Patients also 
had echo done looking for systolic or diastolic dysfunction. 
Target condition  - Target condition was heart failure.  Prevalence 77/115 
(67.0%). 
Reference standard - End diagnosis provided by the cardiology service. 
Index and comparator tests- Looked at emergency physician clinical opinion 
and few other clinical and investigative findings. 
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Follow up - Until discharge. 
Disclosures - None. 
Notes - Authors state recruited 125 patients but only 115 patients information 
provided in table, not clear if this is an error or if the patients have been excluded 
but can't see this in the text. 
 
Kang 2006 
Clinical features - Patients with acute dyspnoea suspected to be of cardiac 
origin. 
Settings - one department in Korea. Patients recruited between November 2003 
and May 2004.  
Participants - 69 patients. Mean age 68 ± 12 years. 31 male : 38 female patients. 
Study design - Prospective diagnostic study. All patients had BNP levels 
checked and an echocardiogram. 
Target condition -  Heart failure. 
Reference standard - Target condition was heart failure. The reference standard 
was based on a selection of clinical and investigative findings. 
BNP used but have given cut-off values for systolic dysfunction an 
Index and comparator tests- 
Follow up - Patients with diastolic dysfunction were followed up for a year. 
Disclosures -  None declared. 
Notes -  Korean. Can’t use BNP data as split results up for diastolic and systolic 
dysfunction and have used different cut-off values. 
 
 
Klemen 2009 
Clinical features - Patients presenting with acute dyspnoea. Excluded if any 
other obvious cause for dyspnoea other than heart failure, e.g. pneumonia 
Settings - Pre-hospital setting which was the centre for emergency medicine in 
Maribor, Slovenia. 
Participants - 546 patients recruited. 105 patients were excluded. Mean age 59.8 
years. 271 male: 170 female patients. 
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Study design - Prospective study with consecutive recruitment. All patients were 
admitted to the same hospital following assessment. 
Target condition - Heart failure. 
Reference standard - Discharge diagnosis based on CXR, echo, exercise test, 
pulmonary function test, FBC, biochemistry and invasive tests or angiography. 
Index and comparator tests- NT-proBNP and quantitative capnometry. 
Follow up - Until hospital discharge. 
Disclosures - None. 
Notes - I think pre-hospital means pre-admission? No table 1 provided. Also 
used partial-pressure of end-tidal CO2 as a diagnostic test but not included in my 
table as not blinded and not routinely used in UK practice. 
Knudsen 2004 
Clinical features - Patients with a principal complaint of shortness of breath, 
either of acute onset or an acute exacerbation. Patients with another obvious 
cause were excluded. The study also excluded patients with AMI or advanced 
renal failure. 
Settings - Patients were recruited from 5 US and 2 European hospitals. Recruited 
from June 1999 to December 2000. 
Participants -  1586 patients with a principal complaint of shortness of breath. 
This subgroup analysis excluded the patients with incomplete information from 
the analysis so only looked at 880 patients in total. Mean age 64 ± 16 years. 482 
male: 398 female patients. 
Study design - The patients all had an ECG and a CXR (reported by a 
radiologist at the recruiting hospital). Bloods were taken an a point-of-care BNP 
test done (Biosite). Information from the data was used to calculate the 
Framingham and NHANES scores for heart failure. Univariate analysis was 
made with chi-squared or independent sample t tests. 
Target condition- Heart failure. 
Reference standard - Provided by 2 cardiologists who reviewed all the 
information at around 30 days post-admission. 
Index and comparator tests- Looked at BNP (cut-off 100 pg/ml), radiograph 
findings, ECG findings, historical findings and clinical findings. Also did block 
test to test the hypothesis that the prognostic ability of the model with BNP as a 
co-variable was significantly different from that of the model without BNP. 
Follow up - Notes assessed at around 30 days following admission. 
Disclosure - None stated. 
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Notes - Subgroup of Maisel 2002 study. 
 
Lainchbury 2003   
Clinical features - Adult patients with shortness of breath as part of reason for 
attendance to emergency department. 
Settings - Single emergency department in New Zealand. 
Participants - 205 patients with dyspnoea. Mean age 70 ±14 years. 100 male : 
105 female patients. 
Study design - Prospective study. 
Target condition - Heart failure. 
Reference standard - Two cardiologists who had access to all results apart from 
the BNP / NT-proBNP. In cases of disagreement a 3rd cardiologist was the final 
adjudicatory. 
Index and comparator tests- Patients had medical history, physical 
examination, blood tests, chest x-ray, and other diagnostic tests. 171 patients had 
an echocardiogram and 5 patients had radionuclide ventriculography. 
Follow up - Discharge? 
Disclosures - Supported by the Health Research Council of New Zealand and the 
National Heart Foundation of New Zealand. Triage BNP test strips and analyser 
provided by Biosite Diagnostics. 
Notes - Ethical approval obtained. 
 
 
Liteplo 2009 
Clinical features - Adult patients presenting with dyspnoea who were 
undergoing a NT-proBNP test as part of their investigations. 
Settings - Massachusetts General Hospital , Boston between December 2006 and 
June 2007.  
Participants - 100 hundred patients enrolled, 6 excluded due to incomplete data. 
Mean age 74 ± 14 years. 55 male : 41female patients. 
Study design - Convenience sample, patients recruited when investigator 
available. Each patient had an eight-zone thoracic US performed. Sonographers 
were trained for minimum of 2.5h. Sonographers blinded to NT-proBNP result. 
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Interpreted at time but also recorded and later reviewed by a single sonographer 
blinded to clinical parameters and 
Target condition -  Heart failure (prevalence 42.6%). 
Reference standard - There was a 'criterion standard' diagnosis of CHF based 
on a consensus of chart review. 2 emergency physicians reviewed all data except 
US results, so included NT-proBNP results. 
Index and comparator tests- 
Follow up - Until discharge. 
Disclosures - None stated. 
Notes - Selection bias as doctors would know that if they checked a NT-proBNP 
test then the patient would be eligible for the study and vice versa. 
 
Lo 2007 
Clinical features  - Adult patients with one or more of the following criteria: 
SOB, respiratory rate >20bpm, oxygen saturations less than 90% in room air. 
Exclusion criteria included trauma and pregnancy.  
Setting - Single emergency department at Linko Chang Gung Memorial 
Hospital, Taiwan. 
Participants - 60 patients recruited, 8 excluded due to lack of definite diagnosis. 
Mean age 68.5 ±14.2 years. 14 female : 38 male patients. 
Study design - Convenience sample. Uses impedance cardiography to measure 
beat-to-beat changes of thoracic bio-impedance to calculate haemodynamic 
parameters. Prospective blind study in convenience sample. All patients seen and 
examined by an emergency physician and had blood tests, ECG, CXR and ABG. 
Echocardiograms performed as felt necessary. 
Target condition - Heart failure (prevalence 38.5%).  
Reference standard - A review of medical record by an ED physician blind to 
ICG results and not involved in the treatment of the patient. 
Index and comparator tests- Impedance cardiography data evaluated 
retrospectively. A cardiac index <2.4 or lower or a systolic time ratio of 0.55 or 
higher concurrent with a cardiac index of less than 3.0 used to define cardiac 
cause of dyspnoea. 
Follow up - Until discharge. 
Disclosures - None declared. 
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Notes - 6 patients excluded from authors calculations as no clear end-diagnosis. I 
think that the patients should have been included as non-cardiac breathlessness 
for the calculations. No ethical approval mentioned. 
 
 
Logeart 2002 
Clinical features - All patients presenting to one emergency department with 
severe shortness of breath were recruited over a 2 year period. 
Setting - One emergency department in Clichy, France between June 1999 and 
June 2001. 
Participants - 235 patients were enrolled, 72 patients were excluded due to 
treatment already being started or because emergency echocardiography was not 
feasible. Mean age 67.4 years. 109 male : 56 female patients. 
Study design - All patients had an ECG and chest x-ray and blood taken for 
BNP levels (Biosite). All included patients also had an echocardiogram done 
using a Hewlett-Packard Sonos 1500 with a 2.5 MHz probe. The echo was 
recorded on videotape and reviewed by a cardiologist. 
Target condition - Heart failure. 
Reference standard - The opinion of two cardiologists and one pneumologist 
who were blinded to the BNP and echocardiogram results. 
Index and comparator tests- Data also compiled on historical and clinical 
findings. Ejection fraction visually estimated from echocardiogram. 
Follow up - Not mentioned. 
Disclosure - Supported in part by grant from the French Federation of 
Cardiology. BNP assays provided by Biosite. 
Notes –  
 
Lokuge 2010 
 
Clinical features - All patients presenting to one emergency department with 
severe shortness of breath were recruited between August 2005 and April 2007. 
Setting – Emergency departments in two hospitals in Victoria, Australia. 
Participants - 799 patients recruited, various patients excluded (reasons provided) so 
612 patients left. 328 male: 284 female. 
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Study design – Half of the patients had a BNP test done. The majority of 
patients had a clinical estimation of the likelihood of heart failure by the 
attending physician.  
Target condition - Heart failure. 
Reference standard – A cardiologist and an emergency physician, blinded to 
the BNP results provided the reference standard based on the patient notes and 
investigation results. In the event of a disagreement a third physician made the 
final diagnosis.  
Index and comparator tests- BNP was analysed using the Abbott Laboratories 
assay. 
Follow up – Until discharge. 
Disclosure – Supported by an unrestricted educational grant from Janssen-Cilag 
(part of Johnson & Johnson). 
Notes -  
 
Maisel 2002 
 
Clinical features - Adult patients with acute dyspnoea of either acute onset or an 
acute exacerbation. Excluded patients with another obvious cause for dyspnoea, 
patients with AMI or advanced renal failure. 
Settings - International, Patients recruited from 5 US and 2 European hospitals 
(France & Norway). April 1999 to December 2000. 
Participants - 1586 patients. Mean age 64 ±17 years. 888 male: 698 female 
patients. 
Study design - The patients all had an ECG and a CXR (reported by a 
radiologist at the recruiting hospital). Bloods were taken and a point-of-care BNP 
test done (Biosite). Information from the data was used to calculate the 
Framingham and NHANES scores for heart failure. Univariate analysis was 
made with chi-squared or independent sample t tests. 
Target condition - Heart failure. 
Reference standard - Two cardiologists who reviewed all the information at 
around 30 days post-admission. 
Index and comparator tests - Comparing BNP against reference standard of 
cardiologists opinion. 
Follow up - Notes assessed around 30 days following admission. 
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Disclosures - Biosite supplied the diagnostic kits and managed the technical 
aspects of the data accrual and storage. Biosite provided some financial support. 
Drs Maisel and McCullough have received honorariums from Biosite for 
speaking and consulting. 
Notes - Study that McCullough and Knudsen's data derived from. 
 
Maisel 2010 
 
Clinical features - Adult patients with acute dyspnoea of either acute onset or an 
acute exacerbation. Excluded patients with another obvious cause for dyspnoea, 
patients with AMI or advanced renal failure. 
Settings - International, Patients recruited from 8 US and 6 European hospitals 
and 1 hospital in New Zealand. March 2007 to February 2008. 
Participants - 1641 patients. Mean age 64 ±17 years. 859 male: 782 female 
patients. 
Study design - The patients all had an ECG and a CXR (reported by a 
radiologist at the recruiting hospital). Bloods were taken and a point-of-care BNP 
test done (Biosite). Information from the data was used to calculate the 
Framingham and NHANES scores for heart failure. Univariate analysis was 
made with chi-squared or independent sample t tests. 
Target condition - Heart failure, prevalence 34.6% 
Reference standard - Two cardiologists who reviewed all the information at 
around 30 days post-admission. Third cardiologist available in event of 
disagreement.  
Index and comparator tests - Comparing MR-ANP against reference standard 
of cardiologists opinion and BNP. 
Follow up – Followed up for 90 days.  
Disclosures - Dr. Maisel has received research support from Roche, Biosite, 
and Bayer, and is a consultant to Biosite. Dr. Mueller has received research 
grants from the Swiss National Science Foundation, the Swiss Heart Foundation, 
the Novartis Foundation, the Krokus Foundation, Abbott, Biosite, BRAHMS, 
Roche, and the University of Basel. Dr. Peacock is on the Scientific Advisory 
Board of Abbott, Beckman-Coulter, Biosite, Inverness, Ortho Clinical Diag- 
nostics, and Response Biomedical, and has received research grants from Abbott, 
Biosite, and Inverness. Dr. Ponikowski has received honoraria for serving as a 
consultant for Vifor and Athera, and as a speaker for Merck-Serono, Pfizer, and 
Sanofi-Aventis. Dr. Richards is on the Scientific Advisory Board of Inverness 
Medical, and has received travel support, honoraria, and research grants from 
Roche Diagnostics and Inverness Medical (Biosite). Dr. Filippatos has received 
research support from Biosite, BRAHMS, and Roche. Dr. Di Somma is a 
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consultant to Biosite. Dr. Ng is a consultant for Inverness Medical Innovations 
and BRAHMS AG. Dr. Daniels has received research support from Biosite Inc. 
and Roche Diagnostics. Dr. Neath is a consultant to BRAHMS USA. Dr. 
Christensen is a consultant for Siemens, BG-Medicine, Critical Care Diagnostics, 
Inverness Medical, and Abbott Diagnostics, and has received research support 
from Siemens, BG-Medicine, BRAHMS, Roche, Inverness Medical, and 
Nanosphere. Dr. McCord has received research funding from BRAHMS 
Diagnostics. Oliver Hartmann is an employee of BRAHMS AG, which is a 
company developing and marketing in vitro diagnostic products, including the 
MR-proANP and MR-proADM assays used in this study. Dr. von Haehling has 
received honoraria from BRAHMS. Dr. Bergmann is an employee of BRAHMS 
AG, holds patent applications related to this technology, and is a shareholder of 
BRAHMS AG. Dr. Morgenthaler is an employee of BRAHMS AG. Dr. Anker 
has received research support from BRAHMS, honoraria from Abbott and 
Biosite, and is a consultant to BRAHMS. 
Notes – Some of the variables that were looked at were provided as percentages 
of the patient totals and so in converting them back to raw patient numbers there 
were some slight differences between the calculated and reported patient totals. 
This usually consisted of one or two patients but occasionally there were more 
suggesting some errors in the data provided in the table. This is not likely to 
significantly affect any of the variables.  
 
Marantz 1990 
 
Clinical features - Chief complaint of shortness of breath. 
Settings - Patients presenting to one hospital with shortness of breath. 
Participants - Patients had to be 40y or over, English speaking, have attended 
during study hours and consent. 103 patients were considered, 52 were excluded 
or refused. Mean age 64 years. 20 male : 31 female patients. 
Study design -  
Target condition - The target condition was heart failure (prevalence 45%). 
Reference standard - The reference standard was the investigators blindly 
applying predetermined clinico-radiographic criteria, the Boston criteria. 
Although the Boston criteria has apparently been validated they authors modified 
it by removing wheezing as one of the criterion as they felt that there were 
patients with asthma or COPD who would be included wrongly, presumably the 
modified score has not been validated. No kappa value given for the application 
of these criteria. 
Index and comparator tests- Looked at the presence of hepato-jugular reflux 
and the response of blood pressure to the Valsalva manoeuvre. The hepato-
jugular reflux was elicited by pressing over the abdomen with a partially inflated 
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blood pressure cuff. Pressure was maintained over 10 seconds and an increase of 
at least 3cm water was considered positive. The Valsalva manoeuvre was 
performed with the blood pressure cuff inflated to 15 mmHg above the systolic 
blood pressure. An interpretable result required at least two beats to be heard. A 
normal response was to hear beats then for the beats to disappear but reappear 
once the manoeuvre was stopped. An abnormal result was when there was no 
reappearance of sounds after the release of the manoeuvre or when the sounds 
did not disappear. 
Follow up - None mentioned. 
Disclosures - None declared. 
Notes - Consider removing this study as poor quality. 
 
 
McCullough 2002   
Clinical features and settings - 
Participants -  
Study design -  
Target condition and reference standard - 
Index and comparator tests- 
Follow up -  
Notes - Same study as Maisel 2002 but includes clinical certainty of heart 
failure. 
Moe 2007 
Clinical features - Adult patients with dyspnoea suspected to be of cardiac 
origin. Excluded patients with severe renal impairment, cancer, dyspnoea from 
clinically over causes such as trauma. 
Settings - 7 participating emergency departments in Canada between December 
2004 and December 2005. 
Participants - 534 patients screened, 500 enrolled. Mean age 70.5 years. 258 
male :242 female patients. 
Study design - RCT, double-blind, prospective multi-centre trial. Patients were 
enrolled and had a history taken, examination and investigations. A separate 
sample was taken for NT-proBNP measurement. Patients were then randomised 
into two groups, those who had a known NT-proBNP and those whose NT-
proBNP remained unknown. 
Target condition - Heart failure (prevalence 46%). 
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Reference standard - Provided by 2 cardiologist who reviewed all the data from 
the admission up to the 60 day follow-up by telephone interview apart from the 
NT-proBNP result.  
Index and comparator tests - NT-proBNP analysis performed using Elecsys 
1010, 2010 or E170 proBNP assay from Roche diagnostics. 
Follow up - 60 day patient telephone interview and chart records. 
Disclosures - Dr Moe received a research grant and honoraria from Roche 
Diagnostics Canada. Dr Januzzi received research grants, honoraria, and 
consulting fees from Roche Diagnostics, Dade-Behring and Ortho Clinical 
Diagnostics. H. Zowall received a research grand and consulting fees from 
Roche Diagnostics Canada.  
Notes - IMPROVE-CHF study.  
 
 
Morrison 2002   
Clinical features - Patients with presenting with a prominent complaint of 
dyspnoea at rest, on exertion or on lying down. Excluded patients with another 
obvious cause of the dyspnoea. 
Setting - San Diego Veteran’s Health Care System. 
Participants - 321 patients were recruited. 305 male : 16 female patients. No 
details about age provided. 
Study design - Prospective. Convenience sample. 
Target condition and reference standard - The target condition was heart 
failure (prevalence 42%) and the reference standard was the opinion of 2 
cardiologists based around the Framingham criteria. Any other investigations the 
patient had other than the BNP result were also available to the cardiologists. 
Index and comparator tests- BNP was analysed using the Triage Biosite assay. 
The coefficient of variation for intra-assay precision is 9.5% fro 28.8 ng/l and 
13.9% for 1,180 ng/l. The CV for inter-assay variation is 10% for 28.8 ng/l, 
12.4% for 584 ng/l and 14.8% for 1,180 ng/l. The measurable range for BNP is 
5-13,000 ng/l. 
Follow up - No follow time period stated. 
Disclosure - None declared. 
Notes - According to email from Maisel to Schwam, these patients were not 
included in the Breathing Not Properly study but the Dao study are a subset of 
these patients. (Dao et al.; Schwam) 
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Mueller 2005 
Clinical features - Patients presenting with dyspnoea. Excluded patients with 
STEMI and non-STEMI and trauma. 
Settings - One emergency department in Austria.  All patients presenting 
between October 2003 and February 2004 were recruited. 
Participants - 293 patients presented with dyspnoea. 33 excluded. 17 did not 
meet the criteria, 11 had no reference standard, 5 did not have bloods done 
within four hours. Male 243 : female 17 patients. 
Study design - All patients were examined and had blood taken for BNP and 
NT-proBNP. Estimated GFR by Cockcroft and Gault formula. The echo and 
classification of the patients had to be done within 3 days of the patients 
attendance. The classification was done before the NT-proBNP and BNP results 
were made available. 
Target condition - The target condition was heart failure (prevalence 52.5%).  
Reference standard -Reference standard was one of the investigators reviewing 
all the data about the patient except the BNP and NT-proBNP. The diagnosis was 
based on the Framingham score and/or echocardiography. 
Index and comparator tests- History taken, clinically examined, 12 lead ECG, 
chest x-ray. LVEF was calculated at echo by biplane Simpson's method. If the 
LVEF was less than or equal to 50% then the patient had systolic dysfunction. If 
the LVEF was greater than 50% the patient was examined for diastolic 
dysfunction by looking at pulsed wave Doppler examination of mitral inflow 
before and during a Valsalva Manoeuvre. This could not be done in patients with 
AF. Diastolic dysfunction was graded from 1 to 4. BNP was assayed on a 
AxSYM analyser from Abbot Laboratories. The AxSYM BNP assay had a 
coefficience of variance of 8.1% at a mean concentration of 108 ng/l, a total CV 
of 7.5% at a concentration of 524 ng/l and a total CV of 10% at a mean 
concentration of 2117 ng/l. 
NT-proBNP was measured on an Elecsys 2010 instrument from Roche 
Diagnostics. Fully automated 2 site enzyme immunoassay with 
electrochemiluminescent technology for use with human serum and plasma. The 
total CV was 3.8% at a mean concentration of 246 ng/l, 4.7% at a mean 
concentration of 891 ng/l and a 2.2% at a mean concentration of 10,666 ng/l. 
Follow up - Classified and had all investigations by 3 days. 
Disclosures - Supported in part by a grant from the Upper Austrian Government. 
Reagents provided by Abbott Diagnostics and Roche Diagnostics. 
Notes - My results different from the authors as they have excluded patients with 
an unclear diagnosis from the analysis while I have treated it as intention to 
diagnose and included these patients as not heart failure. 
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Mueller, C 2005 
Clinical features - Patients presenting with acute dyspnoea. Excluded patients 
with obvious traumatic cause, severe renal disease or cardiogenic shock. 
Setting - Single emergency department at the University Hospital in Basel, 
Austria between 
Participants - 452 patients. Mean age 71±15 years. 262 male : 190 female 
patients. 
Study design - All patients were assessed and had history, examination, ecg, 
pulse oximetry, bloods and cxr. Signs and symptoms recorded by the ED 
resident. The original study randomised patients to have a BNP test or not to see 
if this improved outcome, so this was available for 225 of the patients. 
Target condition - The target condition was heart failure (217/ 452 48% 
prevalence).  
Reference standard - Reference standard was the opinion of an internal medical 
specialist based on all the available results, findings and outcomes for the patient. 
Index and comparator tests- Variety of symptoms and signs assessed. 
Significant predictors of heart failure listed. 
Follow up - To discharge. 
Disclosures - None declared. 
Notes - Original study published NEJM 2004. 
 
Nazerian 2010 
Clinical features - Patients with acute dyspnoea presenting to an ED of an 
adult tertiary centre in Italy. Patients with acute onset or worsening of chronic 
dyspnoea. Excluded patients with trauma, STEMI, obvious other cause. Also 
excluded if had intravenous treatment in the ED before echo and NT-proBNP 
checked. Excluded patients with poor acoustic window. Recruited Jan 2007 to 
March 2007.  
Setting – Single ED in adult tertiary centre in Italy between Jan and March 2007. 
Participants – 145 patients recruited (41 excluded). 74 female: 71 male patients. 
Mean age of 77.6 years. 
Study design - Convenience sample of patients. Investigator present for 
average of 14h per day. Four investigators recruiting patients. Patients had 
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history taken, physical examination, ECG, ABG and routine blood tests. Treating 
physicians completed Boston criteria form to estimate risk of heart failure. 
Bloods and echo done within 30 minutes of inclusion. Treating physician blinded 
to NT-proBNP and echo results. NT-proBNP performed with Roche 
immunoassay on Elecsys 1010 analyser. Co-efficient for inter- and intra-assay 
precision 4% according to manufacturers data. Echo performed by emergency 
physicians and included 2D examination and pulsed Doppler analysis of mitral 
flow. Estimated LVEF using cross-sectional diameter measurements. Used apical 
view to take Doppler samples between mitral leaflet tips to look at E/A ratio to 
describe impaired relaxation, normal or restrictive pattern.  
Target condition - Heart failure (prevalence 44%).  
Reference standard - Reference standard provided by three independent 
reviewers, 2 cardiologists and 1 respiratory physician. Reviewers had access to 
ED notes, clinical notes and any other additional information from hospital stay. 
Blinded to NT-proBNP and echo results. 
Index and comparator tests- Variety of symptoms and signs assessed Boston 
criteria as filled in by attending physician. NT-proBNP. ED echo. 
Follow up - To discharge. 
Disclosures - None declared. 
Notes – Small study. 
 
Parrinello 2008 
Clinical features  - Patients presenting with dyspnoea to the ED.  Excluded 
patients with recent history of ACS/MI or cardiac surgery.  Also excluded 
patients with pericardial effusions, PEs, trauma, liver cirrhosis, advanced renal 
failure and nephrotic syndrome.  
Setting – the ED of the University Hospital Palermo between December 2004 
and December 2006. 
Participants – 292 adult patients, selected by physicians for the study, i.e. not 
consecutive. Mean age 67.5 years. 156 male:136 female patients. 
Study design - Patients underwent clinical history, physical exam, ECG, pulse 
oxymetry, blood tests included BNP and CXR. Bioelectrical impedance analysis 
was also recorded on entry to the study.  
Target condition - Target condition heart failure. Prevalence 58.9%.  
Reference standard - Reference standard was by an independent team including 
a cardiologist and an internist who reviewed all the data including the BNP and 
echocardiography results. The patients who were diagnosed with acute heart 
failure were further divided into preserved or impaired systolic function.  
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Index and comparator tests- After the patients had been diagnosed by the 
independent group the researchers looked at the value of BIA in assisting with 
the diagnosis.  
Follow up – 90 days. 
Disclosures - None 
Notes –  
 
Potocki 2010 
Clinical features  - Patients presenting with dyspnoea to. Excluded patients on dialsysis 
or with a history of trauma. 
Setting – the ED of the University Hospital Basel from April 2006 to March 
2007 
Participants – 287 consecutive adult patients. Median age 77 years. 
Study design - Patients underwent clinical history, physical exam, ECG, pulse 
oximetry, blood tests and CXR. ED physicians assessed the probability that the 
patient had heart failure based on all available information including BNP. 
Target condition - Target condition heart failure. Prevalence 54%.  
Reference standard - Reference standard two independent cardiologists who 
had access to all the information including BNP, but not NT-proBNP or 
MRANP. BNP considered as quantitative marker of heart failure and therefore 
interpreted as continuous variable. Absolute BNP variables also adjusted for the 
presence of obesity and renal function. 
 
Index and comparator tests- Blood samples taken for determination of 
MRproANP and NTproBNP levels. MRproANP detected using sandwich 
immunoassay (MRproANP LIA, B.R.A.H.M.S, Hennigsdorf/Berlin, Germany). 
Functional assay sensitivity (interassay coefficient of variance <20%) is 
20pmol/l. NT-proBNP levels were determined by a quantitative 
electrochemiluminescence immunoassay (Elecsys proBNP, Roche Diagnostics, 
Switzerland). BNP was measured by a microparticle enzyme immunoassay (Ax-
Sym; Abbott Laboratories, Abbott Park, USA). 
Follow up – 90 days. 
Disclosures - Supported by research grants from Swiss National Science 
Foundation, Brahms, Brandenburg Ministry of Economics, European Regional 
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Development Fund. Dr Mueller has received research support from Abbott, 
Biosite, Brahms, Roche and Siemens. Dr Morgenthaler is an employer at 
Brahms. Dr Bergmann is a member of the board of directors and shareholder of 
B.R.A.H.M.S. Drs Bergmann and Morgenthaler are inventors of patents related 
to MRporANP. 
Notes –  
 
Ray 2006 
Clinical features - who were at least 65y; had dyspnoea for less than 2 weeks; 
and at least one of the following: a respiratory rate greater than 25 bpm; an Pao2 
of 70mmH g or less; a peripheral oxygen saturation of 92% or less; a PaCO2 of 
45mmHg or more with a pH of 7.35 or less. There were no exclusion criteria. 
Settings - Patients presenting to the Emergency Department of a single hospital 
in Paris between Feb 2001 and Sept 2002. 
Participants - 514 patients. Mean age 80 ±9 years. 253 male : 261 female 
patients. 
Study design - The ED physician took history and examined the patients. ABG, 
CXR and bloods were taken. Dependence and quality of life were assessed by 
the activity of daily living score. Treatment and admission decisions were carried 
out as usual. Some patients had high-resolution CT scans, echocardiograms or 
pulmonary function tests. Some patients had BNP testing done and some had 
NT-proBNP testing plus BNP testing; the attending physician was not informed 
of the results. 
Target condition - The target condition was heart failure (prevalence 43%).  
Reference standard - The reference standard was the opinion of two senior 
physicians from an examination of the complete medical chart, laboratory tests, 
CXR data and the results of the HRCT, echo, PFTs and BNP/NT-proBNP when 
available. In cases of disagreement, a third physician was involved. 
Index and comparator tests- In the 2005 paper, looking at 202 patients from 
this same group, the reference standard is given as the same except that the 
experts don't know the BNP or NT-proBNP results. 
In the 2004 paper, looking at 380 patients from this same group, the reference 
standard is given as the same except that the experts don't know the BNP result. 
The treating ED physician was asked to make a diagnosis while the patient was 
still in the ED. BNP was performed using the Triage BNP from Biosite. The 
biochemist was unaware of the diagnosis and the emergency physician and 
expert panel were unaware of the BNP levels. 
Follow up - until discharge? 
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Disclosures - Biosite and Roche Diagnostics provided the diagnostic tests free of 
charge. 
Notes - Ethics committee approval obtained, the need for informed consent 
waived. This study contained 514 patients. A subgroup of this study consisting of 
308 patients was published by Ray in 2004 in Int Care Med who had BNP testing 
carried out. Another subgroup was published by Ray in 2005 in J Am Geriat Soc. 
This consisted of 202 patients who had NT-proBNP and BNP testing performed. 
The 202 patients were largely a subset of the 308 patients who had BNP testing 
done as it is mentioned in this paper, the 2006 paper, that 375 patients had BNP 
or NT-proBNP testing done. It is not clear from any of the published papers how 
patients were selected for the subgroup studies as the inclusion criteria and time 
periods are described identically in all 3 papers. 
 
 
Study design – Patients taken from the Mueller, C 2005 and Potocki 2010 
studies. Checked uric acid levels on all patients and looked for diagnostic and 
prognostic utility. 743 patients included from these two studies. 
Target condition - The target condition was heart failure (prevalence 51%).  
 
Robaei 2011 
Clinical features – Adult patients presenting with dyspnoea.  
Settings - Patients presenting to the Emergency Department of a single tertiary 
hospital in Australia. Time period not specified.  
Participants - 68 patients. Mean age 73±16 years. 30 male : 38 female patients. 
Study design - The ED physician took history and examined the patients then 
asked to decide if the patient had heart failure. In 38 of the patients a blood 
sample was taken for NT-proBNP and the results were then made available to the 
physician to see if this altered the presumed diagnosis. 
Target condition - The target condition was heart failure (prevalence 40%).  
Reference standard - The reference standard was the opinion of a single 
cardiologist blinded to the NT-proBNP results. 
Index and comparator tests-It isn’t really possible to use the NT-proBNP test 
results as the results were used with a range of age-dependent cut-off values and 
an overall sensitivity and specificity were provided. 
Follow up - until discharge. 
Disclosures – Partially supported by a grant from Roche Diagnostics Australia. 
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Notes – Small study. Difficult to elicit results due to the way that they were 
presented. 
 
Shah 2009 
Clinical features - Patients 18y or older presenting to an ED setting with a 
primary complaint of dyspnoea. Exclusion criteria were overt causes of dyspnoea 
e.g. trauma, pneumothorax or upper airway obstruction and ACS. ACS defined 
as ST segment deviation more than 1mm or a serum troponin concentration rise 
above the upper reference limit for the local laboratory. 
Settings - Patients recruited from 5 centres in US between May 2003 and 
December 2006. 
Participants - 412 patients. Mean age 58 ± 14 years. 251 male : 161 female 
patients. 
Study design - Prospective cohort study. Data obtained by designated study 
coordinator from the medical records and the patients directly. Data collected 
included demographics, symptoms, physical examination results, observations, 
ECG, medical history, CXR and medication status. Data used to adjust 
multivariate models of prognosis and to calculate estimated GFR. 20ml of blood 
taken into plastic tubes, EDTA containing, heparin coated and plain tubes. Blood 
centrifuged within 2h and stored at -20C or colder. Then transferred on dry ice to 
main laboratory where stored at -70C. Samples thawed once in room-temperature 
water bath and assayed within 1h. 
Target condition - Target condition was heart failure (prevalence 35.7%). 
Reference standard - Reference standard was provided by a panel of experts. 2 
clinicians reviewed all results by standardised adjudication form according to the 
Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial 
criteria. A third clinician was used if there was disagreement. 
Index and comparator tests - Measured myeloperoxidase concentrations from 
the EDTA samples, measured by immunoassay on the Dimension RxL system 
(Siemens Healthcare Diagnostics). MPO within run and total imprecision values 
of 3.8% and 4.8% respectively at 428 pmol/l and 3.3.% and 3.6% respectively at 
3642 pmol/l. The detection limit was 13 pmol/l and the assay was linear to 5223 
pmol/l. 
The BNP was measured with Triage BNP 2-site immunoassay reagents (Biosite) 
formatted for Beckman Coulter instrumentation. Performed on an Access II 
system. 
The NT-proBNP was measured with 1-step immunometric Dimension PBNP 
sandwich assay (Dimension RxL system; Siemens Healthcare Diagnostics). 
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All blood sample analysis performed blind to patient data. 
Prospective echocardiography planned for all patients with 96h. Performed by 
expert sonographer and images sent to core laboratory where a single 
investigator, blinded to the clinical data, interpreted all the images and performed 
all the measurements. Simpson biplane analysis was used to determine LV end-
systolic volume and the LV end-diastolic volume. LVEF was calculated as 
LVEDV - LVESV / LVEDV x 100%. LV mass was measured by M-mode 
criteria using formula derived by Devereux. The LV mass was indexed to body 
surface area. 
Diastolic function assessed in the apical 4 chamber view. Doppler evaluations of 
mitral inflow velocities and tissue Doppler imaging sampling from the lateral 
mitral annulus were obtained to grade the severity as stage 1 - impaired 
relaxation, ratio of transmitral peak flow velocity in early diastole to peak flow 
velocity in late diastole (E/A ratio <1, deceleration time >220ms), stage II - 
pseudonormal, E/A ratio between 1 and 2, Dt <220ms, early diastolic mitral 
annular velocity <8.5 ms or stage III - restrictive E/A ratio >2, Dt <150 ms. 
Follow up -  
Disclosures - Dr Christenson is a consultant for Siemens Healthcare Diagnostics 
and Response Biomedical and has received honoraria from these companies and 
Inverness Medical Innovations and Instrumentation Laboratories. He has also 
received research funding from Siemens Healthcare, Roche Diagnostics, 
Response Biomedical, Brahms, Inverness Medical Innovations and 
Instrumentation Laboratories.  
Dr Mehra is a consultant or has an advisory role for Roche, XDx, Debiopharm, 
Sovay, Orqis Medical, Medtronic, St. Jude Medical and Geron. He has received 
honoraria from Inverness Medical Innovations (formerly Biosite) and Roche 
diagnostics and has received research funding from the National Institutes of 
Health, Other Tobacco-Related Diseases Fund and Maryland Industrial 
Parterships. 
Dr deFillippi is a consultant or has an advisory role for Siemens Healthcare 
Diagnostics and Roche Diagnostics. He has received honoraria and research 
funding from Siemens Healthcare Diagnostics and Roche Diagnostics. 
Notes - Data for BNP, NT-proBNP, MPO and echo given as Pearson coefficients 
etc. Not given raw figures to work out sensitivity and specificity for any given 
cut-offs. 
 
Singer 2009 
Clinical features - Patients 18y or over with a primary complaint of SOB. 
Excluded patients with asthma exacerbations, trauma and chronic renal failure 
requiring haemodialysis. 
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Settings - 10 community and university hospitals throughout US in 2005. (New 
York , Boston, North Carolina, New Jersey, Massachusetts, Philadelphia.) 
Participants - 301 patients. Mean age 61 ±18 years. 132 male : 169 female 
patients. 
Study design - Prospective, multi-centre, observational study looking at the 
incremental benefit of a SOB point-of-care biomarker panel. Convenience 
sample of patients, recruited when a member of the investigator team available. 
Demographic and clinical data collected by a trained research assistant or nurse 
on all patients using standardised data collection sheets. After initial evaluation, 
consisting of history and examination, radiography and ECG, the attending 
physician estimated probability of HF, MI and PE. These estimates were 
dichotomised into high (≥80%) and low or medium (<80%). 
Target condition - The target conditions were myocardial infarction, heart 
failure  (prevalence 30.2%) and pulmonary embolism. 
Reference standard - The reference standard was provided by an investigator 
blinded to the biomarker panels results but able to view central laboratory BNP 
results.  
Index and comparator tests- Blood samples collected and analysed using the 
Triage Profiler SOB point-of-care biomarker panel. Fluoresence-based 
immunoassay that measures TnI, myoglobin, CK-MB, D-dimer and BNP 
simultaneously. The following values were considered positive myoglobin >107 
ng/ml, CK-MB >4.2ng/ml, TnI >0.05 ng/ml, D-dimer >200 ng/ml and BNP >100 
ng/ml. The results were not made available to the attending physician. 
Follow up - At 30 days the inpatient records were reviewed and telephone 
interviews were performed to determine the presence of MI, HF and PE based on 
standardised criteria. 
Disclosures - Funded by Biosite Inc., Sand Diego, CA. 
Notes -  
 
 
 
Villacorta 2002   
Clinical features - Patients presenting with dyspnoea. 
Settings - A single ED with acute dyspnoea from April to July 2001.  The centre 
is a described as a referral centre for cardiology in that city. 
Participants - 70 consecutive patients. Mean age 72.4 ± 15.9 years. 33 male : 37 
female patients. 
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Study design - Excluded patients with a diagnosis of a condition causing the 
dyspnoea such as tracheal stenosis or cardiac tamponade. Also excluded patients 
with acute coronary syndromes whose prominent complaint was not dyspnoea. 
All patients underwent laboratory tests and chest x-rays. Echocardiography was 
recommended. After initial assessment the emergency medicine physician 
assigned an initial diagnosis, blinded to BNP values. 
Target condition - The target condition was heart failure (prevalence 51.4%).  
Reference standard - The reference standard was provided by a cardiologist 
who reviewed all patients' data and was blinded to the BNP result. Patients who 
had an echocardiogram showing left ventricular fractional shortening equal to or 
less than 25% were considered as having systolic dysfunction. 
Index and comparator tests- The BNP was measured using the Triage B-Type 
Natriuretic Peptide test by Biosite Diagnostics Inc., San Diego. 5ml of blood 
collected in tubes containing EDTA. The majority of samples were processed 
immediately, a few (not clear how many) were spun, frozen and then analysed 1-
3 days later. BNP is known to be stable so this should not affect the results. 
Follow up - Results until discharge were reviewed. 
Disclosures - None declared. 
Notes - Small study. 
 
 
Wang 2010 
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Clinical features - Patients over 17 years presenting with acute dyspnoea. 
Exclusion criteria included acute MI, trauma or another obvious cause of 
dyspnoea.  
Settings – Tertiary medical centre in Taiwan over a 15 month period.  
Participants – 95 patients screened, 84 enrolled.  
Study design – Various signs and symptoms recorded while in the emergency 
department. Echocardiogram performed by emergency physician. BNP taken 
while in ED.  
Target condition and reference standard - The target condition was heart 
failure (prevalence 58.3%). Two cardiologists blinded to echo and BNP results 
reviewed all other data and made the diagnosis. 
Index and comparator tests- BNP analysed using Abbott laboratories system. 
Follow up – Until discharge. 
Disclosure – None declared. 
Notes – Small study. Does not mention any failure to record 
echocardiogram findings.  
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